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Cerebral small vessel disease (SVD) is a common cause of strokes and dementia. The pathogenesis of
SVD is poorly understood, but imaging and biochemical investigations suggest that subtle blood-brain
barrier (BBB) leakage may contribute to tissue damage. The most widely-used imaging method for
assessing BBB integrity and other microvascular properties is dynamic contrast-enhanced magnetic res-
onance imaging (DCE-MRI). DCE-MRI has primarily been applied in situations where contrast uptake
in tissue is typically large and rapid (e.g. neuro-oncology); the optimal approach for quantifying BBB
integrity in diseases where the BBB remains largely intact and the reliability of resulting measurements
is unclear. The main purpose of this thesis was to assess and improve the reliability of quantitative
assessment of subtle BBB disruption, in order to illuminate its potential role in cerebral SVD.
Firstly, a systematic literature review was performed in order to provide an overview of DCE-MRI
methods in the brain. This review found large variations in MRI procedures and data analysis methods,
resulting in widely varying estimates of tracer kinetic parameters. Secondly, this thesis focused on
the analysis of DCE-MRI data acquired in an on-site clinical study of mild stroke patients. After
performing basic DCE-MRI processing (e.g. selection of a vascular input function), this work aimed
to determine the tracer kinetic modelling approach most suitable for assessing subtle BBB disruption in
this cohort. Using data-driven model selection and computer simulations, the Patlak model was found
to provide accurate estimates of blood plasma volume and low-level BBB leakage. Thirdly, this thesis
aimed to investigate two potential pitfalls in the quantification of subtle BBB disruption. Contrast-
free measurements in healthy volunteers revealed that a signal drift of approximately 0.1 %/min occurs
during the DCE-MRI acquisition; computer simulations showed that this drift introduces significant
systematic errors when estimating low-level tracer kinetic parameters. Furthermore, tracer kinetic
analysis was performed in an external patient cohort in order to investigate the inter-study comparability
of DCE-MRI measurements. Due to the nature of the acquisition protocol it proved difficult to obtain
reliable estimates of BBB leakage, highlighting the importance of study design. Lastly, this thesis
examined the relationship between quantitative MRI parameters and clinical measurements in cerebral
SVD, with a focus on the estimates of blood volume and BBB leakage obtained in the internal SVD
patient cohort. This work did not provide evidence that BBB leakage in normal-appearing tissue
increases with SVD burden or predicts disease progression; however, increased BBB leakage was found
in white matter hyperintensities. Furthermore, this work raises the possibility of a role for blood plasma
volume and dietary salt intake in cerebral SVD.
The work described in this thesis has demonstrated that it is possible to estimate subtle BBB disruption
using DCE-MRI, provided that the measurement and data analysis strategies are carefully optimised.
However, absolute values of tracer kinetic parameters should be interpreted with caution, particularly
when making comparisons between studies, and sources of error and their influence should be estimated
where possible. The exact roles of BBB breakdown and other microvascular changes in SVD pathology
remain to be defined; however, the work presented in this thesis contributes further insights and, together




Small vessel disease is a condition in which the small blood vessels deep in the brain become damaged.
This often happens as we become older and can lead to serious health problems such as stroke and
dementia. At the moment, no one fully understands how and why these changes happen. Some
researchers think that the lining of the tiny blood vessels in the brain becomes damaged and lets harmful
material from the blood leak slowly into the surrounding brain tissue. This is known to happen in several
other diseases, for example in brain tumours. In such diseases, the leakiness of the blood vessels is often
measured using a particular magnetic resonance brain scanning technique. In small vessel disease, the
blood vessel lining is only thought to be damaged very slightly, which makes taking exact measurements
more difficult. The aim of this project was to find the best way of measuring these subtle changes to the
blood vessels. Only if we can measure the degree of blood vessel leakage reliably, will we be able to
better understand its importance in normal ageing, stroke and dementia.
At the beginning of this project, I created an overview of the different methods used by other research
groups to measure the leakiness of vessels in the brain. This helped me to identify the challenges when
measuring very minor leakage. In the second phase of the project, I focused on finding a suitable
approach for analysing brain scans that we had collected in a large group of patients who had suffered
a recent mild stroke. I have written computer software that applies several different analysis methods,
selects the most appropriate method, provides estimates of the degree of damage to the vessels and tests
how accurate these measurements are likely to be. In addition, I examined whether and to what degree
the estimates of subtle vessel leakage are influenced by other factors. For this purpose, I scanned a
group of healthy volunteers, which showed that measurement errors can be produced by the scanning
machine. I also analysed brain scans that had been collected in a different research centre, so as to
compare the measurements with our patient group. However, I found that the particular way in which
these scans were taken made it difficult to measure subtle vessel leakage. Finally, I tested whether there
are any connections between measurements from the brain scans and other medical measurements in our
group of stroke patients. We found that blood vessels were leakier in visibly damaged brain tissue, but
this particular investigation did not provide evidence that leakage of blood vessels in healthy-appearing
tissues causes damage to the brain. However, we found other interesting connections – for example,
people who eat a lot of salty food had more damaged tissue in their brains.
The work presented in this thesis has shown that it is possible to measure subtle damage to the blood
vessel lining. However, it is very important to think carefully about which measurement techniques to
apply and to be aware that there are several sources of error. Exactly what is happening in small vessel
disease is still a fascinating puzzle, but the findings presented in this thesis, together with growing
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This thesis focuses on the measurement of subtle blood-brain barrier (BBB) disruption in
cerebral small vessel disease (SVD) using dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI). The purpose of this chapter is to provide a general background of cerebral
SVD (section 1.1) and DCE-MRI (section 1.2). Furthermore, this chapter presents the chal-
lenges related to measuring subtle BBB disruption (section 1.3). It concludes with an outline
of the resulting aims and the structure of this thesis (section 1.4). Parts of this chapter have
been published in the background section of Heye et al. (2014).
1.1. Cerebral SVD
The term cerebral SVD refers to various pathological processes affecting the small vascular
structures (mainly small arterioles, capillaries and venules) that penetrate into the brain par-
enchyma or in the subarachnoid space. Because small vessels cannot currently be visualised
in vivo using standard neuroimaging techniques, the term cerebral SVD usually refers to the
consequences of small vessel changes seen in the brain parenchyma rather than the underlying
vessel pathology itself (Wardlaw et al., 2013c). Consequently, the term cerebral SVD is com-
monly used to describe a variety of clinical, cognitive, neuroimaging and neuropathological
findings.
1.1.1. Clinical aspects
In the past years, cerebral SVD has been recognised as a serious problem. The clinical mani-
festations are diverse and can range from stroke to subtle neurological symptoms to severe
cognitive deficits including dementia and physical disabilities. Cerebral SVD plays a crucial
role in at least three fields: stroke, normal ageing and dementia.
In developed countries, the proportion of elderly people is rapidly increasing. Ageing is
commonly accompanied by cognitive decline, which significantly affects ability to live in-
dependently and, thus, causes huge costs to society. The prevalence of cerebral SVD increases
with age (de Leeuw et al., 2001). It has been shown in several large studies that imaging
markers of SVD are associated with general cognitive deficits in non-demented elderly subjects
(Debette and Markus, 2010; de Groot et al., 2000; Garde et al., 2000; Longstreth et al., 1996;
van der Flier et al., 2005). Furthermore, there is evidence that cerebral SVD correlates with gait
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disturbances (Baezner et al., 2008), mood disorders (O’Brien et al., 1998) and urinary problems
(Poggesi et al., 2008), all of which contribute to general age-related disability. In addition
to subtle cognitive decline with normal ageing, 5% to 7% of people older than 60 years are
affected by dementia (Prince et al., 2013). The prevalence increases to about 30% for people
older than 80 years (Lobo et al., 2000), invoking large costs to the health system. Cerebral
SVD has been recognised as the most common cause of vascular dementia (Dichgans and
Zietemann, 2012) and also often occurs in Alzheimer’s patients (Kalaria, 2002). Overall, it is
estimated that cerebral SVD contributes to up to 45% of dementias (Gorelick et al., 2011).
Cerebral SVD is responsible for about a fifth of all strokes worldwide and about a quarter of
ischaemic strokes (Sudlow and Warlow, 1997), placing an immense burden on society. Behind
ischaemic heart disease, stroke is the second most common cause of death worldwide and
also represents the leading neurological cause of disability in adults (Murray and Lopez, 1997,
2013). The number of global deaths from stroke is predicted to increase from an estimated
5.7 million in 2005 to 7.8 million in 2030 (Strong et al., 2007). Once a clinical diagnosis of
stroke has been made, it is important to determine the cause of the stroke in order to initiate
appropriate treatment. About 20% of all strokes are due to haemorrhage, which can be either
parenchymal (15%) or subarachnoid (5%) (Feigin et al., 2003). With a proportion of 80%, the
vast majority of strokes are ischaemic strokes. In ischaemic stroke, the underlying cause can be
sub-classified in large artery atheroma (50%), SVD (25%), cardio-embolism (20%) and other
ischaemic types (5%) (Sudlow and Warlow, 1997). Lacunar stroke, i.e. ischaemic stroke caused
by SVD, has long been considered the most benign type of stroke and, therefore, has been
neglected by research with most attention being given to the more disabling large artery stroke.
Consequently, little is known about the exact mechanisms underlying SVD and lacunar stroke,
as well as prevention and treatment options (Wardlaw et al., 2013b). Although the symptoms
of lacunar stroke rarely cause death in the acute phase, they are associated with an increased
risk of late recurrence, cognitive decline and dementia (Jackson and Sudlow, 2005; Norrving,
2003). SVD is often clinically silent and detected in late stage. The focus on lacunar stroke
as a discrete form of cerebral SVD is useful because the discrete, sudden-onset symptoms give
an inception point, from which it is easier to track subsequent disease progression (Wardlaw
et al., 2013b).
1.1.2. Neuroimaging
Although the small vessels of the brain are hard to image in vivo, the consequences of their
malfunction can be studied with brain imaging. Consequently, neuroimaging offers consider-
able insight into the disease and helps the clinical diagnosis. In the 1970s, the invention of
x-ray computed tomography (CT) by Sir Godfrey N Hounsfield revolutionised brain imaging
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by providing high contrast, cross-sectional images. Up to the present day, CT remains widely
used in routine clinical brain imaging because it is quick and accurate in detecting various
pathologies such as brain tumours and haemorrhagic strokes. However, the contrast between
brain tissues in CT images is somewhat limited. In the early 1980s, magnetic resonance
imaging (MRI) was introduced as an additional diagnostic tool for clinical practice (for more
detailed information on MRI see section 1.2.1). Although the scanning time is longer than in
CT, MRI does not use ionising radiation and produces superior image quality for the display
of anatomical structures in the soft tissues of the brain. In SVD, MRI is particularly useful
compared to CT due to its greater sensitivity in detecting small lesions and subtle tissue
differences. A routine MRI brain examination for SVD consists of multiple sequences, com-
monly including: T1-weighted (T1W) imaging, T2-weighted (T2W) imaging, T2∗-weighted
(T2*W) gradient echo (GRE) imaging, fluid attenuated inversion recovery (FLAIR) imaging
and diffusion-weighted imaging (DWI). There are several signs of SVD that can be detected
with conventional MRI; however, the terminology and definitions used vary widely. This
lack of consistency inhibits inter-study comparisons and hinders research progress. In order
to develop definitions and define imaging standards for research into SVD, an international
working group of the Centres of Excellence in Neurodegeneration was assigned with the task
to provide ‘standards for reporting vascular changes on neuroimaging’ (STRIVE). The main
outcomes of this international effort have recently been published by Wardlaw et al. (2013c)
and provide recommendations to standardise image acquisition, interpretation and reporting.
Following the proposed standard terminology, the most common manifestations of SVD on
MRI are:
i) recent small subcortical infarcts,
ii) lacunes of presumed vacular origin,
iii) white matter hyperintensities (WMH) of presumed vacular origin,
iv) enlarged perivascular spaces (EPVS),
v) cerebral microbleeds,
vi) brain atrophy.
These neuroimaging features are depicted in Figure 1.1 and will be discussed in detail below.
Recent small subcortical infarcts are a common sign of SVD and usually cause clinical
symptoms of a lacunar stroke. The infarcts occur in the territory of one perforating arteriole
in the deep parts of the brain; they are often seen in locations such as the basal ganglia,
thalamus, internal capsule and pons (Pantoni, 2010; Gattringer et al., 2015). The imaging
features or clinical symptoms of recent small subcortical infarcts must be consistent with a
lesion occurring in the previous few weeks; the word ‘small’ refers to a lesion that is less
than 20 mm in its maximum diameter in the axial plane (Wardlaw et al., 2013c). On MRI,
they appear hypointense on T1W images, and hyperintense on DWI, T2W and FLAIR images
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(a) Recent lacunar infarct (b) Lacune (c) WMH
(d) EPVS (e) Microbleeds (f) Atrophy
Figure 1.1.: Main MRI findings of cerebral SVD. Example images showing SVD imaging
features on different MRI sequences. (a) The circle highlights a recent small subcortical infarct,
(b) the circle highlights a fluid filled lacune, (c) the arrow points to a region with WMH
characteristics (WMH are diffuse lesions which include all regions of similar hyperintense
signal), (d) the square contains several linear EPVS, which are also visible on the contralateral
side, (e) the circles highlight cerebral microbleeds, (f) the arrows point to the enlarged
ventricles and enlarged sulci respectively, representing cerebral atrophy.
(see Figure 1.1(a)). The DWI sequence is particularly important for the identification of
recent infarcts, as increased DWI signal or a reduced apparent diffusion coefficient help to
discriminate them from old lesions (Wardlaw et al., 2013b). Recent small subcortical infarcts
can have different long term fates: they often cavitate and become lacunes (estimates of
cavitating proportion range from 28% to 94% (Potter et al., 2010; Moreau et al., 2012)), but
can also appear like WMH or disappear completely (Wardlaw et al., 2013c). While small
subcortical infarcts can occasionally be clinically silent (Kang et al., 2012), i.e. present as
lesions on imaging but are asymptomatic, about 30% of patients show clinical symptoms
of lacunar stroke but do not have visible lesions (Doubal et al., 2011). Lacunar infarcts are
associated with cognitive decline (Samuelsson et al., 1996).
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Lacunes are round or ovoid, subcortical, fluid filled cavities of presumed vascular origin and
between 3 mm and 15 mm in diameter (Wardlaw et al., 2013c). Most lacunes are presumed
to be caused by small subcortical infarcts, although they might also result from small deep
haemorrhages (Franke et al., 1991). On MRI, lacunes have a similar signal to cerebrospinal
fluid (CSF), usually with a hyperintense rim around the hypointense cavity on FLAIR images
(see Figure 1.1(b)). Many lacunes appear silently in the brain without causing symptoms
(Vermeer et al., 2007); however, it has been shown that lacunes are implicated in higher risk of
recurrent stroke and dementia (Loeb et al., 1992; Vermeer et al., 2003). Moreover, the number
of lacunes was found to be a predictor of speed and motor control among non-demented elderly
subjects (Benisty et al., 2009).
WMH are signal abnormalities of presumed vascular origin and variable size in the white
matter (WM). They are usually symmetrically distributed in both cerebral hemispheres. WMH
appear hyperintense on T2W and FLAIR images (see Figure 1.1(c)) and can be isointense or
slightly hypointense on T1W images. Such hyperintensities can also occur in grey matter (GM)
and the brain stem; however, these should not be included in the term WMH unless explicitly
stated (Wardlaw et al., 2013c). Several methods are available to measure the presence, size and
progression of WMH, including qualitative rating scales (Breteler et al., 1994; Fazekas et al.,
1987; Longstreth et al., 1996; Mäntylä et al., 1999; Scheltens et al., 1993) and automatic or
semi-automatic quantitative methods (Enzinger et al., 2006; Valdés Hernández et al., 2010;
Jeerakathil et al., 2004; Prins et al., 2004; van Straaten et al., 2006). WMH are strongly
associated with increased risk of strokes, cognitive decline, dementia and death (Debette and
Markus, 2010).
EPVS, previously commonly called enlarged Virchow-Robin spaces (Kwee and Kwee, 2007),
are fluid filled spaces that surround the small deep perforating vessels as they pass through GM
or WM (Wardlaw et al., 2013c). As EPVS contain fluid, they appear similar to CSF on MRI
(see Figure 1.1(d)). Following the course of vessels, visible EPVS are linear when parallel
to the imaging plane (e.g. in the lateral subcortical WM of the temporal, parietal and frontal
lobes with axial imaging), and round or ovoid when perpendicular to the imaging plane (e.g.
in the basal ganglia with axial imaging). Due to their similar appearance on MRI, EPVS must
be discriminated from lacunes. As a general rule, EPVS are usually smaller than 3 mm in
diameter (Bokura et al., 1998). Although the presence of a few visible EPVS can be normal
at any age, they become increasingly frequent with older age (Groeschel et al., 2006). The
clinical significance of EPVS remains controversial; however, a higher number of visible EPVS
has been associated with active inflammation in multiple sclerosis (Wuerfel et al., 2008) and
cognitive decline (Maclullich et al., 2004).
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Cerebral microbleeds are small punctate areas that appear hypointense on T2∗W GRE ima-
ging (see Figure 1.1(e)), but are not visible on other MRI sequences. They are generally
2 mm to 5 mm in diameter, but some authors have considered lesions as large as 10 mm to
be microbleeds (Cordonnier et al., 2007) . Microbleeds most commonly occur in the cortico-
subcortical junction, and subcortical/deep GM (DGM) or WM in the cerebral hemispheres,
brainstem and cerebellum (Wardlaw et al., 2013c). Histopathologically, microbleeds have
been shown to correspond to small collections of haemosiderin-laden macrophages around
small perforating vessels (Gouw et al., 2011; Shoamanesh et al., 2011). Microbleeds are
associated with dementia in the form of Alzheimer’s disease (Vernooij et al., 2008) as well
as cerebral amyloid angiopathy (Knudsen et al., 2001) and, although originally thought to
be asymptomatic, are now considered to be associated with transient neurological symptoms,
especially in the presence of superficial siderosis (Lummel et al., 2015).
Brain atrophy describes a decrease in brain volume, which can be caused by several patholo-
gical processes, such as neuronal loss, cortical thinning and vascular infarcts. In the context of
SVD, atrophy is defined as a reduced brain volume that is not related to a specific macroscopic
focal injury (Wardlaw et al., 2013c). Hence, focal tissue loss from infarctions should not be
included in this term unless explicitly stated. Atrophy can be either general and affect the
whole brain, or focal (only affecting specific brain regions or lobes), or selective (only affecting
a particular tissue type). On MRI, atrophy presents itself as tissue loss from enlargement of
peripheral or central CSF spaces, i.e. increased ventricular volume and/or enlarged superficial
sulci (see Figure 1.1(f)). The amount of tissue loss can be quantified as brain volume or CSF
volume in relation to intracranial volume; however, brain atrophy should ideally be observed
in longitudinal studies. Cerebral atrophy occurs to some degree with normal ageing, but a high
atrophy rate has been associated with cognitive decline in Alzheimer’s disease and vascular
dementia (Fox and Schott, 2004; Jagust et al., 2008).
Several studies have shown that all these common neuroimaging features of SVD are interre-
lated. WMH presence, severity or progression are associated with lacunar strokes (Rost et al.,
2010), lacunes (Gouw et al., 2008), microbleeds (Cordonnier et al., 2007), EPVS in patients
with lacunar stroke (Doubal et al., 2010; Potter et al., 2013) and atrophy (Aribisala et al., 2013;
de Leeuw et al., 2006). Similarly, studies reported correlations between EPVS and lacunar
infarcts (Rouhl et al., 2008), lacunes (Zhu et al., 2010) and microbleeds (Martinez-Ramirez
et al., 2013). Furthermore, several features share vascular risk factors, such as increased age
and hypertension (Debette and Markus, 2010; Dufouil et al., 2001; Vermeer et al., 2007). As
highlighted in Wardlaw et al. (2013c), lesions with different causes can often have a similar
long term appearance on MRI; for instance, both small subcortical infarcts and stroke symp-
toms without acute visible lesion might appear as WMH or normal-appearing tissue in their
chronic stages.
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1.1.3. Pathophysiology and the proposed role of the BBB
Despite the increasing research interest in cerebral SVD, the underlying pathological processes
are still largely unknown. Since the symptoms of SVD are rarely fatal in the acute phase, the
human specimens usually reflect late stage pathology. Further difficulties are caused by the
lack of suitable animal models (Bailey et al., 2009) and the inadequate scanning resolution of
current in vivo imaging techniques.
Many perceptions of SVD aetiology arise from the seminal pathological studies by C Miller
Fisher, in which he studied the appearance of lacunar infarcts, lacunes and perforating small
arteries in about 20 deceased patients (Fisher, 1968, 1979, 1982, 1991, 1998). The commonest
pathological findings described by Fisher are abnormalities of the small arterioles (40 µm to
200 µm). These vessel wall changes are characterised by arterial wall disorganisation and
collagenous sclerosis, leading to narrowing and, in some cases, occlusion and sometimes
dilation of the perforating artery. This process has been attributed to diffuse deposition of
lipid in the arteriolar walls, and is sometimes referred to as lipohyalinosis. The size and
severity of a lacunar infarct was thought to depend on the size of the pathologic vessels,
with larger infarcts being caused by atherosclerosis or embolism in larger perforating arteries
(200 µm to 850 µm). Although Fisher’s work offers an intriguing insight into the pathology
of lacunar stroke, there has been little further research to confirm his hypotheses (Pantoni,
2010; Wardlaw et al., 2013b). Furthermore, while microatheroma and emboli might account
for some SVD features such as lacunar stroke and WMH, they cannot necessarily explain other
SVD manifestations, for instance, EPVS or microbleeds. Consequently, it is now believed
that other mechanisms such as inflammation (Rosenberg, 2009), oligodendrocytes apoptosis
(Brown et al., 2000), endothelial dysfunction (Markus, 2008) and BBB impairment (Wardlaw
et al., 2003) could be involved in the aetiology of SVD.
There is increasing evidence that endothelial failure plays an initiating role in the development
of SVD. Endothelial cells form a key part of the BBB; they line capillaries and are sealed
by tight junctions, which are unique to the brain microvasculature. The endothelium of the
BBB interacts with several cellular and non-cellular elements, such as astrocytes, pericytes,
microglial cells and basement membranes, that provide both functional and structural support
to the BBB (see Figure 1.2). Together they form an interactive cellular complex: the neur-
ovascular unit. The BBB regulates the passage of essential molecules such as glucose, while
restricting the diffusion of potentially harmful substances. There are many mechanisms that can
cause a disruption of the BBB, ranging from extrinsic systemic factors, such as infections and
autoimmune processes, to intrinsic cellular mechanisms secondary to neuroinflammatory in-
jury. Several comprehensive reviews provide detailed information on the molecular biology of
BBB disruption with disease (Abbott and Friedman, 2012; Obermeier et al., 2013; Rosenberg,
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2012). Failure of the BBB can explain many of the imaging and pathological observations
related to SVD (Lammie et al., 1998; Wardlaw et al., 2001, 2003; Wardlaw, 2010; Wardlaw
et al., 2013c). Disruption of the BBB caused by endothelial dysfunction leads to leakage of
substances through the vessel wall, e.g. proteins, inflammatory markers and red cells. These
substances can result in damage to the small vessel wall, ischaemia and oedema (Wardlaw
et al., 2003), which affect the neuronal and glial cells and damage the brain parenchyma.
Figure 1.2.: Schematic drawing of the neurovascular unit. Reprinted from Heye et al.
(2014).
Since the hypothesis that early endothelial failure precipitates SVD was first proposed, it has
been supported by several studies. Several research groups have examined changes of the
BBB with normal ageing, dementia and WMH; a comprehensive systematic literature review
of available published human studies and meta-analysis found that increased BBB permeability
is associated with (i) increasing age, (ii) diagnosis of dementia compared to healthy age-
matched controls, (iii) diagnosis of vascular dementia compared to a diagnosis of Alzheimer’s
disease and (iv) increasing amount of WMH (Farrall and Wardlaw, 2009; Wardlaw, 2010).
Furthermore, studies reported that BBB permeability in WM is increased in patients with
lacunar stroke compared to cortical stroke (Wardlaw et al., 2008, 2009) or healthy age-matched
controls (Topakian et al., 2010). Increased BBB permeability in normal-appearing tissues has
also been reported to correlate with EPVS (Wardlaw et al., 2009) and increased risk of poor
outcome and disability at long term follow-up after stroke (Wardlaw et al., 2013a).
Most of the studies reported in Farrall and Wardlaw (2009) used biochemical tests to assess
BBB permeability, such as the CSF:plasma albumin ratio. Albumin is a medium-sized protein
that is mainly produced on the plasma side of the BBB. Hence, any increase of albumin in
the CSF can indicate a general disruption of the BBB. However, elevated CSF:plasma albumin
ratios can also represent other processes and should be interpreted cautiously (Chen, 2011).
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Moreover, CSF is obtained by lumbar puncture, which is not acceptable to many people. More
recently, contrast-enhanced neuroimaging methods have become the standard method for in
vivo assessment of BBB integrity, most of which are MRI based (Chassidim et al., 2013).
1.2. Assessment of BBB integrity with MRI
This section provides an introduction to MRI and the specific imaging method (DCE-MRI)
that this research focuses on. Moreover, this section will explain how the resulting data can be
analysed in order to obtain measurements of BBB integrity.
1.2.1. Introduction to MRI
MRI is based on the phenomenon of nuclear magnetic resonance (NMR), which was inde-
pendently discovered by Bloch (1946) and Purcell et al. (1946). NMR refers to the interaction
between atomic nuclei with a non-zero magnetic moment and an external magnetic field.
Although the potential of NMR was recognised early on, it took more than two decades to
implement NMR-based imaging. In the early 1970s, Paul C Lauterbur demonstrated that the
NMR signal can be used to obtain images (Lauterbur, 1973) and implemented the first MRI
scanner. During the following years, the development and refinement of processing techniques
and hardware ultimately led to a clinical tool that can provide high-quality images of the human
brain. The following sections will provide a brief introduction to the physics of MRI; for
further information, the interested reader is referred to the detailed literature, e.g. McRobbie
et al. (2006).
Nuclear spins and magnetic fields
Subatomic particles have the quantum mechanical property of spin. Certain nuclei have a





are of particular interest, because hydrogen is a substantial component of water
and lipids, which make up 75% to 80% of the human body. Without an external magnetic
field, nuclei are randomly oriented (see Figure 1.3(a)) and their non-zero magnetic moments m
cancel each other out, resulting in a zero net magnetisation M. When spinning nuclei are
subjected to a static magnetic field B0, their non-zero magnetic moments tend to align with the
field (see Figure 1.3(b)). Some spins will align parallel and some anti-parallel to the orientation
of the magnetic field, with a slight excess of parallel spins because this is a lower energy state
(following the laws of quantum mechanics that, for simplicity, will not be discussed here). The
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alignment of the spins and their magnetic moments produces a bulk magnetisation M0 in the
direction of the static field. However, the nuclear spins do not align exactly with the external
field, and therefore precess around the direction of the field (see Figure 1.3(c)). The frequency
of this precessional movement is called the Larmor frequency ω0 and is directly proportional
to the strength B0 of the external magnetic field:
ω0 = γB0, (1.1)
where γ is the gyromagnetic ratio that, for hydrogen, is equal to 42.57 MHz T−1. While all
spins have the same frequency, they are of random phase orientation. Consequently, their
magnetic moments in the transverse (xy) plane cancel to zero and the net magnetisation M0 is
non-zero in the direction of the static field (z) only.
As the net magnetisation of the nuclei is very small compared to the external magnetic field, it
cannot be easily measured in its equilibrium state. In order to measure the magnetisation, it has
to be tipped into the transverse plane. This can be achieved by exposing the nuclei to an oscil-
lating magnetic field in the transverse direction (usually referred to as a radio frequency (RF)
pulse) that has to be applied at the Larmor frequency, i.e. be in resonance with the nuclear
spins. The duration and strength of the RF pulse determine the flip angle α , which describes
how far the magnetisation has been tipped away from its original orientation. A 90◦ pulse
moves the magnetisation exactly into the transverse plane, whereas a 180◦ pulse flips it into the
opposite direction of the static field. After the RF pulse, all spins are phase-coherent and M is
in the transverse plane; consequently, M precesses, creating an oscillating magnetic field in the
transverse plane (see Figure 1.3(d)), which can be detected as a voltage with an electromagnetic
coil.
Spin relaxation
The precessing field in the transverse plane induces a voltage in an electromagnetic receive coil,
creating the magnetic resonance (MR) signal. Once the RF field is turned off, the amplitude
of the measured signal decays quickly. This typical MR signal is called the free induction
decay (FID) and is depicted in Figure 1.4(a). The decay of the signal is caused by the nuclei
returning to their equilibrium state. This process is called relaxation and consists of two main
mechanisms: longitudinal relaxation and transverse relaxation. Nuclear relaxation is formally
described by the Bloch equations, whose solutions are given in equations 1.2 and 1.3 below.
Longitudinal relaxation describes the recovery of the longitudinal component of the net mag-
netisation towards its equilibrium value. During the RF pulse, the nuclei absorb energy;
longitudinal relaxation is caused by the loss of this additional energy by interaction with the
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(a) Spin ensemble in a field-free space (b) Spin ensemble in a static magnetic
field
(c) Spin precession and net magnetisa-
tion in the equilibrium state
(d) Effect of a RF pulse on the net mag-
netisation
Figure 1.3.: Behaviour of nuclear spins in external magnetic fields. (a) Without an external
magnetic field, spinning nuclei are randomly oriented and their non-zero magnetic moments
cancel each other out, (b) when subjected to a static magnetic field B0, nuclear spins tend to
align with the field, (c) precessing nuclear spins produce a net magnetisation M0 in direction
of the static B0 field, (d) during a RF pulse with flip angle α , M0 is tipped into the transverse
plane.
surrounding tissue, or lattice. Consequently, the process is also known as spin-lattice relaxa-
tion. In addition to the external static field, the nuclei are subjected to the magnetic moments
of neighbouring particles and their fluctuations due to molecular motion. By interacting with
these magnetic fields, especially the ones that fluctuate close to the Larmor frequency, the
nuclei emit energy and the net magnetisation vector returns to the equilibrium state. This
recovery of magnetisation in the longitudinal direction (Mz) is typically an exponential process
with time constant T1 (longitudinal relaxation time) and can be described as follows:
Mz(t) = M0[1− exp(−t/T1)], (1.2)
where t is the time after the (90◦) RF pulse is switched off, and M0 is the amplitude of the net
magnetisation M0 at equilibrium. The rate of decay depends on the molecular environment of
the nuclei and is therefore tissue-specific; for instance, large molecules such as lipids and
proteins fluctuate at a rate close to the Larmor frequency and are, thus, subject to quick
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relaxation, while smaller molecules such as free fluids fluctuate much faster, resulting in slower
relaxation. Consequently, T1 is short in fatty tissue, but relatively long in CSF.
Transverse relaxation describes the decay of the transverse magnetisation due to dephasing
of the spins. As mentioned before, the spins are phase-coherent in the transverse plane dir-
ectly after the RF pulse. However, the magnetic moments of the spins interact with each
other, causing transient field inhomogeneities that lead to small differences in the precessional
frequencies of the spins. Due to these spin-spin interactions, the spins quickly dephase and
the transverse magnetisation decays. Consequently, this mechanism is also known as spin-
spin relaxation. The decay of the transverse magnetisation Mxy is characterised by the time
constant T2 (transverse relaxation time) and can be described by
Mxy(t) = M0 exp(iω0t)exp(−t/T2). (1.3)
Similar to longitudinal relaxation, transverse relaxation is an exponential process; however, it
tends to happen much more rapidly (see Figure 1.4(b)) and T2 values are therefore generally
smaller than T1 values. As with T1, T2 is tissue-specific; typical T1 and T2 values for human
brain tissues are displayed in Table 1.1.
As transverse relaxation is much quicker than longitudinal relaxation, one could expect that the
FID decays with the time constant T2. However, the MR signal decays with a shorter effective
time constant T2*. This is due to extrinsic field inhomogeneities, for instance variations in the
static magnetic field, which lead to further dephasing of spins and, hence, to a quicker decay
of the signal.
(a) FID (b) Longitudinal and transverse relaxation
Figure 1.4.: MR signal and spin relaxation after the RF pulse. (a) Oscillating signal
induced in the electromagnetic receive coil (FID), (b) relaxation mechanisms: decay of the
transverse magnetisation Mxy with time constant T2 (transverse relaxation) and recovery of the
longitudinal magnetisation Mz with time constant T1 (longitudinal relaxation).
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Table 1.1.: Typical longitudinal (T1) and transverse (T2) relaxation times for healthy
brain tissues. Values are given for a magnetic field strength of 1.5 T (Warntjes et al., 2008).
Tissue type T1 (ms) T2 (ms)
WM 576 77
DGM 829 78
Cortical GM 1048 94
CSF 3940 1910
Generating echoes
In MRI, the FID is rarely measured directly; instead, pulse sequences are used in order to
generate echoes. There are two basic methods for echo generation: spin echo and gradient
echo (GRE). The GRE is particularly important for DCE-MRI acquisition and, thus, will be
focused on in the following sections.
The principle of a GRE sequence is schematically depicted in Figure 1.5. The sequence starts
with an RF pulse that creates the FID as described previously. Immediately after this excitation
pulse, a negative gradient is applied. The term gradient refers to an additional magnetic field
with linearly increasing field strength that is superimposed on the static magnetic field. As
the precession frequency ω0 is directly proportional to the magnetic field strength, the Larmor
frequency of the spins varies along the direction of the gradient. Consequently, the applied
gradient causes the spins to dephase, which results in a much faster decay of the FID. The
polarity of the gradient is then reversed and the spins begin to rephase; the time after which the
spins are fully phase-coherent is called the echo time TE. The amplitude of the GRE decays
with T2*, as the positive gradient does not reverse dephasing due to spin-spin interactions or
local magnetic field inhomogeneity.
Spatial encoding
During a simple MR experiment as described previously, the measured echo is the sum of all
NMR effects in the entire body. In order to generate an image, it is necessary to spatially
allocate individual MR signals. This is achieved by imposing additional gradient fields. As
the resulting spatial variations in the magnetic field lead to different Larmor frequencies at
different positions, this allows one to distinguish between MR signal at different positions in
space. Three separate gradients, Gx, Gy and Gz, are used in an MRI scanner in order to encode
each spatial dimension.
For slice selection, a gradient is applied simultaneously to the RF pulse. This gradient is called
the slice-selective gradient (GS). When the gradient is applied, the Larmor frequency becomes
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Figure 1.5.: Schematic principle of GRE generation. A negative gradient after the RF pulse
dephases the spins, which are then rephased by applying a positive gradient. The echo occurs
after echo time TE and its amplitude decays with the effective transverse relaxation time T2*.
spatially dependent, e.g. for a gradient in z-direction the frequency at position z is given by
ω = γ(B0 + z ·Gz). Consequently, the frequency of the RF pulse (ωRF) can be chosen to excite
only nuclei in a specific position along the gradient axis (see Figure 1.6(a)). The slice thickness
can be controlled by altering the bandwidth of the RF pulse or the strength of the gradient.
The three separate gradients Gx, Gy and Gz or combinations of these allow for flexible slice
orientation.
For in-plane localisation of the MR signal, two concepts are used: frequency encoding and
phase encoding (see Figure 1.6(b)). Frequency encoding involves the application of a gradient
in a direction orthogonal to the slice selection simultaneously with the echo measurement.
This gradient is called the readout or frequency-encoding gradient (GF). As a result, nuclei at
different positions along the frequency encoding direction precess with different frequencies.
The measured MR signal is a combination of all signals along the frequency-encoding axis.
In case of a simple one-dimensional image, the spatial information could then be extracted by
applying a one-dimensional Fourier transform, which decomposes the frequency spectrum into
its component signals in the frequency-encoding direction.
For the second in-plane resolution, an additional gradient (known as phase-encoding gradi-
ent GP) is applied between the RF pulse and echo. This gradient causes the spins to precess at
different speeds for a short time and, consequently, to dephase. After the gradient is switched
off, the nuclei will return to their original frequency but show phase differences depending on
their position along the phase-encoding direction. The degree of this phase shift is determined
by the duration and amplitude of GP.
1. Introduction 17
In combination with frequency encoding, the phase distribution within each frequency provides
information on the spatial origin along the phase-encoding axis. However, the phases of the
individual spins cannot be encoded from a single signal. Consequently, in order to create unique
phase- and frequency-encoded MR signals, the phase-encoding step has to be repeated after
repetition time TR with different gradient strengths for each line of the plane. All measured
signals are recorded in the frequency domain, known as k-space. A two-dimensional (2D)
Fourier transform can then be applied to convert the raw data to a 2D MR image.
Sometimes it is desirable to acquire three-dimensional (3D) images for a whole volume rather
than multiple 2D slices. This can be achieved by applying an additional phase-encoding
gradient along the third direction. The in-plane spatial encoding procedure as described above
must then be repeated for each phase-encoding step along the third dimension.
(a) Slice selection (b) Frequency and phase encoding
Figure 1.6.: Spatial encoding of the MR signal. (a) Selective excitation of a single slice by
applying a gradient at the same time as the RF pulse (schematic illustration for ωRF = ω0),
(b) in-plane locations are encoded by giving the spins a unique frequency in one direction and
a unique phase in the second direction. In order to create unique phase- and frequency-encoded
signals, the phase encoding step has to repeated with different gradient strengths for each line
of the plane.
The GRE pulse sequence and tissue contrast
A full MRI pulse sequence includes three main components: RF excitation, spatial encoding
and echo readout. Figure 1.7 illustrates a general GRE pulse sequence, which is repeated
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with different phase-encoding steps until k-space is fully sampled. The repetition time TR
can be reduced significantly by using RF pulses with small flip angles (α < 90◦). After
several RF pulses, the magnetisation reaches a steady state where the longitudinal recovery
during TR is equal to the loss of longitudinal magnetisation during the RF pulse; consequently,
the magnetisation remains the same after each RF pulse. If TR is very short (< T2), some
transverse magnetisation remains when the next RF pulse is applied. In this case, the next RF
pulse leads to rephasing of the spins and generates a spin echo. In a regularly spaced train of RF
pulses, this echo occurs at exactly the same time as the next RF pulse, so that it coincides with
the new FID signal. Since the spin echo arose from previous excitations, it may have different
spatial encoding. Consequently, remaining transverse magnetisation may cause artefacts if
left unattended. GRE sequences can generate different types of contrast, in particular images
with T1, T2*, proton density and, in some instances, T2 weighting. The contrast behaviour is
mainly determined by how the residual transverse magnetisation is dealt with, i.e. whether the
coherences between the FID and spin echoes are utilised or eliminated.
For T1W GRE imaging, which is of particular interest for DCE-MRI, the residual transverse
magnetisation is removed by gradient or RF spoiling. Hence, this technique is called incoherent
GRE or spoiled GRE. As a result of spoiling the transverse magnetisation, the signal mainly
depends on the effect of the RF pulse on the longitudinal magnetisation. The signal S measured
with a spoiled GRE sequence is given by
S = ρ
sin(α) · [1− exp(−TR/T1)] · exp(−TE/T2*)
1− cos(α) · exp(−TR/T1)
, (1.4)
where ρ denotes the proton density. The signal is highly dependent on the flip angle; the
angle that results in the highest signal for a specific T1 is called the Ernst angle and given by
αErnst = cos−1[exp(−TR/T1)]. While T1 weighting generally occurs at flip angles greater than
αErnst, it is possible to obtain proton density weighted images with smaller flip angles.
Technical components of the MRI system
The MRI system consists of three main components that are necessary for creating and meas-
uring a spatially encoded signal: (i) the main magnet, (ii) the gradient system and (iii) the RF
system. The basic setup of these components in an MRI scanner is shown in Figure 1.8.
The main magnet generates the static magnetic field in z-direction. Modern clinical MRI
systems typically use superconducting magnets with field strengths between 0.5 T and 3.0 T.
These magnets consist of superconducting wires, which have zero electrical resistance at very
low temperatures close to absolute zero. Consequently, once a current is established in the
coil, it will circulate indefinitely and no additional electrical power is required to maintain the
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Figure 1.7.: Schematic principle of a general GRE pulse sequence. A positive slice-
selective gradient GS is applied simultaneously to the RF pulse with flip angle α . The
echo is generated by the frequency-encoding gradient GF at echo time TE. A phase-encoding
gradient GP is applied between the RF pulse and echo. The sequence is repeated with a different
phase-encoding gradient after repetition time TR. A 3D volume acquisition can be achieved by
applying an additional phase-encoding gradient after the slice-selective gradient and repeating
the whole acquisition for each slice.
magnetic field. Liquid helium is used as a coolant to keep the temperature of the magnet con-
sistently low. As all magnets suffer from some non-uniformity, a process known as shimming
is used to optimise the field homogeneity by incorporating electrical coils and/or steel into the
system. Furthermore, the system is shielded in order to reduce the magnetic effect outside the
scanner as well as to prevent interference with external magnetic fields.
The gradient system includes three gradient coil arrangements for the x-, y- and z-direction.
The z-gradient is typically generated via a pair of coils with counter-rotating currents; this is
known as a Maxwell pair. In contrast, x- and y-gradients are generated through an arrangement
of four coils each (known as Golay configuration). Large electrical currents are needed for
operating the gradient coils. Hence, high-power RF amplifiers are used to supply the necessary
currents.
The RF system consists of transmit and receive coils. The transmit coil produces the RF field;
the same coil can often also act as a receive coil and detect the MR signal. A whole-body
RF coil is usually built into the scanner. However, depending on the body region to examine,
special local coils are often used in order to maximise the signal-to-noise ratio (SNR). The
transmitter generates RF pulses of specific centre frequency, bandwidth, amplitude and phase,
which need to be amplified before application. The receiver measures the MR signal, filters
and amplifies it.
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In order to control the three sub-systems and evaluate the measured signals, a high-performance
computer system is needed. In a typical MRI system, a host computer controls and monitors
the whole system. The operator defines the scan parameters on the host computer; they are
then converted into commands for hardware control by a microprocessor system. A processing
unit allows for real time signal post-processing and image reconstruction.
Figure 1.8.: Schematic illustration of a tunnel-shaped MRI system. An MRI scanner
consists of three main components: the main magnet, the gradient system and the RF system.
The gradient system consists of three gradient coil arrangements for the x-, y- and z-directions.
The system includes a whole-body RF coil; a special local (usually receive-only) coil is usually
used for imaging of the brain.
1.2.2. Principles of DCE-MRI
Disruption of the BBB can enable the extravasation of low-molecular weight contrast agents,
which can be detected using contrast-enhanced MRI. MRI signal changes caused by contrast
agent extravasation are determined by several factors, including tissue perfusion and capillary
permeability. In the brain, T1W DCE-MRI is considered to be the standard MRI approach for
assessing permeability, while T2*W dynamic susceptibility contrast MRI (DSC-MRI) is the
method of choice for perfusion imaging (Sourbron and Buckley, 2013). However, it has been
shown that DCE-MRI can combine perfusion and leakage measurements by using a sufficiently
long acquisition time with high temporal resolution early on (Larsson et al., 2009; Li et al.,
2000, 2012a; Sourbron et al., 2009).
The most commonly used agents for contrast-enhanced MRI are based on complexes of gad-
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olinium(III), an ion with strong paramagnetic susceptibility. The molecule is too large to cross
through the healthy BBB and does not enter brain cells. However, where the BBB is disrupted,
gadolinium leaks into the extravascular extracellular space (EES). A gadolinium(III) complex
has seven unpaired electrons with non-zero spin, which interact with the surrounding tissue and
cause changes in its relaxation time. Firstly, the paramagnetic ions can directly interact with
protons of water molecules in close proximity by formation or dissociation of covalent bonds.
This accelerates the transition to lower energy states (spin-lattice relaxation) and, hence, leads
to reduced T1. Secondly, the unpaired electrons create field inhomogeneities that decrease T2.
At low doses as generally used in clinical practice, T1 shortening is the dominant effect. As a
result, extravasation of contrast agent leads to reduced T1 and, hence, increased signal intensity
in T1W images. DCE-MRI exploits this T1 enhancement in order to detect and evaluate regions
of BBB disruption. The DCE-MRI procedure typically consists of intravenous injection of
contrast agent followed by the repeated acquisition of T1W images (see Figure 1.9), providing
measurements of signal enhancement as a function of time.
Figure 1.9.: Illustration of DCE-MRI in a patient with a glioma. The repeated acquisition
of T1W images after contrast agent injection allows the calculation of signal enhancement as
a function of time (middle) when compared to the pre-contrast signal intensity (left). These
curves can be used to calculate maps of quantitative tracer kinetic parameters (e.g. KTrans,
right). DCE-MRI images by courtesy of Paul Armitage; reprinted from Heye et al. (2014).
Different approaches have been used to analyse DCE-MRI data, ranging from relatively simple
visual assessment of signal enhancement curves to more complex fitting of tracer kinetic
models (see section 1.2.3). Semi-quantitative analysis usually aims at describing general char-
acteristics of the signal enhancement curve. Established measurements include, for instance,
the area under the curve and the time to maximum enhancement. Such measurements are easy
to obtain but difficult to interpret (Budde et al., 2012).
More advanced analysis often involves relating the measured signal enhancement to the con-
trast agent concentration, which requires an appropriate signal model. While early DCE-
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MRI studies assumed a linear relationship between signal enhancement and contrast uptake,
it is well known that the signal enhancement is non-linear and highly dependent on intrinsic
tissue and acquisition parameters (Armitage et al., 2005, 2011). Consequently, more complex
approaches were developed in order to control for the effect of tissue characteristics, such as the
longitudinal and transverse contrast agent relaxivities r1 and r2 and the pre-contrast longitudinal
relaxation time T10 (Armitage et al., 2005). The gold standard method for measuring T1 is a
series of inversion recovery sequences with variable inversion time TI (Larsson et al., 1988).
While this method has been shown to be very exact (Zhang et al., 1998), it requires long
imaging times to achieve a sufficient SNR, spatial resolution and coverage. Consequently, it
usually only allows for single-slice coverage. Several more time-efficient methods have been
introduced for clinical practice, for instance the Look-Locker approach (Look and Locker,
1970) and the commonly used 3D T1W spoiled GRE sequence repeated with different flip
angles (Brookes et al., 1999). While these methods allow for large spatial coverage and high
spatial resolution, they often suffer from a low SNR. Furthermore, there are several factors
that can compromise the accuracy of T1 measurements, such as blood flow artefacts and flip
angle uncertainty (Tofts, 2005). Every method for T1 measurement involves a compromise
between spatial resolution/coverage, accuracy and acquisition time; thus, the optimal method
will depend on the requirements of the specific application. Since intrinsic tissue properties
such as T1 and r1 affect the relationship between signal enhancement and contrast agent
concentration, uncertainties in these parameters propagate through to quantitative estimates
of BBB functionality. Consequently, measurement errors or the use of assumed values can
introduce significant bias in the analysis of DCE-MRI data (Armitage et al., 2011; Schabel and
Parker, 2008).
1.2.3. Quantitative analysis of DCE-MRI data
Quantitative analysis aims to provide a link between the tissue signal enhancement and physiolo-
gically relevant parameters, such as microvascular permeability, blood flow, blood volume
fraction and interstitial volume fraction. Tracer kinetic modelling was first introduced for the
analysis of DCE-MRI in the early 1990s by Brix et al. (1991), Larsson et al. (1990) and Tofts
and Kermode (1991), followed by a consensus paper on the notation (Tofts et al., 1999). Since
then, improvement of the imaging techniques (e.g. higher temporal resolution and contrast-
to-noise ratio) and a better understanding of the underlying physiology have promoted the
development of several more complex tracer kinetic models. The following sections will
provide a brief introduction to tracer kinetic modelling in DCE-MRI; detailed reviews have
been published by Sourbron and Buckley (2012, 2013) and Koh et al. (2011). A summary of
the main notations and parameters is provided in Table 1.2.
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Table 1.2.: List of the main quantities and target parameters in tracer kinetic modelling.
The parameters are generally normalised by either tissue volume or tissue mass, resulting in
different possible units.
Symbol Description Units
C(t) Contrast agent concentration in tissue mM
ca(t) Contrast agent concentration in arterial blood plasma mM
cp(t) Contrast agent concentration in capillary blood plasma mM
ce(t) Contrast agent concentration in EES mM
v Distribution volume dimensionless (ml/ml) or ml/g
J Flux mmol/min/ml or mmol/min/ml
F Clearance 1/min (ml/min/ml) or ml/min/g
R(t) Residue function dimensionless
I(t) Impulse response function 1/min (ml/min/ml) or ml/min/g
Fp Plasma flow 1/min (ml/min/ml) or ml/min/g
PS Permeability-surface area product 1/min (ml/min/ml) or ml/min/g
E Extraction fraction dimensionless (mM/mM)
KTrans Volume transfer constant 1/min (ml/min/ml) or ml/min/g
vp Fractional plasma volume dimensionless (ml/ml) or ml/g
ve Fractional interstitial volume dimensionless (ml/ml) or ml/g
General tracer kinetic theory
All tracer kinetic models are based on the general tracer kinetic theory of linear and stationary
systems (Lassen and Perl, 1979). Tracer kinetic theory describes the transport of an indicator,
such as a gadolinium based contrast agent, in a tissue sample. The tissue sample is considered
to have at least one inlet and one outlet, through which indicator is delivered and extracted.
The tissue concentration C(t) (in mM) is the amount of indicator in the tissue sample at time t
relative to the tissue volume. While C(t) is of interest in DCE-MRI because it is related to
the signal enhancement and can, thus, be measured directly, the concepts of tracer kinetic
theory are most naturally defined in terms of the local concentration c(t) (Sourbron, 2014).
The concentration c(t) is defined as the amount of indicator within the distribution volume v,





The amount of indicator that passes through an inlet per unit of time and tissue volume is
referred to as flux J. The clearance F is defined as the ratio of the flux and the concentration at
the inlet or outlet (Sourbron and Buckley, 2013), so that
J(t) = Fc(t). (1.6)
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The volume of distribution, flux and clearance are usually normalised to either the volume (in
ml) or the mass (in g) of tissue. As a result, different units can be found in the DCE-MRI
literature (both notations for all parameters are given in Table 1.2). However, brain tissue has a
density close to 1 g/ml (Barber et al., 1970), which generally makes the units interchangeable.
If not stated otherwise, all tracer kinetic parameters in this thesis will be normalised to tissue
volume; a normal tissue density of 1 g/ml is assumed when converting parameters reported
elsewhere.
According to the principle of conservation of mass, no indicator can be created or destroyed in-
side the tissue. Consequently, the change of indicator inside the tissue sample can be expressed













If the clearances F are independent of concentration c, the system is called linear; it is called
stationary if F does not depend on t. In a linear and stationary system, a solution of the




where ∗ denotes the convolution product and Ri(t) is the residue function (Sourbron and
Buckley, 2013). The residue function describes the fraction of indicator particles that entered
an inlet i at t = 0 and are still present at time t.
In most applications, the system is considered to have a single inlet, i.e. the indicator enters
the tissue sample through a single arterial vessel. In this case, the total influx is given by the






Fici(t) = Fpca(t). (1.9)
ca(t) is called the arterial input function (AIF) and generally has to be known for tracer kinetic
modelling. There are several strategies for determining the AIF (Calamante, 2013), including
the use of experimentally derived population-averaged AIFs (Parker et al., 2006; Weinmann
et al., 1984) and the simultaneous individual measurement of the AIF in a feeding vessel close
to the tissue of interest (Sourbron et al., 2009). Applying this single inlet to equation 1.8 leads
to the following expression for the tissue concentration:
C(t) = FpR(t)∗ ca(t) = I(t)∗ ca(t), (1.10)
where I(t) is the tissue-characteristic impulse response function. The aim of tracer kinetic
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modelling is to extract physiological information from the measured impulse response function.
In order to achieve this, assumptions on the distribution of indicator inside the tissue have to
be made.
Figure 1.10 displays a general tissue model with exchange of contrast agent between blood
plasma and the EES. Target parameters of tracer kinetic modelling in DCE-MRI are the frac-
tional plasma volume vp, the fractional interstitial volume ve, the plasma flow Fp and the
permeability-surface area product PS, which measures the rate at which contrast agent particles
leak out of the plasma and into the EES over an assumed surface area per unit tissue volume and
plasma concentration. An important physiological parameter that is widely reported in DCE-
MRI studies is the volume transfer constant KTrans, which is the rate at which contrast agent is
delivered to the EES per volume of tissue and contrast agent concentration in the arterial blood
plasma. While the terms PS and KTrans are sometimes used interchangeably in the literature,
PS represents the clearance for contrast agent leaking from the capillary plasma into the EES,
i.e. the flux of contrast agent across an assumed surface area of the BBB normalised to the
tissue plasma concentration and tissue volume. In contrast, KTrans (as implicitly defined by
Tofts et al., 1999), is the contrast clearance normalised to the arterial plasma concentration
and therefore depends on the plasma flow Fp supplying the capillaries in addition to PS (the
mathematical form of this relationship is model-dependent). KTrans is necessarily equal to the
product of plasma flow Fp and the extraction fraction E (i.e. the fraction of contrast agent
molecules that leak into the EES).
Figure 1.10.: Schematic illustration of a generic tissue model. The exchange between the
EES (volume fraction ve) and capillary blood plasma (volume fraction vp) is determined by




The general tissue architecture presented in Figure 1.10 is usually modelled as a single space or
a system of several spaces. A complete model for vascular-interstitial exchange can be formed
with two spaces: the blood plasma and the EES. There are different approaches to modelling
each of these two spaces: the blood plasma can be modelled as a well-mixed compartment,
i.e. a region where the contrast agent concentration is spatially uniform, or as a plug-flow
system, i.e. a region of flow with a constant velocity. Similarly, the interstitium can be modelled
as well-mixed compartment or a distributed system, which assumes instant contrast transport
perpendicular to the capillary. A complete model for vascular-interstitial exchange can be
formed by combining two models for the blood plasma and the EES, leading to four different
possible models. A detailed overview of the different tissue models has been provided by
Sourbron and Buckley (2013); this thesis will focus on models that consider both the blood-
plasma and the EES to be well-mixed compartments, because they are the most commonly
used in DCE-MRI of the brain.
In multi-compartment models, the total tissue concentration consists of contributions of each
subspace, so that the tissue concentration C(t) is given by
C(t) = vpcp(t)+ vece(t), (1.11)
where cp(t) is the concentration of indicator in the capillary plasma space and ce(t) the inter-
stitial indicator concentration. The principle of conservation of indicator mass (equation 1.7)
must be fulfilled for each subspace, resulting in a system of differential equations. The only
well-mixed compartment model that allows for the estimation of all four target parameters
(Fp, PS, vp and ve) and has been applied in brain DCE-MRI is the two-compartment exchange
model (2CXM) (Sourbron and Buckley, 2013). In many situations, it is not possible to measure
all four parameters reliably. Hence, several simpler models have been proposed, which con-
strain the general four-parameter model to specific situations. Figure 1.11 shows an overview
of the constrained models that can be derived from the 2CXM. The following section will
present the compartment models most commonly used for DCE-MRI of the brain.
The conventional Tofts model (Tofts and Kermode, 1991) considers bidirectional flux of tracer
between the two blood plasma and EES compartments with the volume transfer constant KTrans.
The plasma compartment is assumed to have negligible volume (vp ≈ 0), which makes the
conventional Tofts model a one-compartment model for weakly vascularised tissues. The
impulse response function is given by
I(t) = KTrans exp(−tKTrans/ve), (1.12)
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In a permeability-limited situation, i.e. Fp PS, KTrans equals PS; in a flow-limited situation,
i.e. Fp PS, KTrans represents Fp.
Tofts et al. extended their classic model by introducing the blood plasma as a second well-
mixed compartment (Tofts et al., 1999); this model is known as the modified Tofts model. In
addition to the two parameters KTrans and ve, the model allows for vp to be estimated and, hence,










The tissue is assumed to be highly perfused, i.e. Fp = ∞, which means that the entire blood
pool is well-mixed so that cp(t) = ca(t). If the model fits the data well with a non-negligible vp
value, then the system is permeability-limited with KTrans = PS (Sourbron and Buckley, 2013).
The impulse response function is given by
I(t) = vpδ (t)+KTrans exp(−tKTrans/ve). (1.15)
Finally, the Patlak model (Patlak et al., 1983) also describes a highly perfused two-compartment
tissue but considers unidirectional transport from the blood plasma into the EES. It can be seen
as a special case of the modified Tofts model that ignores backflux from the EES into the blood.
The impulse response function is reduced to
I(t) = vpδ (t)+KTrans. (1.16)





When first introducing this approach, Patlak and colleagues proposed a linear graphical ana-
lysis method, which is often used as it permits simple and fast fitting. In this analysis, the ratio
C(t)/ca(t) is regressed against
∫ t
0 ca(τ)dτ/ca(t), yielding a straight line with slope K
Trans and
y-intercept vp.
It should be noted that all tracer kinetic models paint a significantly simplified picture of the true
complex biological system. The simpler the model, the greater is the amount of assumptions
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regarding tissue structure and the transport of blood plasma and contrast agent. This over-
simplification can lead to bias in the estimated physiological parameters. For example, all
models discussed here assume that the water exchange between the vascular, EES and intra-
cellular compartments is in the fast-exchange limit, i.e. that the tissue relaxes with a single
T1 (Sourbron and Buckley, 2011). However, transendothelial water exchange is likely to
be limited in brain tissues with largely intact BBB. Violation of this assumption can lead to
systematic errors in estimates of contrast agent concentrations and tracer kinetic parameters
(Bains et al., 2010; Larsson et al., 2001). While it is tempting to apply a model accounting
for as many biological processes as possible, the resulting high number of free parameters can
lead to estimates with low accuracy and precision. Instead, the optimum model depends on
both the nature of the tissue and the acquisition protocol employed (Sourbron and Buckley,
2013; Ewing and Bagher-Ebadian, 2013).
1.3. Challenges of DCE-MRI in cerebral SVD
Historically, DCE-MRI has been mainly applied in body tissues without BBB or the assessment
of diseases that show relatively large abnormalities in BBB functionality, such as brain tumours
and acute ischaemic strokes. Only recently has there been growing interest in the application
of DCE-MRI to pathologies associated with subtle BBB disruption, such as diabetes and
Alzheimer’s disease (Starr et al., 2003, 2009). In cerebral SVD, observed signal enhancement
in normal-appearing tissue and lesions is of the order of only a few percent. This subtle nature
of the process poses various challenges for the imaging procedure and data analysis:
1. Although there is a variety of approaches for the analysis of DCE-MRI data, these have
mostly been developed for oncology applications, where vessel density and permeability
are typically high. The optimal approach for research in cerebral SVD is unclear. In
addition to very low target levels of BBB dysfunction, DCE-MRI in SVD is likely to
suffer from compromised temporal resolution, as the diffuse nature of the disease makes
a high spatial coverage and resolution desirable. Hence, it needs to be examined whether
tracer kinetic modelling is suitable and yields valid results in this situation.
2. The small DCE-MRI changes linked to subtle BBB breakdown are particularly suscept-
ible to sources of error, such as uncertainty in relaxation times and contrast agent relax-
ivities. Moreover, low-level DCE-MRI measurements may be susceptible to influences
by secondary processes, such as random noise, scanner drift or partial volume effect
(Armitage et al., 2011). In order to enable reliable quantification of BBB integrity, it
needs to be investigated to what extent the measured changes in DCE-MRI parameters
are influenced by mechanisms other than BBB disruption.
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3. Measurements of BBB disruption are most likely dependent on details of the acquisition
protocol (e.g. type and dose of contrast agent, field strength, MRI pulse sequence),
especially when looking at subtle abnormalities. Therefore, it is important to critically
review clinical results and explore inter-study comparability.
Although there is growing interest in the application of DCE-MRI for the measurement of low-
level BBB disruption as related to ageing and SVD, only very few groups have investigated the
optimum methodology and reliability of resulting quantitative parameters. Consequently, there
is a need for substantially more work to determine the optimum acquisition strategy and data
analysis methods.
1.4. Aims and outline of the thesis
The work described in this thesis aims to assess and improve the methodology of DCE-MRI
measurements in cerebral SVD and, thus, move closer towards reliable quantification of subtle
BBB abnormalities. In addition to developing and assessing methods, this thesis also aims to
investigate the role of BBB disruption and other MR imaging markers in cerebral SVD, by
applying the methodology to a large clinical cohort of mild stroke patients. Reliable estimation
of low-level BBB disruption can help to illuminate the role of endothelial failure in cerebral
SVD, which may ultimately offer possibilities for early treatment and prevent severe outcomes
such as strokes and dementia. This thesis is organised in five parts, which are further divided
into different chapters. The following sections will present the specific aims and key contents
of the subsequent eight chapters of this thesis.
Part I introduces the fundamental concepts that the work in this thesis is based on and gives a
summary of DCE-MRI methods. This part has one further chapter:
Chapter 2 aims to provide an overview of applications, scanning protocols and data analysis meth-
ods used in DCE-MRI of the brain. A systematic literature review is performed, including all studies
that assessed BBB integrity using T1W DCE-MRI techniques in animals and humans in normal or
abnormal brain tissues.
Part II focuses on the analysis of DCE-MRI data acquired within the scope of an on-site
clinical study of mild stroke patients.
Chapter 3 introduces the patient cohort, study procedures and image processing methods. Further-
more, this chapter aims to investigate some basic aspects of DCE-MRI analysis processes, such as
AIF measurement and tracer concentration calculation.
Chapter 4 aims to determine the tracer kinetic model most suitable for analysis of the clinical data
presented in chapter 3 and provides quantitative DCE-MRI parameters for normal-appearing tissues
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and brain lesions. Moreover, this chapter tests the robustness of the model to its assumptions using
simulations.
Part III investigates two potential pitfalls in the quantification of subtle BBB disruption.
Chapter 5 aims to investigate instrumental/physiological drift and its influence on tracer kinetic
parameters. Signal drift is assessed in healthy volunteers, and its effect on quantitative parameters is
modelled using computer simulations.
Chapter 6 aims to analyse an external DCE-MRI data set and to compare the results to the findings
in the MSSII cohort. This chapter also discusses issues concerning inter-study comparability and
study design, which arise from this work.
Part IV examines the relationship between MRI parameters and clinical measurements in the
large cohort of mild stroke patients.
Chapter 7 focuses on statistical analyses of the DCE-MRI parameters obtained in chapter 4. The
main purpose of this chapter is to investigate the relationship between measurements of BBB leakage
and cerebral blood volume with clinical characteristics, SVD imaging markers and disease progres-
sion.
Chapter 8 presents work that was performed within the wider scope of our on-site clinical study of
mild stroke patients; this work aims to investigate the association between MR imaging findings in
cerebral SVD and blood pressure, dietary salt intake and plasma sodium concentration.
Part V provides final conclusions and perspectives.
Chapter 9 summarises the main findings and outlines the contributions that this work has made to
the field. In addition, this chapter highlights limitations of the work presented in this thesis and
suggests avenues for future research.
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Figure 1.11.: Overview of compartment models for DCE-MRI. Schematic drawings of
the 2CXM and derived simpler models with their assumptions (according to review by
Sourbron and Buckley, 2013). Target parameters: plasma flow Fp, permeability-surface area




2. Assessment of blood-brain barrier
disruption using dynamic
contrast-enhanced magnetic resonance
imaging: a systematic literature review
This chapter aims to provide an overview of applications, scanning protocols and data analysis
methods used in dynamic-contrast enhanced magnetic resonance imaging (DCE-MRI) of the
brain. A previous version of this literature review has been published in Heye et al. (2014).
2.1. Introduction
DCE-MRI has been used to study pathological changes of blood-brain barrier (BBB) function-
ality in a large variety of diseases. However, there is no standard approach of measuring and
analysing DCE-MRI data: studies differ widely in their MR imaging procedures and several
methods for analysing the data are available, ranging from relatively simple non-model based
methods to several tracer kinetic models. DCE-MRI has been mainly applied in body tissues
without BBB and in diseases with large abnormalities in BBB functionality. Consequently,
most previous literature reviews have focused on specific applications such as oncology (Barnes
et al., 2012; Bergamino et al., 2014; Jain, 2013; Türkbey et al., 2010). Only recently has there
been growing interest in the application of DCE-MRI to pathologies associated with subtle
BBB disruption, and there are no literature reviews that cover the application of DCE-MRI in
ageing, microvascular disease or dementia.
The aim of this systematic literature review was to provide an overview of all applications and
imaging procedures used in DCE-MRI of the brain. Furthermore, the purpose of this work
was to identify the most commonly used methods for data analysis and to provide an overview
of the resulting parameter ranges for pathological and normal-appearing tissues. Finally, this
review aimed to investigate studies that have attempted to measure subtle BBB changes and to
assess whether their approaches differ from the ones used in other applications.
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2.2. Methods
2.2.1. Search strategy
The existing literature was systematically reviewed up to May 2015 by performing an electronic
search in PubMed, EMBASE, MEDLINE and Web of Knowledge databases. Multiple combin-
ations of the following search terms were used: ‘permeability’, ‘brain’, ‘blood-brain barrier’,
‘MRI’, ‘dynamic’, ‘DCE-MRI’ and ‘contrast enhancement’. English as well as non-English
literature was sought. Ross D Culling, a medical student at the University of Edinburgh,
performed the initial literature search, removed duplicates and screened all papers’ titles and
abstracts in order to identify those relevant for full assessment. The electronic search was
supplemented by hand searching the reference lists of review papers. Before final inclusion or
exclusion of studies, the full text of all selected articles was read and the relevant data extracted.
Disagreements between reviewers about inclusion or exclusion of papers were resolved through
discussion with Dr Maria del C Valdés Hernández. Dr Michael J Thrippleton, Dr Maria del C
Valdés Hernández and Prof Joanna M Wardlaw complemented the search and assisted with
the data analysis. The original systematic literature search included articles published up to
February 2014; in order to update the review, an additional manual search was performed in
May 2015.
2.2.2. Eligibility criteria
This literature review focuses on studies which assessed BBB integrity using DCE-MRI tech-
niques. Studies on humans and animals were included in all diseases known or thought to affect
BBB function. Consequently, other applications of DCE-MRI such as breast or prostate cancer
as well as publications that focus on theoretical aspects of image processing or modelling
without testing them in a clinical setting (e.g. Gal et al., 2008) were excluded. Furthermore,
only primary research articles available as full-text were accepted; however, review articles
were checked for additional primary references.
Studies using dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI), non-
MRI methods or non-dynamic MRI methods, which are not generally quantitative, were ex-
cluded from this review. The literature search yielded several papers that focused on therapeutic
BBB disruption for novel anti-cancer drugs. Since these mainly addressed pharmaceutical or
technical aspects of the disruption method on a molecular level, these studies were rejected.
An excellent review on DCE-MRI in clinical trials of antivascular therapies has been published
by O’Connor et al. (2012). However, studies that focused on the clinical effect of treatment
strategies and its link with BBB disruption were included if they provided baseline DCE-MRI
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parameters. Moreover, single case reports and articles in which substantial information about
the MRI procedure or the data analysis was lacking were rejected.
2.2.3. Data extraction and analysis
Relevant data were extracted from each included study. Information was cross-checked with
preliminary data that had previously been extracted by Ross D Culling. Extracted data included
the studied disease or pathology, sample size and subjects’ ages (in the case of human studies).
Moreover, details of the DCE-MRI protocol were extracted, including scanner field strength,
MRI sequence with repetition time TR, echo time TE, flip angle, field of view (FoV), matrix
size, slice thickness, overall duration and temporal resolution. Extracted data also included the
type and dose of contrast agent. Furthermore, it was noted whether post-processing techniques
were applied prior to data analysis, the analysis method used and the tissues/locations analysed.
Where given, quantitative measurements were extracted. Additionally, the main study purpose
and the overall conclusion of the study were summarised.
2.3. Results
2.3.1. Systematic literature search results
The electronic search yielded 829 results, 31 of which were in non-English languages. After
removing duplicates, 352 publications were further analysed for inclusion. After scanning
abstracts and titles, studies using non-dynamic and non-MRI methods were excluded (n= 179).
In addition, review papers (n = 46), technical protocols (n = 2) and DSC-MRI studies (n = 38)
were rejected, leaving 87 articles for full-text assessment. At this stage, 29 studies were
identified as not being relevant to the focus of this review. Moreover, conference abstracts
that were not detailed enough for full data extraction and that had not subsequently been
published in full (n = 8), single-case reports and publications with missing information on
the imaging methodology (n = 2) and publications that were based on previously published
data (n = 1) were excluded. In addition to the resulting 47 relevant DCE-MRI studies, 23
relevant articles were identified by hand searching the bibliographies of review papers. Overall,
the full literature search to February 2014 provided 70 DCE-MRI studies that were eligible
for inclusion in this review. The search was manually updated in May 2015, yielding 10
relevant publications that had been missed previously and 15 relevant papers published between
February 2014 and May 2015 (see Figure 2.1).
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Figure 2.1.: Flow diagram summarising the literature search and inclusion process.
Previous version published in Heye et al. (2014).
2.3.2. Study characteristics
Subjects and sample sizes
Table 2.1 summarises the main study sample characteristics and scanning protocols related to
each pathology. Of the 95 included studies, 24 used animals (i.e. rodents, apart from two studies
of dogs (Su et al., 1998; Li et al., 2014) and one of rabbits (Wei et al., 2011)). The sample size
was not made available in one of these publications (Ewing et al., 2003). The mean sample size
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of the remaining animal studies was 21 animals, with a total number of 495 animals (including
19 healthy controls; 447/495 were rodents). The largest included study involved 113 rats (Abo-
Ramadan et al., 2009), whereas seven studies used a sample size smaller than 10 (Chwang et al.,
2014; Ferrier et al., 2007; Hormuth et al., 2014; Lee et al., 2014; Li et al., 2010, 2014; Skinner
et al., 2012).
The remaining 71 studies were in humans, including 2295 subjects in total (235 of which were
healthy controls). Although duplicate publications that were undoubtedly based on the same
data were excluded, it should be noted that some of the included studies were performed by the
same research group and, thus, might share some patient data; consequently, the total number
of individual patients is likely to be smaller than stated above. The mean sample size for
human studies was 32. Only two studies involved more than 100 subjects (Haris et al., 2008a;
Sahoo et al., 2013) and seven studies were based on fewer than 10 humans (Jelescu et al., 2011;
Larsson et al., 1990; Kermode et al., 1990; Kleppestøet al., 2014; Li et al., 2012a; Thompson
et al., 2012; Vidarsson et al., 2009). Information regarding patient age was not provided in eight
of the 71 studies (Aksoy et al., 2013; Awasthi et al., 2012; Larsson et al., 1990, 2014; Li et al.,
2000, 2012a; Miyati et al., 1997; Sourbron et al., 2009). A further eight publications stated
only the age range of the study subjects (Bagher-Ebadian et al., 2012; Gupta et al., 2012; Haris
et al., 2008b; Kassner et al., 2005; Manuchehri et al., 2007; Roberts et al., 2000; Vidarsson
et al., 2009; Sahoo et al., 2013). Mean age as stated in the remaining 55 human studies was
highly dependent on the studied pathology, ranging between 9 years (paediatric brain tumours,
Thompson et al., 2012) and 74 years (mild cognitive impairment, Wang et al., 2006).
A complete list of included publications and their main characteristics is provided in the
appendix (Table A.1).
Pathologies studied
The majority of animal studies concerned intracranial neoplasms (Ali et al., 2010; Aryal et al.,
2014; Budde et al., 2012; Chwang et al., 2014; Engelhorn et al., 2013; Ferrier et al., 2007;
Hoff et al., 2012; Hormuth et al., 2014; Krueck et al., 1994; Li et al., 2010; Nagaraja et al.,
2013; Quarles et al., 2012; Skinner et al., 2012) including a total of 215/495 animals. Five
publications investigated changes in the BBB caused by induced focal cerebral ischaemia
in 154/495 animals overall (Abo-Ramadan et al., 2009; Ewing et al., 2003; Durukan et al.,
2009; Nagaraja et al., 2010; Taheri et al., 2009). Moreover, two studies focused on traumatic
head injuries (Li et al., 2014; Wei et al., 2011) and one study each investigated the influence
of pneumococcal meningitis (Brandt et al., 2008), normal ageing (Su et al., 1998) or zinc
deficiency (Noseworthy and Bray, 2000) on the BBB.
38 2. BBB assessment using DCE-MRI: literature review
The pathology most studied in humans was intracranial neoplasms (43 publications, 1266/2295
subjects), including primary brain tumours and brain metastases. 12 studies investigated changes
in BBB integrity caused by stroke and/or cerebrovascular disease (Aksoy et al., 2013; Armitage
et al., 2011; Hanyu et al., 2002; Kassner et al., 2005, 2009; Taheri et al., 2011a,b; Thornhill
et al., 2010; Topakian et al., 2010; Vidarsson et al., 2009; Wardlaw et al., 2008, 2009) with
a total of 506/2295 subjects. 11 studies focused on multiple sclerosis (MS) (Cramer et al.,
2014; Cramer and Larsson, 2014; Gaitán et al., 2011; Ingrisch et al., 2012; Jelescu et al.,
2011; Kermode et al., 1990; Larsson et al., 1990; Leppert et al., 2014; Montagne et al., 2015;
Shinohara et al., 2011; Taheri et al., 2011b) including a total of 270/2295 subjects. Six articles
investigated changes of the BBB related to normal ageing (Montagne et al., 2015), mild cog-
nitive impairment (Montagne et al., 2015; Wang et al., 2006) or dementia (Hanyu et al., 2002;
Starr et al., 2009; Taheri et al., 2011b; Wahlund and Bronge, 2000). Other studied pathologies
included brain tuberculomas (Haris et al., 2008b; Singh et al., 2007), optic neuritis (Cramer
and Larsson, 2014), infective brain lesions (Haris et al., 2008a), multiple system atrophy (Song
et al., 2011), diabetes (Starr et al., 2003) and neurocysticercosis (Gupta et al., 2012).
2.3.3. MRI procedures
Scanning techniques
The majority of human studies (41/71) were performed with a magnetic field strength of 1.5 T,
while 29 studies used a 3 T scanner; one study each was performed using a 0.5 T (Kermode
et al., 1990) and a 1.9 T scanner (Starr et al., 2003). A wider range of magnetic field strengths
from 1.5 T (Krueck et al., 1994; Su et al., 1998) to 11.75 T (Li et al., 2010) were found in
animal studies, with the majority of studies using 4.7 T or 7 T scanners. Two studies did not
provide this information (Li et al., 2012a; Wei et al., 2011). Sahoo et al. (2013) compared DCE-
MRI results from a 1.5 T and a 3 T scanner; while they found differences in the average tracer
kinetic parameter values, the scanners performed equally well in classifying glioma grades.
The MRI pulse sequence types used are summarised in Figure 2.2(a). Most DCE-MRI ac-
quisitions were based on gradient echo (GRE) sequences (79/95 studies), with spoiled GRE
techniques being the most common. Further protocols include seven spin echo methods (Hanyu
et al., 2002; Kermode et al., 1990; Krueck et al., 1994; Larsson et al., 1990; Su et al., 1998;
Noseworthy and Bray, 2000; Wahlund and Bronge, 2000) and five unspecified T1-weighted
(T1W) imaging sequences (Ahn et al., 2014; Choi et al., 2013; Farjam et al., 2014; Song
et al., 2011; Starr et al., 2003). In addition, five studies used DCE-MRI methods that consist
of repeated T1 measurements (Ewing et al., 2003; Nagaraja et al., 2010; Taheri et al., 2009,
2011a,b).
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A complete list of the imaging procedures applied in the included studies is provided in the
appendix (Table A.2), and also provides information about the spatial resolution and coverage.
While some studies apply DCE-MRI methods with whole-brain coverage (e.g. Harrer et al.,
2004; Ingrisch et al., 2012; Topakian et al., 2010; Wardlaw et al., 2009), most studies only
image a limited FoV with a few slices (e.g. Cramer et al., 2014; Ewing et al., 2003; Larsen
et al., 2013; Sourbron et al., 2009) or one single slice (e.g. Abo-Ramadan et al., 2009; Durukan
et al., 2009; Lüdemann et al., 2000; Quarles et al., 2012), with slice thicknesses ranging from
1 mm to 8 mm.
Contrast agent and dose
The type and dose of contrast agents used in the included publications are shown in Fig-
ure 2.2(a). Information about the type and dose of contrast agent was not given in one study
(Lee et al., 2014). In most studies, the contrast agent used was Gd-DTPA (gadopentetate
dimeglumine, 53/95 studies) or its variants Gd-DTPA-BMA (gadodiamide, 19/95 studies),
Gd-BT-DO3A (gadobutrol, 16/95 studies) or Gd-DOTA (gadoterate meglumine, 3/95 studies),
given as an intravenous bolus injection. Single studies employed different gadolinium-based
agents such as Gd-BOPTA (gadobentate-dimeglumine) (Montagne et al., 2015), gadoteridol
(Thompson et al., 2012), gadofosveset (Chwang et al., 2014) and albumin-labelled Gd-DTPA
(Ali et al., 2010). Chwang et al. (2014) compared two different contrast agents (Gd-DTPA
and gadofosveset) in nine glioma-bearing rats; they found that the resulting mean estimates
of KTrans were significantly different, but highly correlated.
In 46/95 studies, the contrast agent was given in the standard dose (0.03 mmol/kg body weight
for gadofosveset, 0.1 mmol/kg for all others). However, delivered doses ranged from a fifth
(Awasthi et al., 2012) to fivefold (Abo-Ramadan et al., 2009; Brandt et al., 2008; Durukan
et al., 2009) of the recommended dose. 10 studies delivered a fixed quantity of contrast agent,
ranging between 7.5 mmol (Kassner et al., 2009; Thornhill et al., 2010; Vidarsson et al., 2009)
and 20 mmol (Armitage et al., 2011; Wardlaw et al., 2008, 2009) in humans. We did not
find any study that investigated the influence of different contrast agent concentrations, though
Abo-Ramadan et al. state that different doses lead to an increase or decrease in signal-to-noise
ratio (SNR) (Abo-Ramadan et al., 2009).
Duration and temporal resolution of DCE-MRI
The duration of data collection following contrast injection varied widely with values from
1.5 min (Shin et al., 2014) to 155 min (Shinohara et al., 2011). The median DCE-MRI imaging
durations (not stated in seven publications, Bergamino et al., 2013; Brandt et al., 2008; Chu
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et al., 2012; Engelhorn et al., 2013; Larsson et al., 1990; Li et al., 2010; Provenzale et al., 2006)
according to pathology studied are shown in Table 2.1, together with the median temporal
resolution (not stated in five publications, Bergamino et al., 2013; Brandt et al., 2008; Chu
et al., 2012; Engelhorn et al., 2013; Provenzale et al., 2006). The highest temporal resolution
of 1 s was found in tumour studies (Larsson et al., 2009; Quarles et al., 2012), whereas one
study on diabetes used the longest intervals, in the range of 10 min to 30 min (Starr et al.,
2003). Vidarsson et al. (2009), Larsson et al. (2013) and Cramer et al. (2014) investigated
the influence of the temporal resolution and/or overall scan time on the quantification of BBB
disruption. In both clinical data and simulation studies, they found that reducing the overall
scanning time and sampling with a lower temporal resolution result in increased uncertainty of
the tracer kinetic parameters.
As shown in Table 2.1, the overall scanning duration and the temporal resolution varied sig-
nificantly between applications. In general, the highest temporal resolution was used in brain
tumours. This is necessary to measure the fast kinetics typically seen in malignant neoplasms,
but may limit spatial resolution and coverage. Conversely, studies that assess tissues with slow
leakage rates (e.g. healthy appearing tissue in MS patients, ageing or dementia) often used
lower temporal resolutions that allow for better spatial resolution and coverage. In order to
combine the advantages of both approaches, Jelescu et al. (2011) and Li et al. (2012a) presented
a dual temporal resolution scanning method with high temporal resolution during the bolus first
pass and high spatial resolution during the later phase. A similar approach was later used by
Leppert et al. (2014).
2.3.4. Data processing and analysis
Use of post-processing techniques
56 of the 95 included studies (59%) did not report the use or method of image post-processing.
The most commonly used technique reported was image registration, aligning the DCE-MRI
images to a pre-contrast acquisition and/or anatomic images, in order to remove patient move-
ment (32/95 studies). Several studies reported a lack of precision of quantitative values due
to limited spatial resolution or poor SNR (Cha et al., 2006; Ferrier et al., 2007; Gaitán et al.,
2011; Kassner et al., 2009), but only five studies report the use of image processing techniques
for noise reduction, including Gaussian smoothing (Lüdemann et al., 2009), Kalman filtering
(Taheri et al., 2011a,b), unspecified smoothing of the signal enhancement curves (Ferl et al.,
2010) and ‘removing and compensation of noisy time points’ (Artzi et al., 2015).
An additional confounding factor is signal drift, which was mentioned in four studies. Cramer
et al. (2014) reported a signal drift of 1% to 3% over 15 min in healthy volunteers without
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(a) MRI sequence and contrast agent/dose (b) Data analysis methods
Figure 2.2.: Overview of methods used in the included studies. (a) MRI sequences, contrast
agents and contrast doses used in the included studies. The bar height indicates the number of
studies using a particular method, subdivided by pathology, (b) data analysis methods used
in the included studies. Numbers indicate the count of studies using the particular tracer
kinetic model (in blue-green colours) and model-free method (in yellow-red colours). Please
note that some studies applied more than one approach and/or investigated more than one
pathology; consequently, the numbers do not add up to the 95 included studies. Previous
versions published in Heye et al. (2014).
contrast administration. Armitage et al. (2011) recommend that studies should investigate and
if necessary correct for scanner drift in order to prevent systematic errors. However, only two
studies corrected DCE-MRI data for scanner signal intensity drift using phantom or healthy
volunteer measurements (Starr et al., 2003; Topakian et al., 2010).
Data analysis methods and tracer kinetic models
A wide variety of approaches to data analysis were used in the included studies (Figure 2.2(b)).
The most simple analysis method was the visual assessment of spatiotemporal enhancement
patterns in MS lesions (Gaitán et al., 2011; Kermode et al., 1990; Shinohara et al., 2011).
Model-free analysis was most commonly based on the calculation of semi-quantitative para-
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meters from the signal enhancement curves (Brandt et al., 2008; Mills et al., 2009; Miyati
et al., 1997; Provenzale et al., 2006; Starr et al., 2003, 2009; Topakian et al., 2010; Wang et al.,
2006; Wardlaw et al., 2008, 2009; Wilkinson et al., 2006), contrast agent concentration curves
(Armitage et al., 2011; Budde et al., 2012; Shin et al., 2014) or T1 changes over time (Hanyu
et al., 2002; Wahlund and Bronge, 2000). Further model-free analysis approaches included
model-free deconvolution (Awasthi et al., 2012; Cramer et al., 2014; Cramer and Larsson,
2014; Ferl et al., 2010; Gupta et al., 2012; Haris et al., 2008a,b,c; Larsen et al., 2013; Larsson
et al., 2009; Roy et al., 2013; Singh et al., 2007), principal component analysis (Farjam et al.,
2014) and the fitting of empirical functions (i.e. mathematical functions that do not aim to
model the tissue physiology, Bergamino et al., 2015).
The majority of included studies used tracer kinetic models for the DCE-MRI analysis. The
most commonly used tracer kinetic models were the conventional Tofts model (21/95 studies),
the modified Tofts model (29/95 studies) and the Patlak model (26/95 studies, including a
simplified version of the Patlak model as introduced by Shames et al. (1993) and Iannotti
et al. (1987). Table 2.2 summarises the range of KTrans estimates for different tissue types and
tracer kinetic models as reported in the included publications (a complete list can be found in
Table A.3 in the appendix). Other modelling approaches included an arterial input function
(AIF) free reference region model introduced by Yankeelov et al. (2005), which was applied
to tumours in three studies (Lee et al., 2014; Quarles et al., 2012; Skinner et al., 2012). In
addition, several studies aimed primarily at introducing a new method for data analysis or
comparing different approaches; these will be briefly presented below.
A non-parametric method for evaluating DCE-MRI in n = 16 glioma patients was presented by
Ferl et al. (2010), who showed that their resulting parameters closely approximate the conven-
tional Tofts model parameters. Li et al. (2000) introduced a variant of the conventional Tofts
model that only considers the first pass of the contrast bolus. They evaluated this method in
n= 11 patients with primary brain neoplasms, finding that the results were visually comparable
with those of the conventional Tofts model but less noisy and less susceptible to large vessel
contributions. Harrer et al. (2004) evaluated the same model in n = 18 patients with high-grade
gliomas, reporting a good correlation with the modified Tofts model but no correlation with
the conventional Tofts method, though it should be noted that the AIF used differed between
the models due to software limitations. Values obtained with the conventional Tofts model
were considerably higher, indicating an overestimation of quantitative parameters due to vessel
contributions. Sahoo et al. (2013) introduced a variant of the modified Tofts model, which
includes an additional tissue uptake leakage compartment. When tested in n = 184 glioma
patients, they found that the resulting parameter estimates were significantly different from the
ones obtained with the modified Tofts model, and less sensitive to changes in the acquisition
time. Li et al. (2010) considered the effect of water exchange, finding the Patlak model
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to significantly underestimate the fractional blood volume when compared to their three-site
equilibrium shutter-speed model. Lüdemann et al. (2000, 2002, 2009) introduced a modified
two-compartment exchange model (2CXM), which includes two extravascular extracellular
space (EES) compartments (one in slow and one in fast exchange with the blood compartment),
but did not compare it to conventional models. Bergamino et al. (2013) compared the Patlak
and modified Tofts model in n = 25 tumour patients. Although the two models resulted in sig-
nificantly different parameter estimates in high-grade tumours, the authors did not investigate
the model validity and/or accuracy but concluded that both methods are feasible (Bergamino
et al., 2013).
Sourbron et al. (2009) used a set of two-compartment models for the analysis of DCE-MRI
in the brain, including the 2CXM and two-compartment uptake model (2CUM). The approach
was evaluated in n = 15 brain tumour patients, showing that the 2CXM provided accurate
perfusion and permeability estimates in tumour tissue, while the 2CUM is sufficient to describe
the tracer kinetics in healthy tissues. Larsson et al. (2009) used simulated data in order to
investigate the accuracy of the 2CXM and the Patlak model. In agreement with Sourbron’s
results, they found that the 2CXM provides more accurate results for high KTrans values,
whereas the Patlak method is appropriate for low values of KTrans. These findings were also
confirmed by Cramer and Larsson (2014) and Barnes et al. (2015) in simulated data, suggesting
the use of the Patlak model for measurement of low permeability and the 2CXM for high
permeability.
Acknowledging the need for different models when investigating heterogeneous tissues, Bagher-
Ebadian et al. (2012) presented a method for quantifying BBB disruption in glioma patients
based on a voxel-by-voxel selection from a set of nested models: the most complex model
with three parameters was required to fit the data in regions of aggressive tumour growth,
while simpler models predominated in less aggressive tumour portions and in healthy tissues.
This method has since been applied by several other groups (Artzi et al., 2015; Chwang et al.,
2014; Li et al., 2014; Nagaraja et al., 2013). Similarly, Ingrisch et al. (2012) investigated BBB
disruption in MS patients using automatic model selection from the modified Tofts model,
2CUM and 2CXM on a region of interest (ROI) level.
2.3.5. Clinical findings
Pronounced, localised BBB changes with disease
Most studies focused on diseases that cause brain lesions with pronounced BBB disruption,
resulting in visible localised contrast enhancement on T1W images. For instance, studies
showed significant differences in BBB integrity between healthy tissue and acute ischaemic
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Table 2.2.: Overview of KTrans values reported for different tissue types and tracer
kinetic models. Given values are the range of cohort averages as reported in the included
articles. Where necessary, units were converted assuming unity tissue density and values
were transferred from whole blood to blood plasma notation assuming a haematocrit of 0.45.
Please note that some subjects included in these studies (e.g. high grade glioma patients)
underwent treatment before entering the study. Hence, the reported baseline parameters might
be influenced by interventions that were not the focus in the study. It should also be noted
that these values were obtained in different cohorts and with different methods and, hence, are
difficult to compare directly; a complete list, including studies that compared different models
in the same cohort, can be found in Table A.3 in the appendix.






White matter 0.04 to 16.00 0.04 to 0.44 −0.03 to 0.05
Grey matter 0.05 0.03 to 0.50 −0.01 to 0.06
Mixed tissue types 0.00 to 4.30 0.30 to 3.10 −0.24 to 6.20
Tumour tissues
Gliomas −0.20 to 136.00 0.10 to 83.00 0.19 to 6.04 0.70 to 109.00
Brain metastases 13.00 38.00
Brain lymphomas 44.00
Meningeomas 27.80 to 47.00
Schwannomas 22.80 8.30
Mixed tumour types 25.00 34.00
Stroke lesions
Ischaemic strokes −0.12 to 3.10
Hemmorrhagic strokes 5.50
MS lesions 9.24 3.53
Tuberculomas 204.00 to 281.00
Traumatic injuries 0.40 to 4.90
Infective lesions 210.00
Neurocysticercosis 2.00 to 5.00
stroke lesions (Abo-Ramadan et al., 2009), brain metastases (Budde et al., 2012) and enhancing
MS lesions (Ingrisch et al., 2012). In such diseases, DCE-MRI has been shown to be useful
for distinguishing between different types or grades of pathology. 13 studies showed with
statistical significance that DCE-MRI derived parameters differentiate primary brain tumour
types and grades (Abe et al., 2015; Ahn et al., 2014; Bergamino et al., 2013; Choi et al.,
2013; Jia et al., 2013; Lüdemann et al., 2000, 2002; Mills et al., 2009; Roberts et al., 2000;
Roy et al., 2013; Sahoo et al., 2013; Zhang et al., 2012; Zhu et al., 2000). Furthermore,
significant differences were found between infective versus neoplastic brain lesions (Haris
et al., 2008a), asymptomatic versus symptomatic neurocysticercosis (Gupta et al., 2012) and
severe and moderate versus mild traumatic brain injuries (Wei et al., 2011). In addition, Aksoy
et al. (2013) reported significantly different DCE-MRI parameters for haemorrhagic strokes
depending on their size and location, and Kassner et al. (2005, 2009) found significantly
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different permeability scores in ischaemic stroke lesions between patients who proceeded to
haemorrhage and those who did not, with and without thrombolytic therapy.
Moreover, several studies focused on the effect of tumour treatments on BBB disruption and/or
the potential of DCE-MRI derived parameters for predicting treatment response after radio-
therapy. Krueck et al. (1994) showed significantly higher permeability in glioma-bearing
animals following radiotherapy when compared to untreated controls. Moreover, two studies
showed that DCE-MRI derived parameters can differentiate between tumour recurrence and
radiation necrosis (Larsen et al., 2013; Shin et al., 2014), while Almeida-Freitas et al. (2014)
reported that an increase in KTrans after stereotactic radiosurgery was predictive of tumour
progression. Similarly, Farjam et al. (2014) found that the subvolume of high KTrans in brain
metastases can predict the response to radiotherapy. Furthermore, Cao et al. (2009) found
a correlation between BBB disruption in brain cancer patients during radiotherapy and the
degree of radiation-induced dysfunction found six months after therapy.
Hoff et al. (2012) observed a significant decrease in tracer kinetic parameters in VEGF-Trap
(a vascular endothelial growth factor inhibitor) treated gliomas versus controls. In contrast,
Ali et al. (2010) made the unexpected, paradoxical observation that VEGF tyrosine kinase
inhibitor treatment significantly increased BBB capillary permeability, microvessel density
and glioma size. Furthermore, one publication each showed a significant change in BBB
leakiness after dexamethasone treatment of cerebral mass lesions (Wilkinson et al., 2006),
cilengitide treatment in glioma (Nagaraja et al., 2013) and after dopamine agonist treatment
in prolactinoma (Manuchehri et al., 2007).
Subtle, diffuse BBB changes with disease
15/95 studies aimed to investigate the correlation between a particular disease and subtle BBB
dysfunction in normal-appearing tissues. Significantly increased BBB dysfunction compared
to healthy control subjects was found in the periventricular white matter (WM) but not basal
ganglia of multiple system atrophy patients (Song et al., 2011), in the basal ganglia of patients
with type-II diabetes (Starr et al., 2003), normal-appearing brain tissue of zinc-deficient rats
(Noseworthy and Bray, 2000) and normal-appearing white matter (NAWM) in MS patients
(Cramer et al., 2014; Taheri et al., 2011b).
There are a number of studies that applied DCE-MRI in elderly subjects with dementia an-
d/or white matter hyperintensities (WMH), reflecting the recent interest in the role of BBB
dysfunction in normal ageing, cognitive decline and cerebral small vessel disease. Su et al.
(1998) showed a non-significant increase in BBB permeability with normal ageing in normal-
appearing canine brain tissue, while Montagne et al. (2015) found a significant increase of BBB
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permeability with age in the hippocampus of non-demented subjects. Moreover, Montagne
et al. (2015) reported significantly increased BBB permeability in the hippocampus of patients
with mild cognitive impairment when compared to the non-demented age-matched cohort
and young controls. Increased BBB disruption in the hippocampus of patients with mild
cognitive impairment compared to healthy elderly controls was also found by Wang et al.
(2006); however, this did not reach the significance level. Furthermore, Starr et al. (2009)
observed differences in signal intensity profiles over time between Alzheimer’s disease patients
and controls, but did not quantify BBB disruption. Taheri et al. (2011a,b) reported significantly
increased BBB leakage in NAWM of patients with vascular cognitive impairment compared
to healthy controls. Both Wahlund and Bronge (2000) and Hanyu et al. (2002) estimated
BBB permeability in WMH by calculating T1 change during the DCE-MRI acquisition; while
Wahlund and Bronge (2000) failed to detect T1 changes in WMH of demented subjects, Hanyu
et al. (2002) found increased T1 changes in WMH of patients with Binswanger’s disease when
compared to WMH of patients with cerebrovascular events. Wardlaw et al. (2008, 2009)
showed that post-contrast signal enhancement was higher in cerebrospinal fluid and WM in
lacunar than in cortical stroke patients. Similar results were reported by Topakian et al. (2010),
who found a significantly larger area under the signal enhancement curve in the NAWM of
lacunar stroke patients compared to healthy controls.
2.4. Discussion
This systematic review of the available literature revealed 95 studies involving methods to
assess BBB disruption in 18 pathologies in up to 495 animals and 2295 humans. These studies
showed considerable heterogeneity with regard to image acquisition and analysis methods.
This is partly a consequence of the wide range of tissues, pathologies and study objectives.
However, it should be noted that only a minority of the articles explicitly justified the method-
ology used. The factors influencing inter-study comparability, implications for future studies
and important considerations when assessing low-level BBB disruption are discussed in the
following paragraphs.
2.4.1. Inter-study comparability of quantitative DCE-MRI parameters
Due to the wide range of analysis techniques used and their strong dependence on underlying
assumptions and acquisition parameters, a lack of inter-study comparability represents a major
problem. Care must be taken when comparing results from different studies as shown by
the wide parameter ranges in Table 2.2. Some of this variability is inevitable due to the
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heterogeneity of the study populations (e.g. subject age) and study designs. Several con-
trast agents are approved for the use in contrast-enhanced MRI; since they differ in their
properties (e.g. molecular size and weight), they are likely to show different tracer kinetics
in their extravasation from the microvasculature (Chwang et al., 2014). However, the exact
extravasation dynamics are not fully understood; for instance, evidence is emerging of chronic
gadolinium retention in the cerebral vascular endothelium and extracellular space (McDonald
et al., 2015).
Since most articles did not explicitly justify the analytical method employed, differences in
the choice of tracer kinetic model may account for some of the variation. Biased parameter
estimates are likely to be obtained when the assumptions of the model are not met in the tissue
or when the data acquired are inadequate to determine a unique solution. For example, several
studies (e.g. Ali et al., 2010; Zhang et al., 2012) apply the same model to tumour tissue and
contralateral healthy tissue, although the underlying tissue physiology is very different and one
model is unlikely to be valid in both situations. The importance of appropriate model selection
has been demonstrated both theoretically (Sourbron and Buckley, 2011) and experimentally
in gliomas (Harrer et al., 2004) and low-permeability brain tissue (Cramer and Larsson, 2014;
Larsson et al., 2009) and is discussed further in section 2.4.2. Several additional factors may
also influence the results of DCE-MRI studies.
Firstly, the calculation of contrast agent concentration from signal enhancement requires reli-
able estimation of intrinsic tissue parameters such as the pre-contrast longitudinal relaxation
time T10. As mentioned in section 1.2.2, there are several methods of estimating T10, with
variable flip angle (Brookes et al., 1999) and variable inversion delay (Larsson et al., 1988) be-
ing the most common. The effect of uncertainty in T10 estimation on the calculation of contrast
agent concentrations has been investigated by Schabel and Parker (2008). They demonstrate
that T10 produces a significant concentration bias, which shows the importance of accounting
for T10 when assessing BBB disruption in different tissue types (Armitage et al., 2011). It
should also be noted that, unless T1 is measured at each time point, drifts in signal intensity
may introduce further errors in tracer kinetic parameters; as noted above, the issue of scanner
stability was seldom addressed in the included articles.
Secondly, most tracer kinetic models require the AIF to be known. Hence, determination
of AIF represents a key issue in the reliable estimation of tracer kinetic parameters. As
mentioned before, there are several strategies for AIF selection and the optimal method varies
according to pathology, study aims and clinical requirements (Calamante, 2013). In most
applications, direct measurement of the AIF is generally considered preferable to a standard
or averaged AIF (Lavini and Verhoeff, 2010). However, this method is not always possible
(Parker et al., 2006) and is susceptible to partial volume and inflow artefacts; uncertainty
remains regarding which vessel should be sampled and how, with approaches ranging from
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manual ROI selection to methods for automatic vessel detection (Chen et al., 2008). There
is also disagreement on whether to describe the capillary bed in terms of blood concentration
or plasma concentration by correcting for the haematocrit. In the latter case, the haematocrit
should ideally be determined for every subject, but a standard value such as Hct = 0.45 is
often assumed (Sourbron and Buckley, 2013). In theory, all model equations and resulting
parameter values can easily be converted between conventions. However, most studies included
in this literature review did not report this and other details, impeding reliable comparison of
parameter values from different studies.
Other sources of uncertainty rarely considered in DCE-MRI studies may arise due to a lack
of available data. For example, relaxivity values specific to a contrast agent, field strength
and tissue/pathology are rarely known, with the consequence that uniform relaxivity across
tissues and compartments is generally assumed. A further common assumption is that of fast
water exchange between compartments; the influence of restricted water exchange has been
described in the literature (see Ewing and Bagher-Ebadian, 2013, and references therein) but
models accounting for this effect have received relatively little attention.
2.4.2. Implications for future DCE-MRI studies of BBB disruption
Given the diversity of DCE-MRI applications in the brain, it is impossible to prescribe a
universal ‘recipe’ for future studies, though attempts have been made to better standardise
methodology and reporting (DCE MRI Technical Committee, 2012; Leach et al., 2012; Tofts
et al., 1999). Instead, it is essential to recognise that the optimal method is highly dependent
on the specific application. An extensive body of primary DCE-MRI literature and a number
of excellent review articles should help to facilitate optimal study design in the future. The
following paragraphs will discuss some of the key aspects of acquisition protocol design and
data analysis. In addition to these technical aspects, it should be noted that the overall design of
a study (e.g. large sample size, appropriate control group) will be particularly important given
the limitations of present DCE-MRI methods.
For most applications, changes in the longitudinal relaxation rate rather than signal intensity
should be measured, since the former more accurately reflects contrast agent concentration,
required for quantitative tracer kinetic analysis. A range of pulse sequences are available to
obtain these data, and the optimal choice may be a compromise between speed, accuracy,
spatial coverage and other factors. Two of the most critical acquisition parameters to determine
are the temporal resolution and total duration of the scan, since the optimal values depend
on the nature of the tissue being investigated and the quantities to be measured (Sourbron
and Buckley, 2012). For example, temporal resolution of the order of a second is required
to quantify tissue plasma flow. Temporal resolution must also be set against requirements for
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spatial resolution and coverage, which differ markedly between applications (e.g. focal versus
diffuse pathology). For accurate measurement of the permeability-surface area product PS, the
scan duration should be long enough for significant contrast extravasation to occur: this may
be of the order of a few minutes in tissues such as brain tumours, but longer scans are required
in less permeable tissues such as normal-appearing brain. If the EES volume fraction ve is to
be accurately measured then imaging should continue well into the ‘washout’ phase, when the
EES contrast agent concentration begins to fall.
A wide range of tracer kinetic models have been proposed for fitting DCE-MRI data, the
most popular of which divide the tissue into well-mixed compartments. It is essential to
recognise the assumptions built into these models and to assess their likely validity for a
given application (Sourbron and Buckley, 2013). The original Tofts model, for example,
is strictly valid only in weakly vascularised tissues, where contrast agent in the capillaries
can be neglected; furthermore, the fitted KTrans is equal to PS only when the blood flow
is sufficiently high. For tissues where the vascular contribution to signal enhancement is
significant, the Patlak or modified Tofts models may be more appropriate, provided again
that plasma flow is high. The choice of model should also reflect the MRI protocol: if the
acquisition duration is short and BBB leakage is slow then models that do not allow back-
diffusion (e.g. Patlak and tissue-uptake models) may be suitable, while application of a model
that does include back-diffusion (e.g. modified Tofts model) can result in increased uncertainty
in the fitted parameters. Similarly, application of a model that includes flow (e.g. 2CUM and
2CXM) is counter-productive if the acquired temporal resolution is insufficient. These and
other considerations have been investigated theoretically by Sourbron and Buckley (2011)
and are summarised accessibly in their recent review (Sourbron and Buckley, 2013). If it is
unclear which model to select a-priori, data-driven approaches can be used to determine the
most suitable model (Ewing and Bagher-Ebadian, 2013), although this does not guarantee that
the model assumptions are met.
2.4.3. Special considerations for assessment of subtle BBB disruption
Only a small proportion of the studies included in this literature review applied DCE-MRI
to normal- or abnormal appearing brain tissues with subtle BBB abnormalities. On average,
these studies used longer imaging durations and lower temporal resolutions compared with
studies of highly permeable tissues such as tumours. As described above, the longer scan
duration is necessary to allow for significant contrast extravasation to occur. On the one hand,
lower temporal resolutions might negatively effect the accuracy of quantitative measurements
(Cramer et al., 2014) and preclude the measurement of blood flow; even if blood flow is of
no interest, it may be necessary to account for flow in order to accurately assess permeability.
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The likely influence of blood flow may be determined using computer simulations, providing
plausible tissue parameter ranges are available and relevant to the subjects and tissues being
studied (Larsson et al., 2009; Sourbron et al., 2009). On the other hand, lower temporal
resolutions allow for higher spatial resolution and coverage. This is especially important for
the assessment of diffuse diseases with subtle BBB abnormalities; nonetheless, most of the
studies included in this review only imaged a single or very few slices (e.g. Cramer et al.,
2014). Limited spatial resolution and coverage not only compromises the reliability of ROI
based DCE-MRI measurements, but also complicates important image processing steps such
as image registration for motion compensation.
Most groups studying subtle BBB disruption have applied semi-quantitative analysis approaches,
for instance comparing signal enhancement-time curves statistically modelled between patient
groups (Wardlaw et al., 2008; Starr et al., 2009), calculating heuristic quantities such as the
area under the curve (Topakian et al., 2010) or change in T1 (Hanyu et al., 2002; Wahlund and
Bronge, 2000). These approaches have the advantage of being straightforward to implement
and do not require advanced image processing, but they do not distinguish between intra- and
extra-vascular contrast and are influenced by the acquisition parameters and other variables.
Recently, a number of more complex, model-based approaches to quantifying subtle BBB
leakage have been suggested, with applications in normal ageing (Montagne et al., 2015),
vascular cognitive impairment (Taheri et al., 2011b) and in the normal-appearing tissue of
patients with MS (Cramer et al., 2014) and primary brain tumours (Sourbron et al., 2009).
Compared with conventional applications, studies of subtle BBB breakdown are particularly
sensitive to the choice of analysis technique and also particularly susceptible to the sources
of error mentioned above, such as T10 measurement uncertainty. This may partly account
for the wide variation in KTrans values reported in the literature for normal-appearing brain
tissue, which span three orders of magnitude (see Table 2.2). Furthermore, the small DCE-
MRI changes linked to subtle BBB breakdown are more likely to be influenced by secondary
processes, such as random noise, scanner drift or partial volume effect (Armitage et al., 2011).
However, such issues have received very little attention in the articles included in this literature
review, with very few studies applying denoising strategies (Taheri et al., 2011a,b) or correct-
ing for scanner instability (Starr et al., 2003; Topakian et al., 2010). Additionally, normal-
appearing tissues suffer from a lower contrast-to-noise ratio when compared to e.g. cancerous
tissue, due to low levels of signal enhancement. While it is common to perform DCE-MRI
analysis on a voxel-by-voxel basis in conventional applications (e.g. Bagher-Ebadian et al.,
2012; Singh et al., 2007), analysis of subtle BBB disruption was mostly performed on a ROI
level (e.g. Hanyu et al., 2002; Wardlaw et al., 2009) in order to reduce noise and facilitate model
fitting. In cases where voxel-by-voxel maps of DCE-MRI parameters are shown, for instance
in Israeli et al. (2011), they generally have a noisy appearance and do not indicate areas of
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visually increased BBB disruption in the normal-appearing tissues. Moreover, the voxel-wise
low-level BBB permeability estimates are likely to be compromised by partial volume effects,
especially in acquisitions with thick slices as in Montagne et al. (2015).
2.5. Conclusion
This systematic review has highlighted the wide range of applications where DCE-MRI has
been used to assess BBB integrity. We found large variations in MRI procedures and data ana-
lysis methods resulting in widely varying estimates of permeability parameters. Nevertheless,
DCE-MRI has been shown to provide valuable information in a growing field of applications,
ranging from the grading of primary brain tumours to the assessment of healthy-appearing
tissue in MS patients or dementia. In methodological terms, DCE-MRI is a relatively mature
technique, but the lack of agreed standards for image acquisition, data modelling and study
reporting hinders inter-study comparison and meta-analysis. As most current data apply to
tumours, more data are especially required for assessing low-level BBB abnormalities. The
relative lack of studies investigating the best methods of measuring low-level BBB disruption
in ageing, dementia or brain microvascular disease argue for substantially more work to assess
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3. Dynamic contrast-enhanced magnetic
resonance imaging in the Mild Stroke
Study II
This chapter presents an on-site clinical study of mild stroke patients, which provided the
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data that form the basis
of this thesis. In addition to introducing the clinical cohort, study procedures and image
processing (section 3.2), this chapter also aims to describe and investigate some fundamental
aspects of the DCE-MRI processing and analysis (section 3.3).
3.1. Introduction
Several previous on-site clinical studies assessed subtle blood-brain barrier (BBB) integrity
using DCE-MRI in Alzheimer’s disease (Starr et al., 2009), type-II diabetes (Starr et al.,
2003) and mild ischaemic stroke (Wardlaw et al., 2008, 2009). These studies applied semi-
quantitative approaches for DCE-MRI analysis, comparing signal enhancement-time curves
between patient groups. In the two studies of ischaemic stroke, DCE-MRI signal enhancement
was found to be higher in lacunar than cortical stroke patients in normal-appearing white
matter (NAWM) and cerebrospinal fluid (CSF) (Wardlaw et al., 2008, 2009), supporting the
hypothesis that cerebral small vessel disease (SVD) may be associated with diffuse endothelial
dysfunction and abnormal BBB functionality (Wardlaw et al., 2003). The Mild Stroke Study
II (MSSII) aimed to confirm these findings and to investigate whether BBB dysfunction is
associated with presence and progression of clinical and imaging markers of cerebral SVD.
While the semi-quantitative analysis approach used in the previous studies had the advantage of
being straightforward to implement and did not require advanced image processing, it suffered
from limited interpretability regarding specific processes such as BBB leakage. Hence, one of
the main objectives of this PhD project was to explore more complex, quantitative approaches
for data analysis. Although baseline assessment including image acquisition for the MSSII
was completed before this project started, the patient cohort, data collection and structural
image processing procedures of the MSSII form the basis of the original work presented in this
thesis. Therefore, the following sections describe the general characteristics and data collection
methods of the study before focusing on DCE-MRI related aspects.
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3.2. The MSSII
The MSSII was designed as a prospective observational case control study and was approved by
the Lothian Ethics of Medical Research Committee (REC 09/81101/54) and the NHS Lothian
Research and Development Office (2009/W/NEU/14); all patients gave written informed con-
sent. Prof Joanna M Wardlaw designed the study, obtained funding from the Wellcome Trust
(grant 088134/Z/09/A), acted as principal investigator and supervised the whole project.
3.2.1. Overview
The aim of the MSSII was to further elucidate the aetiology of lacunar stroke as a discrete
manifestation of cerebral SVD, particularly with regard to the proposed role of endothelial
dysfunction. While the previous on-site studies provided some evidence that the BBB may be
damaged in lacunar stroke patients, it was not possible to determine whether the relationship
is causative or simply an association. In addition to confirming previous findings (Wardlaw
et al., 2008, 2009), the MSSII was designed to identify whether increased BBB permeability at
initial presentation predates the progression of clinical and imaging SVD markers, leading to
disability and cognitive decline. In order to achieve this aim, clinical features (including, for
instance, blood and urine markers, stroke symptoms and vascular risk factors), MRI markers
of SVD and cognitive ability were assessed at baseline and one year follow-up. An overview
of the study and the performed patient assessments is shown in Figure 3.1.
3.2.2. Participants
The MSSII recruited patients who presented to the Lothian stroke service with symptoms of
mild ischaemic stroke; a summary of the recruitment and progression of participants in the
MSSII is shown in Figure 3.2.
Patient recruitment was performed by Dr Stephen Makin, a clinical research fellow and trainee
stroke physician, and overseen by Prof Martin Dennis, a consultant stroke physician, and
Prof Joanna M Wardlaw. 471 potential participants were identified from the in- and out-patient
stroke services in Edinburgh in several different ways. Firstly, the research fellow reviewed the
stroke and acute receiving units at the Western General Hospital (Edinburgh, UK) on a daily
basis and approached suitable patients as identified through their clinical symptoms and/or
diagnostic imaging. Secondly, treating clinicians were informed of the study and referred
suitable patients to the research fellow. Thirdly, stroke patients were referred from the Royal
Infirmary by a research nurse.
3. DCE-MRI in the MSSII 57
Figure 3.1.: Overview of the MSSII. Flow chart showing the patient assessments in the
MSSII. Study data was collected at three different times: at presentation as soon as possible
after the stroke, one to three months and one year after the index stroke.
In order to be eligible for the study, patients had to be over 18 years old and able to give
consent, which excluded patients who lacked mental capacity due to e.g. cognitive impair-
ment (defined as Mini Mental State Examination score below 24). All patients had to have
a probable or definite diagnosis of lacunar or mild cortical ischaemic stroke with no other
good explanation for their symptoms, which excluded patients whose initial clinical or imaging
assessment showed an alternative diagnosis such as multiple sclerosis, cancer or haemorrhagic
strokes. We excluded patients with transient ischaemic attacks (TIA), i.e. patients whose stroke
symptoms resolved within 24 hours. Furthermore, participants had to be able to have an MRI
scan, excluding patients with contraindications to MRI such as pacemakers, metal implants or
claustrophobia. Patients with unstable diabetes or hypertension and major medical conditions
including renal failure, which would preclude use of intravenous gadolinium contrast agents,
were excluded; however, patients with stable hypertension, diabetes and other vascular risk
factors were generally included. Moreover, suitable patients had to be likely to be able to return
for assessments at one month and one year after the stroke. This excluded patients who were
disabled by the stroke and patients with cancer or other severe, life threatening illnesses.
Overall, 264 patients were eligible and consented to enter the study from May 2010 to April
2012, including 118 patients with lacunar and 146 patients with cortical stroke. Participants
were aged 66.9± 11.8 years on average and 42% of subjects were female. Other relevant
clinical characteristics of the cohort such as SVD burden and vascular risk factors will be
reported in chapters 7 and 8 of this thesis.
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Figure 3.2.: Participant recruitment and retention in the MSSII. Flow chart showing the
number of participants that were referred to the study, entered into the study and underwent the
different study assessments.
3.2.3. Data collection
Patient assessments were performed at three different times: at presentation as soon as possible
after the stroke, one to three months and one year after the index stroke. The following sections
will describe the data that was collected at these study visits (see Figure 3.1).
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Initial clinical assessment
All 264 participants underwent an initial clinical assessment as soon as possible after stroke
onset (median of 6 days, interquartile range [3, 15] days). The research fellow recorded the
patient’s demographic details and past medical history, including previous strokes or TIA,
ischaemic heart disease and peripheral vascular disease. He also recorded if there was a history
or current medication of hypertension, diabetes, hyperlipidaemia, hypercholesterolaemia or
atrial fibrillation. Furthermore, family history of stroke and lifestyle information were re-
corded, including smoking status, alcohol consumption and dietary salt intake. A detailed
clinical examination was performed in order to record the details of the presenting stroke. This
included the date and time of stroke onset and first assessment by the stroke service, presence
and duration of symptoms such as limb weakness, sensory loss, speech disturbance, neglect and
visual disturbance and the affected side if applicable. In addition, the research fellow assessed
dependency using the modified Rankin score and the stroke severity on the National Institutes
of Health stroke scale (NIHSS) at the time of assessment and estimated the worst NIHSS score
from the patient’s history. Further records comprised the patient’s dominant hand, whether
the stroke was treated with thrombolysis or clot retrieval, a full list of medications and the
patient’s blood pressure. The research fellow also recorded blood test results as provided by
the NHS Lothian Biochemistry laboratory (including haematocrit, cholesterol, glucose, urea,
creatinine, sodium, potassium and estimated glomerular filtration rate), the degree of carotid
artery stenosis measured with doppler ultrasound and electro- and echocardiography findings
(where available).
Diagnostic MRI
As part of the initial assessment, all 264 patients underwent a diagnostic MRI scan on a 1.5 T
MRI scanner (Signa HDxt, General Electric, Milwaukee, WI) in the Brain Research Imaging
Centre at the Western General Hospital using an 8-channel phased-array head coil. The same
MRI scanner was used throughout the study and underwent regular quality assurance proced-
ures. The imaging protocol included three-dimensional (3D) T1-weighted (T1W) inversion
recovery (IR) prepared spoiled gradient echo (GRE), T2-weighted (T2W) fast spin echo (SE)
with radial k-space sampling, T2*-weighted (T2*W) GRE, fluid attenuated inversion recovery
(FLAIR) and diffusion tensor MRI (DT-MRI) with 30 diffusion directions (single-shot SE
echo-planar imaging, diffusion weighting factor b= 1000 s/mm2) and two baseline acquisitions
with b = 0 s/mm2. A susceptibility-weighted imaging (SWI) acquisition was performed in
addition to the conventional T2*W GRE acquisition, because it had recently been shown to
provide better contrast for the detection of microbleeds (Nandigam et al., 2009). The imaging
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parameters for all sequences are shown in Table 3.1; the total scan time was approximately
30 min.
Diagnostic MRI assessment
All MRI scans were assessed by an experienced consultant neuroradiologist (Prof Joanna M
Wardlaw), who recorded whether an acute lesion relevant to the recent stroke symptoms was
present. A recent ischaemic stroke was defined as a hyperintense area on the diffusion-weighted
image (with corresponding reduced signal on the apparent diffusion coefficient image) with or
without increased signal on T2W or FLAIR images, in a location that corresponded to a typical
vascular territory. The neuroradiologist recorded the location of the index lesion as well as the
presence and location of old stroke lesions including lacunes. Old cortical or lacunar stroke
lesions (infarcts) were wedge-shaped hyperintense regions on the FLAIR or T2W image, and
hypointense on the T1W image including cortex and/or subcortical tissues, with or without
cavitation, and with ex vacuo effect reflecting tissue loss. Periventricular and deep white matter
hyperintensities (WMH) were rated from 0 (none) to 3 (severe) using the Fazekas scale for the
left and right hemispheres separately and for both hemispheres combined (Fazekas et al., 1987).
Moreover, WMH were scored on the Wahlund scale (Wahlund et al., 2001). The presence
of enlarged perivascular spaces (EPVS) was rated on a score from 0 (none) to 4 (>40) as
described in Potter et al. (2015). The rating was performed for the left and right hemispheres
separately and for both hemispheres combined for each of the following locations: midbrain,
hippocampus, basal ganglia and centrum semiovale. Deep and superficial cerebral atrophy
were each rated in comparison to a standard age matched template (Farrell et al., 2009), using
a scale from 1 (mild) to 6 (severe). The total number of microbleeds was counted on the
SWI and T2*W GRE sequences in the following regions: deep white matter (WM), the basal
ganglia, the grey matter (GM) and WM junction, the external/internal capsule, the thalamus
and the posterior fossa. Numbers were recorded for the left and right hemispheres separately
and for both hemispheres combined. Iron deposits in the basal ganglia were rated on a visual
rating scale from 0 (none) to 4 (medium-high) based on comparison with four standard cases
(Penke et al., 2012).
Stroke diagnosis and classification
Each patient’s case was discussed at a multi-disciplinary meeting involving neurologists, stroke
physicians and neuroradiologists before deciding on a final diagnosis of stroke and stroke
subtype. Firstly, the final diagnosis of an ischaemic stroke was made after assessing both
clinical and imaging findings. If there was a lesion that matched the clinical features, i.e. was
in a relevant location of the brain and of the right apparent age to coincide with symptom
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onset, the diagnosis was clearly one of stroke. If there was no relevant lesion on imaging, but
a clear clinical diagnosis of ischaemic stroke and no other explanation for the symptoms, the
patient was included in the study. If neither the clinical nor the imaging findings were typical
of ischaemic stroke, the patient was excluded from the study.
Secondly, the acute stroke was classified as lacunar or cortical subtype. All patients were
diagnosed according to clinical features using the Oxfordshire Community Stroke Project clas-
sification (Bamford et al., 1991). In addition, if there was a relevant lesion on the MRI scans, a
subtype classification was made based on the imaging appearance blinded to the clinical results.
Acute lacunar infarcts were required to be less than 20 mm in maximum axial diameter and in
the deep WM or GM of the cerebral hemispheres or brainstem. Infarcts involving the cortex, or
subcortical infarcts larger than 20 mm diameter, i.e. large striatocapsular infarcts, were likely to
be of large artery atherothromboembolic origin and were classed as cortical strokes. All cases
were discussed in the weekly multi-disciplinary stroke meeting; if the radiological diagnosis
differed from the clinical, the imaging classification was used as the final subtype (Mead et al.,
2000).
DCE-MRI and additional clinical assessments at one to three months post
stroke
All participants were invited to attend a second MRI appointment at least one month and up
to three months after the initial presentation. The aim of this MRI session was to assess BBB
integrity using DCE-MRI, the delay being to avoid acute effects of the stroke on the local
BBB. Of the 264 recruited patients, 56 did not return for the second MRI assessment because
they declined the scan (n = 42), were too unwell (n = 7), lacked a venous access for contrast
administration (n = 4) or had insufficient renal function (n = 3). On average, DCE-MRI was
performed 38 days after the initial assessment (interquartile range [31, 54] days). The technical
details of the MRI protocol are shown in Table 3.2. DCE-MRI consisted of 20 consecutive
3D T1W spoiled GRE acquisitions with a temporal resolution of 73 s and a total acquisition
time of approximately 24 min. The acquisition was initiated simultaneously with an intra-
venous bolus injection of 0.1 mmol/kg gadoterate meglumine (Gd-DOTA, Dotarem, Guerbet,
France) using a power injector. Two additional spoiled GRE acquisitions were obtained prior to
contrast administration with flip angles of 2◦ and 12◦ respectively for calculation of T10. The
DCE-MRI procedure was designed and tested by Dr Paul A Armitage, MRI physicist and image
analyst (Armitage et al., 2011). In addition to DCE-MRI, the protocol included a pre-contrast
sagittal T1W SE acquisition, a post-contrast 3D T2W fast SE acquisition and a pre- and post-
contrast FLAIR acquisition. Overall, the MRI took approximately 45 min to complete. Of the
208 patients that underwent DCE-MRI, data suitable for analysis was obtained in 201 patients;
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data for seven subjects were rejected due to ‘tissueing’ of contrast, technical faults during the
scan or unacceptable data quality caused by patient movement.
Table 3.1.: Acquisition details of the diagnostic MRI sequences. ‘–’ indicates that the
parameter is not applicable for the sequence. The same protocol was used for the one year
follow-up.











Sagittal 7.3/2.9/500 / 8
33.0×21.5 /
256×146 100 / 1.8/0.0
T2W fast SE Axial 6000/90/– / –
24.0×24.0 /
384×384 28 / 5.0/1.0
T2*W GRE Axial 800/15/– / 20
24.0×18.0 /





384×224 28 / 5.0/1.0
SWI Sagittal 80/50/– / 15
24.0×24.0 /
288×224
DT-MRI Axial 7700/82/– / –
24.0×24.0 /
128×128 38 / 5.0/1.0
Table 3.2.: Acquisition details of the MRI sequences at one to three months after
presentation. ‘–’ indicates that the parameter is not applicable for the sequence.





Number of slices /
slice thickness/slice
gap (mm)
T1W SE Sagittal 400.0/14.0/– / –
24.0×24.0 /




384×224 28 / 5.0/1.0
3D spoiled GRE Axial 8.2/3.1/– / 2
24.0×24.0 /
256×192 42 / 4.0/0.0
3D spoiled GRE Axial 8.2/3.1/– / 12
24.0×24.0 /
256×192 42 / 4.0/0.0
3D spoiled GRE
x 20 Axial 8.2/3.1/– / 12
24.0×24.0 /




384×224 28 / 5.0/1.0




320×320 128 / 1.4/0.0
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All participants were asked to bring an early morning specimen of urine to their second appoint-
ment. The urine samples were analysed in the NHS Lothian Biochemistry laboratory, which
provided measurements of albumin, microalbumin, creatinine, sodium and potassium levels.
Moreover, the research fellow recorded a full list of medications that the patient was taking at
the time and assessed the patient’s cognition in order to detect mild cognitive impairment and
dementia.
One year follow-up
One year after the first presentation, all participants were invited for a follow-up clinical and
MRI assessment; 197 of the 264 patients returned for a follow-up appointment. If patients
were unable or declined to come to the Western General Hospital for the MRI scan, the
clinical assessment was performed by telephone or during home visits. If a patient could not
be contacted by post or telephone, the clinical research fellow obtained as much information
as possible from a relative/carer or the patient’s medical records. Collected clinical data was
similar to the initial assessment and included a complete medical history of the previous year
(particularly for new events like recurrent stroke or myocardial infarction and new diagnoses of
hypertension or diabetes), lifestyle information, a full list of medications, NIHSS score, pulse
and blood pressure measurements. Moreover, patients underwent diagnostic MRI as performed
at the initial assessment and cognitive testing as performed at one month post stroke. Firstly,
the structural MRI scans were assessed by an experienced neuroradiologist, who recorded the
same features (on the same scales) as described above and was blinded to the baseline imaging
and clinical findings. Secondly, the MRI scans were compared to the baseline scans in order
to assess all features for change (atrophy, WMH ratings, number of microbleeds, iron deposits
and EPVS, status of the old index lesion).
3.2.4. General image processing and analysis
This section presents the computational image processing and analysis procedures that have
been performed in the MSSII. Processing of the DCE-MRI data was performed by myself and
will be discussed separately (see section 3.3), as it is the main focus of this thesis. All image
analysis was performed blind to clinical data.
Pre-processing
All MR images were converted from DICOM to Analyze 7.5 format. Moreover, all structural
and DCE-MRI images were aligned to the pre-contrast T1W spoiled GRE image (acquired
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during the scan appointment one month post stroke). All registrations were performed with
rigid-body transformations using FSL-FLIRT (Jenkinson et al., 2002). For participants that did
not undergo MRI assessment at one month post stroke, images were instead co-registered to
the T2W fast SE acquisition of the initial diagnostic MRI assessment.
Tissue segmentation and volume measurements
Information about brain tissue types and volumes were extracted semi-automatically by Dr
Maria del C Valdés Hernández, an image analyst, using the in-house developed software
MCMxxxVI (Valdés Hernández et al., 2010). All segmentation masks were manually checked
by an independent trained image analyst (Eleni Sakka) and manually edited as necessary.
The MCMxxxVI method is based on minimum variance quantisation after fusing two co-
registered MRI sequences in the red-green colour space. In the quantised images, maximum
and minimum thresholds of the tissue of interest were selected; the red-green colour space
was used because the human eye cones are most sensitive to the frequencies in this range
of the visible spectrum (Valdés Hernández et al., 2010). The software then automatically
constructed the tissue segmentation mask from the quantised colour-fused volume. WMH in
the brain parenchyma were extracted using the baseline FLAIR and T2*W GRE acquisitions.
The resulting binary masks were manually refined using Analyze 11.0 (AnalyzeDirect, KS).
WMH were identified as punctate or diffuse areas in the WM and deep/subcortical GM (DGM)
of the cerebral hemispheres or in the brainstem that were 3 mm or larger in diameter and
hyperintense with respect to NAWM and GM on T2W and FLAIR images (Valdés Hernández
et al., 2010); some hypointensity on T1W MRI was allowed as long as not less intense than
CSF. In addition, stroke lesions were manually outlined and classified as old stroke lesions or
recent stroke lesions (RSL) (following the definitions used in the visual MRI assessment as
described above) using the ‘Region of Interest Tool’ in Analyze 11.0. All stroke lesion masks
were checked for accuracy by Prof Joanna M Wardlaw. NAWM masks were generated using
MCMxxxVI as described in Valdés Hernández et al. (2010). DGM masks were generated
automatically by a software pipeline that used FSL-SUSAN (Smith and Brady, 1997) for noise
reduction, an age-relevant brain template (Farrell et al., 2009), FSL-FLIRT (Jenkinson et al.,
2002) for aligning the template to each image dataset, and FSL-FIRST (Patenaude et al.,
2011) for extracting the subcortical structures, followed by manual boundary correction. To
minimise any residual contamination of the DGM, the mask was eroded by one voxel. Using
MCMxxxVI, parts of the globus pallidus and thalamus are consistently included within the
WM; consequently, the NAWM masks were corrected using the DGM masks. An example of
MR images and segmentation masks is shown in Figure 3.3.
The intracranial volume (ICV) was defined as contents within the inner skull including brain
tissue, CSF, veins and dura, and limited inferiorly by the tip of the odontoid peg at the foramen
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Figure 3.3.: Representative MRI data and tissue segmentation. FLAIR image (left) and
tissue masks superimposed on FLAIR image. Reprinted from Heye et al. (2016a).
magnum. It was extracted from the T2*W GRE image acquired at the initial MRI assessment
using the ‘Object Extraction Tool’ in Analyze 11.0, followed by manual editing as described
in Valdés Hernández et al. (2012). Non-brain tissue (CSF, venous sinuses, choroid plexus and
meninges) was extracted using MCMxxxVI and subtracted from the ICV, providing binary
masks of total brain tissue. The resulting segmentation masks were used to calculate the brain
tissue and WMH volumes as a percentage of ICV.
DT-MRI processing
DT-MRI images were processed by Dr Maria del C Valdés Hernández using in-house soft-
ware created by Dr Paul A Armitage, which removed bulk motion and eddy current induced
distortions using FSL-FLIRT (Jenkinson et al., 2002) and generated a directionally averaged
diffusion weighted image, mean diffusivity (MD) and fractional anisotropy (FA) parametric
images using standard methods based on multivariate linear regression. For each dataset,
nonlinear registration (Modat et al., 2010) was used to align the tissue masks in the structural
space (T2W) with the parametric maps in the diffusion space using the NiftyReg tool (http:
//sourceforge.net/projects/niftyreg/) applied using TractoR software (http://ww
w.tractor-mri.org.uk/diffusion-processing) to obtain the transformation between the
brain-extracted structural T2W image and the baseline diffusion volume. To avoid partial
volume averaging with CSF due to registration inaccuracies, the CSF mask was dilated by
one voxel in each direction and then subtracted from the NAWM, WMH and DGM masks
in the diffusion space. Median MD and FA were extracted for NAWM and DGM in each
patient; DT-MRI data for two subjects were rejected due to failure of the non-linear image
registration.
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3.3. Basic DCE-MRI analysis in the MSSII cohort
This section describes the basic DCE-MRI processing and analysis procedures that were per-
formed with the MSSII data and presents resulting measurements. If not explicitly stated
otherwise, all DCE-MRI related processing was performed by myself, under direct supervision
of Dr Michael J Thrippleton (MRI physicist), using custom-written software programmed in
MATLAB (MathWorks, Natick, MA, USA).
3.3.1. Methods
Vascular input function measurement
As discussed in section 2.4.1, measurement of the arterial input function (AIF) is a key issue
in the analysis of DCE-MRI data and the optimal approach for AIF determination is still a
matter of debate. In DCE-MRI of the brain, the AIF is often sampled in the superior sagittal
sinus (SSS), since partial volume effects and inflow artefacts are usually reduced at that location
compared with obtaining the AIF from a feeding artery (Lavini and Verhoeff, 2010). As the
SSS contains venous rather than arterial blood, the AIF will be referred to by the more general
term ‘vascular input function’ (VIF).
In order to determine the optimum approach and location for VIF measurement in the MSSII
data, several different VIFs were extracted and compared in a subset of 20 patients. Firstly,
VIFs were measured in the SSS, using a slice proximal to the basal ganglia structures (see
Figure 3.4(a) and (b)). VIFs were obtained by (i) placing a rectangular region of interest
(ROI) in the SSS on the T2W image using the ‘Region of Interest Tool’ in Analyze 11.0
and (ii) selecting a single voxel from the SSS on the DCE-MRI series, which provides the
highest peak signal enhancement and smooth variation during the DCE-MRI time course (as-
sessed visually using the ‘Timeseries’ view in FSLView). Secondly, VIFs were measured in
the internal carotid artery (ICA), using a slice where the blood flow is perpendicular to the
slice direction (see Figure 3.4(c)). VIFs were obtained by selecting a single voxel from the
(iii) left and (iv) right ICA, following the same selection criteria as in method (ii). In order to
assess reproducibility of the single-voxel selection methods, VIF extraction was repeated by
Dr Michael J Thrippleton, who acted as an independent second observer and was blinded to
my results, using methods (ii)-(iv). In order to obtain a noise estimate, a biexponential curve
was fitted to all extracted VIFs and the sum of squared residuals (SSR) was calculated.
Based on this exploratory analysis, we chose the method that provided the most robust VIFs
with high peak enhancement and a smooth decline. This method was then applied in the whole
patient cohort.
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The chosen VIF signal was converted into signal enhancement and contrast agent concentration
as will be described below, yielding the whole-blood concentration cb(t) that was converted
to blood plasma concentration using the formula cp = cb/(1−Hct). In patients where no
haematocrit measurement was available in the clinical records (n = 3), an assumed value of
Hct = 0.45 was used.
(a) ROI in SSS on T2W image (b) Single voxel in SSS on DCE-MRI (c) Single voxel in ICA on DCE-MRI
Figure 3.4.: Methods for VIF measurement. (a) For VIF measurement in the SSS a slice
containing the basal ganglia structures and the lateral ventricles was used; a rectangular ROI
was placed in the SSS based on the anatomical location on the T2W image, (b) a single
voxel was selected from the SSS on the pre-contrast T1W spoiled GRE image (same slice
as before), based on the signal intensity variation during the DCE-MRI time course; the voxel
that provided the highest peak signal enhancement and a smooth decline was selected, (c) a
single voxel was selected from the right and left ICA on the pre-contrast T1W spoiled GRE
image, following the same criteria as the SSS voxel selection; a slice where the blood flow is
perpendicular to the slice direction was chosen.
Calculation of tracer dynamics and T10
For each of the post-contrast time points t, the measured signal intensities S(t) were averaged
over all voxels for each tissue type. The signal enhancement E(t) (representing the fractional
signal increase above baseline) was then calculated as E(t) = (S(t)− S0)/S0, where S0 is the
signal intensity of the 12◦ pre-contrast acquisition.
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where SR = Sa/Sb, with Sa and Sb representing the signal intensities of the two pre-contrast
acquisitions with flip angles αa = 2◦ and αb = 12◦.
The contrast agent concentration C(t) was then estimated by numerical solution of the follow-




1− exp(−P−Q)− cosα2 (exp(P)− exp(−2P−Q))
1− exp(P)− cosα2 (exp(P−Q)− exp(−2P−Q))
]
−1, (3.2)
where P = TR/T10, Q = r1C(t)TR and r1/r2 = 4.2/6.7 s−1mM−1 (Rohrer et al., 2005).
Negative concentration values were set to zero.
In addition to analysing the data based on whole-tissue averages, a subset of the DCE-MRI
data (n = 20) was also processed on a voxel-by-voxel basis.
Calculation of semi-quantitative parameters
Semi-quantitative analysis is one of the easiest ways to characterise DCE-MRI signal enhance-
ment curves. A semi-quantitative parameter that is frequently used in clinical brain studies is
the area under the curve (AUC) (e.g. Ferl et al., 2010; Mills et al., 2009; Topakian et al., 2010;
Wardlaw et al., 2008). In the MSSII data, the AUC was calculated by numerically integrating
the tissue signal enhancement curves E(t) from t = 0 (administration of contrast agent) to
t = 24 min. In order to correct for inter-subject variability of the vascular input, the AUC







As a second semi-quantitative parameter, the late phase slope of the signal enhancement
curve (slopeE) was calculated. The parameter was obtained by linear regression on the signal
enhancement data between time points 4 and 20 inclusive; the first three post-contrast time
points were omitted in order to exclude non-linear signal enhancement changes during the first
pass of the contrast bolus. For a statistical comparison between semi-quantitative parameters
in different tissue types, the Wilcoxon signed rank test was applied.
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3.3.2. Results
VIF measurement
Figure 3.5 shows the vascular signal enhancement curves that were extracted from the SSS
using methods (i) and (ii). Similar results were achieved with the two methods; however,
selecting a single voxel from the DCE-MRI acquisition generally provided a higher peak
enhancement when compared to the VIF extracted from a ROI in the T2W image. Moreover,
the single-voxel VIFs were more uniform within the cohort, with a larger standard deviation
seen in the ROI-based VIFs.
A comparison between single-voxel VIFs obtained from the SSS and ICA are shown in Fig-
ure 3.6. As demonstrated in Figure 3.6(a), the ICA showed significantly smaller signal en-
hancement when compared to the SSS. Furthermore, signal curves measured in the ICA were
significantly noisier. When choosing the voxel for VIF measurement, at least one observer
noted that the extracted signal curves visually appeared noisy in 12/20 patients for the left and
right ICA, compared to 1/20 patients for the SSS. This visual impression was confirmed when
looking at the SSR values between the extracted curves and biexponential fits (Figure 3.6(b)),
which are significantly higher for the ICA. The results provided by the two independent ob-
servers were visually very similar; with the same voxel being chosen in 8/20 patients for the
left ICA, 10/20 patients in the right ICA and 4/20 patients in the SSS.
Based on these results, we decided to select the VIF from a single voxel in the SSS for the
whole patient cohort. The same voxel was selected in 85/201 patients (42%); where the
observers chose different voxels, the VIF with the highest peak enhancement was selected
for all subsequent analyses unless the signal curve was significantly noisier.
DCE-MRI measurements on a voxel-by-voxel basis
An example of DCE-MRI tracer dynamics obtained on a voxel-by-voxel basis is shown in
Figure 3.7. This example is representative of the patient cohort and demonstrates that the
obtained voxel-by-voxel signal enhancement curves have a low contrast-to-noise ratio (CNR).
Due to the low levels of contrast uptake, the signal enhancement curves contain many negative
values that resulted in physiologically unrealistic negative contrast agent concentration values.
On average, the percentage of voxels that exhibit negative signal enhancement at least once
over the DCE-MRI acquisition time ranged from 39% in CSF to 65% in NAWM (based on the
subset of 20 patients).
Figure 3.8 presents voxel-by-voxel maps of T10 and semi-quantitative DCE-MRI parameters
for the same example patient as in Figure 3.7. While the index stroke lesion is visually
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Figure 3.5.: Comparison of signal enhancement curves in the SSS obtained from different
ROIs. Displayed curves are the sub-sample average (n = 20); error bars indicate the standard
deviation. VIFs are based on (i) the average signal in a rectangular ROI placed on the T2W
image (in blue), and (ii) a single voxel selected from the DCE-MRI acquisition (in purple).
enhanced in both AUCbnE and slopeE maps, all other tissues have a generally noisy appearance
and show signs of ring-shaped Gibbs artefacts.
DCE-MRI measurements on a tissue-average basis
When analysing the DCE-MRI data based on whole-tissue average values, the resulting tracer
kinetic curves were significantly smoother (see example in Figure 3.9) and negative signal en-
hancement values occurred in only 0% (CSF) to 6% (WMH) of patients. Figure 3.10 shows the
cohort-averaged signal intensity, signal enhancement and contrast agent concentration curves
in NAWM, DGM, WMH, RSL and SSS. All tissues showed a signal enhancement of approx-
imately 2% to 8%, with abnormal tissues (WMH and RSL) showing a steeper increase in signal
over time compared with normal-appearing tissues (NAWM and DGM).
Figure 3.11 shows the relationship between the tissue-average T10 values and the distribution
of voxel-by-voxel T10 values in a single patient that is representative of the subset. In all
tissue types, the voxel-by-voxel T10 values showed a positively skewed distribution, with the
tissue-average T10 being a close approximation of the distribution median.
Tables 3.3 and 3.4 present the cohort average T10 values and semi-quantitative DCE-MRI
parameters. The late phase slope values were in line with the visual appearance of the signal
enhancement curves: slopeE values were significantly higher in RSL compared to all other
tissues (p < 0.001), and also significantly higher in WMH compared to NAWM (p < 0.001).
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(a) Signal enhancement curves (b) Noise estimates
Figure 3.6.: Comparison of VIF measurements in the SSS and ICA.
All measurements are based on a manually selected voxel that provided the highest peak signal
enhancement and smooth variation during the DCE-MRI time course. VIF extraction was
performed by two independent observers; results obtained by the two observers are shown
in different shades of the same colour. Voxels were selected in both the left and right ICA;
however, the results were very similar and only the left ICA is shown here. (a) Cohort
average signal enhancement curves (n = 20) obtained from the SSS (in purple) and the left
ICA (in turquoise); error bars indicate the standard deviation, (b) boxplots showing the sum of
squared residuals (SSR) between the extracted vascular signal enhancement curve and a fitted
biexponential curve, giving an indication of the ‘smoothness’ of the VIF.
Figure 3.7.: Example of voxel-by-voxel signal enhancement curves.
Pre-contrast T1W spoiled GRE image of a single patient; voxel-by-voxel signal enhancement
curves are shown for two ROIs (5×5 voxels) in NAWM (right) and a RSL (left, see
Figure 3.8(a)) respectively.
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(a) FLAIR image (b) T10 (in s) (c) AUCbnE (dimensionless) (d) slopeE (in %/min)
Figure 3.8.: Example of voxel-by-voxel maps of T10 and semi-quantitative DCE-MRI
parameters. All images are shown for the same slice in a single patient; (a) FLAIR image,
showing a RSL and WMH, (b) map of the pre-contrast longitudinal relaxation time T10 in
seconds, (c) map of the blood-normalised area under the signal enhancement curve AUCbnE
(dimensionless), (d) map of the late phase slope of the signal enhancement curve slopeE (in
%/min).
Similarly, all tissue types had significantly different AUCbnE (p< 0.001), with the highest values
in DGM and the lowest values in NAWM.
Table 3.3.: T10 values by tissue type. Values are shown as cohort mean ± standard deviation.






Table 3.4.: Semi-quantitative DCE-MRI parameters by tissue type. Values are shown as
cohort median and interquartile range (data not generally normally distributed).
Tissue type AUCbnE (%) slopeE ( ·10
-2 %/min)
NAWM 1.59 [1.30, 1.95] 2.59 [−0.04, 4.70]
WMH 2.30 [1.79, 2.93] 3.21 [0.18, 6.45]
DGM 3.78 [3.30, 4.51] 0.96 [−2.83, 3.84]
RSL 2.85 [1.92, 4.60] 6.49 [1.74, 12.26]
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(a) Signal intensity (b) Signal enhancement
(c) Contrast concentration
Figure 3.9.: Example of DCE-MRI tracer dynamics by tissue type.
Graphs show the (a) signal intensity, (b) signal enhancement and (c) contrast concentration
curves over time for a single patient that is representative of the cohort. Values were obtained
from the median signal of all voxels in each tissue type. Y-axis scales for the tissue and SSS
curves are shown on the left and right respectively.
3.4. Discussion
The MSSII is a comprehensive clinical study that, in addition to a wide range of clinical
information, provided DCE-MRI data for a large cohort of mild stroke patients with various
degrees of cerebral SVD. The DCE-MRI protocol was designed to yield whole-brain coverage
with high spatial resolution, in order to detect diffuse and subtle changes in BBB functionality.
In the interest of optimising spatial resolution and coverage, the dynamic acquisitions were
performed with a low temporal resolution of 73 seconds. On the downside, this precludes the
measurement of blood flow and fast tracer exchange across the BBB. However, the MSSII
aimed to detect low-level BBB leakage; this is a slow process and requires sufficiently long
overall imaging duration rather than high temporal resolution (Barnes et al., 2015).
Different methods and locations for VIF selection were explored in the MSSII data. In order
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(a) Signal intensity (b) Signal enhancement
(c) Contrast concentration
Figure 3.10.: Cohort average DCE-MRI tracer dynamics by tissue type. Graphs show
the cohort average (a) signal intensity, (b) signal enhancement and (c) contrast concentration
curves over time. Values were obtained from the median signal of all voxels in each tissue type
and averaged over all patients (n = 201). Error bars indicate the mean ± standard error. Y-axis
scales for the tissue and SSS curves are shown on the left and right respectively.
to obtain an accurate measurement of contrast agent inflow, the VIF should ideally be sampled
in an artery close to the tissue to be analysed (Lavini and Verhoeff, 2010), e.g. in the ICA for
analysis of brain tissues. However, obtaining a VIF from the ICA proved to be difficult in the
MSSII cohort due to partial volume effects and low CNR. Alternatively, the VIF was measured
in the SSS whose larger size allowed for a more reliable VIF measurement. Although tracer
dynamics are usually described in terms of arterial blood plasma concentrations, deriving the
VIF from the SSS is a widely accepted method in DCE-MRI of the brain (Lavini and Verhoeff,
2010; Yuan et al., 2013). It should be noted that previous studies deriving the VIF from the
SSS use a significantly higher temporal resolution than is employed in the MSSII; however, the
potential errors introduced by sampling the venous rather than arterial input are limited by the
nature of this particular application. Firstly, the delay between arterial and venous responses
is very short in comparison with the temporal resolution in the MSSII (Sourbron et al., 2009;
Sourbron and Buckley, 2012). Secondly, the amount of extravasated contrast agent is very
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Figure 3.11.: Relationship between tissue-average and voxel-by-voxel T10 values. Graph
showing the tissue-average T10 value in relationship to the distribution of voxel-by-voxel T10
values. Data are shown a single patient that is representative of the subset. For each tissue
type, plots show the probability density of voxel-by-voxel T10 values, with the median and
interquartile range of the distribution indicated in black. The grey line represents the line of
identity.
small in normal-appearing brain tissues, so that the venous contrast agent concentration is
approximately equal to the arterial inflow of contrast agent. Consequently, the SSS-derived
VIF is expected to be a good approximation of the AIF.
Furthermore, we compared two different methods for ROI placement: selecting a single voxel
in the SSS based on its signal enhancement during the DCE-MRI acquisition was shown to
provide preferable results when compared to a ROI placed in the SSS on T2W images. This
finding indicates that choosing a VIF based on structural information alone is likely to include
voxels with low enhancement due to partial volume effects; thus, VIF selection should always
make use of time-intensity information. A disadvantage of the method applied in this study is
that it is fully manual and rather time intensive. Automatic methods for vessel detection and
VIF extraction do exist, but have been reported to suffer from over-segmentation of vessels in
the brain (Chen et al., 2008). Moreover, the manual selection of a single voxel is observer-
dependent. Nonetheless, we achieved an acceptable inter-observer agreement of 42%; the
extracted VIFs were very similar even in cases where different voxels were selected by the two
observers.
A significant limitation with regards to VIF measurement is the low temporal resolution of the
MSSII DCE-MRI data. In order to accurately sample the first pass of the contrast bolus, a
temporal resolution of 1 s to 2 s is desirable (de Bazelaire et al., 2011; Essig et al., 2013).
However, a temporal resolution of this order was not achievable in the MSSII due to the
requirements for high spatial resolution and coverage. In order to overcome this problem,
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several research groups have presented dual temporal resolution scanning methods with high
temporal resolution during the first pass and high spatial resolution during the later phase
(Jelescu et al., 2011; Leppert et al., 2014; Li et al., 2012a). Since the MSSII DCE-MRI data was
collected before this project started, testing this approach was not possible within the scope of
this PhD; however, a dual temporal resolution acquisition protocol may be considered for future
studies. The given temporal resolution of 73 seconds does not allow for reliable sampling of the
first pass of the contrast bolus and, hence, is likely to introduce errors into quantitative estimates
of BBB functionality. In cases like this, the reproducibility of tracer kinetic parameters can be
increased by using a generic AIF (Parker et al., 2006). However, factors such as age, heart
rate, haematocrit and kidney function have been shown to cause inter-patient variability in the
AIF (Port et al., 2001). Figure 3.12 compares the VIFs of three different patients in the MSSII,
demonstrating that the intravascular contrast dynamics are highly variable between patients,
even at later time points. Using an assumed AIF does not account for these individual variations
and can, hence, also introduce systematic errors in tracer kinetic parameters (McGrath et al.,
2009). In addition, we were mainly interested in the slow contrast extravasation processes that,
in contrast to perfusion measurements, are less likely to be influenced by errors in first pass
measurements. Consequently, the decision was made to use a patient-individual VIF despite its
limitations. Another major potential source of error in VIF measurements is the blood inflow




spins flowing into the imaging volume, which
leads to differences in longitudinal magnetisation saturation. Use of inflow-affected VIFs has
been shown to cause errors of up to 80% in tracer kinetic parameters (Roberts et al., 2011).
However, blood inflow effects decrease as blood travels through the imaging volume, so that
VIF measurements from the SSS are likely to suffer little from inflow effects.
Figure 3.12.: Comparison of VIFs obtained from three different patients. Graphs showing
the contrast agent concentrations over time measured in the SSS of three different patients in
the MSSII cohort.
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The DCE-MRI data was processed on a voxel-by-voxel basis in a small subset of the MSSII
cohort (n= 20). The resulting signal enhancement curves over time were very noisy and, due to
the low levels of enhancement, included a lot of negative values. While these negative values
do not represent an immediate problem for the calculation of semi-quantitative parameters,
they do result in negative contrast agent concentrations that are physiologically not applicable.
Moreover, the high noise levels are expected to cause problems for tracer kinetic modelling, as
they increase the instability of curve fitting algorithms, e.g. local minima. As a result of the
high temporal resolution and whole-brain coverage, calculating voxel-by-voxel maps of T10
and semi-quantitative parameters was also very time consuming. Furthermore, the voxel-by-
voxel AUCbnE and slopeE maps are significantly affected by artefacts. In addition to motion
artefacts in the phase direction, the maps most noticeably suffer from truncation artefacts in
the slice direction, which manifest themselves as a series of dark rings parallel to the skull.
In addition, the images are likely to be contaminated by Gibbs ringing around blood vessels
with high inflow enhancement. These artefacts can cause significant differences in estimated
tracer kinetic parameters, e.g. by changing the baseline signal and/or signal upslope (Di Bella
et al., 2005). Although these issues could be partially addressed by applying four-dimensional
post-processing algorithms (Balvay et al., 2011; Taheri and Sood, 2006), voxel-by-voxel maps
of semi-quantitative and tracer kinetic parameters are unlikely to detect subtle BBB differences
in normal-appearing tissues where the DCE-MRI signal enhancement is generally very low.
In the MSSII, a higher CNR was achieved by analysing the DCE-MRI data on an ROI basis.
Although the ROI approach does not allow for the detection of local variations in BBB func-
tionality, it provides a measurement of overall background BBB status, which is expected
to be more powerful when looking for subtle differences between patient groups. Semi-
automatic segmentation of different tissue types provided the largest possible ROIs; averaging
the measured signal intensities over these large ROIs allowed for significant noise reduction
before performing further calculations in the analysis pipeline. As a result, the tissue-average
tracer dynamics were significantly smoother and only contained very few negative values. In
order to avoid physiologically impossible values, all negative concentration values were set to
zero. It should be noted that this may introduce a tissue-dependent positive bias. However,
the percentage of negative data points was very small; in addition, there was no general trend
in the amount of negative values with the level of enhancement (e.g. there was no significant
difference between the number of negative values in NAWM and RSL). Moreover, it should
be highlighted that the ROI measurements may also be contaminated by the aforementioned
Gibbs artefact, potentially introducing additional positive bias.
The importance of correcting DCE-MRI signal enhancement profiles for intrinsic parameters
such as T10 has been highlighted previously and comes into play when converting signal
enhancement into contrast agent concentration. If T10 is not taken into account, it is impossible
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to know whether differences in signal enhancement are due to a true contrast uptake difference
or different tissue properties (Armitage et al., 2011). In this and many other studies, T10
was measured using the variable flip angle method (also known as ‘DESPOT1’, Homer and
Beevers, 1985). The resulting T10 values are overestimated in comparison to values obtained
using the gold standard IR method (Stikov et al., 2015). However, they correlate well with
variable flip angle T10 measurements at 1.5 T in other cohorts (Muñoz Maniega et al., 2015;
Zhang et al., 2013). The variable flip angle method has the advantage of yielding T10 maps with
whole-brain coverage and adequate signal-to-noise ratio within an acceptable acquisition time.
However, it is sensitive to flip angle variations across the brain, i.e. deviations of the actual
from the operator defined flip angles caused by radio frequency (RF) field inhomogeneities,
resulting in errors in T10 and other parameters (Armitage et al., 2011; Schabel and Parker,
2008). There are several potential sources for such errors. Firstly, RF non-uniformity can arise
from standing wave effects caused by the dielectric properties of human tissues. This effect is
worse at higher field strengths, because the RF wavelength is shorter and, thus, more frequently
of the same size as the imaged structures. Moreover, field inhomogeneities can be caused by
imperfections in the slab excitation profile of the RF pulse and the coil design (e.g. surface coils
have poor RF uniformity compared to volume coils). Several methods have been proposed
for the minimisation of RF field inhomogeneity, including special coils and tailored pulses
(Roberts et al., 2011). There are also T1 measurement approaches that include estimation
and/or correction for flip angle errors, such as DESPOT1-HIFI (Deoni, 2007). Unfortunately
it was not possible to estimate the RF profile in this patient group; however, at 1.5 T and using
a RF transmit volume coil, flip angle variations should be limited and reasonably consistent
within the cohort. In future studies, especially on scanners with higher field strength, it would
be prudent to correct for RF field non-uniformity. Look-Locker based methods such as TAPIR
(Shah et al., 2001) also provide an alternative approach for T10 measurement, permitting faster
sampling of the magnetization recovery curve than the conventional IR method. The sensitivity
of these methods to flip-angle variations is reduced since the flip angle can be modelled as an
unknown parameter during fitting of the IR curve.
So far, the measured signal enhancement profiles have been assessed visually and by calcu-
lating the semi-quantitative parameters AUCbnE and slopeE . The cohort average results give
a first indication of differences in BBB function between tissue types. The higher late phase
slope values in RSL and WMH are expected to be related to BBB leakage, as a linear increase
in signal is likely to be caused by slow contrast extravasation. Similarly, AUCbnE is likely to
be proportional to blood volume, because it represents the relative amount of contrast agent
present in the tissue. Nevertheless, these semi-quantitative parameters should be interpreted
with caution, because their exact relationship with physiologically relevant parameters such as
blood flow and BBB permeability is unclear. In order to draw conclusions about BBB leakage,
it is necessary to perform a quantitative analysis by applying tracer kinetic modelling.
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3.5. Conclusion
This chapter introduced an on-site clinical study of mild stroke patients, the MSSII. This
comprehensive study provides a wide range of clinical and MRI data, including DCE-MRI
data with whole-brain coverage in n = 201 patients. In addition to presenting the study cohort
and procedures, this chapter addressed several basic aspects of DCE-MRI processing and
analysis. Different methods for VIF extraction were explored, with the selection of a single
voxel in the SSS yielding the best results. Due to high noise levels and small overall signal
enhancement, analysis of the DCE-MRI data on a voxel-by-voxel basis was found not to
be suitable for the detection of subtle changes in BBB functionality. Alternatively, signal
intensity, signal enhancement and contrast concentration profiles as well as T10 were calculated
on a whole-tissue basis. The signal enhancement curves were characterised using the semi-
quantitative measurements AUCbnE and slopeE . Although these parameters were shown to be
significantly different between tissue types and can give an indication of BBB function, their
interpretability regarding specific processes is limited. In order to obtain quantitative estimates
of physiologically relevant parameters, a more complex, tracer kinetic analysis should be
performed. Consequently, the next chapter aims to investigate the applicability of tracer kinetic
modelling for analysis of the MSSII DCE-MRI data.
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4. Tracer kinetic modelling in the Mild
Stroke Study II cohort
This chapter aims to determine the tracer kinetic modelling approach most suitable for analysis
of the clinical data presented in chapter 3. Besides applying a set of models to the Mild
Stroke Study II (MSSII) data (section 4.2), this chapter also investigates the robustness of
the modelling to its assumptions using simulations (section 4.3). Furthermore, it examines the
relationship between tracer kinetic and semi-quantitative parameters both in theory and in the
clinical cohort. Most contents of this chapter have been published in Heye et al. (2016a).
4.1. Introduction
As illustrated in chapters 1 and 2 of this thesis, many tracer kinetic models have been proposed
for fitting dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data, most of
which have been developed and applied primarily in neuro-oncology and body imaging, where
contrast uptake in tissue is typically large and rapid. However, the optimal modelling approach
for research in small vessel disease (SVD) where the blood-brain barrier (BBB) remains largely
intact (and extravascular contrast uptake is therefore slow) is unclear.
In their extensive review of tracer kinetic models, Sourbron and Buckley (2013) emphasised
the importance of appropriate model selection. In order to find the most adequate model for
a given data set, they recommended to identify a limited number of possible models using
prior knowledge and then select the optimal model (i.e. the simplest model that fits the data)
using a data-driven approach. Data-driven model selection has recently gained popularity in
DCE-MRI, with applications in cervix carcinoma (Donaldson et al., 2010) and cerebral glioma
(Artzi et al., 2015; Bagher-Ebadian et al., 2012; Ewing et al., 2006). However, a good model
fit does not guarantee that the assumptions made by the model are valid and that the fitted
parameters are accurate (Sourbron and Buckley, 2011). This highlights the importance of
recognising the assumptions built into tracer kinetic models and assessing their likely validity
for a given application, as has been discussed previously (see section 2.4). As the accuracy of
tracer kinetic parameters cannot usually be assessed in clinical DCE-MRI data, several groups
have used computer simulations for this purpose (Barnes et al., 2015; Larsson et al., 2009;
Sourbron et al., 2009). Such simulations allow for the generation of synthetic DCE-MRI data
from ‘true’ tissue parameters, which can be compared to fitted model parameters.
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This work aimed to determine the tracer kinetic modelling approach most suitable for assessing
subtle BBB leakage in the MSSII cohort using a data-driven approach, and to test its validity
in theory using simulations. Ultimately, the purpose of this work was to obtain reliable tracer
kinetic parameters for normal-appearing tissues and lesions in the MSSII cohort.
4.2. Model selection in the MSSII cohort
This section focuses on tracer kinetic analysis of the DCE-MRI data acquired within the scope
of the MSSII. All analyses were performed using custom-written software programmed in
MATLAB (MathWorks, Natick, MA, USA).
4.2.1. Methods
DCE-MRI data
Details of the MSSII clinical cohort and MRI procedures have been given in chapter 3; in
short, DCE-MRI was performed in 208 patients with mild lacunar or cortical ischaemic stroke,
and consisted of 20 consecutive three-dimensional (3D) T1-weighted (T1W) spoiled gradient
echo (GRE) acquisitions (TR/TE = 8.24/3.1 ms, α = 12◦, 24×24 cm field of view, 256×192
acquisition matrix and 42 × 4 mm slices) with a temporal resolution of 73 s and a total
acquisition time of approximately 24 min. The acquisition was initiated simultaneously with
an intravenous bolus injection of 0.1 mmol/kg gadoterate meglumine (Gd-DOTA, Dotarem,
Guerbet, France) using a power injector. For calculation of T10, two additional 3D T1W
spoiled GRE acquisitions were obtained prior to contrast administration with flip angles of
2◦ and 12◦ respectively.
Model choice and fitting
An overview of compartment models for the quantification of DCE-MRI data has been provided
in section 1.2.3. Not all of the models depicted in Figure 1.11 are appropriate for analysis of
the MSSII data. Firstly, the low temporal resolution does not allow for a reliable estimation
of blood flow, because the first pass of the bolus is not adequately sampled; this excluded
models that measure Fp such as the two-compartment exchange model (2CXM) and two-
compartment uptake model (2CUM). Secondly, the assumptions made by some models clearly
conflict with the nature of brain tissue with largely intact BBB. For instance, the original Tofts
model is strictly valid only in situations where contrast agent in the capillaries can be neglected;
however, brain tissue is highly vascular and low BBB permeability results in small amounts of
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extravascular tracer so that the signal contribution from intravascular tracer is dominant and
cannot be disregarded. As it was not clear which of the remaining models yields the most
reliable parameter estimates and what level of model complexity is needed to accurately fit the
MSSII data, a set of three nested models was fitted to the tissue concentration curves: (i) the
modified Tofts model (Tofts et al., 1999), (ii) the Patlak model (Patlak et al., 1983), and (iii) the
steady state model (Sourbron and Buckley, 2013). As a reminder, a schematic overview of
these models and their relationship with the 2CXM is shown in Figure 4.1.
Figure 4.1.: Set of nested tracer kinetic models applied in the MSSII. Target parameters of
DCE-MRI modelling are the fractional plasma volume vp, the fractional interstitial volume ve,
the plasma flow Fp and the permeability-surface area product PS. The three models applied
in the MSSII (modified Tofts, Patlak and steady state) are related to the 2CXM by a series of
simplifying assumptions. Reprinted from Heye et al. (2016a).
Model fitting was performed by non-linear minimisation of the sum of squared residuals (SSR)
in the following tissue types: normal-appearing white matter (NAWM), deep/subcortical grey
matter (DGM), white matter hyperintensities (WMH) and recent stroke lesions (RSL), using
a vascular input function (VIF) measured in the superior sagittal sinus. All parameters were
restricted to positive values and vp + ve was constrained to be less or equal to 1. In order to
reduce the probability of selecting local minima (Ahearn et al., 2005), fitting was repeated 25
times with different initial values. The first three post-contrast time points of all contrast agent
concentration curves were omitted from SSR calculation, since the rapid concentration changes
during and immediately after the first pass are not adequately resolved by the acquisition
protocol and depend more strongly on Fp, which is not included in the models (Larsson et al.,
2009).
Model comparison
The competing models were ranked according to the Akaike information criterion (AIC, Akaike,
1974), which offers a data-driven criterion for the selection of the most appropriate model and
has been applied in DCE-MRI by other groups (Brix et al., 2009; Ingrisch et al., 2010). The
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AIC accounts for the trade-off between goodness-of-fit and model complexity, by combining
the SSR associated with the model m (SSRm) with the number of free parameters Km:






where N denotes the number of data points. For small samples, i.e. N/Km < 40 as in our case,
the AIC should be extended with a second-order bias correction term (Burnham, 2004), giving
the small-sample version




The Akaike weight AWm describes the probability that the model m is best amongst a set of
M models, i.e. the model that results in the least information loss when approximating real data






with ∆m = AICcm−min(AICc1, ...,AICcM). (4.3)
4.2.2. Results
Model selection
As reported previously, DCE-MRI data suitable for analysis were obtained in 201 patients. An
example of tracer kinetic model fitting in NAWM and RSL for a single patient is shown in
Figure 4.2; the Patlak and modified Tofts models provided good fits to the measured signal but
the steady state model was not adequate to describe the data. This observation is confirmed by
analysis of the Akaike weights, which showed that the Patlak model best represents the data in
most subjects for all tissue types (see Figure 4.3(a)), and was selected as the optimum model
in 74% to 78% of patients for the four tissues measured (see Figure 4.3(b)).
Resulting tracer kinetic parameters
A comparison of KTrans and vp values obtained from the different tracer kinetic models is
shown in Figure 4.4. For a statistical comparison between tracer kinetic parameters obtained
with the different models, Wilcoxon’s signed rank test was used. The modified Tofts model
resulted in significantly higher KTrans values in all tissue types when compared to the Patlak
model (p < 0.001); moreover, the additional free parameter of the modified Tofts model lead
to uncertainty in parameter fitting as indicated by the wider range of KTrans values. Similarly,
the blood volume estimates obtained from the steady state, Patlak and modified Tofts models
were significantly different from each other in all tissue types (p < 0.001), with vp values from
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(a) NAWM (b) RSL
Figure 4.2.: Example of tracer kinetic model fitting in the MSSII data. The graphs show
the concentration-time curves in (a) NAWM and (b) RSL (legend as in (a)) of a single patient.
Note that the first three data points were omitted for model fitting for reasons explained in the
text. Partly reprinted from Heye et al. (2016a).
the steady state model being the highest and vp values from the modified Tofts model being
the lowest. The cohort-average parameters obtained with the Patlak model are summarised in
Table 4.1 and will be discussed in detail in chapter 7.
(a) Akaike weights for each model and tissue type (b) Optimum model according to Akaike weights
Figure 4.3.: Model selection according to Akaike weights. (a) Comparison of Akaike
weights between the steady state, Patlak and modified Tofts models in all tissue types (the
results for the three models are colour-coded as shown in (b)), (b) bar graph showing the
percentage of patients in which a particular model was selected as the optimum model
according to Akaike weights. Partly reprinted from Heye et al. (2016a).
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(a) KTrans values (b) vp values
Figure 4.4.: Comparison of KTrans and vp values obtained from three different tracer
kinetic models. (a) KTrans values obtained from the Patlak and modified Tofts models in the
different tissue types (legend as in (b)), (b) vp values obtained from the steady state, Patlak and
modified Tofts models in the different tissue types.
Table 4.1.: Patlak parameters by tissue type. Values are shown as cohort median and
interquartile range (data not generally normally distributed) for the four different tissue types.
Tissue type KTrans ( ·10-4 min-1) vp ( ·10-2)
NAWM 2.75 [1.85, 4.12] 0.57 [0.32, 0.80]
WMH 3.91 [2.80, 4.94] 0.72 [0.40, 1.07]
DGM 3.85 [2.83, 4.68] 1.20 [0.94, 1.43]
RSL 5.02 [3.24, 7.25] 0.72 [0.39, 1.05]
Relationship between Patlak and semi-quantitative parameters
The Pearson correlation coefficient was used in order to investigate the relationship between
the semi-quantitative parameters (AUCbnE and slopeE) and the Patlak parameters (K
Trans and vp)
in the MSSII cohort. The corresponding graphs are shown in Figure 4.5. There was a strong
positive correlation between slopeE and KTrans, with Pearson’s correlation coefficient R ranging
from 0.63 in WMH to 0.82 in RSL (p < 0.001). Moreover, slopeE was significantly negatively
correlated with vp in all tissues but RSL (−0.72 < R < −0.59, p < 0.001). AUCbnE correlated
strongly with both KTrans (0.39 < R < 0.87, p < 0.001) and vp (0.44 < R <−0.70, p < 0.001)
in all tissue types.
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(a) Relationship between slopeE and the Patlak parameters KTrans (left) and vp (right)
(b) Relationship between AUCbnE and the Patlak parameters K
Trans (left) and vp (right)
Figure 4.5.: Relationship between semi-quantitative and Patlak parameters in the MSSII
patient cohort. Scatter plots showing the relationship between the semi-quantitative para-
meters (a) slopeE and (b) AUCbnE and the Patlak parameters K
Trans and vp. Each data point
represents the values measured in a single patient of the MSSII cohort and is colour-coded by
tissue type; lines of best fit were calculated using the linear least square method and are shown
for each tissue type separately.
4.3. Assessment of model validity using computer
simulations
The in vivo experiments presented in the previous section showed that the Patlak model pro-
duces good fits to the DCE-MRI data from the MSSII cohort. However, this does not guarantee
that the assumptions made by the Patlak model (infinite blood flow, no back-diffusion) are
valid and that the fitted parameters are accurate (Sourbron and Buckley, 2011). Consequently,
numerical simulations were performed in order to systematically investigate the validity of the
Patlak model. As before, all simulations were implemented in MATLAB (MathWorks, Natick,
MA, USA).
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4.3.1. Methods
Generation of a high-resolution VIF
First, a high-resolution (∆ t = 0.1 s) VIF was generated using a modified version of the function
introduced by Parker et al. (2006), which consists of two Gaussians plus an exponential term
modulated by a sigmoid function. This function is based on acquisitions with a high-temporal
resolution and an overall acquisition time of approximately 6 min and, hence, provides an
accurate representation of the first pass of the bolus. For longer acquisitions times however,
it has been shown that VIFs typically exhibit a biexponential decay (Weinmann et al., 1984),
which is consistent with the VIFs measured in the MSSII cohort. Consequently, in order to
generate a simulated VIF with realistic first pass behaviour that also matched the MSSII data
at longer times post-injection, the original function by Parker et al. (2006) was extended by an























For the Gaussian functions and sigmoid modulation, which describe the first and second pass
of the VIF, the parameters given by Parker et al. (2006) were used (An, σn, Tn, s, τ). The
parameters αn and βn were obtained by fitting equation 4.4 to the population-average VIF from
the MSSII data. Figure 4.6 shows the resulting function and the population-average VIF from
the MSSII data. Finally, the whole-blood VIF was converted to blood plasma concentration
using the formula cp = cb/(1−Hct), with Hct = 0.45.
Simulation of DCE-MRI measurements
Simulated tissue concentration curves were generated by convolving this VIF with the impulse
response function of the 2CXM (Sourbron and Buckley, 2013). PS and vp values were chosen
to represent the range of values obtained in normal-appearing tissue, WMH and stroke lesions;
ve was chosen to be 0.2 (Syková and Nicholson, 2008) and Fp values between 10 ml/100g/min
and 50 ml/100g/min were selected to represent typical values for NAWM, WMH and DGM
(Brickman et al., 2009). Random noise was added to the curves to give a contrast-to-noise
ratio (CNR) of 8, similar to the one observed in NAWM and DGM in the MSSII cohort; the
CNR was defined as the peak contrast agent concentration divided by a noise estimate, which
was calculated as the standard deviation of the difference between the measured concentration
curve and the Patlak model fit (CNR = max[C(t)]/std[C(t)−CPatlak(t)]). The VIF and tissue
concentration curves were then down-sampled to the experimental temporal resolution (∆ t =
73 s) and these were fitted to the Patlak model as described above. As for the clinical data, the
4. Tracer kinetic modelling in the MSSII cohort 89
Figure 4.6.: High temporal resolution VIF generated for the simulation study. The VIF
was generated based on the generic function introduced by Parker et al. (2006), yielding
realistic first pass behaviour. In order to match the MSSII data at longer times post-injection,
the function was extended by an additional exponential term. Shown is the whole-blood VIF,
which was converted to blood plasma concentration using the formula cp = cb/(1−Hct), with
Hct = 0.45.
first three post-contrast data points were neglected for calculating the SSR during model fitting.
Moreover, the semi-quantitative parameters AUCbnE and slopeE were calculated as described in
section 3.3.1. The simulations were repeated 1000 times for every set of parameters to quantify
the influence of noise. All simulations were based on a tissue T1 of 992 ms, corresponding to
typical NAWM values measured in the MSSII patient cohort.
4.3.2. Results
Accuracy of tracer kinetic parameters
The results of simulations performed to determine the validity of the Patlak model are shown
in Figure 4.7. These compare the fitted Patlak parameters with the ‘true’ parameters used to
generate synthetic signal-time curves using the 2CXM model when neglecting the first three
post-contrast data points during model fitting (as in the clinical data). Both KTrans and vp
were accurately estimated when PS is low, despite the very low temporal resolution and the
simplifying assumptions of the Patlak model. At higher PS values, KTrans was underestimated
and vp slightly overestimated as a result of back-diffusion, which is neglected in the Patlak
model. The model was robust to differences in blood flow, with low flow only resulting in a
slightly greater underestimation of KTrans. For comparison, Figure 4.8 shows the simulation
results when considering all post-contrast data points during model fitting. Due to the low
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temporal resolution, the accuracy of both KTrans and vp was highly dependent on the blood
flow. In particular, low Fp values lead to significant overestimation of PS for high vp.
(a) Relationship between permeability surface area product PS and fitted Patlak KTrans
(b) Relationship between blood plasma volume vp and fitted Patlak vp
Figure 4.7.: Simulated accuracy of Patlak parameters. Relationship of (a) permeability
surface area product PS and (b) blood plasma volume vp values, with corresponding fitted
Patlak parameters. Results are shown for two different Fp, PS and vp values. For all
simulations, ve was set to 0.2. Error bars indicate the mean ± 1.96 standard deviations; the
grey line represents the identity line. The first three post-contrast data points were omitted for
model fitting. Reprinted from Heye et al. (2016a).
Theoretical relationship between semi-quantitative and tracer kinetic parameters
Figure 4.9 shows the theoretical relationship between PS and vp, and the semi-quantitative
parameters AUCbnE and slopeE in the simulated data. AUC
bn
E correlated strongly with vp, but
was also influenced by PS. Similarly, the enhancement slope correlated with PS, but was not
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(a) Relationship between permeability surface area product PS and fitted Patlak KTrans
(b) Relationship between blood plasma volume vp and fitted Patlak vp
Figure 4.8.: Simulated accuracy of Patlak parameters considering all post-contrast data
points. Relationship of (a) permeability surface area product PS and (b) blood plasma
volume vp values, with corresponding fitted Patlak parameters. Results are shown for two
different Fp, PS and vp values. For all simulations, ve was set to 0.2. Error bars indicate the
mean ± 1.96 standard deviations; the grey line represents the identity line. All post-contrast
data points were used for model fitting.
independent of vp. Moreover, the degree of correlation varied with T10 and is, thus, tissue-
dependent.
4.4. Discussion
The clinical DCE-MRI data from the MSSII cohort was analysed using a set of three nested
tracer kinetic models. The three models produced significantly different parameter estimates,
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(a) Relationship between slopeE and PS for different vp and T10 values
(b) Relationship between AUCbnE and vp for different PS and T10 values
Figure 4.9.: Simulated relationship between semi-quantitative parameters and tissue
properties. (a) Relationship between slopeE and PS for different vp values; results are shown
for two different T10 values, which correspond to typical values measured in the MSSII cohort
in NAWM (left) and RSL (right), (b) Relationship between AUCbnE and vp for different PS and
T10 values. All results are shown for Fp = 10 ml/100g/min and ve = 0.2; error bars indicate
the mean ± 1.96 standard deviations. Reprinted from Heye et al. (2016a).
highlighting the influence of model choice on clinical results and the importance of investigat-
ing the model fit and validity. A model comparison using the AIC revealed the Patlak model
to be the most appropriate of the three models for quantification of subtle BBB disruption in
this cohort. The steady-state model does not adequately fit the data; while both the Patlak
and modified Tofts models fit the data similarly well, the simpler Patlak model does so using
fewer free parameters and is therefore selected. The additional complexity of the modified
Tofts model results in over-fitting in the low-permeability situation, consistent with a previous
report regarding the behaviour of Tofts parameters in a smaller study of healthy volunteers
and multiple sclerosis (MS) patients (Cramer et al., 2014). Data-driven model selection has
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recently gained popularity in DCE-MRI and is often applied on a patient-individual voxel-by-
voxel basis (Bagher-Ebadian et al., 2012; Ewing et al., 2006; Donaldson et al., 2010). However,
it has been shown that this approach can increase bias and/or uncertainty of parameter estimates
(Luypaert et al., 2012). This work aimed to overcome this limitation by identifying the model
that is most suitable for the vast majority of tissues and patients and applying this model to
the whole patient cohort, rather than selecting a different model based on the AIC for every
individual region of interest (ROI). This avoids errors in model selection due to uncertainty in
Akaike weights, which is particularly likely to occur in data with a low signal to noise ratio, and
ensures that all data is analysed with the model that has been identified as generally the most
adequate for the data. A detailed analysis of the tracer kinetic parameters obtained from the
MSSII data and their relationship with clinical measurements will be presented in chapter 7.
The DCE-MRI data in this study has been analysed at the level of ROIs rather than voxels.
As discussed in detail in chapter 3, this approach was selected due to the low CNR in single
voxels and due to the influence of artefacts (e.g. Gibbs ringing and motion). Figure 4.10 shows
voxel-wise maps of Patlak parameters obtained in two different MSSII subjects; these maps
demonstrate that artefacts, while typically at the level of only a few percent, have a similar
magnitude to the small contrast-induced signal changes, and therefore have a disproportionate
influence on voxel-wise tracer kinetic parameters. Averaging over a large ROI reduces the
influence of noise and artefact, enabling more robust measurement of background BBB status,
especially in normal-appearing tissue where signal changes are small. However, a limitation of
this approach is that it does not allow the detection of local variation in BBB function.
Numerical simulations were performed in order to investigate the validity of the Patlak model.
The simulations confirmed that the Patlak model yields reliable estimates of KTrans and vp
when PS is low. By omitting data that is acquired during the first pass of the contrast bolus,
accurate parameter values can be obtained independent of cerebral blood flow. It should be
noted that omitting the first three data point removes a significant amount of information from
the curves, which may introduce bias. However, the simulations indicate that this potential bias
is negligible; in fact, considering the first three time points in the simulations led to significant
overestimation of KTrans at low flow values. In the MSSII data, considering the first three data
points led to worse fits to data at later stages in the acquisition, which carry the information
about slow extravasation processes that this work is mainly interested in. The simulations also
demonstrated that accurate parameter values can be obtained despite the use of a temporal
resolution much lower than is typically employed in DCE-MRI. A consequence of this finding
is that DCE-MRI protocols for investigating diffuse subtle BBB pathology may benefit from
prioritising spatial resolution, whole-brain coverage and CNR over sampling rate. However, a
disadvantage of low temporal resolution acquisition is that blood flow cannot be determined in
addition to vp and PS; where knowledge of Fp is required and temporal resolution is adequate,
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the 2CUM model may be substituted for the Patlak model in low-permeability tissue (Sourbron
et al., 2009; Ingrisch et al., 2012). It should also be higlighted that numerical simulations as
performed in the present work are likely to depend on the choice of VIF.
The findings presented in this chapter are consistent with recent investigations by Cramer and
Larsson (2014) and Barnes et al. (2015). Similar to this work, both studies investigated the ac-
curacy of tracer kinetic parameters using computer simulations, showing that the Patlak model
yields reliable estimates of low BBB permeability. However, the investigations by Cramer
and Larsson (2014) and Barnes et al. (2015) include limited clinical data, with both studies
being based on small samples of young, healthy volunteers and/or MS patients. In contrast, the
MSSII data allowed for investigating the validity of quantitative BBB permeability estimates in
a large clinical cohort of patients with SVD. Moreover, the DCE-MRI acquisitions performed
by both groups employ higher temporal resolutions at overall lower acquisition times, resulting
in limited spatial resolution and much less coverage than in the MSSII. Although the recent
findings by Cramer and Larsson (2014) and Barnes et al. (2015) provide some guidance on
acquisition parameters and postprocessing methodology for the assessment of subtle BBB
leakage, it would have been unclear without the present work whether their recommendations
apply in the MSSII data with a different pathology, higher spatial resolution and coverage but
lower temporal resolution.
In the MSSII cohort, a comparison of semi-quantitative and Patlak parameters showed that
both AUCbnE and slopeE correlate with K
Trans as well as vp, with the strength of correlation
varying between tissue types. This was confirmed in the simulated data, showing that the semi-
quantitative measurements are highly dependent on several tissue properties, such as PS, vp
and T10. These findings are in line with a previous study by Walker-Samuel et al. (2006),
who demonstrated that the area under the curve (AUC) has an non-traceable relationship with
all three parameters of the modified Tofts model. In contrast to the present work, the study
by Walker-Samuel et al. (2006) was based on simulated data only, which had a much higher
temporal resolution of 5 s. Furthermore, the focus was on the initial AUC, which comprises the
first pass only and is commonly used to assess treatment effects in oncology drug trials. The
work presented in this chapter confirmed that, in contrast to the fitted tracer kinetic parameters,
semi-quantitative parameters reflect a combination of underlying tissue properties, hindering
their interpretability regarding specific processes.
Nevertheless, it should be noted again that tracer kinetic analysis also has several limitations.
Firstly, all tracer kinetic models necessarily make assumptions regarding tissue structure and
the transport of blood plasma and contrast agent, which may not reflect true physiology. For
instance, all tracer kinetic models considered in this work are based on the 2CXM, i.e. both the
blood plasma and the interstitium are modelled as well-mixed compartments. Alternatively,
the tissues could be modelled as plug-flow systems (see section 1.2.3), with both models
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representing a simplification of reality while realistic tissues are likely to be a mixture of these
extremes (Sourbron and Buckley, 2013). Furthermore, as the low temporal resolution of the
MSSII acquisition protocol does not permit estimation of blood flow, the present work focused
on three models that assume the tissue to be highly perfused (i.e. Fp = ∞). Although this is not
the case in real tissues, it remains a good approximation when the blood flow is sufficient to
equalise the arterial and capillary concentrations (requiring PS Fp) (Sourbron and Buckley,
2011), with the simulations confirming the validity of this approximation; the choice of models
should also be seen in relation to temporal resolution, which in this case is much longer than
the transit time of the tissue blood compartment. Secondly, it should also be emphasised
that while PS (or KTrans) is commonly used as a marker of BBB permeability, it is equally
influenced by the capillary surface area, which will depend on the anatomy and pathology of
micro vessels. Future studies should try to determine vessel density and size so as to include
realistic estimates of capillary endothelial surface area in the permeability calculations. Thirdly,
the fitting of tracer kinetic models is computationally complicated, with most research groups
using their own hand-written software. Consequently, the resulting values are most likely
influenced by details of the implementation, for instance the curve fitting algorithm and the
number of starting points (Ahearn et al., 2005). Moreover, as discussed previously, DCE-MRI
studies are limited by additional sources of error such as uncertainty in T10, VIF and tissue
relaxivity. These factors have been described in detail elsewhere (e.g. Armitage et al., 2011;
Cheng, 2008; Roberts, 1997; Schabel and Parker, 2008) and will not be analysed further in this
work. Lastly, the small signal enhancements linked to subtle BBB breakdown are likely to be
susceptible to influences by secondary processes such as scanner drift; however, as highlighted
in section 2.4.3, such issues have received very little attention in the DCE-MRI literature.
4.5. Conclusion
This chapter aimed to determine the tracer kinetic modelling approach most suitable for as-
sessing subtle BBB disruption in the large MSSII patient cohort and to assess its validity using
simulations. Using a data-driven approach, the Patlak model was shown to be an appropriate
method for measuring low-level KTrans. The simulation study demonstrated that the Patlak
model yields accurate parameter estimates and is reasonably robust to the assumptions of
high blood flow and negligible back-diffusion. Although the temporal resolution is very low
compared to conventional DCE-MRI applications, it is adequate for the measurement of slow,
subtle leakage and has the benefit of allowing high spatial resolution and coverage. These
results justify the emerging popularity of the Patlak model in the study of disorders involving
subtle BBB disruption and of healthy-appearing tissue (Cramer et al., 2014; Montagne et al.,
2015; Taheri et al., 2011b). Semi-quantitative parameters were shown to correlate with both
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KTrans and vp, thus reflecting a combination of underlying tissue properties. In contrast, tracer
kinetic parameters provided accurate measures of PS and vp that were near-independent of
each other, and should hence be preferred over semi-quantitative parameters. Due to the subtle
nature of BBB leakage in cerebral SVD, the tracer kinetic parameters obtained in this work are
particularly susceptible to sources of error. Hence, the next chapter aims to investigate whether




Figure 4.10.: Example of voxel-by-voxel maps of Patlak parameters. Fluid attenuated
inversion recovery (FLAIR) images, spoiled GRE images, KTrans (in min−1) maps and vp maps
are shown for two different patients. Both patients exhibit a RSL, which is visible in the FLAIR
image (indicated by white arrow). A corresponding area of increased BBB disruption can be
seen in the KTrans maps. While the tracer kinetic parameter maps for patient 1 are acceptable,
those of patient 2 are strongly influenced by low-level motion artefact, even though it is barely
visible in the raw spoiled GRE images. Such artefacts restrict the utility of voxel-wise analysis.
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5. Signal drift and its influence on tracer
kinetic parameters
The purpose of this chapter is to investigate signal drift unrelated to contrast effects during
the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) acquisition and to
consider its influence on tracer kinetic parameters. Drift measurements were performed in
a group of healthy volunteers (section 5.2), and its effect on quantitative parameters was
modelled using computer simulations (section 5.3). Most contents of this chapter have been
published in Heye et al. (2016a).
5.1. Introduction
The work presented in the previous chapter provided quantitative estimates of blood-brain
barrier (BBB) disruption for the Mild Stroke Study II (MSSII) patient cohort. The Patlak model
was shown to produce good fits to the data and to yield accurate parameter values despite the
simplifying assumptions of the model and the low temporal resolution. The resulting cohort-
average KTrans values range from approximately 3 ·10−4 min−1 to 6 ·10−4 min−1 (in normal-
appearing white matter (NAWM) and recent stroke lesions (RSL) respectively), which is three
to four orders of magnitude smaller than values reported for more conventional applications
such as brain tumours (see Table 2.2). As discussed previously, this subtle nature of BBB leak-
age in cerebral small vessel disease makes the tracer kinetic parameters particularly susceptible
to sources of error, which are less likely to be problematic in typical DCE-MRI applications
with larger, more rapid contrast uptake. With the DCE-MRI acquisition time being particularly
long in the MSSII and the observed signal enhancements ranging from only 2% to 8%, one of
the main concerns when analysing the data was the influence of signal drift.
Signal drift measurements are rarely reported in the DCE-MRI literature (see section 2.3.4), an
exception being Cramer et al. (2014) and Armitage et al. (2011) who reported a drift of 1% to
3% over 15 min at 3 T but did not investigate its likely effect on the results. The causes of MRI
signal drift are not well-understood, but may not only be introduced by instrumental instability
but also by subtle biological changes (Lowe and Russell, 1999). This becomes evident when
looking at the mathematical expression of signal intensity; for a spoiled gradient echo (GRE)
experiment with flip angle α and short echo time TE, the signal intensity is given by the regular
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where M0 is the equilibrium magnetisation. Consequently, a change in signal intensity over
time can not only be caused by instability of instrumental parameters (e.g. flip angle, B0 field),
but also biological changes that cause variations in T1.
This chapter presents contrast-free ‘sham’ experiments in healthy volunteers, which were per-
formed in order to assess whether instrumental drift and/or physiological changes occur during
the DCE-MRI acquisition as performed in the MSSII. Furthermore, this chapter investigates
how these factors may influence tracer kinetic parameters using the simulation framework
introduced in the previous chapter.
5.2. Healthy volunteer study
In order to assess whether signal drift occurs during the DCE-MRI acquisition as performed in
the MSSII cohort, contrast-free ‘sham’ experiments were performed in healthy volunteers. The
MRI study described in the following sections was approved by the local ACCORD Healthy
Volunteer Research Ethics Committee (REC 14/HV/0001). Dr Michael J Thrippleton and
Dr Andreas Glatz assisted with the design and testing of the MRI protocol; Prof Joanna M
Wardlaw acted as principal investigator and assessed all MRI scans for clinical reporting.
5.2.1. Methods
Participants
Brain MRI scans were performed in a total of 15 participants, which were recruited through
University of Edinburgh mailing lists between January 2013 and April 2015. Volunteers with
no significant history of neurological or cardiovascular disease were considered as healthy and
eligible to enter the study. All participants gave written informed consent.
MRI
MRI scanning was performed in the Brain Research Imaging Centre at the Western General
Hospital using the same 1.5 T MRI scanner as the MSSII (Signa HDxt, General Electric, Mil-
waukee, WI) and the same 8-channel phased-array head coil. In order to assess signal changes
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unrelated to the contrast agent, all 15 participants underwent the same DCE-MRI protocol as
applied in the MSSII cohort but without administration of contrast agent (20 consecutive three-
dimensional (3D) T1-weighted (T1W) spoiled GRE acquisitions with TR/TE = 8.24/3.1 ms,
α = 12◦, 24×24 cm field of view (FoV), 256×192 acquisition matrix, 42 × 4 mm slices,
temporal resolution of 73 s and a total acquisition time of approximately 24 min).
In order to assess whether biological changes occur during the DCE-MRI acquisition, T1 was
measured before and after the dynamic sequence using two different methods. Firstly, T1 was
measured using the variable flip angle method as performed in the MSSII cohort (consisting
of two additional 3D T1W spoiled GRE acquisitions with flip angles of 2◦ and 12◦ respect-
ively). In addition, T1 was measured using the gold standard inversion recovery (IR) method
(Larsson et al., 1988) in eight volunteers. For this purpose, two-dimensional (2D) IR spin
echo (SE) echo-planar imaging (EPI) acquisitions were performed with multiple inversion
delays (TR/TE = 10000/25.4 ms, 24×24 cm FoV, 256×192 acquisition matrix, 1 x 4 mm slice,
TI = [100, 340, 580, 820, 1060, 1300, 2000, 3000] ms). The 2D acquisitions were set up to
match a single slice of the 3D T1W spoiled GRE acquisition, which contained the basal ganglia
structures and the lateral ventricles.
Image processing and analysis
All images were converted from DICOM to NIfTI format. Moreover, all 3D images were
aligned to the first 12◦ T1W spoiled GRE image with rigid-body transformations using FSL-
FLIRT (Jenkinson et al., 2002); 2D rigid-body registration was used to align the IR SE EPI
acquisitions to the corresponding slice in the 3D T1W spoiled GRE image. Multiple small
regions of interest (ROIS) were manually placed in NAWM and deep/subcortical grey matter
(DGM), using a simplified version of a standard template (Wardlaw et al., 2008). An example
of ROI placement is shown in Figure 5.1. For each tissue, median signal intensities were
calculated over all ROIs and converted to signal enhancement curves as described previously
(see section 3.3.1). Signal drift was calculated as the change in signal intensity per minute
acquisition time and is given as a percentage of the time-averaged signal.
T1 values were calculated for two different time points (before and after DCE-MRI acquisi-
tion) and the two different methods (variable flip angle and IR with variable inversion delay).
Equation 3.1 was used to calculate T1 from the pair of 2◦ and 12◦ 3D T1W spoiled GRE
acquisitions. As regards the IR method, T1 was calculated by fitting the following equation to
the measured signal intensities S:
S = |A+Bexp(−TI/T1)|. (5.2)
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All values are reported as cohort mean ± standard deviation.
Figure 5.1.: Example of ROI placement in the healthy volunteer MRI data. Shown are
three different slices of the first 12◦ 3D T1W spoiled GRE image. Several small rectangular
ROIs were placed in DGM and NAWM.
5.2.2. Results
‘Sham’ DCE-MRI data was obtained in 15 healthy volunteers with a mean age of 31.4± 7.4
years. Figure 5.2 shows the corresponding average signal enhancement curves in NAWM and
DGM. Although no contrast agent was given, the data show an approximately linear increase
in signal intensity of 0.06±0.03 %/min in NAWM and 0.10±0.06 %/min in DGM.
Figure 5.2.: Contrast-free DCE-MRI measurements in healthy volunteers. Shown are the
cohort-average signal enhancement curves (n= 15) NAWM and DGM, showing a drift in signal
intensity; error bars indicate the mean ± standard error. Reprinted from Heye et al. (2016a).
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T1 measurements using the variable flip angle method were performed in n = 14 volunteers;
the resulting T1 values are given in Table 5.1. As in the MSSII cohort, these values were
overestimated in comparison to literature values measured with the IR method. After having
performed MRI scanning in seven participants, it became evident that there is a decrease in
T1 over the period of the DCE-MRI acquisition in both NAWM (∆T1 = −0.9± 4.4 %) and
DGM (∆T1 = −1.6± 4.6 %). However, it was unclear whether these differences reflect true
biological changes or are due to compromised measurement accuracy of the variable flip angle
method. Consequently, T1 measurements using the gold standard IR method were added to
the MRI protocol for the remaining eight volunteers; IR acquisitions of one participant were
subsequently discarded due to significant movement artefacts. The resulting T1 values were in
line with previous literature (Vymazal et al., 1999) and showed a similar decrease in T1 (see
Table 5.1). However, a paired-sample t-test indicated that the measured change in T1 was not
statistically significant (using either method).
Figure 5.3 investigates whether this non-significant change in T1 could cause the observed
signal drift. It shows the estimated change in signal intensity as a function of change in
T1, which was calculated using equation 5.1. Baseline T1 values were chosen as 680 ms in
NAWM and 903 ms in DGM, corresponding to the cohort-average IR SE EPI measurements.
According to these investigations, the measured decrease in T1 (−0.9% in NAWM and −1.2%
in DGM) accounts for approximately 38% of the measured signal drift (0.06 %/min in NAWM
and 0.10 %/min in DGM). The remaining signal drift is likely to be caused by instrumental
instability (e.g. B0 and flip angle instability); patient motion may also contribute to signal
drift.
Table 5.1.: T1 measurements in healthy volunteers. T1 values were obtained at two different
time points: before (T1pre) and after (T1post) the DCE-MRI acquisition. Moreover, two
different methods were used for the measurement of T1: the variable flip angle method based
on a pair of 3D T1W spoiled GRE acquisitions with different flip angles and the IR method
based on multiple 2D IR SE EPI acquisitions with variable TI. All values are given as cohort
mean ± standard deviation; paired-sample t-tests indicate that the measured change in T1 is
not statistically significant.
Tissue type Measurement method T1pre (ms) T1post (ms) ∆T1 (%) p
NAWM
variable flip angle 794±29 787±39 −0.9±4.4 0.20
IR with variable TI 680±25 674±19 −0.9±2.1 0.19
DGM
variable flip angle 1209±54 1188±46 −1.6±4.6 0.46
IR with variable TI 903±35 892±32 −1.2±1.1 0.27
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Figure 5.3.: Relationship between change in T1 and change in signal intensity. Change
in signal intensity as a function of change in T1, estimated using the regular Ernst equation
(equation 5.1). The relationship is shown for two different baseline T1 values, corresponding
to the cohort-average IR SE EPI measurements in NAWM and DGM. Boxes indicate the
T1 change measured in the healthy volunteer cohort and the corresponding change in signal
intensity.
5.3. Computer simulations
The effect of scanner drift on tracer kinetic parameters was investigated using computer simu-
lations, which are based on the simulation framework introduced in the previous chapter.
5.3.1. Methods
A detailed description of the simulation methods has been given in section 4.3.1. In short,
simulated tissue concentration curves were generated by convolving a synthetic high temporal
resolution VIF with the impulse response function of the two-compartment exchange model,
using a range of typical KTrans, vp and Fp values for normal-appearing tissues. In addition to
random noise, a signal drift of 0.08 %/min (similar to that observed in the healthy volunteers)
was added to both the tissue curve and the vascular input function (VIF). The VIF and tissue
concentration curves were then down-sampled to the experimental temporal resolution (∆ t =
73 s) and these were fitted to the Patlak model. In order to investigate whether the effect of drift
on the tracer kinetic parameters is T1-dependent, the simulations were repeated for several T1
values representing typical values measured in the MSSII cohort.
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5.3.2. Results
Figure 5.4 compares the fitted Patlak parameters with the ‘true’ parameters when adding a sig-
nal drift of 0.08 %/min. The plots show that the signal drift leads to systematic overestimation
of KTrans and underestimation of vp with respect to expected values. However, KTrans and vp
remained approximately linear functions of the specified values, largely independent of plasma
flow and of one another.
(a) Relationship between permeability surface area product PS and fitted Patlak KTrans
(b) Relationship between blood plasma volume vp and fitted Patlak vp
Figure 5.4.: Simulated accuracy of Patlak parameters including a 0.08 %/min signal drift.
Relationship of (a) permeability surface area product PS and (b) blood plasma volume vp
values, with corresponding fitted Patlak parameters. Results are shown for two different Fp, PS
and vp values. For all simulations, ve was set to 0.2 and a signal drift of 0.08 %/min was added
to the curves before model fitting. Error bars indicate the mean± 1.96 standard deviations; the
grey line represents the identity line. The first three post-contrast data points were omitted for
model fitting. Reprinted from Heye et al. (2016a).
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Figure 5.5 shows the magnitude of the systematic error introduced by signal drift for different
T1 values, which correspond to the cohort-average values measured in the MSSII cohort for
NAWM, white matter hyperintensities (WMH), DGM and RSL. Across these tissue types, the
maximum error ranged from approximately 2.2·10−4 min−1 to 3.2·10−4 min−1 for KTrans and
−2.4·10−3 to −1.6·10−3 for vp, with bigger errors occurring for smaller T1 values.
(a) Error in KTrans (b) Error in vp
Figure 5.5.: T1-dependency of the systematic error introduced by signal drift. Plots
showing the error between the fitted Patlak parameters and the corresponding ‘true’ values of
(a) permeability surface area product PS and (b) blood plasma volume vp. Results are shown
for different T1 values, which correspond to the cohort-average values measured in the MSSII
cohort for NAWM, WMH, DGM and RSL. For all simulations, ve was set to 0.2 and a signal
drift of 0.08 %/min was added to the curves before model fitting. Error bars are omitted for
clarity.
5.4. Discussion
Contrast-free DCE-MRI acquisitions (otherwise identical to the ones performed in the MSSII
cohort) were carried out in a group of young, healthy volunteers. Although the subjects did
not receive contrast, there was a linear signal increase of approximately 0.08 %/min. These
measurements are comparable to the ones reported by Cramer et al. (2014) for DCE-MRI at
3 T, who found a signal drift of 1% to 3% over 15 min. The drift observed in this study was
also within the range of values obtained in a multi-centre survey of functional MRI quality
assurance parameters, which concluded that ‘stable scanners generally average around 1.0%
[signal drift over 6.7 min] or less’ (Friedman and Glover, 2006). The influence of signal drift
in functional MRI is much less severe than here, since it typically has a lower frequency than
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the task-related signal change, is suppressed using a high-pass filter and the scans are shorter. In
DCE-MRI on the other hand, it is harder to distinguish between drift and contrast enhancement
as both occur on similar time scales in the tissues considered here.
Signal drift is rarely reported in the DCE-MRI literature and the causes of signal drift unrelated
to contrast agent are not well understood. In order to investigate whether signal drift may be
influenced by subtle biological changes as suggested by Lowe and Russell (1999), T1 was
measured before and after the DCE-MRI acquisition. Using two different methods (variable
flip angle method as performed in the MSSII cohort and the gold standard IR method), a
non-significant decrease in T1 was found over the acquisition time of approximately 24 min.
According to the present investigations, this small T1 change may explain approximately 38%
of the observed signal drift. This confirms that biological changes may be a contributing
factor to signal drift, which is also consistent with a previous report of tissue-dependent drift
(Armitage et al., 2011). However, there are multiple other possible sources of drift (e.g. flip
angle instability, B0 instability, motion), whose contributions remain unknown. The present
study is limited by its small sample size, which makes it difficult to draw clear conclusions
about the significance of changes in T1.
In typical DCE-MRI applications with larger, more rapid signal enhancements over shorter
acquisition times, the observed level of signal instability is unlikely to be problematic. Even
in studies of subtle BBB leakage, the effects of scanner drift have previously been considered
negligible (Cramer et al., 2014). However, the computer simulations presented in this chapter
showed that the drift is predicted to cause a substantial overestimation of KTrans and under-
estimation of vp in the low-permeability regime. These findings are consistent with recently
published investigations by Barnes et al. (2015), who added signal drifts between -10% and
10% to their computer simulations. The systematic error introduced by signal drift could
account for some of the apparent leakage reported in the literature for normal-appearing tissues.
Furthermore, the magnitude of drift (and hence the bias it introduces) is likely to differ between
studies, which may partly account for the wide range of KTrans values reported in the literature
for normal-appearing brain tissues. The error introduced by signal drift is also T10 dependent,
which further complicates the interpretation of low-level tracer kinetic parameters because it
may introduce apparent differences between tissue types. For instance, this T1 dependency may
partly account for the finding in the MSSII cohort of higher vp in WMH compared to NAWM.
As a result, attempts to quantify low levels of permeability should be interpreted with caution,
unless information regarding scanner drift and its likely effect on the values are available.
Barnes et al. (2015) state that the systematic error introduced by signal drift can essentially
be eliminated by correcting for a previously measured level of drift. However, in practice,
corrections for signal drift are limited by several factors. Firstly, a correction based on drift
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measurements in a single phantom may not be sufficient if the magnitude of drift is tissue-
dependent. Secondly, phantoms (particularly simple water or oil based phantoms as used by
Starr et al., 2003) are often subject to temperature changes at long acquisition times, which
cause changes in T1 and, hence, may lead to unreliable drift measurements. Thirdly, the
magnitude of drift is likely to vary between subjects (and tissues) and may depend on factors
such as age or overall health status. Consequently, drift measurements obtained in young
healthy volunteers may not be adequate for the correction of DCE-MRI data obtained in
elderly, diseased patients (as for instance performed by Topakian et al., 2010). Finally, the
drift itself is small with regard to the often compromised signal-to-noise ratio in DCE-MRI
acquisitions, which raises the question of how reliable drift estimates are (Armitage et al.,
2011). It is also worth noting that DCE-MRI methods consisting of repeated T1 measurements
(e.g. Taheri et al., 2011b) should largely self-compensate for signal drifts of instrumental origin
and, depending on the pulse sequence used, changes in the radio frequency field strength but
not for changes in T10.
5.5. Conclusion
This chapter aimed to investigate signal drift unrelated to contrast effects and its influence on
tracer kinetic parameters. Drift measurements were performed in a group of healthy volunteers,
showing linear signal increase of approximately 0.08 %/min. Computer simulations suggested
that this drift introduces a systematic error when estimating low-level tracer kinetic parameters.
Despite the confounding influence of drift, the simulations indicate that KTrans and vp estimates
remain approximately linear independent functions of the extravasation rate and plasma volume
respectively. They provide a valuable if relative indication of BBB integrity and blood plasma
volume for applications in well-designed studies with appropriate control groups and statistical
correction for confounds; such quantities remain easier to interpret than semi-quantitative
measurements. Nevertheless, it is important to optimise study MRI protocols for measurement
of low-level permeability and interpret quantitative results with caution.
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6. Tracer kinetic modelling in an external
patient cohort – lessons for inter-study
comparability and study design
The work presented in this chapter is the result of a collaboration with the Diagnostic Imaging
Unit at the Università Campus Bio-Medico in Rome, Italy, which I visited within the scope
of a ‘Postdoctoral and Early Career Researcher Exchange’ award from the Scottish Funding
Council organised by the SINAPSE (Scottish Imaging Network – A Platform for Scientific
Excellence) Collaboration. During this visit, the local researchers kindly shared a dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) dataset of patients with common,
non-specific neurological complaints with me; this chapter aims to analyse these data and to
compare the results to the findings in the Mild Stroke Study II (MSSII) cohort.
6.1. Introduction
The systematic literature review presented in chapter 2 has highlighted the large variations
in DCE-MRI procedures and data analysis methods, resulting in widely varying estimates
of quantitative parameters. Some of this variability is inevitably due to the heterogeneity
of studied pathologies and study objectives. However, even studies with similar populations
and target tissues have reported significantly different parameter estimates (see Table A.3).
One reason for this inconsistency is the limited comparability between estimates obtained
using different tracer kinetic models; this has been demonstrated in the MSSII cohort, where
the three tracer kinetic models resulted in significantly different KTrans and vp values despite
being based on the same acquisition protocol and participants (see chapter 4). While same-
model comparisons are more likely to be valid, there is also a wide range of other factors
that influence tracer kinetic parameters. As discussed previously, two of the most influential
aspects are accurate measurements of patient-individual T1 and vascular input functions (VIF)
(Cheng, 2008; Just et al., 2011; Parker et al., 1996; Roberts, 1997; Schabel and Parker, 2008).
Moreover, details of the acquisition protocol (including overall acquisition time, temporal and
spatial resolution) impose limitations on data analysis methods and influence tracer kinetic
parameters (Cramer et al., 2014; Fluckiger et al., 2012; Heisen et al., 2010; Kershaw and
Cheng, 2010). Further factors that can influence DCE-MRI measurements are the scanner
field strength (Pineda et al., 2015), contrast agent type and dose (Chwang et al., 2014) and
region of interest (ROI) selection (Braunagel et al., 2015).
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Compared with conventional applications, studies of tissues with largely intact blood-brain
barrier (BBB) are particularly sensitive to the above-mentioned sources of variability. The
availability of an external data set provided the opportunity to investigate the inter-study com-
parability of DCE-MRI methods for the measurement of subtle BBB disruption. The work
presented in this chapter focuses on the secondary analysis of DCE-MRI data that targets the
same tissue types as the MSSII data, but was acquired using a very different MRI protocol.
The purpose of this work was to identify the tracer kinetic modelling approach most suitable
for these data and to compare the results to the findings in the MSSII cohort.
6.2. Study description
This section describes the external study data, courtesy of the research team at the Università
Campus Bio-Medico in Rome, Italy. Study design, participant recruitment and data collection
were performed in the Diagnostic Imaging Unit, led by Prof Bruno Beomonte Zobel. The
research team consisted of Dr Yuri Errante, Dr Carlo A Mallio, Dr Laura Scarciolla, Dr Luciano
Carideo and Dr Carlo C Quattrocchi, who kindly permitted me to perform a secondary analysis
of their DCE-MRI data and to include it in this thesis. Throughout this work, the study will be
referred to as the CBMS (Campus Bio-Medico Study).
6.2.1. Participants
The data made available included 31 adult subjects who underwent MRI scanning in the
Diagnostic Imaging Unit at the Campus Bio-Medico in Rome, Italy. All subjects had presented
to their general practitioner with non-specific neurological symptoms such as mild headaches
or subjective memory complaints, but showed no severe or focal neurological deficits. In order
to exclude an underlying neurological disorder, they were referred for a head MRI examination.
Patients that showed abnormalities of non-vascular origin (e.g. tumours, n = 2) were excluded
from this analysis. Furthermore, four participants were excluded due to incomplete data (n =
3) or ‘tissueing’ of contrast agent (n = 1). The remaining 25 participants (10 men and 15
women, average age of 64.7±15.6 years) displayed a wide range of white matter hyperintensity
(WMH) burden, with white matter disease being mild in 15/25 patients and moderate to severe
in 10/25 patients.
6.2.2. MRI procedures
MRI scanning was performed on a 1.5 T scanner (Magnetom Avanto, Siemens Healthcare,
Erlangen, Germany) in the Diagnostic Imaging Unit at the Università Campus Bio-Medico
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in Rome. DCE-MRI was performed using the time-resolved imaging with stochastic traject-
ories (TWIST) technique. TWIST consists of three-dimensional T1-weighted gradient echo
acquisitions with partial k-space undersampling, i.e. the center of k-space (region A) is sampled
more frequently than the periphery of k-space (region B) in order to reduce the acquisition time
(Lim et al., 2008; Vogt et al., 2007). This method has previously been used in DCE-MRI of
breast cancer (Fusco et al., 2012), astrocytoma (Jia et al., 2013) and uterine fibroids (Davenport
et al., 2013). The degree of TWIST undersampling is described by two parameters: %A and
%B. %A determines the proportion of the central region A; for this study %A was chosen as
0.3, i.e. 30% of k-space is fully sampled each time. %B specifies the relative sampling density
of region B and was chosen as 0.25; thus, 25% of k-space points in region B are sampled
each time (i.e. four acquisitions are needed to completely fill region B of the k-space). Other
acquisition parameters were the following: flip angle α = 12◦, TR/TE = 4.2/1.6 ms; resulting
in-plane matrix size of 128×128 with a pixel size of 2.03×2.03 mm; 64, 72 or 80 slices with a
thickness of 2 mm were acquired to achieve whole-brain coverage. DCE-MRI consisted of 30
consecutive acquisitions; depending on the number of slices, the temporal resolution was 6.3 s,
7.0 s or 8.2 s respectively (n = 18/6/1), leading to an overall acquisition time of 3.15 min,
3.50 min or 4.10 min. It should be noted that this is approximately the temporal range that was
discarded in the MSSII data. 0.1 mmol/kg of contrast agent (gadodiamide, Gd-DTPA-BMA,
Omniscan, General Electric Healthcare, Amersham, UK) were administered at the beginning of
the second acquisition as an intravenous bolus at a constant flow rate of 3 ml/s, followed by 20
ml saline flush. Three additional TWIST acquisitions were obtained prior to contrast adminis-
tration with flip angles of 5◦ and 15◦ respectively for calculation of T10. The imaging protocol
also included conventional diagnostic sequences; these varied between patients depending on
their symptoms at presentation but always included an axial fluid attenuated inversion recovery
(FLAIR) acquisition with TR/TE/TI= 11460/102/2360 ms, 320×280 acquisition matrix, pixel
size 0.94×0.94 mm, 37 slices with slice thickness of 3 mm and a 0.9 mm slice gap.
6.3. Methods
This section describes the secondary analysis of the CBMS data described above. All image
processing and analyses described in this section were performed by myself.
6.3.1. Image processing
All MR images were converted from DICOM to NIfTI format. Moreover, the FLAIR image
and all TWIST images were aligned to the first TWIST image with rigid-body transformations
using FSL-FLIRT (Jenkinson et al., 2002). As in the MSSII cohort (see section 3.3), obtaining
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an arterial input function (AIF) from the internal carotid artery proved to be difficult due to
partial volume and inflow effects. Instead, a VIF was extracted from a single voxel in the
superior sagittal sinus (SSS) that provided the highest peak signal enhancement and smooth
variation during the DCE-MRI time course (assessed visually using the ‘Timeseries’ view in
FSLView). Multiple small ROIs were manually placed in WMH using the FLAIR image;
normal-appearing white matter (NAWM) and deep/subcortical grey matter (DGM) ROIs were
placed in the first 12◦ TWIST image using the same template as in chapter 5, but avoiding
WMH visible in the FLAIR image. An example of ROI placement is shown in Figure 6.1;
this approach was chosen because tissue segmentation using the MCMxxxVI method was not
feasible in the CBMS data, which did not include all the necessary structural images.
For each time point, the median signal intensity was calculated over all ROIs for the same tissue
and converted to signal enhancement as described previously (see section 3.3.1). T10 values
were calculated based on the 5◦ and 15◦ TWIST acquisitions using equation 3.1. The contrast
agent concentration was then estimated using equation 3.2 with r1/r2 = 4.6/6.9 s−1mM−1
(Rohrer et al., 2005). Negative concentration values were set to zero.
6.3.2. Tracer kinetic modelling
Quantitative analysis of the measured contrast agent concentration curves was approached in
the same manner as described in chapter 4, starting with the identification of suitable tracer
kinetic models. Firstly, the assumptions made by some models do not apply to brain tissues
with largely intact BBB. Furthermore, although the temporal resolution of 6.3 s to 8.3 s is
significantly higher than in the MSSII cohort, it is not sufficient to reliably estimate flow
(de Bazelaire et al., 2011; Essig et al., 2013). Blood flow measurements rely on an accurately
and rapidly sampled AIF; in addition to suffering from a low temporal resolution, the VIF could
only be extracted from the SSS and, thus, is delayed and dispersed relative to the arterial input.
These two constraints are similar to the situation in the MSSII cohort, and limit the range of
suitable models to the same set of three nested models (steady state, Patlak and modified Tofts
models). All three models were fitted to the measured contrast agent concentration curves as
described in section 4.2. As before, the competing models were ranked according to the Akaike
information criterion (AIC), a data-driven approach that accounts for the trade-off between
goodness-of-fit and model complexity.
6.3.3. Computer simulations
As discussed previously, a good model fit does not guarantee that the assumptions made by the
model are valid with respect to the specific acquisition protocol and that the fitted parameters
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Figure 6.1.: Example of ROI placement in the CBMS cohort. Images show three different
slices of the first 12◦ TWIST image (top row) and the corresponding slices of the FLAIR image
(bottom row). Several small rectangular ROIs were placed in NAWM, DGM and WMH. The
VIF was extracted from a single voxel in the SSS.
are accurate. Consequently, numerical simulations were performed in order to theoretically
investigate the validity of potentially suitable models (as identified through the data-driven
model selection described above). All simulations were based on the framework described
in section 4.3 and implemented in MATLAB (MathWorks, Natick, MA, USA). First, a high-
resolution (∆ t = 0.1 s) VIF was generated by fitting the generic function introduced by Parker
et al. (2006) to the population-average VIF measured in the CBMS DCE-MRI data with an
overall acquisition time of 3.25 min. As before, the whole-blood VIF was converted to blood
plasma concentration using the formula cp = cb/(1−Hct), with Hct = 0.45. Simulated tissue
concentration curves were generated by convolving this VIF with the impulse response function
of the two-compartment exchange model (2CXM) (Sourbron and Buckley, 2013). PS and
vp values were chosen to represent the range of values obtained in normal-appearing tissue
and WMH; ve was chosen to be 0.2 (Syková and Nicholson, 2008) and Fp values between
10 ml/100g/min and 50 ml/100g/min were selected to represent typical values for NAWM,
WMH and DGM (Brickman et al., 2009). The VIF and tissue concentration curves were then
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down-sampled to the experimental temporal resolution (∆ t = 6.5 s). The models were fitted to
the down-sampled curves by non-linear minimisation of the sum of squared residuals; finally,
the fitted parameters were compared with the ‘true’ parameters used to generate the synthetic
data. In order to investigate the influence of signal drift, the simulations were repeated after
adding a signal drift of 0.08 %/min to both the tissue curve and the VIF.
6.4. Results
6.4.1. Tissue characteristics
Table 6.1 presents the cohort average T10 values, which are broadly similar to the T10 values
obtained in the MSSII cohort. An example of DCE-MRI tracer dynamics by tissue type
is shown in Figure 6.2. Signal enhancements in NAWM, WMH and DGM ranged from
approximately 3% to 20%, with DGM showing the highest enhancement levels, followed by
WMH and NAWM. The tissue curves found in the CBMS cohort resembled the dynamics
measured in the MSSII cohort (see Figure 3.10), with contrast agent concentrations in NAWM,
WMH and DGM ranging between 0.01 mM and 0.03 mM. In contrast, the peak concentration
of the VIF was significantly lower in the CBMS cohort compared to the MSSII cohort. This
difference may be due to partial volume effects as a result of the larger voxel size; this is also
consistent with the large spread seen in blood T10 values.
Table 6.1.: T10 values by tissue type (CBMS cohort). T10 values obtained in the MSSII
cohort are shown for comparison; all values are given as cohort mean ± standard deviation.
Tissue type T10 (s)






An example of tracer kinetic model fitting in a single patient is shown in Figure 6.3. Generally,
the three different models provided very similar fits in NAWM and DGM, indicating that the
one-parameter steady state model sufficiently describes the data. On the other hand, contrast
agent concentrations in WMH stayed slightly higher during the later stage of the acquisition,
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(a) Signal intensity (b) Signal enhancement
(c) Contrast concentration
Figure 6.2.: Example of DCE-MRI tracer dynamics by tissue type (CBMS cohort). Graphs
show the (a) signal intensity, (b) signal enhancement and (c) contrast concentration curves over
time for a single patient that is representative of the cohort. Values were obtained from the
median signal of all voxels in each tissue type. Y-axis scales for the tissue and SSS curves are
shown on the left and right respectively.
which could not be captured by the steady state model. This finding suggests that there is
non-negligible BBB leakage in WMH and, thus, a more complex model may be required to ac-
curately fit the data. These observations were confirmed by analysis of the Akaike weights (see
Figure 6.4). In NAWM and DGM, the steady state model was chosen as the most appropriate
model in the vast majority of patients. However, model choice was less clear-cut in WMH,
where the steady state model was sufficient to describe the measured tracer kinetics in 45%
of patients, but the Patlak model was preferred in 36% of patients. In all tissues, the modified
Tofts model was in general the least suitable choice of the three models; thus, it was disregarded
in all subsequent analyses.
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(a) NAWM (b) WMH
(c) DGM
Figure 6.3.: Example of tracer kinetic model fitting (CBMS cohort). The graphs show
the measured contrast agent concentrations and the corresponding model fits in (a) NAWM,
(b) WMH and (c) DGM of a single patient.
6.4.3. Tracer kinetic parameters
A comparison of tracer kinetic parameters obtained with the Patlak and steady state models
is provided in Table 6.2. The vp estimates obtained using the Patlak model were significantly
lower compared to the steady state model (p < 0.001 using Wilcoxon’s signed rank test). In
comparison with the MSSII cohort, the vp values obtained in the CBMS cohort are of the same
order of magnitude but approximately twice as high. The Patlak KTrans estimates in WMH are
approximately three times higher in the CBMS cohort than in the MSSII cohort. Since the
data-driven model selection did not reveal an obviously dominant model in WMH, the validity
of both the steady state and Patlak models were investigated using computer simulations before
deciding on the best approach for obtaining quantitative parameters.
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(a) Akaike weights for each model and tissue type (b) Optimum model according to Akaike weights
Figure 6.4.: Model selection according to Akaike weights (CBMS cohort). (a) Comparison
of Akaike weights between the steady state, Patlak and modified Tofts models in all tissue
types (the results for the three models are colour-coded as shown in (b)) (b) bar graph showing
the percentage of patients in which a particular model was selected as the optimum model
according to Akaike weights.
Table 6.2.: Tracer kinetic parameters by tissue type (CBMS cohort). Values are shown as
cohort median and interquartile range (data not generally normally distributed) for each tissue
type. Values obtained in the MSSII cohort are shown for comparison.
NAWM WMH DGM
Steady state model
vp ( · 10−2) 1.26 [0.95, 1.97] 1.27 [0.95, 2.38] 2.12 [1.50, 2.98]
Patlak model
vp ( · 10−2) 1.20 [0.90, 1.72] 1.12 [0.75, 1.92] 1.96 [1.37, 2.98]
KTrans ( · 10−4 min−1) 2.45 [0.02, 4.80] 12.09 [4.42, 18.40] 2.08 [0.00, 9.70]
MSSII cohort (Patlak model)
vp ( · 10−2) 0.57 [0.32, 0.80] 0.72 [0.40, 1.07] 1.20 [0.94, 1.43]
KTrans ( · 10−4 min−1) 2.75 [1.85, 4.12] 3.91 [2.80, 4.94] 3.85 [2.83, 4.68]
6.4.4. Model validity
Figure 6.5 shows the synthetic VIF that was used in all computer simulations; the paramet-
ers of the fitted generic function introduced by Parker et al. (2006) were as follows: A1 =
0.62 mmol ·min, A2 = 0.12 mmol ·min, σ1 = 0.33 min, σ2 = 0.10 min, T1 = 0.95 min, T2 =
0.68 min, α = 0.78 mmol, β = 0.13 min−1, s = 7.45 min−1, τ = 1.35 min.
The results of simulations performed to determine the validity of the steady state model are
shown in Figure 6.6, which compares the fitted vp (steady state model) with the ‘true’ vp used
to generate synthetic signal-time curves (2CXM model). For low PS and high Fp, vp was
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Figure 6.5.: High temporal resolution VIF generated for the simulation study (CBMS).
The VIF was generated by the generic function introduced by Parker et al. (2006) to the
population-average VIF measured in the CBMS DCE-MRI data. Shown is the whole-blood
VIF, which was converted to blood plasma concentration using the formula cp = cb/(1−Hct),
with Hct = 0.45.
accurately estimated; however, the assumption of negligible exchange across the BBB results
in a systematic overestimation of vp for high PS. Moreover, the assumption of infinite blood
flow leads to underestimation of vp at low flow values (as found in, for instance, WMH).
Figure 6.7 shows the accuracy of tracer kinetic parameters obtained with the Patlak model. The
model performance was highly sensitive to differences in blood flow, with low flow resulting
in significant underestimation of vp and overestimation of KTrans. This is consistent with the in
vivo finding of lower vp estimates obtained using the Patlak model compared to the steady state
model (see Table 6.2). In contrast to the simulations performed for the MSSII data, KTrans and
vp were not largely independent of one another. Due to the short overall acquisition time, the
addition of signal drift did not lead to further significant errors in estimated parameters (data
not shown as there was no visible difference to Figures 6.6 and 6.7).
6.5. Discussion
DCE-MRI analysis was performed in an external patient cohort, which shared some imaging
findings with the MSSII cohort. Although the target tissues were the same in both cohorts
(NAWM, DGM and WMH), the acquisition protocols and methods were vastly different, par-
ticularly with regard to temporal resolution and overall acquisition time. Consequently, the data
analysis methods applied in the MSSII were not directly transferable. A previous analysis of the
CBMS data set was performed by the research team at the Campus Bio-Medico using the ori-
ginal Tofts model (Errante et al., 2013), since this was the default method in the manufacturer’s
commercial software tool (Tissue 4D, Siemens Healthcare, Erlangen, Germany). However,
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Figure 6.6.: Simulated accuracy of steady state model vp (CBMS). Relationship between
2CXM blood plasma volume vp values and corresponding fitted steady state model vp. Results
are shown for two different Fp, PS and vp values. For all simulations, ve was set to 0.2. The
grey line represents the identity line.
this method disregards the signal contribution from intravascular tracer, which is dominant
in normal-appearing brain tissues, and hence is not appropriate in this setting (Sourbron and
Buckley, 2011). Data-driven model comparison revealed that the one-parameter steady state
model was sufficient to describe the tracer dynamics in NAWM and DGM, indicating that
there is no significant BBB leakage in normal-appearing tissues during the acquisition time
of approximately 3 min to 4 min. This finding is consistent with a model selection study
by Bagher-Ebadian et al. (2012) in glioblastoma patients, which used a similar DCE-MRI
protocol with regard to temporal resolution and overall acquisition time. In WMH, there was
no clear preference for one model; while the steady state model provided an adequate fit in
45% of patients, there was a trend towards an advantage of the Patlak model. This suggests
that there may be increased BBB leakage in WMH compared to normal-appearing tissues;
however, the short overall acquisition time is most likely not sufficient to capture slow contrast
extravasation and, thus, does not allow for reliable quantification of subtle BBB leakage.
Several other studies with longer measurement durations have indeed reported non-zero KTrans
values in normal-appearing tissues (Cramer and Larsson, 2014; Montagne et al., 2015) and
WMH (Taheri et al., 2011a); nonetheless, it should be noted that some of this apparent leakage
may be accounted for by the confounding effect of scanner drift (see chapter 5).
Since there was no obviously dominant model in WMH, applying a single model to the whole
patient cohort may bias parameter estimates. Alternatively, the steady state or Patlak model
could be chosen based on the AIC for every individual patient and tissue. However, as discussed
previously, providing a good fit does not guarantee that the model assumptions are valid and
that the fitted parameters are accurate. Consequently, numerical simulations were performed
in order to investigate the validity of the steady state and Patlak models with regard to the
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(a) Relationship between blood plasma volume vp and fitted Patlak vp
(b) Relationship between permeability surface area product PS and fitted Patlak KTrans
Figure 6.7.: Simulated accuracy of Patlak parameters (CBMS). Relationship of (a) blood
plasma volume vp and (b) permeability surface area product PS values, with corresponding
fitted Patlak parameters. Results are shown for two different Fp, PS and vp values. For all
simulations, ve was set to 0.2. The grey line represents the identity line.
acquisition protocol in the CBMS. For both models, the assumption of infinite flow led to
errors in estimated parameters at low flow values. The Patlak model was particularly sensitive
to differences in blood flow, with low flow resulting in significant underestimation of vp and
overestimation of KTrans. WMH are well-known to have reduced blood flow (Brickman et al.,
2009; Marstrand et al., 2002); consequently, the Patlak model is unlikely to provide reliable
estimates of either vp or PS in WMH in this dataset. The computer simulations also confirmed
that the steady state model overestimates vp when PS is high, which may lead to inaccurate
vp values in WMH if there is indeed non-negligible leakage across the BBB. Nevertheless, the
magnitude of this error is limited by the subtle nature of any potential BBB leakage likely in
WMH and small compared to the flow-induced errors in Patlak parameters. In the MSSII, the
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confounding effect of blood flow was minimised by excluding data acquired during the first
pass of the contrast bolus. Due to the short overall acquisition time in the CBMS cohort,
a similar approach would disregard the majority of the acquired data and, hence, was not
considered appropriate. Consequently, we conclude that the steady state model, although
limited, is the most suitable model for analysis of the DCE-MRI data in the CBMS cohort.
As a result, the only quantitative parameter that could be obtained with reasonable accuracy in
the CBMS cohort is the blood plasma volume vp.
The tracer kinetic analyses performed in this chapter are likely to suffer from errors in VIF
estimation. Firstly, it was not possible to obtain an AIF from a feeding vessel due to partial
volume and inflow effects. The VIF extracted from the SSS is subject to bolus delay and
dispersion (Sourbron and Buckley, 2013). While the differences between arterial and venous
responses were negligible in the MSSII due to the very low temporal resolution, they were
captured with the higher temporal resolution in the CBMS and can introduce significant errors
in tracer kinetic modelling (Calamante, 2005). Secondly, there was a very large spread of T10
values obtained in the SSS. This uncertainty in T10 leads to bias in contrast agent concentra-
tions (Schabel and Parker, 2008), which, in turn, affect tracer kinetic modelling results. Thirdly,
the extracted VIFs showed very slow enhancement with unusually low peaks, suggesting that
the contrast was injected by hand and at a slow rate; unfortunately, this could not be confirmed
with the research team at the Università Campus Bio-Medico in Rome. Another possible
explanation for the unusual VIF shape could be a confounding effect of the partial k-space
undersampling employed in the TWIST sequence (see further discussion below). Since all
subsequent analyses were dependent on the measured VIF, this may have introduced significant
errors in tracer kinetic parameters and simulation results. In cases like this, where it is not
possible to obtain reliable AIF measurements, the reproducibility of tracer kinetic parameters
can be increased by using a generic AIF (Parker et al., 2006). However, factors such as age,
heart rate, haematocrit and kidney function have been shown to cause inter-patient variability
in the AIF (Port et al., 2001). Using an assumed AIF does not account for these individual
variations and can, hence, also introduce systematic errors (that might be correlated with
variables of interest) in tracer kinetic parameters (McGrath et al., 2009).
The TWIST sequence that was used to acquire the DCE-MRI data in the CBMS cohort was
initially proposed for MR angiography. High temporal resolution is achieved by partial k-space
undersampling: while the k-space centre is fully sampled at each time frame, the periphery is
only partially sampled and missing points are shared with the previous or subsequent images
to allow for reconstruction with full k-space data. Similar sequences have recently been intro-
duced by all major MRI manufacturers, including General Electric’s TRICKS (time resolved
imaging of contrast kinetics) and Philips’ 4D-TRAK (4D-time resolved MR angiography with
keyhole). Since then, these methods have been increasingly applied in DCE-MRI because
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they offer significantly improved temporal resolution. However, it is unclear how the unique
method of k-space undersampling influences the measured signal dynamics. Although it has
been shown that measurements from TRICKS/TWIST DCE-MRI acquisitions closely match
those from full-k-space-sampling acquisitions in the human breast (Tudorica et al., 2012) and
in the rabbit aorta (Kershaw and Cheng, 2011), the effects of k-space undersampling on the
assessment of brain tissues have not yet been evaluated.
The difficulty in obtaining reliable quantitative parameters in the CBMS cohort highlights
the importance of well thought-out study design. Both the temporal resolution and the total
duration of the scan need to be carefully optimised with regard to the nature of the tissue
being investigated and the target parameters. In order to quantify blood flow, a temporal
resolution in the order of 1 s to 2 s is required (de Bazelaire et al., 2011; Essig et al., 2013).
For accurate measurement of the BBB leakage, the scan duration needs to be long enough for
significant contrast extravasation to occur; hence, target tissues with largely intact BBB (e.g.
normal-appearing tissues) require longer scanning times than highly permeable tissues (e.g.
tumours). Unfortunately, neither of these two requirements was fulfilled in the CBMS data,
which consists of whole-brain MRI acquisitions with an overall scan duration of approximately
3 min to 4 min. The temporal resolution of 6.3 s to 8.2 s is too slow to reliably estimate flow
(de Bazelaire et al., 2011; Essig et al., 2013), but fast enough to make quantitative measure-
ments highly dependent on blood flow. In order to avoid such potential pitfalls of study design,
numerical simulations should be performed prior to a study using the planned acquisition
parameters. As discussed previously, whole-brain coverage is desirable when assessing diffuse
diseases such as cerebral small vessel disease (SVD). However, decreasing the spatial coverage
could have allowed for a higher temporal resolution and enabled blood flow measurements.
Alternatively, increasing the overall acquisition time would have facilitated the quantification
of BBB leakage. In this case, the temporal resolution can be relaxed further in order to improve
spatial resolution and minimise partial volume effects.
The availability of an external data set promised an opportunity to investigate inter-study
comparability of DCE-MRI measurements in cerebral SVD. The MSSII and CBMS cohorts
displayed broadly similar tracer dynamics in NAWM, DGM and WMH. The small discrepan-
cies may be caused by the different types of contrast agent used in the two studies (Chwang
et al., 2014). Furthermore, differences may be accounted for by differences in ROI placement
(Braunagel et al., 2015). DCE-MRI analysis in the MSSII cohort was based on whole-tissue
segmentation masks; unfortunately, it was not possible to apply the same segmentation method
in the CBMS cohort, because the necessary structural sequences were not available for all
patients. The only tracer kinetic parameter that could be obtained in both the CBMS and
MSSII cohorts is the blood plasma volume vp. The estimates obtained in the CBMS cohort
were approximately twice as high as in the MSSII cohort; due to the number of dissimilarities
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between the CBMS and MSSII, it is hard to pinpoint the origin of these differences. Firstly,
the vp values were obtained with different models as a result of the particular limitations
imposed by temporal resolution and overall acquisition time. Comparisons of tracer kinetic
models within both cohorts showed that vp estimates obtained using the Patlak model were
significantly lower compared to the steady state model, which may partly explain higher vp
estimates in the CBMS cohort. Secondly, the work presented in chapter 5 showed that the long
DCE-MRI acquisitions in the MSSII were most likely influenced by signal drift, which causes
a systematic underestimation of vp. Thirdly, the lower spatial resolution in the CBMS data
led to uncertainty in VIF estimation; higher vp estimates in the CBMS cohort may partly be
accounted for by the lower apparent VIF concentrations. Lastly, differences in measured blood
volumes may be due to true variations between the patient cohorts. Although the patient groups
were of similar age and both exhibited a range of cerebral SVD features, the MSSII exclusively
recruited patients who had had a minor stroke. In contrast, participants of the CBMS presented
with a wide range of mild, non-specific neurological symptoms. In order to systematically
investigate the influence of a particular factor on tracer kinetic parameters, as many details
of the study protocol as possible should be kept the same. However, as demonstrated in this
chapter and in the literature review (chapter 2), this is seldom the case in independent studies;
consequently, a lack of inter-study comparability is a major problem in DCE-MRI.
6.6. Conclusion
The work presented in this chapter focused on the secondary analysis of DCE-MRI data ac-
quired at the Università Campus Bio-Medico in Rome, Italy. The purpose of this chapter was
to identify the tracer kinetic modelling approach most suitable for the particular acquisition
protocol in the CBMS (which was vastly different to the protocol employed in the MSSII)
and to compare the results to the findings in the MSSII cohort. Due to the nature of the
acquisition protocol it proved difficult to obtain reliable quantitative parameters in this cohort.
For instance, the scan duration of approximately 3 min to 4 min was not long enough to reliably
capture subtle BBB leakage. Moreover, the temporal resolution of approximately 6.5 s was
not sufficient to quantify blood flow; unaccounted differences in blood flow were shown to
introduce significant errors in estimated tracer kinetic parameters, particularly the permeability-
surface area product PS. Consequently, the only quantitative parameter that could be obtained
with reasonable accuracy in the CBMS cohort is the blood plasma volume vp using the steady
state model. The findings of this chapter highlight the importance of carefully planned study
design and of understanding the limitations of quantitative DCE-MRI measurements. Since the
application of DCE-MRI to pathologies associated with subtle BBB disruption is a relatively
new research area, there has been limited investigation of or guidance on appropriate meth-
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odology. As a result, acquisition parameters, postprocessing and analysis approaches differ
widely between studies. This leads to significant differences in tracer kinetic parameters: here,
vp estimates obtained in the CBMS cohort were approximately twice as high as in the MSSII
cohort. The increasing research in this field (including work arising from this thesis (Heye
et al., 2016a) and related investigations by e.g. Cramer and Larsson (2014) and Montagne et al.
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7. Blood-brain barrier permeability and
blood volume in cerebral small vessel
disease
The purpose of this chapter is to analyse the dynamic contrast-enhanced MRI (DCE-MRI)
parameters measured in the Mild Stroke Study II (MSSII) cohort and to investigate whether
they are linked to small vessel disease (SVD) burden and progression. In particular, this
chapter presents the MSSII cohort characteristics and compares the Patlak parameters obtained
in chapter 4 between different tissue types (section 7.3.1), examines the associations of KTrans
and vp with patient characteristics (section 7.3.2) and SVD imaging markers (section 7.3.3).
Furthermore, this chapter investigates whether measurements of blood-brain barrier (BBB)
leakage and blood volume predict disease progression over one year (section 7.3.4). Some
contents of this chapter have been published in Heye et al. (2016a).
7.1. Introduction
Cerebral SVD is responsible for about a fifth of all strokes worldwide and about a quarter of
ischaemic strokes (Sudlow and Warlow, 1997). Despite this large burden of cerebral SVD, the
underlying pathological processes are still largely unknown (see section 1.1.3). Disruption of
the BBB can explain many of the imaging and pathological observations related to SVD and,
hence, may play an initiating role in the development of SVD (Wardlaw et al., 2003). BBB
leakage has previously been shown to increase subtly with advancing age (Farrall and Wardlaw,
2009), mild cognitive impairment (Montagne et al., 2015), vascular dementia (Taheri et al.,
2011b), lacunar stroke (Topakian et al., 2010; Wardlaw et al., 2009) and increasing amount of
white matter hyperintensities (WMH) (Wardlaw, 2010). Most groups studying subtle BBB
disruption have used semi-quantitative approaches for the analysis of DCE-MRI data (see
chapter 2). These approaches provide a simple measurement of contrast uptake, but are difficult
to interpret regarding physiologically relevant properties (e.g. BBB permeability, blood flow,
blood volume).
As detailed in chapters 3 and 4 of this thesis, quantitative DCE-MRI measurements of BBB
permeability and blood volume were obtained in the MSSII cohort of patients exhibiting a
spectrum of SVD severity. This work aimed to investigate the association between these
128 7. BBB Permeability and blood volume in cerebral SVD
parameters and SVD imaging features at baseline and one year follow-up and, thus, shed light
on the role of BBB disruption in cerebral SVD.
7.2. Methods
7.2.1. Participants
The details of patient recruitment, inclusion and exclusion criteria have been given in sec-
tion 3.2.2. In short, 264 adult patients with mild, i.e. anticipated to be non-disabling, lacunar
or cortical ischaemic stroke were recruited from the local stroke services. This chapter focuses
on the role of BBB disruption in cerebral SVD; consequently, all analyses in this chapter are
based on the subset of the MSSII cohort that successfully underwent DCE-MRI between one
and three months after the index stroke.
7.2.2. Data collection and analysis
The following sections will provide a brief summary of the data collection procedures in the
MSSII that are relevant for this chapter; please refer to section 3.2.3 for detailed information.
Clinical assessments
All participants underwent an initial clinical assessment as soon as possible after stroke onset
by a qualified stroke physician. The clinical research fellow (Dr Stephen Makin) collected
demographic details, clinical data, life style information and medical history, including atrial
fibrillation, ischaemic heart disease and peripheral vascular disease. Hypertension was defined
as blood pressure of 140/90 mmHg or greater on presentation or a previous diagnosis. Smokers
were defined as currently smoking or having given up within the previous 12 months and
non-smokers as having never smoked or having given up more than 12 months previously.
Diabetes was defined as a previous or new diagnosis at presentation following the World Health
Organisation criteria for diagnosis of diabetes. Hypercholesterolaemia was defined as a total
cholesterol level (measured from blood samples taken during clinic) above the recommended
level of 5 mmol/L or a previous diagnosis.
One year after the first presentation, all participants were invited for a follow-up clinical and
MRI assessment. If patients were unable or declined to return for the MRI scan, the clinical
research fellow obtained as much clinical information as possible by phone, from the patient’s
medical records, a relative or carer. Collected clinical data were similar to those obtained at the
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initial assessment and included a complete medical history of the previous year, in particular
whether the patient had suffered from a recurrent neurovascular event (i.e. a transient ischaemic
attack (TIA) or a further stroke).
Diagnostic MRI and SVD imaging markers
As part of the initial assessment, all 264 patients underwent a diagnostic MRI scan on the
same 1.5 T MRI scanner. The protocol included three-dimensional (3D) T1-weighted (T1W)
inversion recovery prepared spoiled gradient echo (GRE), T2-weighted fast spin echo, T2*-
weighted GRE, fluid attenuated inversion recovery, susceptibility-weighted imaging and diffu-
sion tensor MRI acquisitions. All MRI scans were assessed by an experienced neuroradiologist
(Prof Joanna M Wardlaw), who was blinded to the clinical findings and recorded the presence
and location of an index stroke lesion and old stroke lesions, including lacunes. WMH burden
was rated from 0 (none) to 3 (severe) using the Fazekas scale; for this analysis, the Fazekas
scores for periventricular and deep white matter (WM) were summed, resulting in total score
ranging from 0 to 6. The presence of enlarged perivascular spaces (EPVS) was rated on a score
from 0 (none) to 4 (>40) for the midbrain, hippocampus, basal ganglia and centrum semiovale;
a combined EPVS score was calculated by adding up the scores for the subregions, yielding a
score ranging from 0 to 16. Deep and superficial cerebral atrophy were each rated on a scale
from 1 (mild) to 6 (severe) in comparison to a standard age matched template (Farrell et al.,
2009); for this analysis, the scores were added up to a total atrophy score, ranging from 2 to
12. Total numbers of microbleeds were obtained by adding up the numbers counted in each
subregion (deep WM, basal ganglia, grey matter (GM) and WM junction, external/internal
capsule, thalamus and posterior fossa) and both hemispheres of the brain. The acute stroke was
classified as lacunar or cortical subtype by a panel of stroke experts using the clinical syndrome
and MRI finding of a relevant small subcortical or cortical infarct. In case of discrepancies
between the clinical and imaging appearance, the imaging subtype was used.
The diagnostic MRI was repeated at approximately one year after the first assessment using the
same 1.5 T MRI scanner. As before, the structural MRI scans were assessed by Prof Joanna M
Wardlaw, who recorded the same features (on the same scales) as described above and was
blinded to the baseline imaging and clinical findings. For statistical analysis, the degree of
disease progression over one year was summed in an ordinal ‘SVD progression score’ that
ranges from 0 to 5. One point on this scale was awarded for each of the following compared
to baseline: (i) recurrent neurovascular event (i.e. TIA, further stroke or new stroke lesion on
imaging), (ii) worsening of Fazekas score, (iii) worsening of brain atrophy score, (iv) worsening
of EPVS score and (v) increased number of microbleeds. This approach was chosen because it
allows for analysing the combined progression of the various SVD features as one disorder; a
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similar method has been used previously to measure the total MRI load of cerebral SVD (Staals
et al., 2014).
Tissue segmentation and volume measurements
The brain tissues and volumes were extracted semi-automatically by Dr Maria del C Valdés
Hernández. As described in section 3.2.4, segmentation masks were generated for the intracra-
nial volume (ICV) and the following tissue types (see Figure 3.3): cerebrospinal fluid (CSF),
normal-appearing WM (NAWM), WMH, deep/subcortical GM (DGM) and recent stroke le-
sions (RSL). The resulting segmentation masks were used to calculate the brain tissue volume
as a percentage of ICV (%BTV) and WMH volume as a percentage of ICV (%WMHV). All
image analysis was performed blind to clinical data.
DCE-MRI measurements
Participants returned approximately one to three months after presentation for DCE-MRI,
which consisted of 20 consecutive 3D T1W spoiled GRE acquisitions with a temporal res-
olution of 73 s and a total acquisition time of approximately 24 min. For calculation of T10,
two additional 3D spoiled GRE acquisitions were obtained prior to contrast administration with
flip angles of 2◦ and 12◦ respectively.
DCE-MRI were processed by myself on a region of interest (ROI) basis as described in sec-
tion 3.3. Firstly, average T10 values and contrast agent concentration curves were calculated for
each tissue type. Secondly, the Patlak model was fitted to the curves (see chapter 4), yielding
the parameters KTrans and vp that provide quantitative measurements of BBB leakage and blood
plasma volume, respectively.
7.2.3. Statistical analyses
Differences in KTrans and vp values between tissue types were investigated using Wilcoxon’s
signed rank test, since the data were not generally normally distributed. For each tissue
type, the relationship between Patlak parameters and age was investigated using Pearson’s
correlation coefficient. Furthermore, both KTrans and vp were tested for differences between
stroke subtypes and sexes using Wilcoxon’s rank sum test.
Associations between the Patlak parameters and SVD imaging markers were investigated using
a three-step approach. Firstly, simple linear regression analysis was performed for KTrans and
vp in each tissue type as the dependent variable and one of the following SVD features as
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explanatory variable: WMH burden, atrophy, number of microbleeds, number of lacunes,
EPVS score. Secondly, predictors of KTrans and vp were investigated using multiple linear
regression models with all SVD imaging markers as predictors and correction for age, stroke
subtype and gender. Thirdly, multiple linear regression analysis was performed in order to
investigate whether the found significant relationships also survive correction for vascular risk
factors (hypertension, hypercholesterolaemia, diabetes, smoking) and T10, which is known to
influence tracer kinetic parameters (Armitage et al., 2011).
Ordinal logistic regression was used to investigate predictors of disease progression over one
year. The following variables at baseline were used as predictors of the SVD progression score:
KTrans and vp in each tissue type, age, stroke type, %WMHV, %BTV and vascular risk factors
(hypertension, hypercholesterolaemia, diabetes, smoking).
All regressions were assessed by examination of the differences between the data and model
predictions, and collinearity by variance inflation factors. All statistical analyses were per-
formed by myself in Matlab (MathWorks, Inc., MA, USA).
7.3. Results
7.3.1. Baseline cohort characteristics
Of the 264 patients recruited, 56 did not undergo DCE-MRI because they were too unwell
or declined to have the scan. Of the 208 patients that underwent DCE-MRI, data suitable
for analysis was obtained in 201 (data for seven subjects were rejected due to ‘tissueing’ of
contrast, technical faults during the scan or unacceptable data quality caused by patient move-
ment). The baseline characteristics of this sub-cohort, including SVD imaging markers and
DCE-MRI parameters, are detailed in Table 7.1. For all following linear regression analyses,
the WMH and brain tissue volumes %WMHV and %BTV were used as quantitative measure-
ments of WMH and atrophy burden because they provide continuous variables; qualitative and
quantitative measurements were highly correlated (see Figure 7.1).
A comparison of Patlak parameters between tissue types is shown in Figure 7.2; all differences
between tissue types were significant (p < 0.001) except for KTrans in WMH and DGM and vp
in WMH and RSL. In particular, KTrans and vp were significantly higher in WMH compared
to NAWM; KTrans was significantly higher in RSL compared to all other tissues. Exemplary
contrast agent concentration curves and the corresponding Patlak fits for patients at different
ends of the disease spectrum are presented in Figure 7.3.
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(a) WMH burden (b) Atrophy
Figure 7.1.: Relationship between visual rating scores and volume measurements. Graphs
showing the relationship between (a) Fazekas score and percentage WMH volume (%WMHV)
and (b) atrophy score and percentage brain tissue volume (%BTV). The degree of correlation
was investigated using Spearman’s R; the correlation coefficient and p-value are indicated for
each relationship.
Figure 7.2.: Comparison of fitted Patlak parameters between tissue types. Boxplots
showing the distribution of KTrans (left) and vp (right) in the different tissue types. Brackets
with ‘n.s.’ indicate non-significant differences with p > 0.50; all other differences between
tissue types are significant with p < 0.001 (brackets omitted for clarity). Reprinted from Heye
et al. (2016a).
7.3.2. Associations with age, gender and stroke type
Figure 7.4 shows the relationship between the Patlak parameters and age. Both KTrans and
vp decreased with age in NAWM, WMH and DGM; the association remained statistically
significant after correction for stroke subtype, gender and SVD imaging markers in all three
tissues for KTrans and in WMH for vp (see Table 7.2).
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(a) Patient with low WMH burden (b) Patient with high WMH burden
(c) Patient with low amount of atrophy (d) Patient with high amount of atrophy
(e) Patient with lacunar stroke (f) Patient with cortical stroke
Figure 7.3.: Examples of contrast dynamics in patients at different ends of the SVD
spectrum and different tissue types. Subfigures (a) to (f) are showing exemplary data for
six different patients of the MSSII cohort. A single axial slice of the FLAIR image is shown on
the left; the graphs on the right display the contrast agent concentration over time in a particular
tissue type and the corresponding Patlak fit.
Table 7.3 provides a comparison of Patlak parameters between lacunar and cortical stroke
patients, who share similar risk factors and medication histories but were previously found
to differ in BBB functionality (Wardlaw et al., 2009). KTrans was significantly higher in recent
cortical compared to lacunar stroke lesions (p = 0.02); this association survived correction for
age, gender and SVD imaging markers (see Table 7.2). An additional simple linear regression
analysis showed that KTrans in RSL is significantly positively associated with the infarct size
(β = 1.0·10−8 min−1mm−3; p < 0.001), which is likely to account for the difference between
stroke subtypes. No other tissues showed significant differences between lacunar and cortical
stroke patients. A comparison of Patlak parameters between genders is provided in Table 7.4.
In all tissue types, KTrans and vp were higher in men compared to women; there was no
significant difference in age between men and women (p = 0.71).
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(a) Relationship between KTrans and age
(b) Relationship between vp and age
Figure 7.4.: Relationship between Patlak parameters and age. Graphs showing (a) KTrans
and (b) vp as a function of age in the different tissue types. Grey lines are the least squares linear
regression fit; Pearson’s correlation coefficient R and p-value are indicated for each tissue type.
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Table 7.1.: Baseline characteristics of the MSSII cohort (DCE-MRI subset). Descriptive
statistics for demographic, clinical and imaging variables including DCE-MRI parameters in
the different tissue types. Values for continuous imaging variables and ordinal scores are given
as cohort median and interquartile range, because they were not generally normally distributed;
age is given as cohort mean and standard deviation. Please note that these values apply to the
subset of patients that had usable DCE-MRI data (n = 201); descriptive statistics for the whole




Gender (% female) 39.3
Clinical variables





Combined Fazekas score 3 [2, 5]
Combined Atrophy score 4 [2, 6]
Microbleeds present (%) 16.4
Lacunes present (%) 26.4
Combined EPVS score 5 [4, 6]
Imaging variables
Structural MRI
WMH volume (%) 0.91 [0.31, 2.36]
Brain tissue volume (%) 80.45 [77.03, 84.18]
Stroke lesion volume ( ·103 mm3) 1.82 [0.88, 6.78]
DCE-MRI
KTrans ( ·10−4 min−1)
NAWM 2.75 [1.85, 4.12]
WMH 3.91 [2.80, 4.94]
DGM 3.85 [2.83, 4.68]
RSL 5.02 [3.24, 7.25]
vp ( ·10−2)
NAWM 0.57 [0.32, 0.80]
WMH 0.72 [0.40, 1.07]
DGM 1.20 [0.94, 1.43]
RSL 0.72 [0.39, 1.05]
7.3.3. Associations with SVD imaging features
The results of all simple linear regression analyses between SVD features at baseline and
Patlak parameters are provided in Table 7.5. Most significant associations between DCE-MRI
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Table 7.2.: Multiple linear regression analyses of DCE-MRI parameters and SVD imaging
markers at baseline. Separate models were fitted for KTrans and vp in each tissue type
as dependent variable and age, stroke type, gender, WMH volume %WMHV, brain tissue
volume %BTV, number of microbleeds, number of lacunes and EPVS score as explanatory
variables. Results are given as β coefficient, 95% confidence interval (CI) and p-value.
Tissue Predictor K
Trans ( ·10-5 min-1) vp ( ·10-4)
β (95% CI) p β (95% CI) p
NAWM Age (years) −0.33 (−0.63, −0.03) 0.031 −0.4 (−1.0, 0.25) 0.23
Gendera −4.5 (−9.3, 0.36) 0.069 −2.4 (−13, 7.9) 0.65
Stroke subtypeb −3.5 (−8.1, 1.2) 0.15 6.0 (−4.0, 16) 0.24
%WMHV (%) 0.54 (−1.2, 2.3) 0.55 2.3 (−1.5, 6.1) 0.23
%BTV (%) 0.045 (−0.57, 0.66) 0.89 0.97 (−0.36, 2.3) 0.15
EPVS score 0.63 (−0.50, 1.8) 0.27 −0.38 (−2.8, 2.0) 0.76
Microbleeds −0.11 (−0.55, 0.34) 0.64 0.6 (−0.36, 1.6) 0.22
Lacunes −1.3 (−3.6, 1.1) 0.29 −0.98 (−6.0, 4.0) 0.70
WMH Age (years) −0.43 (−0.75,−0.097) 0.011 −1.2 (−2.1, −0.24) 0.014
Gendera −4.5 (−9.7, 0.79) 0.095 −9.8 (−25, 5.0) 0.19
Stroke subtypeb −0.021 (−5.1, 5.1) 0.99 6.4 (−8.0, 21) 0.38
%WMHV (%) 0.88 (−1.1, 2.8) 0.37 −7.3 (−13, −1.8) 0.0090
%BTV (%) −0.26 (−0.93, 0.42) 0.45 −0.024 (−1.9, 1.9) 0.98
EPVS score 0.16 (−1.1, 1.4) 0.79 −0.7 (−4.2, 2.8) 0.69
Microbleeds −0.0065 (−0.49, 0.48) 0.98 0.75 (−0.63, 2.1) 0.28
Lacunes −1.5 (−4.1, 1.0) 0.24 −1.8 (−9.0, 5.4) 0.62
DGM Age (years) −0.67 (−0.96, −0.37) <0.001 −0.61 (−1.3, 0.12) 0.099
Gendera −2.9 (−7.6, 1.9) 0.23 −3.3 (−15, 8.3) 0.57
Stroke subtypeb −2.7 (−7.3, 1.9) 0.25 6.3 (−5.0, 18) 0.27
%WMHV (%) 1.4 (−0.4, 3.1) 0.13 1.3 (−3.0, 5.6) 0.55
%BTV (%) −0.70 (−1.3, −0.089) 0.025 0.57 (−0.92, 2.1) 0.45
EPVS score 0.18 (−0.92, 1.3) 0.74 −1.9 (−4.6,0.82) 0.17
Microbleeds −0.10 (−0.54, 0.34) 0.64 0.7 (−0.38, 1.8) 0.20
Lacunes −0.93 (−3.2, 1.4) 0.43 1.2 (−4.5, 6.9) 0.67
RSL Age (years) −0.59 (−1.6, 0.47) 0.27 −0.5 (−1.7, 0.75) 0.43
Gendera −7.9 (−26, 9.9) 0.38 −4.6 (−26, 16) 0.67
Stroke subtypeb −23 (−39, −5.7) 0.0093 −11 (−31, 8.7) 0.26
%WMHV (%) −2.1 (−8.4, 4.1) 0.50 −2.7 (−10, 4.7) 0.47
%BTV (%) −1.9 (−4.1, 0.28) 0.088 −0.14 (−2.7, 2.4) 0.91
EPVS score 1.3 (−2.8, 5.4) 0.53 −0.6 (−5.4, 4.2) 0.80
Microbleeds −0.12 (−1.7, 1.4) 0.87 1.2 (−0.57, 3.0) 0.18
Lacunes −1.1 (−8.5, 6.3) 0.77 −4.6 (−13, 4.1) 0.29
aMale=0, female=1, bcortical=0, lacunar=1
parameters and SVD features were found for vp in WMH, which was significantly negatively
correlated with WMH volume, cerebral atrophy and EPVS score (see Figure 7.5). After
correction for age, stroke type, gender and all other imaging features (see Table 7.2), only the
association with %WMHV remained statistically significant (β = −7.3·10−4; p = 0.0090).
This relationship also survived correction for vascular risk factors and T10 (see Table 7.6).
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Table 7.3.: Comparison of Patlak parameters between lacunar and cortical stroke
patients. Summary of group-average KTrans and vp for lacunar versus cortical stroke patients
in the different tissue types. Given values are the cohort median and interquartile range;
Wilcoxon’s rank-sum test was used to test for differences between groups.
Tissue K
Trans ( ·10-4 min-1) vp ( ·10-2)
Lacunar Cortical p Lacunar Cortical p
NAWM 2.73 [1.93, 3.86] 2.77 [1.80, 4.21] 0.36 0.58 [0.37, 0.79] 0.54 [0.25, 0.80] 0.24
WMH 3.95 [2.82, 4.87] 3.81 [2.77, 4.96] 0.90 0.73 [0.45, 1.07] 0.70 [0.37, 1.08] 0.47
DGM 3.85 [2.81, 4.53] 3.87 [2.88, 4.75] 0.61 1.21 [0.98, 1.45] 1.17 [0.90, 1.39] 0.27
RSL 4.51 [3.13, 6.14] 5.71 [3.56, 8.35] 0.02 0.71 [0.28, 1.00] 0.73 [0.48, 1.13] 0.14
Table 7.4.: Comparison of Patlak parameters between male and female patients. Summary
of group-average KTrans and vp for men versus women in the different tissue types. Given values
are the cohort median and interquartile range; Wilcoxon’s rank-sum test was used to test for
differences between groups.
Tissue K
Trans ( ·10-4 min-1) vp ( ·10-2)
Male Female p Male Female p
NAWM 2.99 [2.17, 4.22] 2.59 [1.60, 3.67] 0.05 0.58 [0.29, 0.76] 0.56 [0.34, 0.80] 0.87
WMH 4.07 [2.95, 4.99] 3.69 [2.42, 4.94] 0.14 0.78 [0.48, 1.10] 0.67 [0.34, 1.00] 0.07
DGM 4.06 [3.07, 4.82] 3.62 [2.42, 4.39] 0.03 1.20 [0.94, 1.45] 1.19 [0.94, 1.39] 0.66
RSL 5.25 [3.15, 7.61] 4.54 [3.54, 6.68] 0.44 0.73 [0.46, 1.03] 0.67 [0.28, 1.06] 0.31
Using simple linear regression, none of the SVD imaging markers was a significant predictor
of KTrans. However, in the multivariate model, KTrans in DGM was negatively associated
with brain tissue volume (β = −0.70·10−5 min−1/%; p = 0.025). This relationship was also
significant in the multivariate linear regression model with additional correction for vascular
risk factors and T10 (see Table 7.7).
7.3.4. Disease progression at one year follow-up
180 of the 201 patients returned for a follow-up MRI assessment approximately one year after
the initial stroke. 32 of these patients (17.8%) had a recurrent neurovascular event between
baseline and one year follow-up. 10 patients (5.6%) showed an increase in Fazekas score,
while brain atrophy progressed in 27 subjects (15.0%) and EPVS in 29 subjects (16.1%). 17
participants (9.4%) had more microbleeds at follow-up than at baseline. 32 patients (17.8%)
showed disease progression in more than one of these features, i.e. SVD progression score > 1
(see Figure 7.6).
Table 7.8 provides the results of the ordinal logistic regression analyses of disease progression
at one year follow-up. The strongest predictor of SVD progression was the WMH burden
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Table 7.5.: Simple linear regression analyses of DCE-MRI parameters and SVD imaging
markers at baseline. Separate models models were fitted for KTrans and vp in each tissue type
as dependent variable and one of the following SVD imaging features as explanatory variable:
WMH volume %WMHV, brain tissue volume %BTV, number of microbleeds, number of
lacunes, EPVS score. Results are given as β coefficient, 95% CI and p-value.
Predictor Tissue K
Trans ( ·10-5 min-1) vp ( ·10-4)
β (95% CI) p β (95% CI) p
%WMHV (%) NAWM −0.49 (−1.9, 0.91) 0.49 0.29 (−2.7, 3.3) 0.85
WMH −0.33 (−1.8, 1.2) 0.67 −11 (−15, −6.6) <0.001
DGM −0.13 (−1.5, 1.3) 0.85 −1.6 (−4.9, 1.8) 0.37
RSL −1.9 (−6.8, 3.1) 0.46 −3.7 (−9.4, 2.0) 0.20
%BTV (%) NAWM 0.41 (−0.025, 0.84) 0.064 1.2 (0.32, 2.1) 0.0083
WMH 0.24 (−0.23, 0.71) 0.31 2.4 (1.0, 3.8) <0.001
DGM 0.15 (−0.29, 0.58) 0.51 1.4 (0.34, 2.4) 0.0096
RSL −1.0 (−2.6, 0.57) 0.21 0.63 (−1.2, 2.5) 0.50
Microbleeds NAWM −0.13 (−0.55, 0.29) 0.54 0.51 (−0.39, 1.4) 0.27
WMH −0.023 (−0.48, 0.43) 0.92 −0.44 (−1.8, 0.93) 0.53
DGM −0.091 (−0.51, 0.33) 0.67 0.39 (−0.63, 1.4) 0.45
RSL −0.089 (−1.5, 1.3) 0.90 0.56 (−1.0, 2.2) 0.49
Lacunes NAWM −0.41 (−2.5, 1.7) 0.70 1.1 (−3.4, 5.6) 0.64
WMH −0.37 (−2.6, 1.9) 0.75 −2.0 (−8.8, 4.9) 0.57
DGM 0.14 (−2.0, 2.3) 0.90 2.2 (−2.9, 7.3) 0.40
RSL −2.0 (−8.5, 4.5) 0.55 −5.2 (−13, 2.3) 0.17
EPVS score NAWM 0.19 (−0.78, 1.2) 0.70 −0.044 (−2.1, 2.0) 0.97
WMH −0.051 (−1.1, 1.0) 0.92 −3.8 (−7.0, −0.65) 0.018
DGM 0.027 (−0.95, 1.0) 0.96 −1.5 (−3.9, 0.81) 0.20
RSL −0.21 (−3.7, 3.3) 0.91 −2.0 (−6.1, 2.1) 0.34
(see Figure 7.7(a)). The odds ratio for %WMHV at baseline was 1.5 (p < 0.002), i.e. the
odds of disease progression increased by approximately 50% per point increase in WMH
volume. Moreover, vp in NAWM and DGM was a significant positive predictor of SVD
progression score, with high vp increasing the risk of disease progression (odds ratios of 2.8
per absolute percent increase in NAWM vp and 2.3 per absolute percent increase in DGM vp;
p = 0.029/0.044; see Figure 7.7(b)).
7.4. Discussion
The KTrans estimates obtained with the Patlak model were greater in WMH than in NAWM.
This is consistent with some pathology studies (e.g. Tomimoto et al., 1996; Wharton et al.,
2015; Young et al., 2008) and other DCE-MRI studies that reported increased BBB disruption
in areas of WMH compared to NAWM (Hanyu et al., 2002; Taheri et al., 2011b; Topakian
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Figure 7.5.: Relationship between vp in WMH and WMH volume, brain tissue volume and
EPVS score at baseline. Only the association between vp and WMH volume (Pearson’s R =
−0.33, p < 0.001) survived correction for age, sex, stroke type and all other SVD imaging
features (see Table 7.2).
Table 7.6.: Multiple linear regression analysis of vp in WMH and WMH volume at
baseline. WMH vp was regressed against WMH volume %WMHV, corrected for age, stroke
subtype, gender, vascular risk factors and T10. Results are given as β coefficient, 95% CI and
p-value.
Predictor vp in WMH (·10
-4)
β (95% CI) p
%WMHV (%) −9.2 (−14, −4.4) <0.001
Age (years) −1.4 (−2.2, −0.7) <0.001
Gendera −7.9 (−22, 6.2) 0.27
Stroke subtypeb 6.1 (−7.5, 20) 0.38
Hypertension −12 (−26, 2.6) 0.11
Hypercholesterolaemia −7.3 (−22, 7.0) 0.31
Diabetes 6.3 (−15, 27) 0.55
Smokingc −1.1 (−16, 14) 0.89
T10 97 (45, 150) <0.001
aMale=0, female=1, bcortical=0, lacunar=1, ccurrently smoking
or had given up within the previous 12 months
et al., 2010). In contrast, a recent study by Huisa et al. (2015) found increased BBB disruption
in NAWM surrounding the WMH rather than in the WMH themselves, while others failed to
detect any BBB leakage in or around WMH (Wahlund and Bronge, 2000); however, both of
these studies were based on very small patient cohorts (n = 22 and n = 10 respectively). The
highest KTrans values were found in the RSL, comparable to findings of Thornhill et al. (2010)
in acute-phase stroke lesions and known tissue changes from many pathology examinations.
Moreover, KTrans was found to be significantly higher in recent cortical compared to lacunar
stroke lesions; this finding is likely to be accounted for by the greater severity and greater lesion
size of cortical strokes. We did not find increased BBB disruption in normal-appearing tissues
of lacunar compared to cortical stroke patients. This contradicts previous findings of elevated
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Table 7.7.: Multiple linear regression analysis of KTrans in DGM and brain tissue volume
at baseline. DGM KTrans was regressed against brain tissue volume %BTV, corrected for age,
stroke subtype, gender, vascular risk factors and T10. Results are given as β coefficient, 95% CI
and p-value.
Predictor K
Trans in DGM (·10-5 min-1)
β (95% CI) p
%BTV (%) −0.62 (−1.2,0.0046) 0.052
Age (years) −0.57 (−0.88, −0.26) <0.001
Gendera −1.7 (−6.5, 3.0) 0.48
Stroke subtypeb −3.2 (−7.7, 1.4) 0.17
Hypertension −0.91 (−5.7, 3.8) 0.71
Hypercholesterolaemia −2.0 (−6.8, 2.8) 0.41
Diabetes 2.7 (−4.3, 9.7) 0.45
Smokingc 2.5 (−2.5, 7.6) 0.32
T10 6.8 (−12, 25) 0.47
aMale=0, female=1, bcortical=0, lacunar=1, ccurrently smoking
or had given up within the previous 12 months
BBB permeability in NAWM and CSF of lacunar patients (Wardlaw et al., 2009); however, this
earlier study, amongst other differences, used different image processing methods and did not
calculate quantitative DCE-MRI parameters.
Figure 7.6.: Disease progression at one year follow-up. Bar graph showing the frequency of
SVD progression scores. The degree of disease progression was measured using a combined
score, with points being given for a recurrent neurovascular event, increased number of
microbleeds, worsening of Fazekas score, brain atrophy score and EPVS score. Consequently,
patients with a score of 0 did not show any visible disease progression; patients with a score
> 1 showed disease progression in more than one of these features.
KTrans was greater in DGM than in NAWM, which may partly reflect the higher vessel density
and vascular surface area of GM (Schlageter et al., 1999), consistent with the higher measured
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(a) %WMHV (b) vp in NAWM
Figure 7.7.: Predictors of disease progression at one year follow-up. Relationship between
SVD progression score and (a) relative WMH volume %WMHV and (b) blood plasma volume
vp in NAWM at baseline. Both relationships were statistically significant after correction for
age, sex, stroke type, brain tissue volume and vascular risk factors (see Table 7.8).
blood plasma volume and known higher blood flow in DGM structures (Brickman et al., 2009).
KTrans in DGM was also found to increase with brain atrophy after correction for age and
vascular risk factors. A similar association has been found in a study on Alzheimer’s disease,
where the CSF:plasma albumin ratio was positively correlated with the severity of medial
temporal lobe atrophy (Matsumoto et al., 2007). While several perfusion studies have shown
that reduced cerebral blood flow is linked to brain atrophy (Alosco et al., 2013; Kitagawa et al.,
1985; Zonneveld et al., 2015), information about the relationship between BBB permeability
and brain atrophy is scarce. It should be noted that the finding of increased KTrans with low
brain volume may be influenced by collinearity in the statistical analysis as the brain tissue
volume decreases with age, which was also a predictor in the model. However, the relevant
variance inflation factors did not exceed a value of 2.3, which was well below recommended
cut-off points of between 5 and 10 (Stine, 1995).
Age was negatively associated with both KTrans and vp in normal-appearing tissues and WMH.
A reduction in cerebral blood volume with age is consistent with literature reports (Marchal
et al., 1992; Shaul et al., 2014). However, the finding of decreasing KTrans with age contradicts
previous reports. For instance, a comprehensive literature review and meta-analysis (Farrall
and Wardlaw, 2009) found that BBB permeability increases subtly with age (mostly based
on studies using CSF:plasma albumin ratio). This is consistent with pathological studies,
which have shown that the function and structure of the BBB deteriorate during ageing (De
Reuck, 2012; Elahy et al., 2015; Marques et al., 2013; Popescu et al., 2009). However, using
CSF:plasma albumin ratio as a measure of BBB permeability has its own shortcomings (Chen,
2011) and there is very little information on the association between BBB permeability and
age from DCE-MRI studies. Su et al. (1998) showed a non-significant increase in BBB
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permeability with normal ageing in a small study of normal-appearing canine brain tissue,
while a small study by Montagne et al. (2015) found a significant increase of BBB permeability
with age in the hippocampus of non-demented older subjects, but not in other GM structures or
WM. A possible explanation for the apparent decrease of KTrans with age in our study is that the
KTrans measurements (commonly used as a marker of BBB permeability) are equally influenced
by capillary surface area and/or volume, which are assumed not to change with age or other
features in the models. A reduction in capillary density has been reported to occur with ageing
(Brown and Thore, 2011) and is also consistent with our finding of reduction in cerebral blood
volume with age. It is therefore desirable to obtain estimates of vessel density/size in future
studies so as to include them in the permeability calculations. Moreover, it should be noted
that the measurements may also be influenced by cerebral blood flow, which is well-known to
decrease with age (Aanerud et al., 2012; Leenders et al., 1990; Martin et al., 1991; Stoquart-
ElSankari et al., 2007). However, the numerical simulations presented in chapter 4 suggested
that the Patlak parameters are robust to differences in blood flow, making a confounding effect
unlikely.
WMH were found to have greater vp than NAWM. This may seem surprising, since WMH are
often regarded as ‘ischaemic’ lesions and might therefore be expected to have reduced plasma
volume. However, very few studies have measured cerebral blood volume and blood flow in
WMH themselves, as opposed to general measurements in patients with WMH, and the results
are conflicting. While some studies using dynamic susceptibility MRI (DSC-MRI) have repor-
ted reduced blood volume in WMH compared to NAWM, e.g. Sachdev et al. (2004, n = 55), a
positron emission tomography study by Yamauchi et al. (1990, n = 7) found increased blood
volume in WMH compared to NAWM. Marstrand et al. (2002, n = 21) found no significant
difference in blood volume in WMH compared to NAWM; this is also consistent with our
findings in the external SVD patient cohort (see chapter 6, n = 25). A recent 7 T MRI study
found reduced blood volume in deep WMH, but unchanged blood volume in periventricular
WMH (Anderson et al., 2014, n = 23). Although DCE-MRI is a more quantitative marker of
microvascular properties than DSC-MRI, previous studies applying DCE-MRI in SVD have
not reported vp values for WMH. A possible explanation for the higher WMH blood volume
found in this study is that a few WMH are found in tissue that was originally DGM, especially
in the head of the caudate nucleus, where baseline blood volume is likely to be higher than in
WM. However, the volume of hyperintensities in DGM is small compared to the overall WMH
volume and, hence, unlikely to account for the measured differences. Another explanation for
increased plasma volume in WMH arises from cerebrovascular autoregulation mechanisms. In
the early stages of ischaemia, the human brain counteracts a reduction in blood flow with
vasodilation (Kulik et al., 2008; Kunz and Iadecola, 2009). Thus, elevated blood volume
measurements may be due to dilated blood vessels and indicate early stages of tissue damage.
This is also consistent with our finding that raised blood volume measurements in NAWM and
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DGM increase the risk of visible disease progression over one year. However, it should be
noted that all patients included in this study presented with a stroke; consequently, their brains
have most likely been exposed to ischaemic processes for several years and autoregulatory
function may already be impaired (Powers, 1991). Plasma volume in WMH was also found
to decrease with increasing WMH volume, possibly representing advancing tissue damage as
the disease burden increases and there is less tissue to supply. The exact role of cerebral blood
volume and BBB breakdown in WMH remains to be defined; future studies should assess BBB
permeability, cerebral blood flow and blood volume in WMH as well as normal tissues so as to
resolve this issue.
WMH volume at baseline was found to be a strong predictor of disease progression at one year
follow-up. This confirms findings of a number of other studies, which reported a significant
relationship between WMH burden at baseline and WMH progression (Sachdev et al., 2007;
Schmidt et al., 2003; van Dijk et al., 2008) as well as cognitive decline (Benedictus et al., 2015;
Debette et al., 2007). Several other factors have previously been implicated in the progression
of cerebral SVD, including age (Taylor et al., 2003), hypertension (Verhaaren et al., 2013)
and diabetes (Taylor et al., 2003). In the analysis presented in this chapter, none of these risk
factors were significant predictors of SVD progression; this may be due to the follow-up time
of one year, which is short compared to other longitudinal studies. An additional grant from
Chest Heart and Stroke Scotland is currently funding clinical and cognitive follow-up at three
years post stroke; these data will allow future research to investigate predictors of long-term
disease progression and cognitive decline. Unfortunately, there was no DCE-MRI assessment
at follow-up, which could have enabled the investigation into the progression of subtle BBB
disruption and/or the reproducibility of quantitative estimates. This was not included in the
original grant in order to decrease the imaging time at follow-up; this limited the burden for the
patient and, thus, increased the likelihood of the patient returning. It should also be noted that
the analysis performed here only captures the progression of WMH. However, a reduction in
WMH burden was seen in several patients, which is consistent with a recent report of regressing
WMH in ischaemic stroke patients (Cho et al., 2015). A more complex analysis that considers
this apparent ‘shrinkage’ of WMH and investigates its clinical relevance will be performed in
future work.
The statistical analyses presented in this chapter did not include Bonferroni correction for mul-
tiple comparisons. This decision was made because Bonferroni adjustment has been criticised
for being overly conservative and increasing the likelihood of type II errors (Perneger, 1998).
Nevertheless, it should be noted that the significance of reported results may be overestimated
due to multiple comparisons. Moreover, as discussed previously, the analyses presented in this
chapter are limited by the choice of large-tissue ROIs, which do not allow for an investigation
of local variation in DCE-MRI parameters. However, in comparison to recent work (Huisa
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et al., 2015; Montagne et al., 2015), this study provides whole-brain coverage in a large, well
phenotyped patient sample. Semi-quantitative analysis of spatially-relevant subregions (e.g.
NAWM surrounding WMH, similar to the work presented in Muñoz Maniega et al., 2015)
is currently being performed by other researchers in the group; a similar approach using
quantitative DCE-MRI measurements will be considered in future work.
7.5. Conclusion
The purpose of this chapter was to analyse the DCE-MRI parameters measured in the MSSII
cohort with regard to differences between tissue types and associations with general clinical
characteristics, SVD imaging markers and disease progression. KTrans was found to be higher
in WMH than in NAWM, consistent with previous suggestions of increased BBB disruption in
WM pathology. However, there was no evidence that normal-appearing tissue KTrans is higher
in lacunar versus cortical stroke patients, linked to high SVD burden at baseline (in particular,
the amount of WMH, EPVS, microbleeds and lacunes) or predicts disease progression at
one year follow-up. Both KTrans and vp appeared to decrease with advancing age; while
the reduction in cerebral blood volume with age is consistent the literature, the finding of
decreasing KTrans with age contradicts previous reports and may be governed by changes in
capillary shape, size and/or density rather than true change in subtle BBB permeability, i.e.
overall leakage may decrease due to falling surface area, outweighing an increase (if any) in
permeability. Plasma volume was higher in WMH compared to NAWM; this finding may
be explained by vasodilation in response to the expected reduced blood flow in presumed
ischaemic tissue. Moreover, raised blood volume measurements in NAWM and DGM were
found to increase the risk of disease progression over one year, suggesting that elevated blood
volume measurements may indicate early stages of tissue damage due to SVD. The strongest
predictor of disease progression at one year follow-up was the WMH volume at baseline,
which is consistent with literature reports and supports the potential use of WMH volume
as an outcome measure in preventive trials. In order to further clarify the role of BBB dis-
ruption and other microvascular properties in SVD aetiology and progression, future studies
should include longitudinal observations and assess capillary anatomy to complement DCE-
MRI measurements.
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Table 7.8.: Ordinal logistic regression analyses of disease progression at one year follow-
up. The degree of disease progression was measured using a combined score, with points
being given for a recurrent neurovascular event, increased number of microbleeds, worsening
of Fazekas score, brain atrophy score and EPVS score. Separate models models were fitted
for KTrans and vp in each tissue type and age, stroke subtype, WMH volume %WMHV,
brain tissue volume %BTV and T10 at baseline as predictors of SVD progression score.
The model was also corrected for vascular risk factors (hypertension, diabetes, smoking and
hypercholesterolaemia); however, these factors were statistically insignificant and are omitted
from this table for brevity. Results are given as odds ratio, 95% CI and p-value; the odds ratios
express the relative odds of a high SVD progression score per point increase in the predictor
variable.
Tissue Predictor SVD progression score
Odds ratio (95% CI) p
NAWM KTrans ( ·104 min−1) 0.96 (0.78, 1.2) 0.71
vp ( ·102) 2.9 (1.1, 7.4) 0.029
Age (years) 1.0 ( 0.98, 1.1) 0.27
Gendera 0.92 (0.47, 1.8) 0.8
Stroke subtypeb 1.7 (0.91, 3.1) 0.099
%WMHV (%) 1.5 (1.2, 1.9) <0.001
%BTV (%) 0.93 (0.85, 1.0) 0.1
T10 (s) 0.18 (0.0068, 4.7) 0.3
WMH KTrans ( ·104 min−1) 1.0 (0.87, 1.2) 0.7
vp ( ·102) 1.5 (0.74, 3.0) 0.27
Age (years) 1.0 (0.98, 1.1) 0.36
Gendera 0.98 (0.5, 1.9) 0.94
Stroke subtypeb 1.7 (0.92, 3.2) 0.089
%WMHV (%) 1.5 (1.2, 1.9) <0.001
%BTV (%) 0.94 (0.86, 1.0) 0.15
T10 (s) 0.78 (0.059, 10) 0.85
DGM KTrans ( ·104 min−1) 0.95 (0.77, 1.2) 0.6
vp ( ·102) 2.3 (1.0, 5.2) 0.044
Age (years) 1.0 (0.98, 1.1) 0.31
Gendera 0.89 (0.45, 1.8) 0.74
Stroke subtypeb 1.7 (0.92, 3.2) 0.088
%WMHV (%) 1.5 (1.2, 1.9) <0.001
%BTV (%) 0.92 (0.84, 1.0) 0.087
T10 (s) 0.21 (0.016, 2.9) 0.25
RSL KTrans ( ·104 min−1) 0.95 (0.87, 1.0) 0.24
vp ( ·102) 1.3 (0.66, 2.6) 0.44
Age (years) 0.99 (0.94, 1.0) 0.57
Gendera 0.79 (0.35, 1.8) 0.56
Stroke subtypeb 1.7 (0.78, 3.5) 0.19
%WMHV (%) 1.5 (1.2, 2.0) 0.0019
%BTV (%) 0.92 (0.84, 1.0) 0.12
T10 (s) 2.5 (0.50, 12) 0.27
aMale=0, female=1, bcortical=0, lacunar=1
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8. Blood pressure and sodium: association
with magnetic resonance imaging
markers in cerebral small vessel disease
The previous work described in this thesis was embedded into the Mild Stroke Study II (MSSII),
which is a comprehensive clinical study looking at several aspects of cerebral small vessel
disease (SVD). As such, this project benefited from the various assessments other than dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI; e.g. blood markers, cognitive test-
ing and diffusion tensor MRI (DT-MRI)). The work presented in this chapter was performed
within the wider scope of the MSSII and aimed to investigate the association between MRI
findings and blood pressure, dietary salt intake and plasma sodium concentration. The contents
of this chapter are the result of joint work with Dr Michael J Thrippleton, which has been
published in Heye and Thrippleton et al. (2016b). The author and Dr Michael J Thrippleton
contributed equally to the statistical analyses presented in this chapter. The author also provided
the DCE-MRI measurements used in this work; clinical parameters, volume measurements and
DT-MRI parameters were provided by other members of the research team. These contributions
by others will be clearly indicated throughout the text.
8.1. Introduction
As discussed in section 1.1.3 of this thesis, the pathogenesis of cerebral SVD is poorly under-
stood. However, hypertension and other vascular risk factors have been identified. Previous
work revealed associations between blood pressure and white matter hyperintensity (WMH)
burden and between blood pressure and pre-visible white matter damage assessed by DT-MRI
(Aribisala et al., 2014; Maclullich et al., 2009). The influence of dietary salt intake on stroke
incidence and mortality is well-known (Li et al., 2012b) but may be only partly mediated by its
effect on blood pressure (Strazzullo et al., 2009). Plasma sodium concentration is assumed to
be tightly regulated but there is some evidence to suggest that even small variations can affect
physical and mental health in the elderly population (Decaux, 2006; Schrier, 2010). The role
of dietary and plasma sodium in cerebral SVD is unclear.
This work aimed to investigate the association between blood pressure, dietary salt intake and
plasma sodium concentration with MRI findings in the MSSII cohort of patients exhibiting a
spectrum of SVD severity. In particular, this work assessed associations with WMH volume,
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brain tissue volume, DT-MRI measures of tissue integrity and DCE-MRI measurements of
blood-brain barrier (BBB) leakage and cerebral blood volume.
8.2. Methods
8.2.1. Participants
The details of patient recruitment, inclusion and exclusion criteria have been given in sec-
tion 3.2.2. In short, 264 adult patients with non-disabling lacunar or mild cortical ischaemic
stroke were recruited from the local stroke services.
8.2.2. Data collection
This section will provide a brief summary of the data collection procedures in the MSSII that
are relevant for this chapter; please refer to section 3.2.3 for detailed information.
On presentation, the research fellow Dr Stephen Makin collected clinical data, medical and
life style history. Hypertension was defined as blood pressure of 140/90 mmHg or greater
on presentation or a previous diagnosis. Smokers were defined as currently smoking or hav-
ing given up within the previous 12 months and non-smokers as having never smoked or
having given up more than 12 months previously. Pulse pressure (PP) and mean arterial
pressure (MAP) were calculated from the systolic and diastolic blood pressures (SBP and
DBP) as SBP - DBP and 1/3 SBP + 2/3 DBP, respectively. Salt intake was assessed by asking
participants to describe their addition of salt to food during cooking and at the dining table
using the following salt intake score: 1 = always, 2 = often, 3 = occasionally, 4 = rarely, and
5 = never; the mean of the two scores was subtracted from 6 to give an ordinal categorical
variable in the range of 1 (minimum use of salt) to 5 (maximum use of salt) for use in statistical
analyses. Plasma sodium concentration was measured from blood samples taken during clinic
assessment.
As part of the initial assessment, all 264 patients underwent a diagnostic MRI scan on a 1.5 T
MRI scanner. The protocol included three-dimensional (3D) T1-weighted (T1W) inversion
recovery prepared spoiled gradient echo (GRE), T2-weighted fast spin echo, T2*-weighted
GRE, fluid attenuated inversion recovery, susceptibility-weighted imaging and DT-MRI ac-
quisitions. Participants returned approximately one to three months after presentation for DCE-
MRI, which consisted of 20 consecutive 3D T1W spoiled GRE acquisitions with a temporal
resolution of 73 s and a total acquisition time of approximately 24 min.
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8.2.3. Image processing and analysis
Information about brain tissue types and volumes were extracted semi-automatically by Dr
Maria del C Valdés Hernández. As described in section 3.2.4, segmentation masks were
generated for the intracranial volume (ICV) and the following tissue types (see Figure 3.3):
cerebrospinal fluid, normal-appearing white matter (NAWM), WMH, deep/subcortical grey
matter (DGM) and recent stroke lesions. The resulting segmentation masks were used to
calculate the brain tissue volume as a percentage of ICV (%BTV) and WMH volume as a
percentage of ICV (%WMHV).
DT-MRI data were processed by Dr Maria del C Valdés Hernández to generate mean diffusivity
(MD) and fractional anisotropy (FA) parametric images, using in-house software created by
Dr Paul A Armitage (please refer to section 3.2.4 for detailed information). In each patient,
median MD and FA were extracted for NAWM and DGM.
DCE-MRI were processed as described in section 3.3. Our previously published analysis
(Heye and Thrippleton et al. 2016b) focused on a semi-quantitative area under the curve (AUC)
parameter, because the tracer kinetic modelling work presented in chapter 4 was still ongoing.
Since then, the analysis was repeated using the Patlak parameters KTrans and vp, which provide
quantitative measurements of BBB leakage and blood volume.
8.2.4. Statistical analysis
Descriptive statistics in the text are given as mean ± standard deviation. Regressions were
assessed by examination of the differences between the data and model predictions, and col-
linearity by variance inflation factors. All statistical analyses were performed by myself using
Matlab (MathWorks, Inc., MA, USA) and by Dr Michael J Thrippleton using SPSS version 19
(IBM Corp., NY, USA), with support from Dr Francesca Chappell. Predictors of %WMHV
and %BTV were investigated using multiple linear regression models with correction for age,
smoking status, stroke subtype and additional factors given in the text and tables. Residuals
for the %WMHV model were not approximately normally distributed; to correct for this,
the transformed outcome variable ln(0.005+%WMHV) was regressed instead. DGM MD
(units 10−6 mm2s−1) was also transformed to ln(−700+MD) for this reason.
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8.3. Results
8.3.1. Cohort characteristics
A total of 264 subjects were recruited into the study with a mean age of 66.9±11.8 years and
a ratio of 45:55 for diagnosis of lacunar-to-cortical stroke; 39% of patients were smokers and
72% had hypertension. An overview of cohort-average demographic, clinical, and imaging
variables is provided in Table 8.1.
8.3.2. Associations with WMH and brain tissue volume
PP (β = 0.0092 mmHg−1; p = 0.036) and a diagnosis of hypertension (β = 0.46; p = 0.0093)
were significant predictors of increased WMH volume as a percentage of ICV with correc-
tion for age, stroke subtype and smoking status (see Table 8.2 and Figure 8.1). Repetition
of the analysis with replacement of PP and MAP with diastolic and systolic blood pressure
showed that systolic but not diastolic blood pressure was positively associated with transformed
%WMHV (β = 0.0079 mmHg−1; p = 0.040). Salt intake score was also positively associated
with WMH volume (β = 0.14; p = 0.021; see Figure 8.1); further analyses using the separate
scores for cooking and table salt usage were consistent with this finding (β =−0.11/−0.067;
p = 0.020/0.18 for cooking/table salt; note that the coefficient sign change is expected, since
the combined score was inverted). Regression analysis of brain tissue volume with the same
covariates revealed a positive association between plasma sodium concentration and %BTV
corresponding to an absolute increase in brain tissue volume of 2% ICV per 10 mmol/l sodium
(p = 0.019). Age was the most significant factor in the analyses of both %WMHV and %BTV
(p < 0.0001).
8.3.3. Associations with DT-MRI
DT-MRI data were obtained in 262 subjects (DT-MRI data for two subjects were rejected due to
failure of the non-linear image registration). The influence of blood pressure, added salt intake
and plasma sodium concentration on these variables was modelled with correction for smoking,
stroke subtype and age, as well as normalised WMH volume to account for SVD severity
(see Table 8.3). Plasma sodium concentration was negatively associated with MD in NAWM
(β = −1.2·10−6 mm2s−1mmol−1l; p = 0.011) and FA in DGM (β = −0.9·10−3 mmol−1l;
p = 0.021). Salt intake score was negatively associated with FA in DGM (β = −3.4·10−3;
p = 0.0012); additional analyses using the separate scores for salt usage during cooking and at
the table were consistent with this finding (β = 2.0/2.5; p = 0.016/0.0052 for cooking/table
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Table 8.1.: Baseline characteristics of the MSSII cohort. Descriptive statistics for
demographic, clinical and imaging variables including DT-MRI and DCE-MRI parameters
in NAWM and DGM. Values for continuous demographic and clinical variables are given as
cohort mean and standard deviation; values for imaging variables are given as cohort median
and interquartile range, because they were not generally normally distributed.
Parameter n Value
Demographic variables
Age (years) 264 66.9±11.8
Gender (% female) 264 42
Clinical variables
Stroke subtype (% lacunar) 264 45
Hypertension (%) 264 72
Smokera (%) 262 39
Diabetes (%) 264 11
PP (mmHg) 264 63.1±20.1
MAP (mmHg) 264 102.6±15.2
Salt intake score 250 2.7±1.3
Plasma sodium concentration (mmol/l) 260 139.2±3.3
Imaging variables
Structural MRI
WMH volume (%) 264 0.89 [0.31, 2.39]
Brain tissue volume (%) 264 70.68 [67.31, 73.99]
DT-MRI
MD (·10−4 mm2/s)
NAWM 262 7.87 [7.64, 8.10]
DGM 262 7.89 [7.63, 8.28]
FA ( ·10−1)
NAWM 262 2.56 [2.42, 2.69]
DGM 262 2.32 [2.20, 2.47]
DCE-MRI
KTrans ( ·10−4 min−1)
NAWM 201 2.75 [1.85, 4.12]
DGM 201 3.85 [2.83, 4.68]
vp ( ·10−2)
NAWM 201 0.57 [0.32, 0.80]
DGM 201 1.20 [0.94, 1.43]
aCurrently smoking or had given up within the previous 12 months
salt). In NAWM, there were corresponding trends for reduced FA with increasing salt score
(β = −1.3·10−3; p = 0.19) and lower plasma sodium (β = 0.62·10−3 mmol−1l; p = 0.090)
but these were not significant at the two-tailed 5% type 1 error level.
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Figure 8.1.: Relationship between WMH volume and PP, diagnosis of hypertension and
salt intake score. The association between WMH volume and PP (Spearman’s R = 0.26,
p < 0.001) survived correction for age and all other factors listed in Table 8.2. Reprinted from
Heye and Thrippleton et al. (2016b).
Table 8.2.: Multiple linear regression analysis of %WMHV and %BTV. Separate models
models were fitted with %WMHV and %BTV, respectively, as the dependent variable and
PP, MAP, hypertension, salt intake score, plasma sodium, smoking, stroke subtype and age as
explanatory variables. Results are given as β coefficient, 95% confidence interval (CI) and
p-value.
Predictor ln(0.005+%WMHV) %BTV
β (95% CI) p β (95% CI) p
PP (mmHg) 0.0092 (0.00059, 0.018) 0.036 −0.022 (−0.054, 0.011) 0.20
MAP (mmHg) −0.0037 (−0.015, 0.0073) 0.51 0.013 (−0.029, 0.055) 0.55
Hypertension 0.46 (0.11, 0.81) 0.0093 −0.68 (−2.0, 0.65) 0.31
Salt intake score 0.14 (0.021, 0.25) 0.021 0.26 (−0.19, 0.70) 0.26
Sodium (mmol/l) −0.029 (−0.072, 0.014) 0.18 0.20 (0.033, 0.36) 0.019
Smoking 0.31 (−0.0033, 0.63) 0.052 −1.2 (−2.4, 0.039) 0.058
Stroke subtypea 0.27 (−0.023, 0.57) 0.07 −0.40 (−1.5, 0.73) 0.49
Age (years) 0.053 (0.039, 0.067) <0.001 −0.25 (−0.30, −0.20) <0.001
aCortical=0, lacunar=1
8.3.4. Associations with DCE-MRI
Of the 264 patients recruited, DCE-MRI data suitable for analysis was obtained in 201 patients.
DCE-MRI parameters KTrans and vp were modelled using the same covariates as for DT-MRI
data (see Table 8.4). Plasma sodium concentration was positively associated with vp in NAWM
(β = 2.1·10−4mmol−1l; p = 0.0043) and hypertension was a significant negative predictor
(β =−1.3·10−3; p= 0.032). Age was negatively associated with vp in both NAWM and DGM
(p = 0.015/0.0054); age was also the only significant predictor of KTrans in both NAWM and
DGM (negative association, p < 0.001).
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Table 8.3.: Multiple linear regression analysis of DT-MRI measurements. Separate models
models were fitted with MD and FA in NAWM and DGM as the dependent variable and
PP, MAP, hypertension, salt intake score, plasma sodium, smoking, stroke subtype, age
and %WMHV as explanatory variables. Please note that DGM MD was transformed to
ln(−700+MD) to correct for not approximately normally distributed residuals. Results are
given as β coefficient, 95% CI and p-value.
Tissue Predictor MD (·10
-6 mm2s-1) FA ( ·10-3)
β (95% CI) p β (95% CI) p
NAWM PP (mmHg) 0.16 (−0.021, 0.34) 0.083 −0.030 (−0.17, 0.11) 0.68
MAP (mmHg) −0.14 (−0.38, 0.090) 0.23 −0.041 (−0.22, 0.14) 0.66
Hypertension 0.64 (−6.7, 8.0) 0.86 −2.1 (−7.9, 3.7) 0.48
Salt intake score 0.54 (−1.9, 3.0) 0.66 −1.3 (−3.2, 0.63) 0.19
Sodium (mmol/l) −1.2 (−2.1, −0.28) 0.011 0.62 (−0.096, 1.3) 0.09
Smokinga 3.8 (−2.9, 10.) 0.27 −1.5 (−6.8, 3.7) 0.57
Stroke subtypeb 0.60 (−5.7, 6.9) 0.85 −0.047 (−5.0, 4.9) 0.98
Age (years) 1.2 (0.89, 1.5) <0.001 −0.53 (−0.77, −0.28) <0.001
%WMHV (%) 4.9 (2.8, 7.0) <0.001 −4.5 (−6.1, −2.9) <0.001
DGM PP (mmHg) 0.00079 (−0.0018, 0.0033) 0.54 0.056 (−0.095, 0.21) 0.47
MAP (mmHg) 0.0020 (−0.0013, 0.0052) 0.24 −0.094 (−0.29, 0.10) 0.34
Hypertension 0.046 (−0.058, 0.15) 0.39 −3.7 (−9.8, 2.4) 0.23
Salt intake score 0.013 (−0.022, 0.048) 0.46 −3.4 (−5.5, −1.4) 0.0012
Sodium (mmol/l) −0.0027 (−0.015, 0.010) 0.68 −0.90 (−1.7, −0.14) 0.021
Smokinga 0.016 (−0.078, 0.11) 0.74 2.0 (−3.6, 7.6) 0.48
Stroke subtypeb 0.096 (0.0079, 0.18) 0.033 −9.8 (−15, −4.5) <0.001
Age (years) 0.014 (0.0095, 0.018) <0.001 0.088 (−0.18, 0.35) 0.51
%WMHV (%) 0.15 (0.12, 0.18) <0.001 −2.3 (−4.0, −0.56) 0.0097
aCurrently smoking or had given up within the previous 12 months, bcortical=0, lacunar=1
8.4. Discussion
The finding that arterial blood pressure is associated with increased WMH volume is broadly
consistent with the results of previous studies (Aribisala et al., 2014; Maclullich et al., 2009;
Liu et al., 2012; Shrestha et al., 2009; Verhaaren et al., 2013; Waldstein et al., 2012) and
with the hypothesis that sustained pressure elevation and pressure fluctuations in the small
cerebral vessels result in microvascular damage (O’Rourke and Safar, 2005). The independent
association with clinical diagnosis of hypertension, additional to that of PP, likely reflects the
historical effect of blood pressure elevation on vasculature and end organs in addition to that
at the time of the study. Others have shown that WMH volume is also predicted by increased
large artery stiffness, which may be one cause of increased pressure fluctuations in the small
cerebral vessels (Brisset et al., 2013; Poels et al., 2012).
A novel finding of this study is that routinely adding more salt to food, which likely increases
overall dietary salt intake in addition to the amounts of salt already present in food, is associated
with greater WMH volume. There was also a highly significant negative association between
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Table 8.4.: Multiple linear regression analysis of DCE-MRI measurements. Separate
models models were fitted with KTrans and vp in NAWM and DGM as the dependent variable
and PP, MAP, hypertension, salt intake score, plasma sodium, smoking, stroke subtype, age and
%WMHV as explanatory variables. Results are given as β coefficient, 95% CI and p-value.
Tissue Predictor K
Trans ( ·10-5 min-1) vp ( ·10-4)
β (95% CI) p β (95% CI) p
NAWM PP (mmHg) 0.035 (−0.10, 0.17) 0.60 −0.035 (−0.31, 0.24) 0.80
MAP (mmHg) −0.049 (−0.23, 0.13) 0.58 0.037 (−0.33, 0.40) 0.84
Hypertension 4.3 (−1.4, 10.0) 0.14 −13 (−26, −1.2) 0.032
Salt intake score −0.14 (−2.0, 1.7) 0.88 0.11 (−3.7, 4.0) 0.95
Sodium (mmol/l) 0.084 (−0.61, 0.77) 0.81 2.1 (0.66, 3.5) 0.0043
Smokinga −2.6 (−7.8, 2.6) 0.33 −9.3 (−20, 1.4) 0.090
Stroke subtypeb −4.2 (−9.0, 0.45) 0.076 5.5 (−4.1, 15) 0.26
Age (years) −0.46 (−0.71, −0.20) <0.001 −0.66 (−1.2, −0.13) 0.015
%WMHV (%) 0.66 (−0.92, 2.3) 0.41 3.2 (−0.071, 6.4) 0.055
DGM PP (mmHg) 0.098 (−0.034, 0.23) 0.14 −0.081 (−0.39, 0.23) 0.61
MAP (mmHg) −0.031 (−0.20, 0.14) 0.72 −0.048 (−0.46, 0.36) 0.82
Hypertension 2.8 (−2.9, 8.4) 0.33 −11 (−24, 2.4) 0.11
Salt intake score 0.70 (−1.1, 2.6) 0.45 −0.13 (−4.5, 4.3) 0.95
Sodium (mmol/l) −0.43 (−1.1, 0.25) 0.22 1.1 (−0.50, 2.7) 0.17
Smokinga 2.2 (−2.9, 7.4) 0.39 −10 (−22, 2.1) 0.11
Stroke subtypeb −3.4 (−8.0, 1.3) 0.15 5.2 (−5.8, 16) 0.35
Age (years) −0.52 (−0.77, −0.26) <0.001 −0.86 (−1.5, −0.26) 0.0054
%WMHV (%) 1.0 (−0.53, 2.6) 0.196 2.1 (−1.6, 5.8) 0.26
aCurrently smoking or had given up within the previous 12 months, bcortical=0, lacunar=1
the salt intake score and FA in normal-appearing DGM, suggestive of ‘previsible’ reduced
tissue integrity (Aribisala et al., 2014). The interactions between salt intake, blood pressure
and cerebrovascular disease are not fully understood: it is widely accepted that sodium intake
increases blood pressure (Mente et al., 2014) and that hypertension leads to cardiovascular
disease including stroke (He et al., 2013; O’Donnell et al., 2014) and there is indirect evidence
to support the beneficial effects of reducing the salt intake on the incidence of cardiovascular
disease (O’Donnell et al., 2014; Cappuccio and Ji, 2012). Furthermore, epidemiological studies
indicate that salt intake is associated with increased risk of stroke and cardiovascular disease
independently of blood pressure (Aburto et al., 2013; Gardener et al., 2012; Strazzullo et al.,
2009). The findings presented here, which are corrected for blood pressure (both PP and
MAP), hypertension and age (as much as one can), suggest this might also be the case in
cerebral SVD. Studies in the literature addressing the role of sodium in SVD are lacking
and the pathophysiological mechanism of any harm is unclear. A possible direct effect of
salt on the endothelium, in addition to any effect via elevated blood pressure, might account
for the increased stroke risk due to salt beyond that accounted for by hypertension alone:
for example, salt-sensitive (versus salt-resistant) hypertension is associated with peripheral
endothelial dysfunction (Bragulat et al., 2001) which, if also present in the brain, might account
for the dynamic cerebral and systemic endothelial dysfunction seen in several studies of SVD
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(Stevenson et al., 2010) and the increased level of WMH seen here. However, although the
linear model used here fitted the data well, the significance of salt intake score as an independ-
ent predictor of WMH could also be influenced by complex non-linear interactions between
salt intake, blood pressure and vascular disease, which become steeper with advancing age, in
hypertensives and high salt intake (O’Donnell et al., 2014).
In contrast to dietary sodium consumption, plasma sodium concentration did not predict WMH
volume but was associated with brain tissue volume, corresponding to an increase of 2% of
ICV per 10 mmol/l sodium. Lower plasma sodium was also associated with increased MD
in NAWM and increased FA in DGM. The explanations for these associations are unknown
and should be explored in future studies. Changes in brain volume may occur following
acute changes in osmolality, but are thought to be temporary and rapidly reversed following
changes in solute balance (Verbalis, 2010). Furthermore, none of the participants in this
study were either hypernatraemic (defined as [Na]>146 mmol/l) or severely hyponatraemic
([Na]<125 mmol/l), though 13% were mild to moderately hyponatraemic (125≤[Na]≤135
mmol/l). These findings may reflect transient changes related to hydration state, diet, time
of day or other factors. Most patients were managed as outpatients, not being ill enough to
require hospital admission, and were mobile, cognitively competent outpatients with no clinical
evidence of dehydration. However, plasma sodium was also associated with blood plasma
volume measured with DCE-MRI one month later, corresponding to a relative increase in vp in
NAWM of 36% per 10 mmol/l sodium. This finding suggests that part of the association with
brain volume may be accounted for by differences in blood volume; it is also consistent with
our previous analysis based on the AUC as a semi-quantitative measurement of contrast uptake
(Heye and Thrippleton et al., 2016b). It should be noted that most significant correlations with
salt intake and blood pressure were found for volume measurements rather than DCE-MRI
parameters, indicating that DCE-MRI may be of limited clinical use for this application.
All analyses presented in this work were corrected for whether subjects were smokers. In line
with the previous literature, smokers had both greater WMH volume (Staals et al., 2014) and
lower brain volume (Swan and Lessov-Schlaggar, 2007) corresponding to a total brain volume
difference of approximately 1% of ICV.
The results concerning added dietary salt are limited by the qualitative and self-reported nature
of these data. The index, based on a simple questionnaire, was designed for use in a clinical
setting and did not attempt to assess total salt intake, an acknowledged complex task due to
problems with accurate recall, and by the highly variable amounts of salt present in food or
added by manufacturers during processing. However, the index used here may better reflect
salt appetite and long-term exposure to salt. There is no gold-standard way to assess the salt
intake of these patients retrospectively, and even the validity of a 24 hours urine collection,
which is not practical in this cohort, has been questioned (Titze et al., 2013). More complex
156 8. Blood pressure, sodium and salt in cerebral SVD
questionnaires given by a dietician can provide a measure of intake but also depend on self-
report and would not have been appropriate with this cohort of patients. A disadvantage of
both detailed dietary questionnaires and biochemical tests is that they provide a snapshot of
salt consumption, which may not reflect long-term exposure and habits, particularly during
recovery from a stroke where intake may have been influenced by the recent stroke and lifestyle
advice. Future work might focus on a more quantitative assessment of salt intake in patients
presenting with mild stroke. Despite these reservations, the index used here correlated well
with WMH volume and the trend was preserved when assessed using our two separate salt
scores.
A second limitation is that the blood tests, while quantitative, measured plasma sodium con-
centration at a single point in time contemporaneous with measurement of WMH volume,
brain tissue volume, FA and MD but not KTrans and vp. As plasma sodium concentration
shows strong individuality, it is unlikely to vary much unless the patient is over or under
hydrated (Zhang et al., 2014). The plasma sodium concentration can also be influenced by
kidney function, glucose level and medication (13.3% of patients had reduced kidney function
(estimated glomerular filtration rate <60 ml/min/1.73 m2) and 19.3% of patients took the
diuretic medications Bendrofluimethiazide or Furosemide). However, correcting for these
potential confounds made little difference to the results. It should also be noted that the
DT-MRI measurements used in this work were obtained using a single diffusion weighting
factor b, i.e. assuming a simple monoexponential relationship between MRI signal and b value.
However, it is recognised that this assumption does not fully account for tissue behaviour,
so that the diffusion coefficient is sensitive to capillary perfusion (Koh et al., 2011). A more
sophisticated approach using multiple b values can correct for intravoxel incoherent motion (Le
Bihan et al., 1986) and should be considered in future work. Finally, it should be highlighted
that the age range of participants in this study was wide (34 years to 96 years) and findings may
be confounded by age-related effects not fully eliminated by the model; it is therefore desirable
to replicate the findings in a larger study or in a sample with narrower age range.
8.5. Conclusion
This chapter aimed to investigate the association between blood pressure, dietary salt intake
and plasma sodium concentration with MRI findings in the MSSII cohort. This work was
performed within the wider scope of the MSSII; in addition to DCE-MRI parameters, it also
looked at tissue volumes obtained from structural MRI and DT-MRI measurements. Using
multiple linear regression analyses, we showed that arterial blood pressure and diagnosis of
hypertension predict WMH volume in patients with mild stroke. Added dietary salt intake was
also independently associated with WMH. Plasma sodium concentration, while not associated
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with WMH volume, was a significant predictor of brain tissue volume and of blood volume
in NAWM. These results are consistent with previous findings that raised blood pressure is
associated with WMH burden and raise the possibility of an independent role for dietary salt
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9. Discussion and conclusion
It has been suggested that subtle breakdown of the blood-brain barrier (BBB) plays a role
in the pathophysiology of cerebral small vessel disease (SVD). Dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) is widely used for assessing BBB permeability and
other microvascular properties in brain tumours and body tissues, where contrast agent uptake
is typically large and rapid. However, in diseases where leakage is subtle, the magnitude and
rate of enhancement caused by contrast extravasation are extremely low. Consequently, the
optimal approach for quantifying BBB integrity in this situation and the reliability of resulting
measurements is unclear. The main purpose of this thesis was to assess and improve the reli-
ability of quantitative assessment of subtle BBB disruption, in order to illuminate its potential
role in cerebral SVD. After summarising the main findings (section 9.1), this final chapter
outlines the contributions that this work has made towards achieving these goals (section 9.2).
Moreover, this chapter highlights limitations of the work presented in this thesis and suggests
avenues for future research (section 9.3).
9.1. Summary of findings
Part I of this thesis provided an overview of cerebral SVD and DCE-MRI methods. After
introducing the fundamental concepts that the work in this thesis is based on (chapter 1), a
systematic literature review of DCE-MRI methods in the brain was presented (chapter 2). The
review revealed 95 studies that assessed BBB disruption in 18 different pathologies; these
studies showed considerable heterogeneity with regard to image acquisition and analysis meth-
ods. With the majority of studies investigating tumours, the review identified a relative lack
of studies investigating the best methods of measuring low-level BBB disruption in ageing,
dementia or cerebral microvascular disease.
Part II of this thesis focused on the analysis of DCE-MRI data acquired within the scope of an
on-site clinical study of mild stroke patients, the Mild Stroke Study II (MSSII). The DCE-MRI
data acquired in the MSSII consisted of whole-brain acquisitions (with a temporal resolution
of 73 s and an overall acquisition time of approximately 24 min) in 201 patients. In addition
to presenting the study cohort and procedures, chapter 3 addressed several basic aspects of
DCE-MRI processing and analysis. Patient-individual vascular input functions were extracted
from a single voxel in the superior sagittal sinus. Due to low contrast-to-noise ratio (CNR)
and small overall signal enhancement, analysis of the DCE-MRI data on a voxel-by-voxel
basis was found not to be suitable for the detection of subtle changes in BBB functionality.
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Therefore, signal intensity, signal enhancement and contrast concentration profiles as well as
T10 were calculated on a whole-tissue basis for normal-appearing white matter (NAWM), white
matter hyperintensities (WMH), deep/subcortical grey matter (DGM) and recent stroke lesions.
The signal enhancement curves were characterised using the semi-quantitative measurements
AUCbnE and slopeE . Chapter 4 investigated which of several tracer kinetic modelling approaches
was most suitable for assessing subtle BBB disruption in the MSSII patient cohort. A data-
driven model comparison using the Akaike information criterion suggested that the Patlak
model is an appropriate method for measuring vp and low-level KTrans. Numerical simulations
were performed in order to investigate the validity of the Patlak model. The simulations
confirmed that the Patlak model yields reliable estimates of KTrans and vp when PS is low.
By omitting data that is acquired during the first pass of the contrast bolus, accurate parameter
values could be obtained independently of cerebral blood flow and despite the use of a temporal
resolution much lower than is typically employed in DCE-MRI. Semi-quantitative parameters
were shown to correlate with both KTrans and vp and to be highly dependent on blood flow and
T10, thus reflecting a combination of underlying tissue properties.
Part III of this thesis investigated two potential pitfalls in the quantification of subtle BBB dis-
ruption. Firstly, chapter 5 investigated signal drift unrelated to contrast effects and its influence
on tracer kinetic parameters; this was of particular concern due to the long overall acquisition
time of the MSSII data. Drift measurements were performed in a group of healthy volunteers
(n = 15), showing a linear signal increase of approximately 0.08 %/min. Computer simulations
showed that this drift introduces a systematic error when estimating low-level tracer kinetic
parameters. Despite the confounding influence of drift, the simulations indicate that KTrans
and vp estimates remain approximately linear independent functions of the extravasation rate
and plasma volume respectively. Secondly, chapter 6 addressed issues concerning inter-study
comparability and study design, which arose from the retrospective analysis of DCE-MRI data
acquired in an external study, the Campus Bio-Medico Study (CBMS; n = 25). Due to the
nature of the acquisition protocol it proved difficult to obtain reliable quantitative parameters
in this cohort. For instance, the scan duration of approximately 3 min to 4 min was not
long enough to reliably capture subtle BBB leakage. Moreover, the temporal resolution of
approximately 6.5 s was not sufficient to quantify blood flow. Unaccounted differences in
blood flow were shown to introduce significant errors in estimated tracer kinetic parameters,
particularly the permeability-surface area product PS. Consequently, the only quantitative
parameter that could be obtained with reasonable accuracy in the CBMS cohort is the blood
plasma volume vp using the steady state model. The lack of agreed standards for DCE-
MRI assessment of subtle BBB disruption and the effect of unknown drift lead to significant
differences in tracer kinetic parameters: here, vp estimates obtained in the CBMS cohort were
approximately twice as high as in the MSSII cohort, which is unlikely as the patient populations
were similar in many respects.
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Lastly, part IV of this thesis examined the relationship between MRI parameters and clinical
measurements in the MSSII cohort. Chapter 7 investigated the tracer kinetic parameters ob-
tained in part II with regard to differences between tissue types and associations with clinical
characteristics, SVD imaging markers and disease progression. KTrans was found to be higher
in WMH than in NAWM, indicating that the BBB is impaired in white matter pathology.
However, there was no evidence that BBB permeability in normal-appearing tissues is linked
to higher SVD burden or predicts disease progression. Both KTrans and vp appeared to de-
crease with advancing age; the finding of decreasing KTrans with age is inconsistent with other
literature reports and may be governed by differences in capillary shape, size and/or density
rather than indicating change in BBB permeability. Plasma volume was higher in WMH
compared to NAWM; this finding may be explained by vasodilation in response to the expected
reduced blood flow in presumed ischaemic tissue. Plasma volume in WMH was also found to
decrease with increasing WMH volume, possibly representing advancing tissue damage as
the disease burden increases and there is less tissue to supply. Moreover, raised blood volume
measurements in NAWM and DGM were found to increase the risk of disease progression over
one year, suggesting that elevated blood volume measurements may indicate early stages of
tissue damage due to SVD. The strongest predictor of disease progression at one year follow-up
was the WMH volume at baseline. The work presented in chapter 8 investigated the association
of MRI findings with blood pressure, dietary salt intake and plasma sodium concentration. This
work was performed within the wider scope of the MSSII; in addition to DCE-MRI parameters,
it also looked at tissue volumes obtained from structural MRI and diffusion tensor MRI (DT-
MRI) measurements. Using multiple linear regression analyses, it was shown that arterial
pulse pressure and diagnosis of hypertension are positive predictors of WMH volume. Added
dietary salt intake was also independently associated with WMH volume. Plasma sodium
concentration, while not associated with WMH volume, was a significant predictor of brain
tissue volume and of blood volume vp in NAWM.
9.2. Strengths and contributions
9.2.1. Contributions to DCE-MRI methodology for the assessment of
subtle BBB disruption
In the past, DCE-MRI has been mainly applied in body tissues without BBB and in diseases
with large abnormalities in BBB functionality. Consequently, previous reviews of DCE-MRI
methods (Barnes et al., 2012; Bergamino et al., 2014; Jain, 2013; Türkbey et al., 2010) and
attempts to standardise methodology (DCE MRI Technical Committee, 2012; Leach et al.,
2012) have mainly focused on specific applications such as oncology. As far as the author is
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aware, the comprehensive literature review performed within the scope of this project (Heye
et al., 2014) provided the first systematic overview of DCE-MRI methods in the brain that
covers a wide range of applications including ageing, microvascular disease and dementia.
When this project began, there was very little information available relating to the methodology
for measuring low-level BBB disruption. As regards data analysis methods, most groups
studying subtle BBB disruption have applied semi-quantitative analysis approaches (e.g. Hanyu
et al., 2002; Wardlaw et al., 2008; Starr et al., 2009; Topakian et al., 2010; Wahlund and
Bronge, 2000; Wardlaw et al., 2008). The few studies that have used model-based approaches
to quantifying subtle BBB leakage (e.g. Israeli et al., 2011; Taheri et al., 2011b) did not
explicitly justify their methodology or investigate its validity. Data-driven model selection and
simulation studies have recently gained popularity in DCE-MRI, with most studies focussing
on oncology applications (e.g. Bagher-Ebadian et al., 2012; Ewing et al., 2006; Larsson et al.,
2009; Sourbron et al., 2009). A similar approach in the MSSII cohort showed that the Patlak
model is an appropriate method for measuring vp and low-level KTrans. While this finding only
strictly applies to the particular acquisition protocol used in the MSSII, it is consistent with
recent investigations by Cramer and Larsson (2014) and Barnes et al. (2015). The contem-
poraneous work presented in this thesis sets itself apart from these studies by investigating a
much larger clinical cohort and exploring in depth potential technical influences and biological
confounds. Moreover, the MSSII employs a temporal resolution that is significantly lower
than typically used in DCE-MRI. To the best of the author’s knowledge, it has not been shown
previously that accurate quantitative parameters can be obtained despite a very low temporal
resolution. Ultimately, the model selection work presented in this thesis (in combination with
similar work by e.g. Cramer and Larsson, 2014) increases confidence in applying tracer kinetic
models in disorders with subtle BBB disruption and justifies the emerging popularity of the
Patlak model in this situation. However, this work also serves to highlight that low-level tracer
kinetic parameters should be interpreted with caution; for instance, KTrans is often interpreted
as BBB permeability although it is equally influenced by the capillary surface area, which may
dominate measurements if BBB permeability is subtle (see section 9.3).
A novel finding of the work presented in this thesis is that low-level tracer kinetic parameter
measurements are subject to substantial systematic errors introduced by signal drift. Signal
drift measurements are rarely reported in the DCE-MRI literature and the effect of signal drift
has previously been considered negligible (Cramer et al., 2014). This work highlights the im-
portance of measuring drift during DCE-MRI studies in order to assess its magnitude and likely
effects on quantitative parameters. Since this work was undertaken, another study has examined
the effect of signal drift on tracer kinetic parameters using computer simulations (Barnes et al.,
2015); however, these investigations were not accompanied by in vivo measurements. Despite
the confounding influence of drift, tracer kinetic parameters provided (in this case) independent
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indications of BBB integrity and blood plasma volume; while the work presented in this thesis
sounds a note of caution regarding the absolute values of tracer kinetic parameters, it has also
shown that such quantities remain easier to interpret than semi-quantitative measurements.
This thesis has also highlighted the importance of study design and has given some general
guidance on protocol design for investigating diffuse, subtle BBB pathology. For instance,
the finding in the MSSII that accurate estimates of BBB permeability can be obtained despite
a very low sampling rate, means that temporal resolution can be reduced for the benefit of
spatial resolution, whole-brain coverage and CNR. Moreover, the difficulty in obtaining reli-
able measurements of BBB permeability in the CBMS cohort highlighted the importance of
a sufficiently long acquisition time. Numerical simulations have been shown to be a useful
tool for assessing the validity of tracer kinetic models with regard to a particular acquisition
protocol and should be performed before a study protocol is finalised. While it is impossible
to prescribe a universal ‘recipe’ for future studies, this thesis provides researchers interested
in applying DCE-MRI to the measurement of subtle BBB abnormalities with a number of
important aspects to consider.
9.2.2. Contributions to understanding the pathophysiology of cerebral
SVD
Previous on-site clinical studies suggested that cerebral SVD may be associated with abnormal
BBB functionality, which could explain many of the imaging and pathological observations
related to SVD (Wardlaw et al., 2003). The MSSII aimed to confirm these findings and
to investigate whether BBB dysfunction is associated with the presence and progression of
clinical and imaging markers of cerebral SVD. To the best of the author’s knowledge, this
is the first study that provides quantitative measurements of BBB leakage and blood volume
in a large cohort of patients with cerebral SVD. Related studies either only calculate semi-
quantitative DCE-MRI parameters (e.g. Wardlaw et al., 2008; Topakian et al., 2010) or are
based on significantly smaller sample sizes (e.g. Huisa et al., 2015; Montagne et al., 2015;
Taheri et al., 2011a). Moreover, an important advantage of the MSSII compared to other studies
is that it provides DCE-MRI data with whole-brain coverage; this not only better captures the
diffuse nature of the disease, but also facilitates pre-processing steps such as image registration,
which is important in order to compensate for motion and to allow overlay of tissue masks
derived from structural images. In addition, most studies in the field focus on WMH as the
most prominent manifestation of cerebral SVD, but do not cover the whole disease spectrum
(e.g. Hanyu et al., 2002; Huisa et al., 2015; Wahlund and Bronge, 2000). In contrast, all patients
in the MSSII underwent detailed radiological MRI assessment, which quantified several aspects
of SVD in addition to WMH, e.g. including lacunes and microbleeds.
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The work presented in this thesis could not fully clarify the role of BBB leakage and other
microvascular properties in cerebral SVD. On the one hand, the findings of this study are
consistent with increased BBB leakage occurring in WMH, as previously suggested by some
pathology and imaging studies (Tomimoto et al., 1996; Wharton et al., 2015; Young et al., 2008;
Hanyu et al., 2002; Taheri et al., 2011b; Topakian et al., 2010). On the other hand, there was
no evidence that normal-appearing tissue KTrans increases with SVD burden or predicts disease
progression. While this finding does not support the hypothesis that endothelial failure plays
an initiating role in the development of SVD, it should be noted that the KTrans measurements
are likely to be governed by capillary structure rather than BBB permeability; this limitation
will be discussed in detail below. In contrast, experimental work on a relevant rat model,
which has proceeded in parallel with the human MRI work presented here, has confirmed
earlier findings of weak endothelial tight junctions creating a weak BBB that predisposes to
tissue damage and development of SVD (Bailey et al., 2011, 2014). Raised blood volume
measurements in normal-appearing tissues were shown to increase the risk of visible disease
progression over one year, which is a novel finding. Previous studies applying DCE-MRI
in SVD have either not investigated or not reported cerebral blood volume, although it is
closely linked to other microvascular properties such as blood flow. The work presented in
this thesis has provided some mechanistic insight into the role of blood volume in cerebral
SVD and raises the possibility that elevated blood volume measurements may be used as an
early indicator of impending tissue damage due to SVD. Nevertheless, it should be noted
that elevated blood volume measurements were a significantly weaker predictor of disease
progression when compared to WMH volume at baseline. Since DCE-MRI parameters are
also significantly more difficult to obtain and less reliable, DCE-MRI is currently not the most
appropriate technique for predicting SVD disease progression in clinical practice.
This project benefited from the comprehensive design of the MSSII. The availability of various
clinical and imaging data in addition to DCE-MRI (e.g. blood markers and DT-MRI) allowed
for a range of analyses. Consequently, this thesis presented several findings that go beyond
investigating the role of the BBB. For instance, this work has confirmed previous findings
that WMH burden is linked to raised blood pressure and that disease progression in cerebral
SVD patients is strongly predicted by WMH burden at baseline. Furthermore, the finding that
increased dietary salt intake is associated with greater WMH volume raises the possibility of an
independent role for dietary salt in the development of cerebral SVD, consistent with findings
for other cardiovascular diseases (see Heye and Thrippleton et al. 2016b). Overall, the exact
pathological processes that cause cerebral SVD are still largely unknown; nevertheless, the
work presented in this thesis adds to the knowledge in the field and has yielded novel findings
that can be validated or contradicted in future studies.
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9.3. Limitations and future directions
A significant limitation of this work is that the MSSII data had been collected before this
project started, so that it was not possible to make changes to the image acquisition. There are
a number of potential improvements to the imaging strategy, which should be considered in
future research. The DCE-MRI data that formed the basis of this PhD project were acquired
on a 1.5 T MRI scanner using a three-dimensional T1-weighted spoiled gradient echo (GRE)
sequence. While spoiled GRE methods allow for large spatial coverage and high spatial
resolution, they have two main disadvantages. Firstly, they are known to be sensitive to flip
angle inaccuracy and radio frequency (RF) field inhomogeneity (Subashi et al., 2014; Tofts,
2010), particularly at high field strengths (Cheng and Wright, 2006). Indeed, measurements in
healthy volunteers using the same protocol and scanner as in the MSSII showed that significant
signal drift occurs during the acquisition period. This change in signal intensity over time is
most likely caused by instability of instrumental parameters (e.g. flip angle, B0 field), but true
variations in T1 may also contribute to signal drift; this aspect should be investigated using
larger sample sizes. Future studies could reduce the sensitivity to instrumental instability by
employing DCE-MRI methods that consist of repeated T1 measurements (e.g. Shah et al.,
2001), which can self-compensate for changes in the RF field strength and flip angle and for
signal drift. Nevertheless, scanners with stable and homogeneous magnetic fields are important
in order to improve measurements of subtle BBB abnormalities in the future. Secondly, spoiled
GRE methods often suffer from a low signal-to-noise ratio (SNR); in the MSSII, a low SNR was
found to hinder voxel-by-voxel analysis. Technical developments in hardware and acquisition
methods are likely to improve the quality of DCE-MRI data and facilitate the measurement
of subtle BBB abnormalities in the future. For instance, newer scanners with higher field
strengths not only provide a substantially higher SNR, but also have faster gradients that allow
for shorter repetition times. Consequently, future studies should be performed on a newer
scanner with a higher field strength. In addition, a large number of recent studies focus on
the development of efficient imaging techniques, which significantly shorten acquisition times
without compromising spatial resolution (e.g. Jung et al., 2009; Tsao et al., 2003). Strategies
for improving both temporal and spatial resolution often employ partial k-space acquisition
techniques, including keyhole imaging (van Vaals et al., 1993), view-sharing (such as the
TWIST sequence employed in chapter 6) or compressed sensing (e.g. Han et al., 2012). For
further acceleration of DCE-MRI acquisitions, these approaches have recently been combined
with parallel imaging (Rosenkrantz et al., 2015; Yoon et al., 2014). However, it has not yet
been explored in detail how these unique methods of k-space undersampling influence the
measured signal dynamics. Moreover, most methods that significantly shorten acquisition
times inevitably degrade the SNR; in contrast to traditional DCE-MRI applications, this trade-
off is most likely not sensible for the measurement of subtle BBB leakage, where image quality
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is more important than temporal resolution.
As discussed throughout this thesis, DCE-MRI studies are limited by several assumptions
and sources of error. While the presented work directly investigated some of these aspects
(e.g. validity of model assumptions, influence of signal drift), others received relatively little
attention because they have been explored in detail elsewhere (e.g. arterial input function and
T10 measurement). The importance of correcting DCE-MRI signal enhancement profiles for
intrinsic parameters such as T10 and r1 has been highlighted previously. In this study, the DCE-
MRI analysis relied on assumed in vitro values for contrast agent relaxivities. Since relaxivity
measurements are known to vary significantly between tissue samples and different disease
stages (Armitage et al., 2011), this represents a significant weakness and potential source of
error. However, reliable estimation of r1 is challenging so that relaxivity properties of in vivo
brain tissues remain largely unknown. Moreover, T10 was measured using the variable flip
angle method, which is known to be sensitive to RF field inhomogeneities across the brain
(Schabel and Parker, 2008). In future studies, it would be prudent to employ methods that es-
timate the RF field and can correct for flip angle errors, such as DESPOT1-HIFI (Deoni, 2007).
An additional source of error that was not investigated in this thesis is the water exchange
effect. The tracer kinetic models used in this study assume that the water exchange between the
vascular, EES and intracellular compartments is in the fast-exchange limit, i.e. that the tissue
relaxes with a single T1. While the water exchange between the intracellular and extravascular
extracellular space most likely has a negligible effect on DCE-MRI (Bains et al., 2010), Larsson
et al. (2001) found a significant effect of transendothelial water exchange on DCE-MRI derived
parameters in the brain. Particularly in brain tissues with a largely intact BBB, as investigated
here, the assumption of fast water exchange is likely to introduce systematic errors. Although
several models that account for water exchange have been developed (e.g. Carreira et al., 2009;
Li et al., 2005), these typically include a large number of free parameters that could not have
been fitted reliably in the MSSII data. The influence of water exchange effects on low-level
DCE-MRI measurements should be investigated in future studies.
A confounding factor that has been identified here and should be investigated in future work
is the effect of noise and artefacts on low-level tracer kinetic parameters. Due to the small
magnitude of contrast-induced signal changes in normal-appearing tissues, low-level motion
artefacts and Gibbs ringing were found to have a disproportionate effect on voxel-wise maps
of tracer kinetic parameters (see Figure 4.10), possibly because of the high enhancements
in vascular, permeable tissues ghosting into the brain tissue. The influence of noise and
artefacts was reduced by averaging over large regions of interest; however, voxel-wise analysis
is desirable in order to detect local variations in BBB function. Several image processing
techniques have been suggested for denoising (Gal et al., 2008; Taheri and Sood, 2006) of
DCE-MRI data as well as compensation of motion effects (Hamy et al., 2014; Melbourne
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et al., 2011), partial volume effects (Taheri and Sood, 2007) and Gibbs ringing (Di Bella et al.,
2005). It would be interesting to apply these methods in the MSSII data and explore whether
they can improve the quality of voxel-wise tracer kinetic analysis.
The main aim of the MSSII was to investigate whether cerebral SVD is linked to BBB permeab-
ility. However, the DCE-MRI parameter KTrans (or PS) is equally influenced by the capillary
surface area. Microvascular architecture is known to vary with age and disease state (Bailey
et al., 2012; Brown and Thore, 2011) and, thus, is likely to have a significant effect on the
obtained KTrans measurements. In the MSSII cohort, falling capillary density could explain
the apparent reduction in KTrans with advancing age, which is at variance with virtually all
other human and experimental model data on the ageing brain. In order to obtain estimates
of BBB permeability (rather than BBB leakage), future studies should try to determine vessel
density and size. Traditionally, this type of information is obtained by pathologists; however,
problems caused by cerebral SVD are rarely fatal so that pathological studies are not usually
accomplishable in this situation. Recently, a number of MRI techniques have emerged for
in vivo measurement of microvessel density and size (Troprès et al., 2015). While most
of these methods have been applied and validated in pre-clinical studies, Xu et al. (2011,
2012) recently showed that vessel size imaging is feasible in acute stroke patients and can
be combined with perfusion imaging. Since most microvascular properties (structural and
functional) are interrelated, such combined approaches may help future studies to obtain several
complementary parameters in a clinically acceptable imaging time and to investigate the bigger
picture of microvascular changes in cerebral SVD. However, it should be noted that quantitative
vessel size imaging is (just like quantitative analysis of DCE-MRI) based on several simplifying
assumptions (Kiselev et al., 2005) and requires special acquisition sequences. Therefore, it
is not yet well established and its potential for human in vivo applications remains to be
explored.
While the work presented in this thesis has demonstrated that it is possible to obtain quantitative
estimates of subtle BBB leakage using DCE-MRI, uncertainty over the physiological meaning
of these parameters remains. There is a concern that DCE-MRI parameters, particularly when
trying to measure subtle effects, are more dependent on the various sources of error than
on the physiological properties of interest. In order to fully clarify whether DCE-MRI can
provide valid measurements of subtle BBB leakage, comparison studies with ‘true’ measures of
microvascular properties are urgently needed. However, obtaining ground truth measurements
for comparison is often difficult in practice. For instance, other in vivo estimates of BBB
disruption (e.g. the commonly used CSF:plasma albumin ratio) also suffer from limited inter-
pretability (Chen, 2011). As mentioned previously, investigations into the pathophysiology of
cerebral SVD are currently being performed in a relevant rat model (Bailey et al., 2014); while
histopathological studies are difficult to implement in humans, animal models may enable a
170 9. Discussion and conclusion
validation of low-level DCE-MRI measurements as performed previously in other pathologies
(e.g. Ferrier et al., 2007; Knight et al., 2005). Furthermore, the validity of DCE-MRI meas-
urements could be explored theoretically using computational fluid dynamics and phantom
measurements. Phantom- and model-based evaluation methods have recently been developed
for dynamic contrast-enhanced computed tomography (Driscoll et al., 2011; Hariharan et al.,
2013; Peladeau-Pigeon and Coolens, 2013) and could potentially be adapted for DCE-MRI
measurements of subtle BBB leakage.
Finally, BBB disruption is only one of several competing theories that seek to explain the causes
of cerebral SVD (Wardlaw et al., 2013b). Following the MSSII, two on-site clinical studies
have been established to investigate other (possibly related) processes that may play a role in
the pathophysiology of cerebral SVD. For instance, vessel wall thickening was seen in early
pathological studies (Bailey et al., 2012; Gouw et al., 2011); this has lead to the suggestion that
the arterioles might also be stiffer and therefore less able to vasodilate to increase blood supply
when necessary. In order to test this hypothesis, 60 patients with lacunar or cortical mild stroke
are undergoing BOLD (Blood Oxygen Level Dependent) MRI, which combined with a CO2
respiratory challenge enables the measurement of cerebrovascular reactivity in vivo (Rostrup
et al., 1994). Furthermore, there is some evidence to suggest that inflammatory processes are
involved in the development of cerebral SVD (Bailey et al., 2012; Gouw et al., 2011; Fazekas
et al., 1993). Novel MRI techniques can image the uptake of ultrasmall superparamagnetic
iron oxide particles (USPIOs) into inflammatory cells and, thus, detect areas of inflammation
(Dousset et al., 2006). An on-site pilot project currently investigates whether this method
allows for detection of inflammation in cerebral SVD. It is hoped that, in combination with
the work presented here, these investigations will ultimately provide a better understanding of
the pathogenesis of cerebral SVD, which is required to develop effective treatments that can
prevent severe outcomes such as strokes and dementia.
9.4. Final summary
The work described in this thesis has demonstrated that it is possible to estimate subtle BBB
disruption using DCE-MRI, provided that the measurement and data analysis strategies are
carefully optimised. However, absolute values of tracer kinetic parameters should be inter-
preted with caution, particularly when making comparisons between studies, and sources of
error and their influence should be estimated where possible. The exact role of BBB breakdown
and other microvascular changes in SVD pathology remain to be defined; however, the work
presented in this thesis contributes further insights and, together with technical advances, will
help to facilitate optimal study design in the future.
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M., and Glaser, C. (2012). Quantification of perfusion and permeability in multiple sclerosis:
dynamic contrast-enhanced MRI in 3D at 3T. Investigative Radiology, 47(4):252–8.
Ingrisch, M., Sourbron, S., Reiser, M., and Peller, M. (2010). Model selection in dynamic
contrast enhanced MRI: The Akaike Information Criterion. In World Congress on Medical
Physics and Biomedical Engineering, IFMBE Proceedings Volume 25/4, pages 356–358.
Israeli, D., Tanne, D., Daniels, D., Last, D., Shneor, R., Guez, D., Landau, E., Roth, Y.,
Ocherashvilli, A., Bakon, M., Hoffman, C., Weinberg, A., Volk, T., and Mardor, Y. (2011).
The application of MRI for depiction of subtle blood brain barrier disruption in stroke.
International Journal of Biological Sciences, 7(1):1–8.
Jackson, C. and Sudlow, C. (2005). Comparing risks of death and recurrent vascular events
between lacunar and non-lacunar infarction. Brain, 128(11):2507–17.
Jagust, W. J., Zheng, L., Harvey, D. J., Mack, W. J., Vinters, H. V., Weiner, M. W., Ellis,
W. G., Zarow, C., Mungas, D., Reed, B. R., Kramer, J. H., Schuff, N., DeCarli, C., and Chui,
H. C. (2008). Neuropathological basis of magnetic resonance images in aging and dementia.
Annals of Neurology, 63(1):72–80.
Jain, R. (2013). Measurements of tumor vascular leakiness using DCE in brain tumors: clinical
applications. NMR in Biomedicine, 26(8):1042–9.
Jeerakathil, T., Wolf, P. A., Beiser, A., Massaro, J., Seshadri, S., D’Agostino, R. B., and
DeCarli, C. (2004). Stroke risk profile predicts white matter hyperintensity volume: the
Framingham Study. Stroke, 35(8):1857–61.
Jelescu, I. O., Leppert, I. R., Narayanan, S., Araújo, D., Arnold, D. L., and Pike, G. B. (2011).
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Muñoz Maniega, S., Valdés Hernández, M. D. C., Clayden, J. D., Royle, N. A., Murray, C.,
Morris, Z., Aribisala, B. S., Gow, A. J., Starr, J. M., Bastin, M. E., Deary, I. J., and Wardlaw,
J. M. (2015). White matter hyperintensities and normal-appearing white matter integrity in
the aging brain. Neurobiology of Aging, 36(2):909–18.
Murray, C. J. and Lopez, A. D. (1997). Global mortality, disability, and the contribution of risk
factors: Global Burden of Disease Study. The Lancet, 349(9063):1436–42.
Murray, C. J. L. and Lopez, A. D. (2013). Measuring the global burden of disease. The New
England journal of medicine, 369(5):448–57.
Nagaraja, T. N., Aryal, M. P., Brown, S. L., Bagher-Ebadian, H., Mikkelsen, T., Yang, J. J.,
Panda, S., Keenan, K. a., Cabral, G., and Ewing, J. R. (2013). Cilengitide-induced temporal
variations in transvascular transfer parameters of tumor vasculature in a rat glioma model:
Identifying potential MRI biomarkers of acute effects. PloS one, 8(12):2–10.
Nagaraja, T. N., Karki, K., Ewing, J. R., Divine, G. W., Fenstermacher, J. D., Patlak, C. S.,
and Knight, R. A. (2010). The MRI-measured arterial input function resulting from a bolus
injection of Gd-DTPA in a rat model of stroke slightly underestimates that of Gd-[14C]DTPA
and marginally overestimates the blood-to-brain influx rate constant determined by Patlak
plots. Magnetic Resonance in Medicine, 63(6):1502–9.
Nandigam, R. N. K., Viswanathan, A., Delgado, P., Skehan, M. E., Smith, E. E., Rosand,
J., Greenberg, S. M., and Dickerson, B. C. (2009). MR imaging detection of cerebral
microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength.
American Journal of Neuroradiology, 30(2):338–43.
194 Bibliography
Norrving, B. (2003). Long-term prognosis after lacunar infarction. The Lancet Neurology,
2(4):238–45.
Noseworthy, M. D. and Bray, T. M. (2000). Zinc deficiency exacerbates loss in blood-brain
barrier integrity induced by hyperoxia measured by dynamic MRI. Proceedings of the
Society for Experimental Biology and Medicine, 223(2):175–82.
Obermeier, B., Daneman, R., and Ransohoff, R. M. (2013). Development, maintenance and
disruption of the blood-brain barrier. Nature Medicine, 19(12):1584–96.
O’Brien, J., Ames, D., Chiu, E., Schweitzer, I., Desmond, P., and Tress, B. (1998). Severe deep
white matter lesions and outcome in elderly patients with major depressive disorder: follow
up study. BMJ, 317(7164):982–4.
O’Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., and Jayson, G. C. (2012).
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nature Reviews.
Clinical Oncology, 9(3):167–77.
O’Donnell, M., Mente, A., Rangarajan, S., McQueen, M. J., Wang, X., Liu, L., Yan, H., Lee,
S. F., Mony, P., Devanath, A., Rosengren, A., Lopez-Jaramillo, P., Diaz, R., Avezum, A.,
Lanas, F., Yusoff, K., Iqbal, R., Ilow, R., Mohammadifard, N., Gulec, S., Yusufali, A. H.,
Kruger, L., Yusuf, R., Chifamba, J., Kabali, C., Dagenais, G., Lear, S. A., Teo, K., and
Yusuf, S. (2014). Urinary sodium and potassium excretion, mortality, and cardiovascular
events. The New England Journal of Medicine, 371(7):612–23.
O’Rourke, M. F. and Safar, M. E. (2005). Relationship between aortic stiffening and
microvascular disease in brain and kidney: cause and logic of therapy. Hypertension,
46(1):200–4.
Pantoni, L. (2010). Cerebral small vessel disease: from pathogenesis and clinical characterist-
ics to therapeutic challenges. The Lancet Neurology, 9(7):689–701.
Parker, G. J. M., Roberts, C., Macdonald, A., Buonaccorsi, G. A., Cheung, S., Buckley, D. L.,
Jackson, A., Watson, Y., Davies, K., and Jayson, G. C. (2006). Experimentally-derived
functional form for a population-averaged high-temporal-resolution arterial input function
for dynamic contrast-enhanced MRI. Magnetic Resonance in Medicine, 56(5):993–1000.
Parker, G. J. M., Tanner, S. F., and Leach, M. O. (1996). Pitfalls in the measurement of tissue
permeability over short time-scales using multi-compartment models with a low temporal
resolution blood input function. In 4th Meeting of the International Society for Magnetic
Resonance in Medicine, page 1582.
Bibliography 195
Patenaude, B., Smith, S. M., Kennedy, D. N., and Jenkinson, M. (2011). A Bayesian model of
shape and appearance for subcortical brain segmentation. NeuroImage, 56(3):907–22.
Patlak, C. S., Blasberg, R. G., and Fenstermacher, J. D. (1983). Graphical evaluation of blood-
to-brain transfer constants from multiple-time uptake data. Journal of Cerebral Blood Flow
and Metabolism, 3(1):1–7.
Peladeau-Pigeon, M. and Coolens, C. (2013). Computational fluid dynamics modelling of per-
fusion measurements in dynamic contrast-enhanced computed tomography: development,
validation and clinical applications. Physics in Medicine and Biology, 58(17):6111–31.
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A. Additional tables for systematic
literature review
This section provides additional data extracted from DCE-MRI publications that were included
in the systematic literature review (Chapter 2). Table A.1 lists all included studies, their sample
characteristics and main purposes. Detailed information about the imaging protocol is given in
Table A.2, while Table A.3 provides a list of KTrans values reported for different tissue types.
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There is increasing recognition of the importance of blood–brain barrier (BBB) disruption in aging, dementia,
stroke and multiple sclerosis in addition to more commonly-studied pathologies such as tumors. Dynamic
contrast-enhancedMRI (DCE-MRI) is amethod for studying BBB disruption in vivo.We review pathologies stud-
ied, scanning protocols and data analysis procedures to determine the range of available methods and their suit-
ability to different pathologies. We systematically review the existing literature up to February 2014, seeking
studies that assessed BBB integrity using T1-weighted DCE-MRI techniques in animals and humans in normal
or abnormal brain tissues. The literature search provided 70 studies that were eligible for inclusion, involving
417 animals and 1564 human subjects in total. The pathologies most studied are intracranial neoplasms and
acute ischemic strokes. There are large variations in the type of DCE-MRI sequence, the imaging protocols and
the contrast agents used. Moreover, studies use a variety of different methods for data analysis, mainly based
on model-free measurements and on the Patlak and Tofts models. Consequently, estimated KTrans values varied
widely. In conclusion, DCE-MRI is shown to provide valuable information in a large variety of applications, rang-
ing from common applications, such as grading of primary brain tumors, tomore recent applications, such as as-
sessment of subtle BBB dysfunction in Alzheimer3s disease. Further research is required in order to establish
consensus-based recommendations for data acquisition and analysis and, hence, improve inter-study compara-
bility and promote wider use of DCE-MRI.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).
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1. Introduction
The blood–brain barrier (BBB) separates the parenchyma of the cen-
tral nervous system from the blood. Quantitative information about the
functional integrity of the BBB can be gained by performing dynamic
contrast-enhanced MRI (DCE-MRI). DCE-MRI has proven valuable in
the assessment of many brain pathologies that cause an opening of
the BBB, such as tumors (Singh et al., 2007), multiple sclerosis (Jelescu
et al., 2011) and acute ischemic strokes (Kassner et al., 2009). While
these diseases show relatively large abnormalities in BBB functionality,
there is also growing interest in the application of DCE-MRI to patholo-
gies associatedwithmore subtle and chronic BBB disruption, such as ce-
rebral small vessel disease (Wardlaw et al., 2008;Wardlaw et al., 2009),
diabetes (Starr et al., 2003) and Alzheimer3s disease (Starr et al., 2009).
Although DCE-MRI has been widely used to study pathological
changes in BBB functionality, studies differ in their MR imaging pro-
cedures and have been performed using a variety of different MRI
sequences, contrast agents and time courses. Furthermore, there is
no standard method for analyzing the data. Established analysis
approaches include relatively simple non-model based methods
(Topakian et al., 2010) as well as a range of pharmacokinetic models
(Tofts, 1991). Several previous reviews have focused on specific applica-
tions such as oncology (Türkbey et al., 2010; Jain, 2013; Barnes et al.,
2012) and on methodological aspects of DCE-MRI (Sourbron and
Buckley, 2012, 2013); as far as we are aware, there are no reviews
that cover the application of DCE-MRI in aging, microvascular disease
or dementia. The aim of this work is to provide an overview of all appli-
cations and scanning protocols used in DCE-MRI of the brain by
performing a systematic review of the literature. First, we describe the
important components of the BBB and available permeability models,
then review available data on BBB permeability imaging. Furthermore,
we aim to identify the most commonly used methods for data analysis
and provide an overview of the resulting parameter ranges.
2. Background
2.1. Blood–brain barrier functionality
The BBB is formed by endothelial cells that line brain capillaries and
are sealed by tight junctions, which are unique to the brainmicrovascula-
ture. The endothelium of the BBB interacts with several cellular and
non-cellular elements, such as astrocytes, pericytes, microglial cells
and basement membranes, that provide both functional support and
structural support to the BBB (Abbott and Friedman, 2012; Obermeier
et al., 2013). Together they form an interactive cellular complex, the
‘neurovascular unit’ (NVU). A schematic drawing of the NVU is shown
in Fig. 1. The BBB regulates the passage of essential molecules such as glu-
cose, while restricting the diffusion of potentially harmful substances.
Many brain pathologies are known to cause a disruption of the BBB.
The mechanisms that cause BBB opening are many and differ between
diseases. In meningitis, for example, damage to the BBB is initiated by
extrinsic systemic factors, such as infections and autoimmune process-
es. Other diseases, including Alzheimer3s disease and ischemic stroke,
are thought to activate intrinsic cellular mechanisms secondary to
the neuroinflammatory injury and other as yet unknown processes
(Rosenberg, 2012). Several comprehensive reviews provide detailed in-
formation on themolecular biology of BBB disruption in disease (Abbott
and Friedman, 2012; Obermeier et al., 2013; Rosenberg, 2012).
2.2. Measurement of blood–brain barrier disruption using DCE-MRI
Disruption of the BBB can enable the extravasation of low-molecular
weight MRI contrast agents. This accumulation of contrast material in
the extravascular extracellular space (EES) of affected tissues leads to
increased longitudinal relaxation rate and, therefore, increased signal
intensity in T1-weighted images. DCE-MRI exploits this T1 enhance-
ment in order to detect and evaluate regions of BBB disruption. The
DCE-MRI procedure typically consists of intravenous injection of con-
trast agent followed by the repeated acquisition of T1-weighted images
(see Fig. 2), providing measurements of signal enhancement as a func-
tion of time. The enhancement kinetics can be used to extract quantita-
tive or semi-quantitative information regarding BBB integrity.
MR signal changes caused by contrast agent extravasation are deter-
mined by several factors, including tissue perfusion and capillary per-
meability. In the brain, DCE-MRI is considered to be the standard MRI
approach for assessing permeability, while dynamic susceptibility con-
trast MRI (DSC-MRI) is the method of choice for perfusion imaging
(Sourbron and Buckley, 2013). However, it has been shown that DCE-
MRI can combine perfusion and permeability measurements by using
a sufficiently long acquisition time (to capture slow interstitial uptake)
with high temporal resolution early on (to capture the first pass of the
contrast bolus) (Li et al., 2000; Li et al., 2012; Sourbron et al., 2009;
Larsson et al., 2009).
2.3. Analysis of DCE-MRI data
Different approaches have beenused to analyzeDCE-MRI data, rang-
ing from relatively simple visual assessment of enhancement curves to
more complex fitting to pharmacokinetic models. Heuristic analysis of
the signal enhancement curves provides semi-quantitative measures
Fig. 1. Schematic drawing of the neurovascular unit. The BBB is formed by endothelial cells
that line brain capillaries and are sealed by tight junctions. Astrocytes, pericytes,microglial
cells and basement membranes interact with the endothelium of the BBB, providing
functional and structural support.
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of BBB disruption, such as the area under the curve (AUC) and the time to
maximum enhancement. Such measurements are easy to obtain but dif-
ficult to interpret (Budde et al., 2012). Quantitative analysis on the other
hand aims to provide a link between the tissue signal enhancement and
physiologically relevant parameters such as microvascular permeability,
blood flow, blood volume fraction and interstitial volume fraction.
In order to relate the measured signal enhancement to the contrast
agent concentration, an appropriate signal model is required. While
early DCE-MRI studies assumed a linear relationship between signal en-
hancement and contrast uptake, it is well known that the signal en-
hancement is highly dependent on intrinsic tissue and acquisition
parameters (Armitage et al., 2005; Armitage et al., 2011). Consequently,
more complex approaches were developed in order to control for the
effect of tissue characteristics such as the pre-contrast longitudinal re-
laxation time and the longitudinal and transverse relaxivities of the con-
trast agent (Armitage et al., 2005).
Pharmacokinetic modeling was first introduced for the analysis of
DCE-MRI in the early 1990s by Brix et al. (1991), Larsson et al. (1990),
and Tofts (1991), followed by a consensus paper on the notation
(Tofts et al., 1999). Since then, improvement of the imaging techniques
(e.g. higher temporal resolution and contrast-to-noise ratio) and a bet-
ter understanding of the underlying physiology have promoted the de-
velopment of several more complex pharmacokinetic models. Detailed
reviews of tracer kinetic modelling approaches in DCE-MRI have been
published by Sourbron and Buckley (2012, 2013). In the following, we
will briefly describe a basic tissue model and the three most commonly
used pharmacokinetic models in DCE-MRI.
Fig. 3A displays a general tissue model with exchange of contrast
agent between blood plasma and the EES. Target parameters of
pharmacokinetic modeling in DCE-MRI are the fractional plasma
volume vp, the fractional interstitial volume ve, the plasma flow Fp
and the permeability-surface area product PS, which measures the rate
at which contrast agent particles leak out of the plasma and into the EES
per unit tissue volume and plasma concentration. An important physio-
logical parameter that is widely reported in DCE-MRI studies is the vol-
ume transfer constant KTrans, which is the rate at which contrast agent is
delivered to the EES per volume of tissue and contrast agent concentra-
tion in the arterial blood plasma. While the terms PS and KTrans are some-
times used interchangeably in the literature, PS represents the clearance
for contrast agent leaking from the capillary plasma into the EES, i.e. the
flux of contrast agent across the BBB normalized to the tissue plasma con-
centration and tissue volume; in contrast, KTrans (as implicitly defined by
Tofts et al., 1999), is the contrast clearance normalized to the arterial
plasma concentration and therefore depends on the plasma flow Fp sup-
plying the capillaries in addition to PS (the mathematical form of this re-
lationship is model-dependent). KTrans is necessarily equal to the product
of plasma flow Fp and the extraction fraction E (i.e. the fraction of contrast
agent molecules that leak into the EES).
Most pharmacokinetic models require the arterial input function
(AIF) to be known, which describes the tracer concentration in blood
plasma over time. There are several strategies for determining the AIF
(Calamante, 2013), including the use of a standard function (Weinmann
et al., 1984), experimentally derived population-averaged AIFs (Parker
et al., 2006) and simultaneous individual measurement of the AIF in a
feeding vessel close to the tissue of interest (Sourbron et al., 2009).
The conventional Tofts model (Tofts, 1991) considers isodirectional
flux of tracer between the two well-mixed blood plasma and EES
compartments with the volume transfer constant KTrans. The plasma
compartment is assumed to have negligible volume (vp ! 0), which
makes the classic Tofts model a one-compartment model for weakly
vascularized tissues. This model is illustrated in Fig. 3B and character-









where Cp(t) is the AIF.
Tofts et al. extended their classic model by introducing the blood
plasma as a second well-mixed and highly perfused compartment
(Tofts et al., 1999; see Fig. 3C). In addition to the two parameters KTrans
and ve, the model allows the fractional plasma volume vp to be estimated
and, hence, separates enhancement effects due to contrast leakage from
those due to intravascular contrast:








If themodelfits thedatawellwith a non-negligible vp value, then the
tissuemust be highly perfused (Fp=$) and the system is permeability-
limited with KTrans = PS (Sourbron and Buckley, 2013).
Finally, the Patlak model also describes a highly perfused two-
compartment tissue but considers unidirectional transport from the
blood plasma into the EES (see Fig. 3D). The tracer concentration in tis-
sue is given by





When first introducing this approach, Patlak and colleagues
proposed a linear graphical analysis method, which is often used as it
Fig. 2. Illustration of DCE-MRI in a patientwith a glioma. The repeated acquisition of T1-weighted images after contrast agent injection allows the calculation of signal enhancement as a function
of time (middle) when compared to the pre-contrast signal intensity (left). These curves can be used to calculate maps of quantitative pharmacokinetic parameters (e.g. KTrans, right).
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Cp!!"d!=Cp!t", yielding a straight line with slope
KTrans and y-intercept vp.
3. Methods
3.1. Search strategy
The existing literature was systematically reviewed up to Febru-
ary 2014 by performing an electronic search in PubMed, EMBASE,
MEDLINE and Web of Knowledge databases. Multiple combinations
of the following search terms were used: ‘permeability’, ‘brain’,
‘blood–brain barrier’, ‘MRI’, ‘dynamic’, ‘DCE-MRI’ and ‘contrast en-
hancement’. English as well as non-English literature was sought.
The electronic search was supplemented by hand searching the ref-
erence lists of review papers.
One reviewer performed the primary literature search, removed du-
plicates and screened all papers3 titles and abstracts in order to identify
those relevant for full assessment. Before final inclusion or exclusion of
studies, a second reviewer continued the search, read the full text of the
selected articles, extracted the relevant data and performed the analysis.
Disagreements between reviewers about inclusion or exclusion of
papers were resolved through discussion with a third reviewer. The
third, fourth and fifth reviewers complemented the search and assisted
with the data analysis.
3.2. Eligibility criteria
We sought studies which assessed BBB integrity using dynamic
contrast-enhanced MRI techniques. We included studies on humans
and animals in all diseases known or thought to affect BBB function.
Consequently, we excluded other applications of DCE-MRI such as
breast or prostate cancer aswell as publications that focus on theoretical
aspects of image processing or modelingwithout testing them in a clin-
ical setting (e.g. Gal et al., 2008). Furthermore, we accepted only prima-
ry research articles which were available as full-text, but checked
review articles for additional primary references.
We excluded studies using non-dynamic MRI methods, DSC-MRI or
non-MRI methods in order to decrease variability between studies,
which is already considerable between DCE-MRI studies. The literature
search yielded several papers that focused on therapeutic BBB disrup-
tion for novel anti-cancer drugs. Since these mainly addressed pharma-
ceutical or technical aspects of the disruption method on a molecular
level, these studies were rejected. An excellent review on DCE-MRI in
clinical trials of antivascular therapies can be found in O3Connor et al.
(2012). However, we did include studies that focused on the clinical ef-
fect of treatment strategies and its link with BBB disruption if they pro-
vided baseline DCE-MRI parameters. Moreover, we rejected single case
reports and articles inwhich substantial information about theMRI pro-
cedure or the data analysis was lacking.
3.3. Data extraction and analysis
One reviewer independently extracted the data from each in-
cluded study and cross-checked information with preliminary ex-
tracted data. Disagreements were resolved by consensus. We
noted the studied disease or pathology, sample size and subjects3
ages (in the case of human studies). Moreover, we extracted details
of the DCE-MRI protocol, noting scanner field strength, MRI se-
quence with repetition time (TR) and echo delay time (TE), field of
view, matrix size, slice thickness, overall duration and temporal res-
olution. Extracted data also included the type and dose of contrast
agent and the injection protocol. Furthermore, we noted whether
post-processing techniques were applied prior to data analysis, the
analysis method used and the tissues/locations analyzed. Where
Fig. 3. Schematic illustrations of common pharmacokineticmodels and target parameters.
The exchange between the extravascular extracellular space (EES, volume fraction ve) and
capillary blood plasma (volume fraction vp) is determined by the plasma flow Fp and the
permeability-surface area product PS. (A) Generic tissue model. (B) Conventional Tofts
model (with negligible blood volume and volume transfer constant KTrans). (C) Modified
Tofts model with non-negligible blood compartment. (D) Patlak model with non-
negligible plasma compartment and one-way transport of contrast agent across the BBB.
For the latter two models, it may be assumed that KTrans = PS for any solution fitting the
data well with a non-negligible vp.
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given, quantitative measurements were extracted. We noted the
main study purpose and the overall conclusion of the study.
In consequence of the large heterogeneity of included studies, qual-
ity assessment using standardized criteria as recommended in Guyatt
et al. (2008) was difficult. However, we extracted limitations of the
methodology where stated and whether any patients had been imaged
but then excluded from further analysis, so as to assess the feasibility
and applicability of the technique.
4. Results
4.1. Systematic literature search results
The electronic search yielded 829 results, 31 of which were in non-
English languages. After removing duplicates, 352 publications were
further analyzed for inclusion (see Fig. 4). After scanning abstracts and
titles, we excluded studies using non-dynamic and non-MRI methods
(n = 179). We also excluded review papers (n = 46), technical proto-
cols (n = 2) and DSC-MRI studies (n = 38), leaving 87 articles for
full-text assessment. At this stage, we identified 29 studies that were
not relevant to the focus of this review. Moreover, we excluded confer-
ence abstracts thatwere not detailed enough for full data extraction and
that had not subsequently been published in full (n = 8), single-case
reports and publications with missing information on the imaging
methodology (n = 2) and duplicate publications (n = 1). In addition
to the resulting 47 relevant DCE-MRI studies, 23 relevant articles were
identified by hand searching the bibliographies of review papers. Over-
all, the full literature search to February 2014 provided 70 DCE-MRI
studies that were eligible for inclusion in this review, published
between February 1990 (Kermode et al., 1990) and December 2013
(Cramer et al., 2014).
4.2. Subjects and sample sizes
Table 1 summarizes themain study sample characteristics and scan-
ning protocols related to each pathology. Of the 70 included studies, 17
used animals (i.e. rodents (Budde et al., 2012; Abo-Ramadan et al.,
2009; Ali et al., 2010; Durukan et al., 2009; Ewing et al., 2003; Ferrier
et al., 2007; Nagaraja et al., 2010; Taheri et al., 2009; Hoff et al., 2012;
Krueck et al., 1994; Li et al., 2010; Noseworthy and Bray, 2000;
Quarles et al., 2012; Aryal et al., 2014; Brandt et al., 2008), apart from
one study of beagle dogs (Su et al., 1998) and one of rabbits (Wei
et al., 2011)). The sample size was not made available in one of these
publications (Ewing et al., 2003). The mean sample size of the remain-
ing animal studies was 25 animals, with a total number of 417 animals
(including 19 healthy controls; 336/417 were rodents). The largest in-
cluded study involved 113 rats (Abo-Ramadan et al., 2009), whereas
Fig. 4. Flow diagram summarizing the literature search and inclusion process.
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two studies used a sample size smaller than ten (Ferrier et al., 2007; Li
et al., 2010).
The remaining 53 studies were in humans, including 1564 subjects
in total (163 of which were healthy controls). The mean sample size
for human studies was 27. Only one study involvedmore than 100 sub-
jects (Haris et al., 2008a) and six studies were based on fewer than ten
humans (Jelescu et al., 2011; Larsson et al., 1990; Kermode et al., 1990;
Thompson et al., 2012).
Information regarding patient age was not provided in seven of the
53 studies (Li et al., 2000; Li et al., 2012; Sourbron et al., 2009; Larsson
et al., 1990; Aksoy et al., 2013; Miyati et al., 1997; Awasthi et al.,
2012). A further seven publications stated only the age range of the
study subjects (Awasthi et al., 2012; Haris et al., 2008b; Roberts et al.,
2000; Vidarsson et al., 2009; Bagher-Ebadian et al., 2012; Kassner
et al., 2005; Manuchehri et al., 2007). Mean age as stated in the remain-
ing 39 human studies was highly dependent on the studied pathology,
ranging between 9 years (Thompson et al., 2012) (pediatric brain tu-
mors) and 74 years (Wang et al., 2006) (mild cognitive impairment).
4.3. Pathologies studied
The majority of animal studies concerned intracranial neoplasms
(Budde et al., 2012; Ali et al., 2010; Ferrier et al., 2007; Hoff et al.,
2012; Krueck et al., 1994; Li et al., 2010; Quarles et al., 2012; Aryal
et al., 2014) including a total of 140/417 animals. Five publications in-
vestigated changes in the BBB caused by induced focal cerebral ischemia
in 154/417 animals overall (Abo-Ramadan et al., 2009; Durukan et al.,
2009; Ewing et al., 2003; Nagaraja et al., 2010; Taheri et al., 2009).More-
over, one study each focused on the influence of pneumococcal menin-
gitis (Brandt et al., 2008), normal aging (Su et al., 1998), zinc deficiency
(Noseworthy and Bray, 2000) or traumatic head injuries (Wei et al.,
2011) on the BBB.
The pathology most studied in humans was intracranial neoplasms
(30 publications, 716/1564 subjects), including primary brain tumors
and brain metastases (Li et al., 2012; Sourbron et al., 2009; Larsson
et al., 2009; Larsson et al., 1990; Haris et al., 2008a,c; Thompson et al.,
2012; Miyati et al., 1997; Awasthi et al., 2012; Roberts et al., 2000;
Bagher-Ebadian et al., 2012; Manuchehri et al., 2007; Cao et al., 2009;
Cha et al., 2006; Chu et al., 2012; Harrer et al., 2004; Ludemann et al.,
2002; Lüdemann et al., 2009; Lüdemann et al., 2000; Mills et al., 2009;
Provenzale et al., 2006; Zhu et al., 2000; Ferl et al., 2010; Jia et al.,
2013; Larsen et al., 2013; Wilkinson et al., 2006; Zhang et al., 2012).
Eleven studies investigated changes in BBB integrity caused by stroke
and/or cerebrovascular disease (Kassner et al., 2009; Wardlaw et al.,
2008; Wardlaw et al., 2009; Topakian et al., 2010; Armitage et al.,
2011; Aksoy et al., 2013; Vidarsson et al., 2009; Kassner et al., 2005;
Thornhill et al., 2010; Taheri et al., 2011a,b) with a total of 482/1564
subjects. Eight studies focused on multiple sclerosis (Jelescu et al.,
2011; Larsson et al., 1990; Kermode et al., 1990; Cramer et al., 2014;
Taheri et al., 2011b; Gaitán and Shea, 2011; Shinohara et al., 2011;
Ingrisch et al., 2012) including a total of 186/1564 subjects. Other pa-
thologies included Alzheimer3s disease (Starr et al., 2009), mild cogni-
tive impairment (Wang et al., 2006), brain tuberculomas (Singh et al.,
2007; Haris et al., 2008b), infective brain lesions (Haris et al., 2008a),
multiple system atrophy (Song et al., 2011), diabetes (Starr et al.,
2003) and neurocysticercosis (Gupta et al., 2012).
4.4. Blood–brain barrier changes in disease
Thirteen of the 70 included studies aimed to investigate the correla-
tion between a particular disease and BBB dysfunction. For this purpose,
BBB disruptionwas quantified in order to test for a significant difference
between diseased subjects and healthy controls. Significant differences
compared to control subjects or healthy tissuewere found in eight stud-
ies, investigating acute ischemic stroke (Abo-Ramadan et al., 2009),
pneumococcal meningitis (Brandt et al., 2008), brain metastases
(Budde et al., 2012), multiple system atrophy (Song et al., 2011), type-
II diabetes (Starr et al., 2003), vascular cognitive impairment (Taheri
et al., 2011a), normal-appearing and lesion tissue in multiple sclerosis
patients (Cramer et al., 2014; Taheri et al., 2011b), mild cognitive im-
pairment (Taheri et al., 2011b), zinc deficiency (Noseworthy and Bray,
2000) and small vessel disease (Topakian et al., 2010). Moreover, Starr
et al. observed differences in signal intensity profiles over time between
Alzheimer3s disease patients and controls (Starr et al., 2009). Increased
BBB disruption without statistical significance was observed in patients
with mild cognitive impairment (Wang et al., 2006). Su et al. showed a
non-significant increase in BBB permeability with normal aging in bea-
gle dogs (Su et al., 1998).
16 studies performed DCE-MRI in order to distinguish between
different types or grades of pathology. Seven of those studies showed sta-
tistical significance that DCE-MRI derived parameters differentiate prima-
ry brain tumor types and grades (Roberts et al., 2000; Ludemann et al.,
2002; Lüdemann et al., 2000; Mills et al., 2009; Zhu et al., 2000; Jia et al.,
2013; Zhang et al., 2012). Furthermore, significant differences were
found between infective vs. neoplastic brain lesions (Haris et al., 2008a),
asymptomatic vs. symptomatic neurocysticercosis (Gupta et al., 2012),
severe and moderate vs. mild traumatic brain injuries (Wei et al., 2011),
and radiationnecrosis vs. tumor recurrence (Larsen et al., 2013).Wardlaw
et al. showed that post-contrast signal enhancement was higher in cere-
brospinal fluid and white matter in lacunar (i.e. small vessel disease
stroke) than in cortical (i.e. large artery atherothromboembolic stroke)
patients (Wardlaw et al., 2008; Wardlaw et al., 2009). Kassner et al.
found significantly different permeability scores between stroke patients
who proceeded to hemorrhage and those who did not with and without
thrombolytic therapy (Kassner et al., 2009; Kassner et al., 2005). Further-
more, Aksoy et al. (2013) reported significantly differentDCE-MRI param-
eters for hemorrhagic strokes depending on their size and location.
4.5. Contrast agent and dose
The type and dose of contrast agents used in the included publica-
tions are summarized in Fig. 5. In most studies, the contrast agent
used was Gd-DTPA (gadopentetate dimeglumine, 45/70 studies) or its
variant Gd-DTPA-BMA (gadodiamide, 15/70 studies), given as an intra-
venous bolus injection. In 31 studies, this contrast agent was given in
the standard dose of 0.1 mmol/kg body weight. However, delivered
Fig. 5. Summary of contrast agents, contrast agent doses and MRI sequences. The bar
height indicates the number of studies using a particular method, subdivided by
pathology.
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doses ranged from 0.02 mmol/kg (Awasthi et al., 2012) to 0.5 mmol/kg
(Ferrier et al., 2007). Ten studies delivered a fixed quantity of contrast
agent, ranging between 7.5 mmol (Kassner et al., 2009; Vidarsson
et al., 2009; Thornhill et al., 2010) and 20 mmol (Wardlaw et al.,
2008; Wardlaw et al., 2009; Armitage et al., 2011) in humans. Single
studies employed different gadolinium-based agents such as Gd-DOTA
(gadoterate meglumine) (Li et al., 2000; Chu et al., 2012), gadobutrol
(Gd-BT-DO3A) (Jelescu et al., 2011; Cramer et al., 2014; Wilkinson
et al., 2006; Ingrisch et al., 2012; Song et al., 2011; Larsson et al.,
2013), gadoteriol (Thompson et al., 2012) and albumin-labeled Gd-
DTPA (Ali et al., 2010). We did not find any study that investigated the
influence of different contrast agent types or concentrations, though
Abo-Ramadan et al. state that different doses lead to an increase or de-
crease in signal-to-noise ratio (Abo-Ramadan et al., 2009).
4.6. Scanning techniques and field strength
The MRI pulse sequence types used are summarized in Fig. 5. The
technique most frequently used was a spoiled gradient echo sequence
(27 studies) and its ultra-fast variants (18 studies). Further protocols in-
clude 11 other gradient recalled echo sequences (Kassner et al., 2009;
Larsson et al., 2009; Budde et al., 2012; Abo-Ramadan et al., 2009;
Durukan et al., 2009; Hoff et al., 2012; Quarles et al., 2012; Kassner
et al., 2005; Cao et al., 2009; Thornhill et al., 2010; Larsson et al.,
2013), six spin-echo methods (Larsson et al., 1990; Kermode et al.,
1990; Taheri et al., 2009; Krueck et al., 1994; Noseworthy and Bray,
2000; Su et al., 1998) and two unspecified T1-weighted imaging se-
quences (Starr et al., 2003; Song et al., 2011). Furthermore, two studies
used a TOMROP (T-One by Multiple Read-Out Pulses) pulse sequence
(Ewing et al., 2003; Nagaraja et al., 2010), two studies used T1mapping
of partial inversion recovery (TAPIR) (Taheri et al., 2011a,b), and one
study each used a THRIVE (Wei et al., 2011), RF-FAST (Wang et al.,
2006) and TWIST (Jia et al., 2013) sequence.
Four publications focused on introducing new scanning methods. A
scanning procedure for combined and consecutive DSC- and DCE-MRI
measurement was introduced by Miyati et al. (1997) and Thompson
et al. (2012) respectively. Moreover, Jelescu et al. (2011) and Li et al.
(2012) presented a dual-temporal resolution scanning method with
high temporal resolution during the bolus first pass and high spatial
resolution during the later phase.
Themajority of human studies (35/53) were performedwith amag-
netic field strength of 1.5 T, while 16 studies used a 3 T scanner; one
study each was performed using a 0.5 T (Kermode et al., 1990) and a
1.9 T scanner (Starr et al., 2003). A wider range of magnetic field
strengths from 1.5 T (Krueck et al., 1994) to 11.75 T (Li et al., 2010)
were found in animal studies, with the majority of studies using 4.7 or
7 T scanners. Two studies did not provide this information (Li et al.,
2012; Wei et al., 2011).
4.7. Duration and temporal resolution of DCE-MRI
The duration of data collection following contrast injection varied
widely with values from 2.1 min (Miyati et al., 1997) to 155 min
(Shinohara et al., 2011). The median DCE-MRI imaging durations (not
stated in five publications (Larsson et al., 1990; Li et al., 2010; Brandt
et al., 2008; Chu et al., 2012; Provenzale et al., 2006)) according to pa-
thology studied are shown in Table 1, together with themedian tempo-
ral resolution (not stated in three publications (Brandt et al., 2008; Chu
et al., 2012; Provenzale et al., 2006)). The highest temporal resolution of
1 s was found in tumor studies (Larsson et al., 2009; Quarles et al.,
2012), whereas one study on diabetes used the longest intervals, in
the range of 10–30 min (Starr et al., 2003).
Vidarsson et al. (2009) and Larsson et al. (2013) investigated the in-
fluence of the temporal resolution and/or overall scan timeon the quan-
tification of BBB disruption, finding that reducing the overall scanning
time and sampling with a lower temporal resolution result in increased
uncertainty of the pharmacokinetic parameters KTrans, ve and vp. As
shown in Table 1, the overall scanning duration and the temporal reso-
lution vary significantly between applications. In general, the highest
temporal resolution is used in brain tumors. This is necessary to mea-
sure the fast kinetics typically seen in malignant neoplasms, but may
limit spatial resolution and coverage. Conversely, studies that assess
tissues with slow leakage rates (e.g. healthy appearing tissue in MS
patients, aging or dementia) often use lower temporal resolutions that
allow for better spatial resolution and coverage.
4.8. Use of post-processing techniques
42 of the 70 included studies (60%) did not report the use ormethod
of image post-processing. Themost commonly used technique reported
was image registration, aligning the DCE-MRI images to a pre-contrast
acquisition and/or anatomic images, in order to remove patient move-
ment (Jelescu et al., 2011; Kassner et al., 2009; Wardlaw et al., 2008;
Wardlaw et al., 2009; Starr et al., 2003; Starr et al., 2009; Topakian
et al., 2010; Budde et al., 2012; Armitage et al., 2011; Taheri et al.,
2009; Haris et al., 2008a,b,c; Aksoy et al., 2013; Lüdemann et al., 2009;
Zhu et al., 2000; Ferl et al., 2010; Zhang et al., 2012; Thornhill et al.,
2010; Taheri et al., 2011a; Gaitán and Shea, 2011; Shinohara et al.,
2011; Larsson et al., 2013). Several studies reported a lack of precision
of quantitative values due to limited spatial resolution or poor signal-
to-noise ratio (Kassner et al., 2009; Ferrier et al., 2007; Cha et al.,
2006; Gaitán and Shea, 2011), but only four studies report the use of
image processing techniques for noise reduction, including Gaussian
smoothing (Lüdemann et al., 2009), Kalman filtering (Taheri et al.,
2011a,b) and unspecified smoothing of the signal enhancement curves
(Ferl et al., 2010). In addition, three studies corrected DCE-MRI data
for scanner signal intensity drift using phantoms. Only one study inves-
tigated the effect of scanner noise and drift on signal enhancement data
(Armitage et al., 2011), concluding that studies should investigate and if
necessary correct for these influences in order to prevent systematic
errors.
4.9. Data analysis methods and pharmacokinetic models
A wide variety of approaches to data analysis were used in the in-
cluded studies (Fig. 6). Model-free methods included the visual assess-
ment of spatiotemporal enhancement patterns in multiple sclerosis
lesions (Kermode et al., 1990; Gaitán and Shea, 2011; Shinohara et al.,
2011), calculation of semi-quantitative parameters from the signal
Fig. 6. Data analysis methods used in the included studies. Numbers indicate the count of
studies using the particular method. (Note that some studies used more than one approach.
Consequently, the numbers of studies do not add up to the 70 included studies.).
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enhancement (Wardlaw et al., 2008; Wardlaw et al., 2009; Starr et al.,
2003; Starr et al., 2009; Topakian et al., 2010; Brandt et al., 2008; Su
et al., 1998; Miyati et al., 1997; Wang et al., 2006; Mills et al., 2009;
Provenzale et al., 2006; Wilkinson et al., 2006) and/or contrast agent
concentration (Budde et al., 2012; Armitage et al., 2011) curves, and
model-free deconvolution (Singh et al., 2007; Larsson et al., 2009;
Cramer et al., 2014; Haris et al., 2008a,c; Awasthi et al., 2012; Ferl
et al., 2010; Larsen et al., 2013; Gupta et al., 2012). The most commonly
used pharmacokinetic models were the conventional Tofts model
(Singh et al., 2007; Jelescu et al., 2011; Li et al., 2000; Noseworthy and
Bray, 2000; Haris et al., 2008a,b,c; Thompson et al., 2012; Manuchehri
et al., 2007; Cha et al., 2006; Harrer et al., 2004; Zhu et al., 2000; Ferl
et al., 2010; Jia et al., 2013; Gupta et al., 2012), the modified Tofts
model (Li et al., 2012; Ali et al., 2010; Hoff et al., 2012; Aryal et al.,
2014; Wei et al., 2011; Awasthi et al., 2012; Bagher-Ebadian et al.,
2012; Cao et al., 2009; Chu et al., 2012; Harrer et al., 2004; Zhang
et al., 2012; Ingrisch et al., 2012; Song et al., 2011; Larsson et al.,
2013), the Patlak model (Larsson et al., 2009; Cramer et al., 2014;
Abo-Ramadan et al., 2009; Durukan et al., 2009; Ewing et al., 2003;
Nagaraja et al., 2010; Taheri et al., 2009; Krueck et al., 1994; Vidarsson
et al., 2009; Bagher-Ebadian et al., 2012; Larsen et al., 2013; Thornhill
et al., 2010; Taheri et al., 2011a,b) and a simplified approach based on
the Patlak model (Kassner et al., 2009; Ferrier et al., 2007; Aksoy et al.,
2013; Roberts et al., 2000; Kassner et al., 2005) as introduced by
Shames et al. (1993) and Iannotti et al. (1987). Other modeling ap-
proaches included a variant of the conventional Tofts model that con-
siders only the first pass of the contrast bolus (Li et al., 2000; Harrer
et al., 2004), a two-compartment exchange (Sourbron et al., 2009;
Larsson et al., 2009) and uptake (Sourbron et al., 2009; Ingrisch et al.,
2012) model, and a modified two-compartment exchange model that
includes two EES compartments (one in slow and one in fast exchange
with the blood compartment) (Ludemann et al., 2002; Lüdemann et al.,
2009; Lüdemann et al., 2000). Furthermore, one study each applied an
AIF-free reference region model introduced by Yankeelov et al. (2005)
in rat gliomas (Quarles et al., 2012) and a shutter-speed model consid-
ering three-site equilibrium water exchange (Li et al., 2010). Table 2
summarizes the range of KTrans estimates for different tissue types and
pharmacokinetic models as reported in the included publications.
Several studies aimed primarily at comparing different approaches
for data analysis. Li et al. (2000) introduced a variant of the conventional
Tofts model that only considers the first pass of the contrast bolus. They
evaluated this method in n = 11 patients with primary brain neo-
plasms, finding that the results were visually comparable with those
of the conventional Tofts model but less noisy and less susceptible to
large vessel contributions. Harrer et al. (2004) evaluated the same
model in n = 18 patients with high-grade gliomas, reporting a good
correlation with the modified Tofts model but no correlation with the
conventional Tofts method, though it should be noted that the AIFs
used differed between the models due to software limitations. Values
obtained with the conventional Tofts model were considerably higher,
indicating an overestimation of quantitative parameters due to vessel
contributions. Larsson et al. (2009) used simulated data in order to in-
vestigate the accuracy of the two-compartment exchange and Patlak
models. As expected, they found that the Patlak method is accurate for
Table 2
KTrans values reported for different tissue types and pharmacokinetic models. Given values are the median [range] of reported study sample means from human (in black) and animal
(in orange) studies. Please note that some subjects included in these studies (e.g. high grade glioma patients) underwent treatment before entering the study. Hence, the reported baseline
parameters might be influenced by interventions that were not the focus in the study.
KTrans (!10-2 min-1)Pathology
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low values of KTrans, whereas the two-compartment exchange model
provides more accurate results for high KTrans values (Larsson et al.,
2009). Li et al. (2010) considered the effect of water exchange, finding
the Patlakmodel to significantly underestimate the fractional blood vol-
ume when compared to their three-site equilibrium shutter-speed
model. A non-parametric method for evaluating DCE-MRI in n=16 gli-
oma patients was presented by Ferl et al. (2010),who showed that their
resulting parameters closely approximate the conventional Tofts model
parameters. Finally, Bagher-Ebadian et al. (2012) presented a method
for quantifying BBB disruption in heterogeneous glioblastoma based
on a voxel-by-voxel selection from a set of nested models: the most
complexmodelwith three parameterswas required to fit the data in re-
gions of aggressive tumor growth, while simpler models predominated
in less aggressive tumor portions and in healthy tissues.
5. Discussion
Our systematic review of the literature revealed 70 studies involving
methods to assess BBB disruption in 15 pathologies in 417 animals and
1564 humans. These studies showed considerable heterogeneity with
regard to image acquisition and analysismethods. This is partly a conse-
quence of the wide range of tissues, pathologies and study objectives.
For example, tumor studies used higher temporal resolution and shorter
imaging duration on average compared with studies of less permeable
tissue such as multiple sclerosis, ischemic stroke and normal appearing
brain. However, it should be noted that a minority of the articles explic-
itly justified the methodology used. The factors influencing inter-study
comparability and implications for futures studies are discussed in the
following paragraphs.
5.1. Inter-study comparability of quantitative DCE-MRI parameters
Due to the wide range of analysis techniques used and their strong
dependence on underlying assumptions and acquisition parameters, a
lack of inter-study comparability represents a major problem. Care
must be taken when comparing results from different studies as
shown by thewide parameter ranges in Table 2. Some of this variability
is inevitable due to the heterogeneity of the study populations (e.g. sub-
jects' age) and study designs. Sincemost articles did not explicitly justify
the analytical method employed, differences in the choice of pharmaco-
kinetic model may account for some of the variation. Biased parameter
estimates are likely to be obtained when the assumptions of the model
are not met in the tissue or when the data acquired are inadequate
to determine a unique solution. For example, several studies (e.g. Ali
et al., 2010, Zhang et al., 2012) apply the same model to tumor tissue
and contralateral healthy tissue, although the underlying tissue phy-
siology is very different and onemodel is unlikely to be valid in both sit-
uations. The importance of appropriate model selection has been
demonstrated both theoretically (Sourbron and Buckley, 2011) and ex-
perimentally in gliomas (Harrer et al., 2004) and low-permeability brain
tissue (Larsson et al., 2009; Cramer and Larsson, 2014) and is discussed
further in Section 5.2. Several additional factors may also influence the
results of DCE-MRI studies.
Firstly, the calculation of contrast agent concentration from signal
enhancement requires reliable estimation of intrinsic tissue parameters
such as the pre-contrast longitudinal relaxation time T10. There are sev-
eral methods of estimating T10, with variable flip angle (Brookes et al.,
1999) and variable saturation time delay (Larsson et al., 1988) being
themost common. The effect of uncertainty in T10 estimation on the cal-
culation of contrast agent concentrations has been investigated by
Schabel and Parker (Schabel and Parker, 2008). They demonstrate that
T10 produces a significant concentration bias, which shows the impor-
tance of accounting for T10 when assessing BBB disruption in different
tissue types (Armitage et al., 2011). It should also be noted that, unless
T1 is measured at each time point, drifts in signal intensity may intro-
duce further errors in pharmacokinetic parameters; as noted above,
the issue of scanner stability was seldom addressed in the included
articles.
Secondly, most pharmacokinetic models require the AIF to be
known. Hence, determination of AIF represents a key issue in the reli-
able estimation of pharmacokinetic parameters. As mentioned above,
there are several strategies for AIF selection and the optimal method
varies according to pathology, study aims and clinical requirements
(Calamante, 2013). In most applications, direct measurement of the
AIF is generally considered preferable to standard or averaged AIFs
(Lavini and Verhoeff, 2010). However, this method is not always possi-
ble and is susceptible to partial volume and in-flow artefacts; uncertain-
ty remains regarding which vessel should be sampled and how, with
approaches ranging from manual region of interest selection to
methods for automatic vessel detection (Chen et al., 2008). There is
also disagreement on whether to describe the capillary bed in terms of
blood concentration or plasma concentration by correcting for the he-
matocrit (Hct). In the latter case, Hct should ideally be determined for
every subject, but a standard value such as Hct = 0.45 is often assumed
(Sourbron and Buckley, 2013). In theory, all model equations and
resulting parameter values can easily be converted between conven-
tions. However, several studies did not report this and other details, im-
peding reliable comparison of parameter values from different studies.
Other sources of uncertainty rarely considered in DCE-MRI studies
may arise due to a lack of available data. For example, relaxivity values
specific to a contrast agent, field strength and tissue/pathology are rare-
ly known, with the consequence that uniform relaxivity across tissues
and compartments is generally assumed. A further common assump-
tion is that of fast water exchange between compartments; the influ-
ence of restricted water exchange has been described in the literature
(see 100 and references therein) but models accounting for this effect
have received relatively little attention.
5.2. Implications for future DCE-MRI studies of BBB disruption
Given the diversity of DCE-MRI applications in the brain, it is impos-
sible to prescribe a universal “recipe” for future studies, though at-
tempts have been made to better standardize methodology and
reporting (Tofts et al., 1999; DCE MRI Technical Committee, 2012;
Leach et al., 2012). Instead, it is essential to recognise that the optimal
method is highly dependent on the specific application. An extensive
body of primary DCE-MRI literature and a number of excellent review
articles should help to facilitate optimal study design in the future. In
the following paragraphs we discuss some of the key aspects of acquisi-
tion protocol design and data analysis. In addition to these technical as-
pects, it should be noted that the overall design of a study (e.g. large
sample size, appropriate control group) will be particularly important
given the limitations of present DCE-MRI methods. We recommend
that for most applications, changes in the longitudinal relaxation rate
rather than signal intensity should be measured, since the former
more accurately reflects contrast agent concentration, required for
quantitative pharmacokinetic analysis. A range of pulse sequences are
available to obtain this data, and the optimal choice may be a compro-
mise between speed, accuracy, spatial coverage and other factors. Two
of the most critical acquisition parameters to determine are the tempo-
ral resolution and total duration of the scan, since the optimal values de-
pend on the nature of the tissue being investigated and the quantities to
be measured (Sourbron and Buckley, 2012). For example, temporal res-
olution of the order of a second is required to quantify tissue plasma
flow; even if this quantity is of no interest, it may be necessary to ac-
count for flow in order to accurately assess permeability. The likely in-
fluence of blood flow may be determined using computer simulations,
providing plausible tissue parameter ranges are available and relevant
to the subjects and tissues being studied (Sourbron et al., 2009;
Larsson et al., 2009). Temporal resolution must also be set against re-
quirements for spatial resolution and coverage, which differ markedly
between applications (e.g. focal vs. diffuse pathology). For accurate
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measurement of the permeability-surface area product PS, the scan du-
ration should be long enough for significant contrast extravasation to
occur: this may be on the order of a few minutes in tissues such as
brain tumors, but longer scans are required in less permeable tissues
such as normal-appearing brain. If the EES volume fraction ve is to be ac-
curately measured then imaging should continue well into the “wash-
out” phase, when the EES contrast agent concentration begins to fall.
Further research is needed to investigate how variations in contrast
agent types and doses affect pharmacokinetic parameters.
A wide range of pharmacokinetic models have been proposed for
fitting DCE-MRI data, the most popular of which divide the tissue into
well-mixed compartments. It is essential to recognize the assumptions
built into these models and to assess their likely validity for a given ap-
plication (Sourbron and Buckley, 2013). The original Toftsmodel, for ex-
ample, is strictly valid only in weakly vascularized tissues, where
contrast agent in the capillaries can be neglected; furthermore, the
fitted KTrans is equal to PS only when the blood flow is sufficiently
high. For tissues where the vascular contribution is significant, the
Patlak or extended Tofts models may be more appropriate, provided
again that plasma flow is high. The choice of model should also reflect
the MRI protocol: if the acquisition duration is short and BBB leakage
is slow then models that do not allow back-diffusion (e.g. Patlak and
tissue-uptake models) may be suitable, while application of a model
that does include back-diffusion (e.g. extended Tofts model) can result
in increased uncertainty in the fitted parameters. Similarly, application
of a model that includes flow (e.g. tissue-uptake and two-compartment
exchange models) is counterproductive if the acquired temporal resolu-
tion is insufficient. These and other considerations have been investigated
theoretically by Sourbron and Buckley (2011) and are summarized
accessibly in their recent review (Sourbron and Buckley, 2013). A recent
investigation by Cramer et al. further emphasized the importance of ap-
propriate model selection in the context of subtle BBB permeability
(Cramer and Larsson, 2014). If it is unclear which model to select a-priori
then data-driven approaches, e.g. use of Akaike information criteria, can
be used to determine the most suitable model (Ewing and Bagher-
Ebadian, 2013), although this does not guarantee that themodel assump-
tions are met.
As most current data apply to tumors, more data are required for
assessing low-level BBB abnormalities. The relative lack of methodolog-
ical assessments to determine the best methods of measuring low level
BBB disruption in normal or abnormal appearing brain in aging, demen-
tia or brain microvascular disease, argue for substantially more work to
determine the optimum contrast and dose, acquisition parameters, and
data analysis methods.
6. Conclusion
This systematic review has highlighted the wide range of applica-
tions where DCE-MRI has been used to assess BBB integrity. We found
large variations in studied pathologies, MRI procedures and data analy-
sis methods resulting in widely varying estimates of permeability pa-
rameters. Nevertheless, DCE-MRI has been shown to provide valuable
information in a growing field of applications, ranging from the grading
of primary brain tumors to the assessment of healthy-appearing tis-
sue in multiple sclerosis patients or dementia. In methodological
terms, DCE-MRI is a relatively mature technique, but the lack of
agreed standards for image acquisition, data modeling and study
reporting hinders inter-study comparison and meta-analysis. Im-
proved reliability of DCE-MRI, especially in subtle permeability
states, is required. Where feasible, further technical development
should be accompanied by attempts to establish consensus-based
recommendations for data acquisition and analysis in order to im-
prove inter-study comparability and promote wider use of DCE-
MRI both clinically and in research (Tofts et al., 1999; DCE MRI Tech-
nical Committee, 2012; Leach et al., 2012).
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Cerebral small vessel disease
There is evidence that subtle breakdown of the blood–brain barrier (BBB) is a pathophysiological component of
several diseases, including cerebral small vessel disease and some dementias. Dynamic contrast-enhanced MRI
(DCE-MRI) combined with tracer kinetic modelling is widely used for assessing permeability and perfusion in
brain tumours and body tissues where contrast agents readily accumulate in the extracellular space. However,
in diseases where leakage is subtle, the optimal approach for measuring BBB integrity is likely to differ since
the magnitude and rate of enhancement caused by leakage are extremely low; several methods have been
reported in the literature, yielding a wide range of parameters even in healthy subjects. We hypothesised that
the Patlak model is a suitable approach for measuring low-level BBB permeability with low temporal resolution
and high spatial resolution and brain coverage, and that normal levels of scanner instability would influence
permeability measurements. DCE-MRI was performed in a cohort of mild stroke patients (n = 201) with a
range of cerebral small vessel disease severity. We fitted these data to a set of nested tracer kinetic models,
ranking their performance according to the Akaike information criterion. To assess the influence of scanner drift,
we scanned 15 healthy volunteers that underwent a “sham”DCE-MRI procedurewithout administration of contrast
agent. Numerical simulationswere performed to investigatemodel validity and the effect of scanner drift. The Patlak
modelwas found to bemost appropriate forfitting low-permeability data, and the simulations showed vp andK
Trans
estimates to be reasonably robust to themodel assumptions. However, signal drift (measured at approximately 0.1%
perminute and comparable to literature reports in other settings) led to systematic errors in calculated tracer kinetic
parameters, particularly at low permeabilities. Our findings justify the growing use of the Patlak model in low-per-
meability states, which has the potential to provide valuable information regarding BBB integrity in a range of dis-
eases. However, absolute values of the resulting tracer kinetic parameters should be interpreted with extreme
caution, and the size and influence of signal drift should be measured where possible.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Imaging and biochemical investigations suggest that breakdown of
the blood–brain barrier (BBB) may be implicated in ageing and the
pathophysiology of several diseases, including cerebral small vessel
disease, lacunar stroke, vascular dementia and Alzheimer's disease
(Farrall and Wardlaw, 2009; Iadecola, 2013; Wardlaw et al., 2013a).
Reliable in vivo methods for measuring microvascular integrity are
therefore essential to investigate the mechanisms underlying such
diseases and to assess potential therapies. The cerebrospinal fluid
(CSF) to plasma albumin ratio is a widely accepted in vivo marker of
BBB integrity but is non-specific and highly invasive.
The most widely used imaging method for assessing BBB integrity
and other microvascular properties is dynamic contrast-enhanced MRI
(DCE-MRI), in which a paramagnetic contrast agent is injected and the
time dependence of the resulting T1-weighted image enhancement
measured. There are many approaches to analysing such data, from
simple heuristic measures to a growing library of tracer kinetic models
(Sourbron and Buckley, 2012), which aim to estimate physiological
parameters including blood flow, blood volume and the rate of extra-
vascular leakage. These techniques have been developed and applied
primarily in neurooncology and body imaging, where contrast uptake
in tissue is typically large and rapid. However, the optimal modelling
approach for research in diseases where the BBB remains largely intact
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(and extravascular contrast uptake is therefore slow) is unclear. Some
groups have applied semi-quantitative approaches, comparing signal
enhancement–time curves between patient groups to avoid assump-
tions inherent in modelling (Wardlaw et al., 2008) or calculating
heuristic quantities such as “area under curve” (Topakian et al., 2010).
These approaches have the advantage of being straightforward to
implement and do not require advanced image processing, but they
do not distinguish between intra- and extravascular contrast and may
be influenced by the acquisition parameters and other variables.
Recently, a number of more complex, model-based approaches to
quantifying subtle BBB leakage have been suggested, with applications
in cognitive impairment (Montagne et al., 2015; Taheri et al., 2011a),
healthy subjects (Cramer and Larsson, 2014), and in the normal-
appearing tissue of patients with multiple sclerosis (Cramer et al.,
2014), primary brain tumours (Larsson et al., 2009; Sourbron et al.,
2009) and acute stroke (Thornhill et al., 2010), involving a range of
acquisition and analysis methods.
In this work, we performed DCE-MRI in a large cohort of mild stroke
patients with a range of small vessel disease features and severity. We
aimed to determine the tracer kineticmodelling approachmost suitable
for assessing subtle BBB leakage using a data-driven approach, to deter-
mine its validity both in theory and experimentally and to obtain tracer
kinetic parameters for normal-appearing tissues and lesions. We
hypothesised that low temporal resolution data analysed using the
Patlak model is appropriate for measuring low-level BBB permeability
with high spatial resolution and brain coverage, and that scanner insta-





We recruited 264 patients with first clinically evident mild
(i.e., expected to be non-disabling) ischaemic stroke from the local
stroke service. Included patients had to be over 18 years old, have a
definite diagnosis of ischaemic stroke, be able to consent themselves,
have anMRI scan at diagnosis and bemedically stable enough to return
for a DCE-MRI scan at between 1 and 3 months post-stroke and a
follow-up at 1 year. All patients underwent clinical assessment by a
stroke physician, diagnostic MR imaging and cognitive testing at pre-
sentation. An expert panel of stroke physicians and neuro-radiologists
assessed each case in order to confirm the diagnosis of ischaemic stroke
and classify the ischaemic stroke subtype. DCE-MRI was performed a
minimum of 1 month after the stroke in order to avoid acute effects of
the stroke on the local BBB. This study was approved by the Lothian
Ethics of Medical Research Committee (REC 09/81101/54) and the
NHS Lothian R + D Office (2009/W/NEU/14), and all patients gave
written informed consent.
MRI
All imaging was performed on a 1.5 T MRI scanner (Signa HDxt,
General Electric, Milwaukee, WI) using an 8-channel phased-array
head coil. Diagnostic MR imaging at presentation included axial
T2-weighted (T2W; TR/TE = 6000/90 ms, 24 × 24 cm field of view
(FoV), 384 × 384 Propeller acquisition, 1.5 averages, 28 × 5 mm slices,
1 mm slice gap), axial fluid-attenuated inversion recovery (FLAIR;
TR/TE/TI = 9000/153/2200 ms, 24 × 24 cm FoV, 384 × 224 acquisition
matrix, 28 × 5 mm slices, 1 mm slice gap), gradient echo (GRE;
TR/TE=800/15ms, 20°flip angle, 24× 18 cmFoV, 384× 168 acquisition
matrix, 2 averages, 28× 5mmslices, 1mmslice gap) and sagittal 3D T1-
weighted imaging (T1W; inversion recovery-prepared spoiled gradient
echo TR/TE/TI = 7.3/2.9/500 ms, 8° flip angle, 330 × 214.5 cm FoV,
256 × 146 acquisitionmatrix, 100 × 1.8mm slices) and diffusion tensor
MRI (single-shot echo-planar imagingwith 30 diffusion directions (b=
1000 s/mm) and 2 × b0 acquisitions, TR/TE = 7700/82 ms, 24 × 24 cm
FoV, 128 × 128 acquisition matrix, 28 × 5 mm slices, 1 mm slice gap).
DCE-MRI was performed at approximately 1 month after first
presentation and consisted of a 3D T1W spoiled gradient echo sequence
with TR/TE= 8.24/3.1ms, 24× 24 cmFOV, 256× 192 acquisitionmatrix
and 42 × 4mm slices. Two pre-contrast acquisitionswere carried out at
flip angles of 2° and 12° to enable the calculation of pre-contrast longi-
tudinal relaxation times (T10). An intravenous bolus injection of 0.1
mmol/kg of gadoterate meglumine (Gd-DOTA, Dotarem, Guerbet,
France) was administered simultaneously with the start of 20 acquisi-
tions with 12° flip angle and a temporal resolution of 73 s, leading to a
DCE-MRI duration of approximately 24 minutes.
Image processing
All image analysis was performed blind to clinical and permeability
data. All structural and DCE-MRI images were aligned to the 12° pre-
contrast image using rigid-body registration (FSL-FLIRT (Jenkinson
and Smith, 2001)) in order to correct for bulk patient movement. We
defined all small vessel features according to agreed STRIVE standards
(Wardlaw et al., 2013b). We used a multispectral MRI data fusion and
minimum variance quantisation technique (Valdés Hernández et al.,
2010) for the segmentation of white matter hyperintensities (WMH)
and normal-appearing white matter (NAWM). Please note that we use
the term “WMH” to include hyperintensities in the white and subcorti-
cal grey matter. The resulting masks were manually refined and, sepa-
rately, old stroke lesions and the index (i.e., which had led to patient
entry to the study) stroke lesion boundaries were semi-automatically
outlined on FLAIR images using the “Region of Interest” tool of Analyze
11.0TM (AnalyzeDirect, KS). Index/recent stroke lesions (RSL) were de-
fined as the hyperintense regions identified on the diffusion weighted
image including any corresponding signal changes on FLAIR, T2W and
T1W images, associated with swelling or lack of ex vacuo effect, that
followed a vascular territory. Stroke lesion masks were checked for ac-
curacy by a neuroradiologist; all other tissue masks were checked visu-
ally for accuracy and manually edited as necessary. Subcortical/deep
grey matter (DGM) masks were generated automatically by a software
pipeline that used FSL-SUSAN (Smith and Brady, 1997) for noise reduc-
tion, an age-relevant brain template (Farrell et al., 2009), FSL-FLIRT for
aligning the template to each image data set and FSL-FIRST
(Patenaude et al., 2011) for extracting the subcortical structures, follow-
ed by manual boundary correction. To minimise any residual contami-
nation of the DGM, the mask was eroded by one voxel. An example of
a FLAIR image and segmentation masks is shown in Fig. 1.
Fig. 1. Representative MRI data and tissue segmentation. FLAIR image (left) and tissue
masks superimposedon FLAIR image (CSF: cerebrospinalfluid, NAWM:normal-appearing
white matter, WMH: white matter hyperintensities, DGM: deep grey matter, RSL: recent
stroke lesion).
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DCE-MRI analysis
For each post-contrast time point i, we calculated the median signal
intensity over all voxels for each tissue type (Si). The signal enhance-
ment Ei (representing the fractional signal increase above baseline)
was then calculated as Ei=(Si− S0) / S0, where S0 is the signal intensity
of the 12° pre-contrast acquisition. T10 was calculated based on the var-










where SR = Sa/Sb, with Sa and Sb representing the signal intensities of
the two pre-contrast acquisitions with flip angles αa = 2° and αb =
12°. The contrast agent concentration Ci was then estimated by numer-
ical solution of the following equation (Armitage et al., 2005):
Ei ¼ exp −r2CiTEð Þ
 1− exp −P−Qð Þ−cosαb exp Pð Þ− exp −2P−Qð Þð Þ
1− exp Pð Þ−cosαb exp P−Qð Þ− exp −2P−Qð Þð Þ
 
−1; ð2Þ
where P=TR/T10,Q=r1CiTR, longitudinal and transverse contrast agent
relaxivities r1 and r2 with r1/r2 = 4.2/6.7 s−1mM−1 (Rohrer et al.,
2005).
We obtained a vascular input function (VIF) from a voxel located on
the superior sagittal sinus (SS) since partial volume effects and inflow
artefact were reduced at that location compared with obtaining the
AIF from a feeding artery (Lavini and Verhoeff, 2010); the delay
between arterial and venous responses is expected to be very small com-
pared with the temporal resolution (Sourbron et al., 2009; Sourbron and
Buckley, 2012). Two observers, independently and blind to each other's
results, manually selected a single voxel for VIF extraction, using a slice
proximal to the basal ganglia structures and the lateral ventricles. This
voxel was chosen to provide a high peak signal enhancement and
smooth variation during the DCE-MRI time course. Where the observers
selected different voxels, the voxel with the highest peak enhancement
was chosen unless the signal curve was significantly noisier (a noise
estimate was calculated as the sum of squared differences between the
signal curve and a fitted bi-exponential curve). The calculated whole-
blood concentration Cb(t) measured in the SS was converted to plasma
concentration using the formula Cp(t) = Cb(t) / (1 − Hct), with the
most recent available haematocrit measurement in the patient's clinical
record (where no haematocrit measurement was available (n = 3) we
assumed Hct = 0.45).
Tracer kinetic modelling
Tracer kinetic modelling aims to provide a link between the tissue
signal enhancement and the physiological parameters, including the
fractional plasma volume vp, the fractional interstitial volume ve and
the permeability-surface area product PS. We fitted the following
three models to the tissue concentration curves: (i) the modified Tofts
model (Tofts et al., 1999), (ii) the Patlak model (Patlak et al., 1983)
and (iii) the steady-state model (Sourbron and Buckley, 2013). A
schematic overview of these models and their relationship with the
more general two-compartment-exchange model (2CXM) (Sourbron
and Buckley, 2013) is shown in Fig. 2.
Themodified Tofts model describes a highly perfused (Fp=∞) two-
compartment tissue, considering bidirectional transport between the
blood plasma and the extracellular extravascular space (EES). The
concentration of contrast agent in the tissue is given by





where the volume transfer constant KTrans represents the rate at which
contrast agent is delivered to the EES per volume of tissue and contrast
agent concentration of the VIF (PS denotes the same transfer constant
with respect to capillary plasma concentration); in general, the mea-
sured KTrans depends on both the plasma flow Fp and the permeability-
surface area product PS; however, if the assumptions of the model are
met (i.e., flow is high enough and the rate of contrast extravasation is
low enough to ensure equal concentration in the arteries and capillary
bed) and the measurement process is accurate, then KTrans ≈ PS is a
good approximation (Sourbron and Buckley, 2013). In the work that
follows, we use the symbol KTrans to indicate experimental or simulated
measurements and PS to indicate the permeability-surface area product
used to generate simulated data.
The Patlak model can be seen as a special case of the modified Tofts
model, which ignores backflux from the EES into the blood plasma
compartment. Consequently, it only allows for the estimation of the
two parameters KTrans and vp:
CtðtÞ ¼ vpCp tð Þ þ KTrans∫t0Cp τð Þ dτ: ð4Þ
If it is further assumed that there is no transfer of contrast to the EES,
the one-parameter steady-state model (Sourbron and Buckley, 2013) is
obtained:
CtðtÞ ¼ vpCp tð Þ: ð5Þ
Model fitting was performed using in-house software programmed
in MATLAB (MathWorks, Natick, MA, USA) by non-linear minimisation
of the sum of squared residuals. All parameters were restricted to posi-
tive values, and vp + ve was constrained to be less than or equal to 1;
fitting was repeated 25 times with different initial values to reduce
the probability of selecting local minima (Ahearn et al., 2005). The
first three post-contrast time points of all contrast agent concentration
curves were omitted from sum of squares calculation since the rapid
concentration changes during and immediately after the first pass are
not adequately resolved by the acquisition protocol and are not accu-
rately modelled by any of the three nested models (Larsson et al.,
Fig. 2. Set of nested tracer kinetic models. Target parameters of DCE-MRI modelling are the fractional plasma volume vp, the fractional interstitial volume ve, the plasma flow Fp and the
permeability-surface area product PS. The four models are related by a series of simplifying assumptions.
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2009), resulting in biased parameter estimates that depend on Fp; this
was confirmed by computer simulations.
Model comparison
The competing models were ranked according to the Akaike
information criterion (AIC) (Akaike, 1974), which has been applied in
DCE-MRI by several groups (Brix et al., 2009; Ingrisch et al., 2010).
The AIC accounts for the trade-off between goodness-of-fit and model
complexity, by combining the sum of squared errors SSm with the
number of free parameters Km associated with the model m:




þ 2 Km þ 1ð Þ; ð6Þ
where N denotes the number of data points. For small samples,
i.e., N/Km b 40 as in our case, the AIC should be extended with a
second-order bias correction term (Burnham and Anderson, 2004),
giving the small-sample version
AICcm ¼ AICm þ
2Km Km þ 1ð Þ
N−Km−1
: ð7Þ
The Akaike weight AWm describes the probability that the model m






with Δm ¼ AICcm−min AICc1;… ; AICcMð Þ:
ð8Þ
For a statistical comparison between tracer kinetic parameters,
Wilcoxon's signed rank test (since the data were in general not normally
distributed) was used.
Healthy volunteers
To assess signal changes unrelated to the contrast agent, we recruited
15 healthy volunteers that underwent the sameDCE-MRI protocol as ap-
plied in the clinical cohort but without administration of contrast agent.
This study was approved by ACCORD Healthy Volunteer Research Ethics
Committee (REC 14/HV/0001), and all volunteers gavewritten informed
consent. We manually placed regions of interest (ROIs) in NAWM and
DGM and calculated median signal intensity and enhancement curves
for each ROI as described previously. Signal drift was calculated as the
overall change in signal intensity per minute and is given as percentage
of the time-averaged signal.
In addition to the dynamic sequence, we accurately measured T1
using the inversion recovery method (Larsson et al., 1988) (IR) in
n = 7 volunteers. For this purpose, we acquired 2D inversion recovery
spin echo echo-planar imaging with multiple inversion times (IR-SE-
EPI; TR/TE= 10000/25.4ms, 24 × 24 cm FOV, 256 × 192 acquisitionma-
trix, 1 × 4 mm slice, TI = [100, 340, 580, 820, 1060, 1300, 2000, 3000]
ms). T1 was calculated by fitting the following equation to the median
ROI signal intensities (SI):




T1 was measured immediately before and after the non-contrast
DCE-MRI acquisition, yielding the two measurements T1,pre (before
DCE-MRI) and T1,post (after DCE-MRI). All values are given as mean
and standard deviation.
Simulations
Numerical simulationswere performed to systematically investigate
model validity. First, we generated a high-resolution (Δt = 0.1 s) VIF
using the function introduced by Parker et al., (2006), which consists
of two Gaussians plus an exponential term modulated by a sigmoid
function. In order to generate a simulated VIF with realistic first-pass
behaviour that also matched our data at longer times post-injection,
we introduced an additional exponential term resulting in the following
function:















n ¼ 12αn exp −βntð Þ




For the Gaussian functions and sigmoid modulation, which describe
the first and second pass of the VIF, we used the parameters given by
Parker et al. (An, σn, Tn, s, τ). The parameters αn and βn were obtained
by fitting Eq. (10) to the population-average VIF from our patient data
(Supplementary Fig. 1). Simulated tissue concentration curves were
generated by convolving this VIF with the impulse response function
of the 2CXM, which has four free parameters: Fp, PS, vp and ve
(Sourbron and Buckley, 2013). PS and vp values were chosen to repre-
sent the range of values obtained in normal-appearing tissue, WMH
and stroke lesions; ve was chosen to be 0.2 (Syková and Nicholson,
2008) and Fp values between 10 and 50 ml/100 g/min were selected
to represent typical values for NAWM, WMH and DGM (Brickman
et al., 2009). Randomnoisewas added to the curves to give a concentra-
tion contrast-to-noise ratio (CNR) similar to that observed in NAWM
and DGM in our clinical cohort; the CNR was defined as the peak
contrast agent concentration divided by a noise estimate, which was
calculated as the standard deviation of the difference between themea-
sured concentration curve and the Patlakmodel fit (CNR=max[Ct(t)] /
std[Ct(t) − CPatlak(t)]). Simulations were repeated, adding a signal drift
to both the tissue curve and the VIF. The added drift was of similar
magnitude to that found in the healthy volunteer cohort (values given
in the results section). We then down-sampled the VIF and tissue con-
centration curves to the experimental temporal resolution (Δt = 73 s),
and these were fitted to the Patlak model as described above. We
also calculated the semi-quantitative parameters AUCnorm (defined as
the area under the tissue enhancement curve divided by the area
under the vascular enhancement curve) and the late slope of the
enhancement curve (obtained by linear regression of the tissue signal
enhancement data). As for the clinical data, the first three post-
contrast data points were neglected for calculating the sum of squared
residuals during model fitting and for calculation of semi-quantitative
parameters. The simulations were repeated 1000 times for every set
of parameters to quantify the influence of noise.
Results
Patients
DCE-MRI was performed on average 38 days after first presentation
and data suitable for analysis were obtained in 201 patients with mean
age of 66.0 ± 11.5 years. Fig. 3 shows the cohort-averaged signal
enhancement curves in NAWM, DGM, WMH, RSL and SS. All tissues
showa signal enhancement of approximately 2%–8%,with abnormal tis-
sues (WMHand RSL) showing a steeper increase in signal enhancement
over time compared with normal-appearing tissues (WM and DGM).
An example of tracer kinetic model fitting for a single patient is
shown in Fig. 4A; the Patlak and modified Tofts models provide good
fits to the measured signal but the steady-state model is not sufficient
to describe the data. This observation is confirmed by analysis of the
Akaike weights (Fig. 4B), which shows that the Patlak model best
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represents the data inmost subjects for all tissue types, andwas selected
as the optimum model in 74%–78% of patients for the four tissues mea-
sured. The resulting Patlak parameters are listed in Table 1. A comparison
between tissue types is shown in Fig. 5; all differences between tissue
types were significant (p b 0.001) except for KTrans in WMH and DGM
and vp in WMH and RSL. In particular, KTrans and vp are significantly
higher in WMH compared to NAWM; KTrans is significantly higher in
RSL compared to all other tissues.
Healthy volunteers
DCE-MRI data without contrast administration was obtained in 15
healthy volunteerswithmean age 31.4±7.4 years. Fig. 6A shows the cor-
responding average signal enhancement curves in NAWM and DGM. The
data show an approximately linear drift in signal intensity of 0.10 ±
0.06%/min in DGM and 0.06 ± 0.03%/min in NAWM. To investigate
whether part of thedrift canbe explainedby subtle physiological changes,
we accuratelymeasured T1 before and after the DCE-MRI sequence in 8 of
the volunteers. T1 values were in line with previous literature (Vymazal
et al., 1999) with T1,pre/T1,post =903 ± 66 ms / 892 ± 53 ms in DGM
and T1,pre/T1,post = 680 ± 40 ms / 674 ± 41 ms in NAWM (see Fig. 6B);
the small decrease in T1 over the period of the DCE-MRI acquisition
was not statistically significant (ΔT1 = −11 ± 20 ms in DGM and
ΔT1=−7 ± 14 ms in NAWM).
Simulations
The results of simulations performed to determine the validity of the
Patlakmodel are shown in Fig. 7. These compare fitted parameters with
the “true” parameters used to generate synthetic signal-time curves
using the 2CXM model. All simulations are based on a CNR of 8 and a
T1 of 969 ms, corresponding to typical NAWM values observed in our
patient cohort. In the absence of drift (Fig. 6A), KTrans ≈ PS and vp is ac-
curately estimatedwhen PS is low, despite very low temporal resolution
and the simplifying assumptions of the Patlak model. At higher PS
values, KTrans underestimates PS, and vp is slightly overestimated as a
result of back-diffusion, which is neglected in the Patlak model. The
model is robust to differences in blood flow, with low flow resulting in
a slightly greater underestimation of PS. To investigate the effect of scan-
ner drift, we included a 0.08%/min signal drift (comparable to that mea-
sured in the healthy volunteer group) in the simulations. This leads to
systematic underestimation of vp and overestimation of leakage
(Fig. 6B), but KTrans and vp remain approximately linear functions of
the specified values, largely independent of plasma flow and of one an-
other. The magnitude of the systematic error introduced by signal drift
is T1 dependent, with an estimated range across the tissues of approxi-
mately 2.2–3.2 × 10−4min−1 forKTrans and−2.4 to−1.6 × 10−3 for vp.
For comparison, Fig. 8 shows the relationship between PS and vp, and
the semi-quantitative parameters AUCnorm and the late slope of the
signal enhancement curve. AUCnorm correlates strongly with vp but is
also influenced by PS. Similarly, the enhancement slope correlates
with PS but is not independent of vp.
Discussion
Analysis of patient DCE-MRI data using the Akaike information crite-
rion revealed the Patlak model to be the most appropriate of the three
models for quantification of subtle BBB disruption, in line with our
hypothesis. The steady-state model does not adequately fit the data;
Fig. 3. Cohort average signal enhancement curves. Post-contrast signal enhancement
versus time obtained from the median signal intensity in each tissue type (NAWM:
normal-appearing white matter, WMH: white matter hyperintensities, DGM: deep
grey matter, RSL: recent stroke lesion, SS: sagittal sinus) and averaged over all patients
(n = 201). Y-axis scales for the tissue and sagittal sinus enhancement curves are shown
on the left and right, respectively.
Fig. 4. Comparison of model fits to the patient data. (A) Example concentration–time curve for normal-appearing white matter in a single patient. In general, the steady-state model does
not fit the data well; while both the Patlak and modified Tofts (mTofts) models typically fit the data similarly well, the Patlak model has a higher Akaike weight (AW) than the modified
Tofts model in most cases due to the lower number of free parameters. (B) Comparison of AW for the three models in normal-appearing white matter (NAWM), white matter
hyperintensities (WMH), deep grey matter (DGM) and recent stroke lesions (RSL). In most patients, the Patlak model had the highest AW for all tissue types (legend as in A).
Table 1
Fitted Patlak parameters. Values are shown as mean ± standard error in normal-
appearing white matter (NAWM), white matter hyperintensities (WMH), deep grey
matter (DGM) and recent stroke lesions (RSL). All differences between tissue types were
significant (p b 0.001) except for KTrans in WMH and DGM and vp in WMH and RSL.
KTrans (×10−4 min−1) vp (×10−2)
NAWM 2.96 ± 0.12 0.58 ± 0.02
WMH 3.96 ± 0.13 0.80 ± 0.04
DGM 3.91 ± 0.12 1.21 ± 0.03
RSL 5.77 ± 0.41 0.80 ± 0.05
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while both the Patlak and modified Tofts models fit the data similarly
well, the simpler Patlak model does so using fewer free parameters
and is therefore selected. The additional complexity of the modified
Tofts model results in over-fitting in the low-permeability regime,
consistent with a previous report regarding the behaviour of Tofts
parameters in a smaller study of healthy volunteers and MS patients
(Cramer and Larsson, 2014). Application of the Patlak model in situa-
tions of subtle BBB leakagewas further supported by the numerical sim-
ulations, confirming that appropriate estimates of PS (≈KTrans), and vp
can be obtained independent of cerebral blood flow (CBF) and despite
the use of a temporal resolution much lower than is typically employed
in DCE-MRI (Heye et al., 2014); this was consistent with simulations
performed by Larsson et al. for a shorter, high temporal resolution
acquisition (Larsson et al., 2009). A consequence of this finding is that
DCE-MRI protocols for investigating diffuse subtle BBB pathology may
benefit from prioritising, as here, spatial resolution, whole-brain cover-
age and contrast-to-noise ratio over sampling rate to allow for analysis
of subtle leakage across all brain structures. In contrast to the fitted
tracer kinetic parameters, we found semi-quantitative parameters to
reflect a combination of underlying tissue properties.
In our cohort ofmild stroke patients,KTranswas greater inWMH than
in NAWM. This is consistent with some pathology studies (e.g.,
Tomimoto et al., 1996; Wharton et al., 2015; Young et al., 2008) and
other DCE-MRI studies that reported increased BBB disruption in areas
of WMH compared to NAWM (Hanyu et al., 2002; Taheri et al., 2011a;
Topakian et al., 2010). In contrast, a recent study by Huisa et al. found
increased BBB disruption in NAWM surrounding the WMH rather
than in the WMH themselves (Huisa et al., 2015), while others failed
to detect any BBB leakage in or around WMH (Wahlund and Bronge,
2000). The exact role of BBB breakdown in SVD pathology remains to
be defined. KTrans was greater still in the recent stroke lesion, compara-
ble to findings of Thornhill et al. in acute-phase stroke lesions (Thornhill
et al., 2010) and known tissue changes frommany pathology examina-
tions. KTrans was greater in GM than in NAWM, whichmay partly reflect
the higher vessel density and vascular surface area of GM (Schlageter
et al., 1999), consistentwith the highermeasured blood plasma volume.
WMH, which are often regarded as “ischaemic” lesions and might
therefore be expected to have reduced plasma volume, had greater vp
than NAWM. This finding is only partly explained by the T1 difference
between the tissues, which results in a predicted greater underestima-
tion of vp in NAWM due to scanner drift. Assumptions such as tissue-
independent relaxivity and water exchange rates may also influence
the values. Another possible explanation is that a few WMH are found
in tissue that was originally subcortical grey matter, especially in the
head of the caudate nucleus, where baseline blood volume is likely to
be higher. Very few studies have measured cerebral blood volume
(CBV) and CBF in WMH themselves, as opposed to general CBV and
CBF in patients with WMH. While some studies using DSC-MRI have
reported reduced CBV in WMH, e.g., Sachdev et al. (2004), Marstrand
et al. (2002) found reduced CBF but similar CBV in WMH compared
with NAWM. Although DCE-MRI is a more quantitative marker of
microvascular properties than DSC-MRI, previous studies applying
DCE-MRI in SVD have not reported vp values for WMH to the best
of our knowledge. We suggest therefore that future studies should
assess CBF and CBV in WMH as well as normal tissues so as to resolve
this issue.
Fig. 5. Comparison of fitted Patlak parameters between tissue types. Box plots showing the distribution of KTrans (left) and vp (right) in normal-appearing white matter (NAWM), white
matter hyperintensities (WMH), deep greymatter (DGM) and recent stroke lesions (RSL). Bracketswith n.s. indicate non-significant differenceswith p N 0.5; all other differences between
tissue types are significant with p b 0.001 (brackets omitted for clarity).
Fig. 6. Contrast-free measurements in healthy volunteers. (A) Average signal enhancement curves (n = 15) in normal-appearing white matter (NAWM) and deep grey matter (DGM),
showing a drift in signal intensity; error bars indicate the mean ± standard error. (B) T1 measurements obtained before and after the DCE-MRI sequence using the inversion recovery
method (n = 7); error bars indicate the mean ± 1.96 standard deviations.
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In subjects who did not receive contrast, we observed a signal
change of approximately 0.08%/min. This level of instability is unlikely
to be problematic in typical DCE-MRI applications with larger, more
rapid signal enhancements over shorter acquisition times. However,
our simulations show that the drift is predicted to cause a substantial
upward shift of KTrans measurements in the low-permeability regime,
which would account for some of the apparent leakage seen in
normal-appearing white matter and other tissues. As a result, attempts
to quantify low levels of permeability should be interpreted with
caution, unless information regarding scanner drift and its likely effect
on the values are available. This finding is consistent with recently
reported simulation results (Barnes et al., 2015) andmay partly account
Fig. 7. Simulated accuracy of Patlak parameters. (A) Relationship of permeability-surface area product PS (top row) and blood plasma volume vp (bottom row) values, with corresponding
fitted Patlak parameters. Results are shown for two different blood plasma flow (Fp), PS and vp values. For all simulations, the interstitial volume was set to 0.2. Error bars indicate the
mean ± 1.96 standard deviations; the grey line represents the identity line. (B) As above but including a 0.08%/min signal drift.
452 A.K. Heye et al. / NeuroImage 125 (2016) 446–455
B. Copies of publications 251
for the wide variation in KTrans values reported in the literature for
normal-appearing brain tissue (Cramer et al., 2014; Larsson et al.,
2009; Montagne et al., 2015; Sourbron et al., 2009; Taheri et al.,
2011a, 2011b; Thornhill et al., 2010), which span three orders ofmagni-
tude and include negative values (Sourbron et al., 2009). Signal drift
measurements are rarely reported in the DCE-MRI literature, an excep-
tion being Cramer et al. who reported a drift at 3 T (1%–3% over 15 mi-
nutes) comparable to our measurements at 1.5 T (Cramer and Larsson,
2014). The drift behaviour of our scanner was also within the range of
values obtained in a multi-centre survey of fMRI quality assurance
parameters, which concluded that “stable scanners generally average
around 1.0% [signal drift over 6.7 minutes] or less” (Friedman and
Glover, 2006). The influence of signal drift in fMRI is much less severe
than here since it typically has a lower frequency than the task-related
signal change, is suppressed using a high-pass filter and the scans are
quicker; in DCE-MRI, it is harder to distinguish between drift and
contrast enhancement as both occur on similar timescales. It is worth
noting that DCE-MRI methods consisting of repeated T1 measurements
(e.g., Taheri et al., 2011b) should largely self-compensate for signal
drifts of instrumental origin and, depending on the pulse sequence
used, changes in the radiofrequency field strength. However, the causes
of signal drift are not well-understood and may also be influenced by
subtle biological changes (Lowe and Russell, 1999), consistent with
our (non-significant) observation of T1 change and by a previous report
of tissue-dependent drift on the same scanner as in the present work
(Armitage et al., 2011). The effect should also be mitigated by
optimising the protocol for sensitivity to changes in contrast agent
concentration.
Despite the potentially confounding influence of drift, our simulations
indicate that KTrans and vp estimates remain approximately linear inde-
pendent functions of the permeability-surface area product and plasma
volume, respectively. They provide a valuable if relative indication of
blood–brain barrier integrity and blood plasma volume for applications
in well-designed studies with appropriate control groups and statistical
correction for confounds; such quantities remain easier to interpret than
semi-quantitative measurements (Budde et al., 2012).
This and other DCE-MRI studies are limited by additional sources of
error, which have been described elsewhere. For example, the variable
flip angle method (also known as “DESPOT1”) used here and in many
other studies (Homer and Beevers, 1985) has the advantage of yielding
T1 maps with whole-brain coverage and adequate SNR within an ac-
ceptable acquisition time. However, it is sensitive to flip angle variations
across the brain, i.e., deviations of the actual from the operator defined
flip angles caused by B1 field inhomogeneities and the slab excitation
profile of the radiofrequency pulse, resulting in errors in T10 and other
parameters (Armitage et al., 2011; Schabel and Parker, 2010). At 1.5 T
and using a radiofrequency transmit volume coil, such flip angle
variations should be limited and reasonably consistent within the co-
hort. In future studies, especially on scanners with higher field strength,
it would be prudent to either employ methods that estimate and/or
correct for flip angle errors, such as DESPOT1-HIFI (Deoni, 2007).
Look–Locker-based methods such as TAPIR (Shah et al., 2001) also
provide an alternative approach for T10 measurement, permitting faster
sampling of the magnetization recovery curve than the conventional
inversion recovery method. The sensitivity of these methods to flip
angle variations is reduced since the flip angle can be modelled as an
unknown parameter during fitting of the inversion recovery curve. It
should also be recognised that all tracer kinetic models necessarily
make assumptions regarding tissue structure and the transport of
blood plasma and contrast agent. For example, as the low temporal
resolution of our acquisition protocol does not permit estimation of
bloodflow,we selected threemodels that assume the tissue to be highly
perfused (i.e., Fp = ∞). Although this is not the case in real tissues, it
remains a good approximation when the blood flow is sufficient to
equalise the arterial and capillary concentrations (requiring PS bbFp)
(Sourbron and Buckley, 2011), with our simulations confirming the
validity of this approximation; the choice of models should also be
seen in relation to temporal resolution, which in this case is much
longer than the transit time of the tissue blood compartment. It should
also be emphasised that while PS (or KTrans) is commonly used as a
marker of “permeability,” it is equally influenced by the capillary surface
area,whichwill depend on the anatomy and pathology ofmicro vessels.
Future studies should try to determine vessel density and size so as to
include realistic estimates of capillary endothelial surface area in the
permeability calculations. Furthermore, a disadvantage of low temporal
resolution acquisition is that cerebral blood flow cannot be determined
in addition to vp and PS; where knowledge of CBF is required and tem-
poral resolution is adequate, the uptake model may be substituted for
the Patlak model in low-permeability tissue (Ingrisch et al., 2012;
Sourbron et al., 2009). Finally, the DCE-MRI data in this study has been
analysed at the level of ROIs rather than voxels. This approach was
selected due to the low contrast-to-noise ratio in single voxels and
due to the influence of artefacts (e.g., Gibbs ringing and motion),
which, while typically at the level of only a few percent, have a similar
magnitude to the small contrast-induced signal changes and therefore
have a disproportionate influence on voxel-wise pharmacokinetic
parameters (Supplementary Fig. 2). Averaging over an ROI reduces the
influence of noise and artefact, enabling more robust measurement of
background BBB status, especially in normal-appearing tissue where
signal changes are small. However, a limitation of this approach is that
it does not allow the detection of local variation in BBB function.
In conclusion, the Patlak model is a simple and appropriate method
for measuring low-level BBB leakage, and our results, based on a large
sample of mild stroke patients, justify its emerging popularity in the
Fig. 8. Relationship between simulated semi-quantitative parameters and tissue properties. (A) Relationship between the signal enhancement slope and the permeability-surface
area product PS for different blood plasma volumes vp. (B) Relationship between normalised area under the signal enhancement curve and vp for different PS values. A signal drift of
0.08%/min was added to the synthetic data; results are shown for blood plasma flow Fp = 10 ml/100 g/min and interstitial volume ve = 0.2.
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study of disorders involving subtle BBB disruption and of healthy-
appearing tissue (Cramer et al., 2014; Montagne et al., 2015; Taheri
et al., 2011a). The model is reasonably robust to the assumptions of
high blood flow and negligible back-diffusion, but the resulting tracer
kinetic parameters are influenced by signal drift particularly at low-
permeability states. It is therefore important to optimise study MRI
protocols for measurement of low-level permeability and to assess the
magnitude and consistency of drift in future studies by performing
non-contrast experiments in volunteers as done here or in a subset of
patients (Armitage et al., 2011; Cramer and Larsson, 2014) and simula-
tions to predict the likely effect on study findings. These considerations
are particularly critical for multi-centre studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neuroimage.2015.10.018.
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Blood pressure and sodium: Association
with MRI markers in cerebral small
vessel disease
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Abstract
Dietary salt intake and hypertension are associated with increased risk of cardiovascular disease including stroke. We
aimed to explore the influence of these factors, together with plasma sodium concentration, in cerebral small vessel
disease (SVD). In all, 264 patients with nondisabling cortical or lacunar stroke were recruited. Patients were questioned
about their salt intake and plasma sodium concentration was measured; brain tissue volume and white-matter hyper-
intensity (WMH) load were measured using structural magnetic resonance imaging (MRI) while diffusion tensor MRI and
dynamic contrast-enhanced MRI were acquired to assess underlying tissue integrity. An index of added salt intake
(P¼ 0.021), pulse pressure (P¼ 0.036), and diagnosis of hypertension (P¼ 0.0093) were positively associated with
increased WMH, while plasma sodium concentration was associated with brain volume (P¼ 0.019) but not with
WMH volume. These results are consistent with previous findings that raised blood pressure is associated with
WMH burden and raise the possibility of an independent role for dietary salt in the development of cerebral SVD.
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Introduction
Cerebral small vessel disease (SVD) accounts for 20%
to 25% of strokes and causes cognitive impairment,
disability, and dementia. The pathogenesis of SVD is
poorly understood but hypertension and other vascular
risk factors have been identified. Previous work in our
group revealed associations between blood pressure
and white-matter hyperintensity (WMH) burden and
between blood pressure and previsible white-matter
damage assessed by diffusion tensor imaging.1,2
The influence of dietary salt intake on stroke inci-
dence and mortality is well known3 but may be only
partly mediated by its effect on blood pressure.4 Plasma
sodium concentration is assumed to be tightly regulated
but there is some evidence to suggest that even small
variations can affect physical and mental health in the
elderly population.5,6 The role of dietary and plasma
sodium in cerebral SVD is unclear.
In this work, we assessed a cohort of patients with
recent nondisabling stroke and exhibiting a spectrum of
SVD severity. We performed magnetic resonance
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imaging (MRI) scans to assess WMH volume, brain
tissue volume, diffusion tensor MRI (DT-MRI) meas-
ures of tissue integrity, and T1-weighted imaging of
contrast uptake. Blood pressure, an index of added
dietary salt intake, and plasma sodium concentration




Participants were 264 adult patients who presented to
our in- and out-patient stroke service. We recruited
consecutive patients with first clinically evident nondi-
sabling lacunar or mild cortical ischemic stroke, includ-
ing those with diabetes, hypertension, and other
vascular risk factors. We excluded patients with
unstable hypertension or diabetes, other neurologic dis-
orders and major medical conditions including renal
failure that would preclude use of intravenous gadolin-
ium contrast agents. We excluded patients unable to
give consent, with contraindications to MRI or intra-
venous contrast, who had hemorrhagic stroke or those
whose symptoms resolved within 24 hours (i.e., transi-
ent ischemic attack). The study was approved by the
Lothian Research Ethics Committee (REC 09/81101/
54) and the NHS Lothian R&D Office (2009/W/
NEU/14) and conducted according to the principles
expressed in the Declaration of Helsinki. All patients
gave written informed consent.
Clinical data, diet and smoking history, WMH
volume, brain tissue volume, and DT-MRI were
obtained at presentation. Participants returned
approximately 1 to 3 months after presentation for
dynamic contrast-enhanced MRI (DCE-MRI), the
delay being to avoid acute effects of the stroke on the
local blood–brain barrier.
Clinical and Laboratory Measurements
On presentation, a clinician trained in stroke obtained
the clinical details of the presenting stroke and deter-
mined the clinical stroke subtype (lacunar and cortical)
using the Oxfordshire Community Stroke Project
(OCSP) classification.7 The same clinical researcher
also recorded age, demographic details, past medical
history of hypertension, previous stroke, previous tran-
sient ischemic attack, ischemic heart disease, peripheral
vascular disease, diabetes mellitus, atrial fibrillation,
hypercholesterolemia, heart failure, smoking and alco-
hol use, as well as all medications used and obtained
blood biochemistry, brain MRI and other stroke inves-
tigations. We defined hypertension as blood pressure of
140/90mmHg or greater on presentation or a previous
diagnosis; smokers were defined as currently smoking
or having given up within the previous 12 months and
nonsmokers as having never smoked or having given up
more than 12 months previously.
An experienced neuroradiologist assessed acute
stroke subtype (lacunar or cortical) on MR diffusion-
weighted imaging (generated from DT-MRI), fluid-
attenuated inversion recovery (FLAIR), T2 and
T1-weighted diagnostic imaging. Acute lacunar infarcts
were required to be less than 20mm in maximum axial
diameter and in the deep white or gray matter (GM) of
the cerebral hemispheres or brainstem. Infarcts invol-
ving the cortex, or subcortical infarcts larger than
20mm diameter (i.e., a large striatocapsular infarct)
were classed as ‘cortical’, likely to be due to large
artery atherothromboembolism. All scans and clinical
details were then reviewed by an expert panel of neur-
ologists, stroke physicians, and neuroradiologists to
establish the final stroke subtype using all clinical and
imaging information. If no lesion was present on ima-
ging, then the stroke was classified based on the clinical
findings alone using the Bamford classification.7
We measured systolic and diastolic blood pressure
(SBP and DBP, respectively) from the brachial artery
in the stroke clinic or stroke ward using hospital blood
pressure devices, which were checked and maintained
by technical staff. Pulse pressure (PP) and mean arterial
pressure (MAP) were calculated as SBPDBP and
DBP, respectively. Plasma sodium concentration was
measured from blood samples taken during clinic
assessment and measured in the NHS Lothian
Biochemistry Department.
Participants were also asked to describe their add-
ition of salt to food during cooking and at the dining
table using the following salt intake score: 1¼ always,
2¼ often, 3¼ occasionally, 4¼ rarely, and 5¼ never;
the mean of the two scores was subtracted from 6 to
give an ordinal categorical variable in the range of 1
(minimum use of salt) to 5 (maximum use of salt) for
use in statistical analyses.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed with a
1.5 Tesla MRI scanner (Signa HDxt, General Electric,
Milwaukee, WI, USA) using an 8-channel phased-array
head coil. Diagnostic MRI was acquired at presenta-
tion, including axial T2-weighted (T2W; repetition time
(TR)/echo time (TE)¼ 6,000/90ms, 24 24 cm field of
view (FoV), 384 384 Propeller acquisition, 1.5 aver-
ages, 28 5mm slices, 1mm slice gap), axial FLAIR
(TR/TE/inversion time (TI)¼ 9,000/153/2,200ms,
24 24 cm FoV, 384 224 acquisition matrix,
28 5mm slices, 1mm slice gap), axial GRE (gradient
echo; TR/TE¼ 800/15ms, 20 flip angle, 24 18 cm
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FoV, 384 168 acquisition matrix, 2 averages,
28 5mm slices, 1mm slice gap) and sagittal 3D T1-
weighted imaging (T1W; inversion recovery-prepared
SPGR (spoiled gradient echo) TR/TE/TI¼ 7.3/2.9/
500ms, 8 flip angle, 330 214.5 cm FoV, 256 146
acquisition matrix, 100 1.8mm slices) and DT-MRI
(single-shot echo-planar imaging with 30 diffusion dir-
ections (b¼ 1,000 s/mm2) and 2 b0 acquisitions, TR/
TE¼ 7,700/82ms, 24 24 cm FoV, 128 128 acquisi-
tion matrix, 28 5mm slices, 1mm slice gap). The
DCE-MRI was performed between 1 and 3 months
after first presentation (median 38, interquartile range
(31,54) days) and consisted of 20 consecutive 3D T1W
SPGR acquisitions (TR/TE¼ 8.2/3.1ms, 12 flip angle,
24 24 cm FoV, 256 192 acquisition matrix,
42 4mm slices, 73 seconds acquisition time) with a
total acquisition time of approximately 24 minutes,
initiated simultaneously with an intravenous bolus
injection of 0.1mmol/kg gadoterate meglumine (Gd-
DOTA, Dotarem, Guerbet, France). Two additional
SPGR acquisitions were obtained before contrast
administration with flip angles of 2 and 12, respect-
ively for calculation of the precontrast longitudinal
relaxation time T1,0.
Image Processing and Analysis
Preprocessing. Magnetic resonance images were con-
verted from DICOM to Analyze 7.5 format.
Structural and DCE-MRI images were aligned to the
precontrast T1W image using rigid-body registration
(FSL-FLIRT8); for participants who did not receive
DCE-MRI, images were instead coregistered to the
T2W image.
Tissue segmentation. The FLAIR and GRE images were
processed using in-house software (‘MCMxxxVI’9) to
extract WMH in the brain parenchyma; these were
manually refined and, separately, old stroke lesions or
index stroke lesions were manually outlined using
Analyze 11.0 (AnalyzeDirect, Stilwell, KS, USA).
White-matter hyperintensity was identified as punctate
or diffuse areas in the white matter and deep GM of the
cerebral hemispheres or in the brainstem that were
3mm or larger in diameter and hyperintense with
respect to normal-appearing white matter and GM on
T2W and FLAIR images; some hypointensity on T1W
MRI was allowed as long as not less intense than cere-
brospinal fluid (CSF). White-matter hyperintensity
included ‘dirty’ or ill-defined diffuse hyperintensities
with varying and erratic intensity patterns emerging
from the lateral ventricle wall10,11 provided such
regions had outstanding intensity differences with
respect to the normal-appearing white matter
(NAWM) identified on T1W images. Index stroke
lesions were defined as the hyperintense regions identi-
fied on the diffusion-weighted image generated from the
DT-MRI scan including any corresponding signal
changes on FLAIR, T2W, and T1W images, associated
with swelling or lack of ex vacuo effect, that followed a
vascular territory. Old stroke lesions were wedge-
shaped hyperintense regions on the FLAIR or T2W
images, and hypointense on the T1W image including
cortex and/or subcortical tissues, with or without cavi-
tation, and with ex vacuo effect reflecting tissue loss.
The NAWM masks were generated using MCMxxxVI
as described in Valdés Hernández et al.12 Subcortical
GM masks were generated automatically by a software
pipeline that used FSL-SUSAN13 for noise reduction,
an age-relevant brain template,14 FSL-FLIRT for
aligning the template to each image data set, and
FSL-FIRST15 for extracting the subcortical structures,
followed by manual boundary correction. To minimize
any residual contamination of the subcortical GM, the
mask was eroded by one voxel. An example of MR
images and segmentation masks is shown in Figure 1.
Brain tissue volume. Intracranial volume (ICV), defined
as contents within the inner skull table including
brain tissue, CSF, veins, and dura, and limited infer-
iorly by the tip of the odontoid peg at the foramen
magnum, was extracted using the GRE image and the
Object Extraction Tool in Analyze 11.0, followed by
manual editing. Nonbrain tissue (CSF, venous sinuses,
and meninges) was extracted using MCMxxxVI. The
volume of the resulting ‘nonbrain’ binary masks was
subtracted from the ICV to provide a measure of
total brain tissue volume. For statistical analysis, the
brain tissue volume as a percentage of ICV (%BTV)
and the WMH volume as a percentage of ICV
(%WMH) were also calculated.
Diffusion tensor magnetic resonance imaging processing. The
DTI images were processed using in-house software,
which removed bulk motion and eddy current induced
distortions using FSL FLIRT8 and generated a direc-
tionally averaged diffusion-weighted image, mean dif-
fusivity (MD), and fractional anisotropy (FA)
parametric images using standard methods based on
multivariate linear regression. For each data set non-
linear registration16 was used to align the tissue masks
in the structural space (T2W) with the parametric maps
in the diffusion space using the NiftyReg tool (http://
sourceforge.net/projects/niftyreg/) applied using
TractoR software (http://www.tractor-mri.org.uk/diff
usion-processing) to obtain the transformation between
the brain extracted structural T2W image and the b0
diffusion volume. To avoid partial volume averaging
with CSF due to registration inaccuracies, the CSF
mask was dilated by one voxel in each direction and
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then subtracted from the NAWM, WMH, and subcor-
tical GMmasks in the diffusion space. Median MD and
FA were extracted for NAWM and subcortical GM in
each patient.
Dynamic contrast-enhanced magnetic resonance imaging.
Median signal intensities for normal-appearing subcor-
tical GM and white matter masks were extracted from
the coregistered precontrast and postcontrast T1W
images. A vascular input function was also determined
by manual selection of a voxel in the superior sagittal
sinus, using a slice proximal to the basal ganglia struc-
tures and the lateral ventricles. This voxel was chosen
to provide a high peak signal enhancement and smooth
variation during the DCE-MRI time course and was
chosen independently by two observers; where the
observers selected different voxels, the voxel with the
highest peak enhancement was chosen unless the
signal curve was significantly noisier (a noise estimate
was calculated as the sum of squared differences
between the signal curve and a fitted biexponential
curve). T1,0 was calculated using the median signal
intensities in the two precontrast images with flip
angles 2 and 12 and used to derive time-concentration
curves for each tissue as described in Armitage et al.;17
contrast agent concentration in the sagittal sinus was
converted to plasma concentration using the factor 1/
(1–Hct) and the most recent available hematocrit meas-
urement in the patient’s clinical record (if no hematocrit
measurement was available (n¼ 3) we assumed
Hct¼ 0.45). To semiquantitatively assess contrast
uptake in tissue, we calculated the normalized area
under curve (nAUC) defined as the area under the
tissue concentration curve divided by the area under
the superior sagittal sinus plasma concentration curve.
Statistical Analysis
Descriptive statistics in the text are given as
mean standard deviation. Regressions were assessed
by examination of the differences between the data and
model predictions, and collinearity by variance infla-
tion factors using SPSS version 19 (IBM Corp.,
Armonk, NY, USA) and Matlab (MathWorks, Inc.,
Natick, MA, USA). Predictors of %WMH and
%BTV were investigated using multiple linear
Figure 1. Representative magnetic resonance imaging (MRI) data and tissue segmentation. (A) Fluid-attenuated inversion recovery
(FLAIR) image, (B) tissue masks superimposed on FLAIR image, (C) fractional anisotropy map, (D) contrast agent concentration curves
obtained from dynamic contrast-enhanced MRI (DCE-MRI); y-axes scales for the sagittal sinus plasma concentration and normal-
appearing tissue concentration curves are shown on the left and the right, respectively.
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regression models with correction for age, smoking
status, stroke subtype, and additional factors given in
the text and tables. Residuals for the %WMH model
were not approximately normally distributed; to correct
for this, the transformed outcome variable
ln(0.005þ%WMH) was regressed instead.
Subcortical GMMD (units 106mm2/s) was also trans-
formed to ln(700þMD) for this reason.
Results
Subjects
A total of 264 subjects were recruited into the study with
mean age 66.9 11.8 years and a ratio of 45:55 for diag-
nosis of lacunar-to-cortical stroke; 39% of patients were
smokers and 72% had hypertension (Table 1). Reasons
for exclusion are shown in Figure 2. After withdrawals
and rejection of imaging data on quality grounds, DT-
MRI and DCE-MRI data suitable for analysis were
obtained in 262 and 201 patients, respectively.
White-Matter Hyperintensity and Brain Tissue
Volume
Mean WMH volume as a percentage of ICV was
1.5 1.6% with a positively skewed distribution. Pulse
pressure (¼ 0.0092/mmHg, P¼ 0.036) and a diagnosis
of hypertension (¼ 0.46, P¼ 0.0093) were significant
predictors of increased WMH volume as a percentage
of ICV with correction for age, stroke subtype, and
smoking status (Table 2 and Figure 3). Repetition of
the analysis with replacement of PP and MAP with
DBP and SBP showed that SBP but not DBP was posi-
tively associated with transformed%WMH (¼ 0.0079/
mmHg, P¼ 0.040). Salt intake score was also positively
associated with WMH volume (¼ 0.14, P¼ 0.021;
Figure 3); further analyses using the separate scores
for cooking and table salt usage were consistent with
this finding (¼0.11/0.067; P¼ 0.020/0.18 for cook-
ing/table salt—note that the coefficient sign change is
expected, since the combined score was inverted).
Regression analysis of brain tissue volume (mean:
71 5% of ICV) with the same covariates revealed a
positive association between plasma sodium concentra-
tion and %BTV corresponding to an increase in brain
tissue volume of 2% ICV per 10mmol/L sodium
(P¼ 0.019). Age was the most significant factor in the
analyses of both %WMH and %BTV (P< 0.0001).
Diffusion Tensor Magnetic Resonance Imaging
The DT-MRI data were obtained in 262 subjects (DT-
MRI data for two subjects were rejected due to failure
of the nonlinear image registration). Mean diffusivity
was distributed with mean values of 801 52 and
787 32 106mm2/s in subcortical GM and
NAWM, respectively, with corresponding FA of
0.234 0.021 and 0.256 0.022. The influence of
blood pressure, added salt intake, and plasma sodium
concentration on these variables was modelled with
correction for smoking, stroke subtype, and age, as
well as normalized WMH volume to account for SVD
severity (Table 3). Plasma sodium concentration was
negatively associated with MD in NAWM
(¼1.2 106 (mm2L)/(smmol); P¼ 0.011) and FA
in subcortical GM (¼0.9 103 L/mmol;
P¼ 0.021). Salt intake score was negatively associated
with FA in subcortical GM (¼3.4 103 L/mmol;
P¼ 0.0012); additional analyses using the separate
scores for salt usage during cooking and at the table
were consistent with this finding (¼ 2.0/2.5; P¼ 0.016/
0.0052 for cooking/table salt). In WM, there were
Table 1. Descriptive statistics for demographic, clinical, and
imaging variables including DT-MRI and DCE-MRI parameters in
normal-appearing white matter and subcortical gray matter.
Parameter N Mean (s.d.)
Age (years) 264 66.9 (11.8)
Sex (% female) 264 42
Stroke subtype (% lacunar) 264 45
Hypertension (%) 264 72
Smokera (%) 262 39
Diabetes (%) 264 11
Pulse pressure (mm Hg) 264 63 (20)
Mean arterial pressure (mm Hg) 264 103 (15)
Salt intake score 250 2.7 (1.3)
Plasma sodium concentration (mmol/L) 260 139 (3)
Structural MRI
%WMH (%) 264 1.5 (1.6)
%BTV (%) 264 71 (5)
DT-MRI
MD (106 mm2/s)
GM 262 801 (52)
NAWM 262 787 (32)
FA
GM 262 0.234 (0.021)
NAWM 262 0.256 (0.022)
DCE-MRI
nAUC (103)
GM 201 16.8 (4.3)
NAWM 201 9.9 (3.7)
Abbreviations: BTV, brain tissue volume; DCE-MRI, dynamic contrast-
enhanced MRI; DT-MRI, diffusion tensor MRI; FA, fractional anisotropy;
GM, gray matter; MD, mean diffusivity; MRI, magnetic resonance imaging;
nAUC, normalized area under curve; NAWM, normal-appearing white
matter. aCurrently smoking or had given up within the previous 12
months.
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corresponding trends for reduced FA with increasing
salt score (¼1.3 103; P¼ 0.19) and lower
plasma sodium (¼ 0.62 103 L/mmol; P¼ 0.090)
but these were not significant at the two-tailed 5%
type 1 error level.
Dynamic Contrast-Enhanced Magnetic
Resonance Imaging
Of the 264 patients recruited, 56 did not undergo DCE-
MRI at 1-month follow-up due to decline in renal func-
tion (3), being too unwell (7), lack of venous access (4),
and declining to have the scan (42). Of the 208 patients
that underwent DCE-MRI, data suitable for analysis
was obtained in 201 (data for seven subjects were
rejected due to ‘tissueing’ of contrast, technical faults
during the scan or unacceptable data quality caused by
patient movement). The DCE-MRI parameters were
modelled using the same covariates as for DT-MRI
data (Table 4). Plasma sodium concentration was posi-
tively associated with nAUC in NAWM
(¼ 0.18 103; P¼ 0.019) but blood pressure, hyper-
tension, and salt intake score were not significant pre-
dictors. The most significant covariate in these analyses
was age, which was negatively associated with nAUC in
both NAWM and subcortical GM (P< 0.0001).
Figure 2. Flow chart showing recruitment to the Mild Stroke Study 2. MRI, magnetic resonance imaging; TIA, transient ischemic
attack.
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Discussion
Our finding that arterial blood pressure is associated
with increased WMH volume is broadly consistent
with the results of previous studies1,2,18–21 and with
the hypothesis that sustained pressure elevation and
pressure fluctuations in the small cerebral vessels
result in microvascular damage.22 The independent
association with clinical diagnosis of hypertension, add-
itional to that of BP, likely reflects the historical effect
of blood pressure elevation on vasculature and end
organs in addition to that at the time of the study.
Others have shown that WMH volume is also predicted
by increased large artery stiffness, which may be one
cause of increased pressure fluctuations in the small
cerebral vessels.23,24
A novel finding of this study is that routinely adding
more salt to food, which likely increases overall dietary
salt intake in addition to the amounts of salt already
present in food, is associated with greater WMH
volume. There was also a highly significant negative
association between the salt intake score and FA in
normal-appearing subcortical GM, suggestive of ‘pre-
visible’ reduced tissue integrity.25 The interactions
between salt intake, blood pressure, and cerebrovascu-
lar disease are not fully understood: it is widely
accepted that sodium intake increases blood pressure26
and that hypertension leads to cardiovascular disease
including stroke27,28 and there is indirect evidence to
support the beneficial effects of reducing the salt
intake on the incidence of cardiovascular disease.28,29
Furthermore, epidemiologic studies indicate that salt
intake is associated with increased risk of stroke and
cardiovascular disease independently of blood pres-
sure.4,30,31 Our findings, which are corrected for blood
pressure (both PP and MAP), hypertension, and age (as
much as one can), suggest this might also be the case in
cerebral SVD. Studies in the literature addressing the
Figure 3. Relationship between white-matter hyperintensity (WMH) volume and pulse pressure (PP), diagnosis of hypertension, and
salt intake score. The association between WMH volume and PP (Spearman’s R¼ 0.26, P< 0.001) survived correction for age and all
other factors listed in Table 2. ICV, Intracranial volume.
Table 2. Multiple linear regression analysis of %WMH and %BTV.
ln(0.005þ%WMH) %BTV
b (95% CI) P b (95% CI) P
PP (mm Hg) 0.0092 (0.00059, 0.018) 0.036 0.022 (0.054, 0.011) 0.20
MAP (mm Hg) 0.0037 (0.015, 0.0073) 0.51 0.013 (0.029, 0.055) 0.55
Hypertension 0.46 (0.11, 0.81) 0.0093 0.68 (2.0, 0.65) 0.31
Salt intake score 0.14 (0.021, 0.25) 0.021 0.26 (0.19, 0.70) 0.26
Plasma sodium (mmol/L) 0.029 (0.072, 0.014) 0.18 0.20 (0.033, 0.36) 0.019
Smoking 0.31 (0.0033, 0.63) 0.052 1.2 (2.4, 0.039) 0.058
Stroke subtype (cortical¼ 0, lacunar¼ 1) 0.27 (0.023, 0.57) 0.070 0.40 (1.5, 0.73) 0.49
Age (years) 0.053 (0.039, 0.067) <0.0001 0.25 (0.30, 0.20) <0.0001
Abbreviations: BTV, brain tissue volume; CI, confidence interval; PP, pulse pressure; MAP, mean arterial pressure; WMH, white-matter hyperintensity.
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role of sodium in SVD are lacking and the pathophy-
siologic mechanism of any harm is unclear. A possible
direct effect of salt on the endothelium, in addition to
any effect via elevated BP, might account for the
increased stroke risk due to salt beyond that accounted
for by hypertension alone: for example, salt-sensitive
(versus salt-resistant) hypertension is associated with
peripheral endothelial dysfunction32 which, if also pre-
sent in the brain, might account for the dynamic cere-
bral and systemic endothelial dysfunction seen in
several studies of SVD33 and the increased level of
WMH seen here. However, although the linear model
used here fitted our data well, the significance of salt
intake score as an independent predictor of WMH
could also be influenced by complex nonlinear inter-
actions between salt intake, blood pressure, and vascu-
lar disease, which become steeper with advancing age,
in hypertensives and high salt intake.28
In contrast to dietary sodium consumption, plasma
sodium concentration did not predict WMH volume
but was associated with brain tissue volume, corres-
ponding to an increase of 2% of ICV per 10mmol/L
sodium. Lower plasma sodium was also associated with
increased MD in NAWM and increased FA in subcor-
tical GM. The explanations for these associations are
unknown and should be explored in future studies.
Changes in brain volume may occur after acute changes
in osmolality, but are thought to be temporary and
rapidly reversed after changes in solute balance.34
Furthermore, none of our participants were either
hypernatremic (defined as [Na]> 146mmol/L) or
severely hyponatremic ([Na]< 125mmol/L), though
13% were mild to moderately hyponatremic
(125[Na]135mmol/L). These findings may reflect tran-
sient changes related to hydration state, diet, time of
day, or other factors. Most of our patients were man-
aged as outpatients, not being ill enough to require
hospital admission, and were mobile, cognitively com-
petent outpatients with no clinical evidence of dehydra-
tion. However, plasma sodium was also associated with
contrast uptake at DCE-MRI measured 1 month later,
corresponding to a relative increase in nAUC in
NAWM of 20% per 10mmol/L sodium; this suggests
that part of the association with brain volume may be
accounted for by differences in blood volume. Age was
a strong negative predictor of nAUC in GM and
NAWM, consistent with literature reports of a reduc-
tion in the cerebral blood supply with age.35 We note
that, although contrast uptake in normal-appearing
brain tissue is likely to be primarily intravascular,
increased blood–brain barrier permeability in patients
with SVD may result in an extracellular contribution to
the nAUC particularly at older ages;36 indeed, the posi-
tive association of nAUC with WMH volume may indi-
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contrast extravasation in this patient group will be con-
sidered in future work.
All analyses presented in this work were corrected
for whether subjects were smokers. In line with the pre-
vious literature, smokers had both greater WMH
volume37 and lower brain volume38 corresponding to
a total brain volume difference of approximately 1%
of ICV.
Our results concerning added dietary salt are limited
by the qualitative and self-reported nature of these
data. The index, based on a simple questionnaire, was
designed for use in our clinical setting and did not
attempt to assess total salt intake, an acknowledged
complex task due to problems with accurate recall,
and by the highly variable amounts of salt present in
food or added by manufacturers during processing.
However, our index may better reflect salt appetite
and long-term exposure to salt. There is no gold-stan-
dard way to assess the salt intake of these patients
retrospectively, and even the validity of a 24-hour
urine collection, which is not practical in this cohort,
has been questioned.39 More complex questionnaires
given by a dietician can provide a measure of intake
but also depend on self-report and would not have been
appropriate with this cohort of patients. A disadvan-
tage of both detailed dietary questionnaires and bio-
chemical tests is that they provide a snapshot of salt
consumption, which may not reflect long-term exposure
and habits, particularly during recovery from a stroke
where intake may have been influenced by the recent
stroke and lifestyle advice. Future work might focus on
a more quantitative assessment of salt intake in patients
presenting with mild stroke. Despite these reservations,
our index correlated well with WMH volume and the
trend was preserved when assessed using our two sep-
arate salt scores.
A second limitation is that our blood tests, while
quantitative, measured plasma sodium concentration
at a single point in time contemporaneous with meas-
urement of WMH volume, %BTV, FA, and MD but
not nAUC. As plasma sodium concentration shows
strong individuality, it is unlikely to vary much unless
the patient is over or under hydrated.40 It should also
be noted that the plasma sodium concentration can be
influenced by kidney function, glucose level, and medi-
cation (13.3% of patients had reduced kidney function
(estimated glomerular filtration rate< 60mL/min/
1.73m2) and 19.3% of patients took the diuretic medi-
cations Bendrofluimethiazide or Furosemide).
However, correcting for these potential confounds
made little difference to our results. Finally, we note
that the age range of participants in this study was
wide (34 to 96 years) and findings may be confounded
by age-related effects not fully eliminated by the model;
it is therefore desirable to replicate the findings in a
larger study or in a sample with narrower age range.
In conclusion, arterial PP and diagnosis of hyperten-
sion predict WMH volume in patients with mild stroke.
Added dietary salt intake was also independently asso-
ciated with WMH. Plasma sodium concentration, while
not associated with WMH volume, was a significant
predictor of brain tissue volume and of gadolinium
contrast agent uptake in NAWM.
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